var title_f34_45_35536="Ciprofloxacin: Drug information";
var content_f34_45_35536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=see_link\">",
"       Ciprofloxacin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=see_link\">",
"       Ciprofloxacin (otic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=see_link\">",
"       Ciprofloxacin (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9267 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35536=[""].join("\n");
var outline_f34_45_35536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35537="Symptoms in the last six months of life in cancer patients";
var content_f34_45_35537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Prevalence of moderate to severe symptoms in the last six months of life in patients with terminal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 382px; background-image: url(data:image/gif;base64,R0lGODlhZgJ+AfcAAENDQ6Cz2SFN/2YzZqN3NIKY//+n/+Di/+/eY/9l/7GNLaCg/8alHf8n/7OKYFRUVAAzmf+fQGZu/9DZ7DCsg9DX///g4JRpSv/s2f+/gDMzMwEy/69gz2C/oINZg+7u7j10i31LGgAAAP///yIiInGL/3hJV5ZzlopxZtKRVbSUeXxOsL0n17TOa9sV6d+KOUiWkYVYTdO3NDhWnCM5/8Svtl9fn5Cm/699T9KbaJJHvgAA/9Nu5REREZSpvVM1F7SR0teo51pnj9zLw2BvnjJZ/1tg/39mZtC2Wb+mkM9U4u+TO4B5jDJHfu+rZ4+Wu/8A//+ZM+XKBQCZZoiIiLu7u/+AgN3d3ZmZmf9AQMzMzGZmZqqqqmCAv/8QEPDz+f+zZoxmjHd3d0CzjDBZrP+A/8Dm2f/AwP8gIP8AANnN2ezXRP9A/4CAgP/mzYCZzP/A/0Bms+zm7P/w8BCfcMDAwPnywfLlgvbz9v+QkP8wMIDMs8azxrOZs//Mmf+wsCBNpvD59hFAnkBm//9gYMDN5v/Q0KCAoOfNFf/58/r10f388ODz7P+goHA/bv/z5nlNeejRJHCNxv9QUPTokv+sWSCmeaCgoP/Zs8DN//9wcP+mTePZ47DA3/Dw8KDZxuDm8//GjZCm01BzuerUNP/fwJDTvNDs49DQ0GBgYODg4KCz//+5c/Dz/6mNqfz54RBA//Xrov/Tpv/g/7Df0PDhc2R//3BwcPfvsu3bU7ymvZCQkFC5lnDGqbDA/9DA0P8Q/7CwsP/w///Q/1Bz//+Q//9Q/9q8Dj8nDQ+PbxER/+8J9R+Fee+PL+/n4cZ3KYBoUe/J9S8cCfLs1+vj3QAf/7+zr++yeZ+Rgn+Gpu/p9unagODNd9rIlOHW01hZfGtVP3Blec+mhsDAzD8AP6CZpr9LzIhft8DG2R8TBs+N4qq/J6+mrI+Mnx6iaa+wwCuefp55c3B4pO/DmaOLk0SjjF6mm5+TmbC5/++Q7+XYru6fUe9Z9W9fbM8s4nCGsSH5BAAAAAAALAAAAABmAn4BAAj/AEcIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkDFqoGLwigYRIrBE3sy5c8MqmCkXfPBgBBcRHzyrXq0agGiCPbgIFFGFte3bjV0bpD1b8wgAmIMLH068uPHjyJMrX868ufPn0KNLn069uvXr2LNr3869u/fvxznq/y4Ye3bt3bjTq/8qQrzoK7xJm0Z9sP36+/ir2scIGjOJEfDVZhlmvqGX34EIMrWfSwsm6OCDQDXIkoQQVmhhTRSqlOGFHHaoYUwbeijiiCCFeJKJJKaoYkUoltTiijDGqNCLI9Eo44032hhSiOD16OOPQAaJHY586VjijETqZGSSaC3pEY9M4uRklGRNyRGUVGKYpV1WboTlljJ1CWZXYmb05ZgvlYlmVmpedOaaE8IJV5sWvSlnSnTeKVWeFNkpUH+YaTDCFv5tkdp8Wwh0BXAiTFYSFiLIZtAHJEg6oAivscQopvWdx6aebfE5kZ8jUAEAQVRokFoVgo5AqQatAv+QaKmljbTFZVoYRAVmh8o6AhY9bATFsMQ65CtouYolKqhNLRsRqQ+IQdADrRIkhgZcBDtCD9IetCtmVXzwgH8jiBHoFR80KsIDl3rq6mTAIpTtn/SBJpB8FhFbbEO+bosFCf7lShtol/WQ7FTOMqtUwg+R2oNwWlxB6LpXjKCFCFpcvOq4InQrULqeAqCqQFSQUDEJVGTrGwC1iXHqxyRoJkZpp/Eq0Mw315oqRWz07DMb+g77s8/DGOQrpBULRIK0A/PWL8IKq8WwQ35qjJAG0gIc3MEAljfQrihbLZDXk+FcqnC1zidcpgM5OkK0Arkt0dA9Bw0F3WwUXdCmWHz/MLEIiTYt0BazQh11kyAiqWu1tKZ2RcwlHxrbA6KBljRBwF7saQ+UUdHDFXC/nfZB6XI9UOn3JgrsoRnZbWzhkKamQeBV2Dto4XsejjhMfv6dGRYTc36xpCNMRgXHGrg7ccyDYvY5pI3W5rUWl4lgskHzGlR9xyNU8TAJ5z3wcr5Bvz7QpSTQbjvh+ul+1tQNkeoWHPTXfxf87gel5qUF/glwD/0jiPzy5yUCVkkj8jkN67ZFGdAscCADNCBG8CdBnqjJa7z5GKe2RTwBKq6CTwIhWNSUwcygynmRqs8HRVhAFpJJIxh010AulqxNYWaFLpxgDrmipgSiJkDn08D4/woSwR02zIha2V/1NANE6D3ggRDEoU1MNZD/PCWDMemPp7BYESomhIJIDFPiviiRCkgAIsQBjQwTQsXJpA93Q6FeoDTDRYXYLiRyMw9FvOhFhIAxjLwbox8jUgFl7MAIEekjRLxIKLbBpA6ngqRDsEYy2jnkjiDpgQzr+BA+DtFAgGxfIMn4kELu4JSI7OT4mgYaLHyLBLn6lghONZkesG8mkpRkQ4RIxCUCqHrSMpUsrUcwERjsbNbTwgcYFSxzYYZr39KAFpYnQF+6BgAmq57qgrMF+GBmCyUD2MiIGEqr/HGQpDzIINbJzkEY8pSnpEE711kBhPSxaZTRwjFnpv+5Uo3Piiy5BAAGSlCR9cCgBSXoLQwyTcwAQGCd+4989FmFktXGdmr8zRb0mauZORCCHRQIDQd1qjpyynO/0UDFHpCoKxxTILHjo8k+AEBQljN3o0SnOudZhHfCU57zrKe3Vlk7+0DPP/8i2SdbItCEIlQDB3XqQhNyqxHwJqnM+40rX4ZR+xDuqNYrlzEjCjjWJbV7/zHpRUWwKNFojUBY2N4VPKm0AFr1plQ5pwrT2RBTonKRRLUdR2eIsbct9SWJGEFiu3eqKpwqsYu9mm+2UNLaJHWitPHiR9e30ZcS5GKXq6lICys+q26yZf8ZD0sJsrT5zLVVXsyqB/GK0zT/SXEhpkylKiFY1K9xs3mNOiwuGytcgzizURW76n8uFcyXfeAy4PNqomS5BUAZ6mGNWmA0BbZJ/9RmPJdi6yvZqk/AxdaueqXtiQS5V4iYcSyeQMUI4ns/9c7kAB1JLzn5at+F6Le/A1nADhZwJfbaFMD8RTBKBHxKAmvkv1FMsIL3O+EFw7PBDzYwhSt8YA6L5AAXhmcJhFonDc/WwxtGcUgOIIAQl8AWsBCALXzBIhNHWMU3xrFHWlEAWNiiAPB08AgqUIIiwIIYq2gFQvDbXgbddiFy0AVZEuGGR+AFwjddhQAGkQmBCFjIBDnADYixgSLcgMQj+HKTW1JEgxzC/xF4iIi57Nqw8wguJpWIQhTc8JB0AZQh4yHiGouCZUBmYhACWEVBmJyQVvgCxgIogS8YPOAOr6TNBJHDAAbQB4jQdKAschcmW4IJPUehEp2E6qDRuOqhFNqIB4BxAZRckUyUYAMhBvNdc7rmhMghDJDYtLDD0GmGAAs+FSvZw1RVTFgiE5Z/C5DWJBooKI6EFaaOgpUbgrJbqsuEIjONwXTzyoYSqAep2ZmrdZwRHvuY0RYBcYh3AO9Cyy8M+M63I4TNbw/kG9+cOAgApEVuEnyAUlRAlugGi7MS9rZUI8tjRzABhopbHAwRyHYlLl7xUBjEgd5LzUmtqIEHaPI3VP9geGkyyDzZ6o/dF9EylzlCaQyf2MkSFsi/8+0BfkNi5wCvjHD+40VZ2a5kYE2rnR/uOzhyhOIcx7jGo+7xgviOjpa1Iny65Zqkm1apXPjzy2HuEHgfOtEfobSud23bnCPkF/w+gUPUTVMuUNGlWLDd7AYLUvN8NFXWLgm2Tb1thdSdZIJSbtzG9d2Ue9aqkqKpxCNE9oaoOdawmHVI1GzpD7n9IH0YgAcOIXqHoGwgW6BccEoDKJUiE3DADdBzw8oxE6Kk1HpGtbG1BSCMKR4ApfGcFsj924lVTAzoJnTlF0JpCbybJPC+OZufjJA+8EEgcjhEF4c4aqDkec8vCfT/upePkJrvwBZtT3+vS6LI7v+EyoVniQKN8uqoyTvE0ceTRvhXkCpozWMpFoAoVn/McgC3lmvqZxE+tECUdBqXI30C6GEEeCcVYAsbYAsHoHa8ZhExRBC3ogX+Z22Y1l8TuCaHlnmMxnkJGGq9QRCs0kgDYUMjaF8lCCZaJgA3QGthJkYZ0YEDUR6H13mzQXY1GCP5525FoGg70UM080O8wS0W4zUROIQzcWcEIX4jUoQrooKYRwxd1hNKRCC9d1HYBYAQeIYKEQu5sAZ3sAgOYTYlFzeOZIUx6EhXaIck8QUEAQoN8TfJIxLuJyUVpnaZYIEYSHkbOIUHgQBS0IhS/4AIbsgQ80JTwYI6gtZ9WBgTAUAGejgCXQAIfTgrhGI6L6Rg5rcBmjd2K4iGB2EHjuiICNAQpcMF1KIF8+J/YkiHAiEy34RWYqgb38ZE29NqFdEFnNgFgjABoTgQcFNuVmVNppJNvXhcWgAsoWEvzFUqJCBOged5AHZ/F5Z/YGhjVHgQa3CO6BgJr9iIiICO6KgIB0E5YkAF84gzNTUvgjMxiQJ8FoMx9xgswBhRb9MqnAQRARAHCJmQCAkBggABgKCQCSkJBnFL/qRyVtU5AOl6q+VSwxODHmMvE6VJJYMuopWIN5UJBVAE1YCA47eKOVYQ7niO6riO7RiT8Kgrtf9Ii9jiTcERIJgoGpkxHG31dVjlGwX5EAcJkQsJARBABkoZBxJpdYUTLV7HG5YzHm+VGSVTVqwySyDYHlkFAFtVVzwoQuI4EAewCsQQY5LWChq4E5+gUzgnlwvhiusYiw2hT5X4MKlRkqb1k67ll8CYdaLTj8RIEcg4AcbYiQtxS4RyBXynR2KQWqKxWgZRkiwFkqWhOedVlhWkggPhC0W2AcRwA9EHmjjxCVNgBuvnja2JEIzoiJD4ED1QK7DiP+Sii78RHA00bShHlP+hBQADMIcpEQGQjALRBXHQh8EhTSTzW8EBPr/5S1uDXarCKLCEjcDkT2RJjoejgRUwZmX/VgJfuGQpoQYSEQh0MAVj8JooMYMjoIZsGIk+AVoewYcDgZ9mUpzNAkLmRwM+tgpn6RKaJgcRsQdTkKBxqYjr9XlJASh4KCX8qSAVBI7wNKAwQXra9xCMkKAJagmBwKAmAZ+0pYW4YQQsWRN94AphMGyuUGwLwQsemqB7IKIuQn0VZqKscXa2EGQ4wQf8JmzXtxBmMKMeygis+J44OmE66hmtIGteVmk5AaT8FgZxphCBQAFjYAZc2qVI+pJx4qAK1qSccQPPh5Y7AXdxNwCHYKAHcQp00AEMYW9LOqa6kwkCUATl2RN4QHqbFmwDgAdy4AqOEAa/UBC0QAemED/e/0mmMuKojXEAa6mEP6EGkHACfBAG6KkGmioQeKALkAAJfBBnn0AHCzqnjZqerPkQPMk9TfEHVpAHFmAsnAJEYQGpisFjG1ACOsinhDqkC5GpjmAPdHAKBoGe7tmgdNkQe2AJEIFs3ROHSjEHWYAGVkAIXmAI/AIwV2CrI4Qm0SdzaNYTlhoGbtoQgVAPlsCmyIp9A3CuSaqsyWoQHToFNeoQ0NqPHyBMbMUoAPABZoN4y+Q8QPRRK2EFejAHAtEIaMAvlAUAAcKTqgIpg2MozOSLJvQ3dOYTuBoYnFcBiEZjQIEHhCplD5GlYxAIctAHhTqkGjqvN+p2YzCzNDuzlv+QoHRQszVrrAWRr6ZlUdp4cJMxL5T1NglHHxV7OybRCFnQtE7rBWjgtFmQBnogtVmgCUZTXZiCRfDBBRR7OwbrL+LmgYyjilRCaQVQApnXq+T6c/DKEKdgCXJKEED6cy4Ko2w3l6+pszY7oznLtzxLEPmqMYw0K1RgKJEycJkjVpzTPZ/DVktrtVkAtVJLtVaLtXuTKBxTBcMXHFjwtexjLpzTquKFXWKHiGcbYgKAoTdBso5gsg9hBnRwrwVBpUEKrHk7fWJKEBRgpIGrEND6gtwZtAj3NgCkl58FuSIzOiqBsAo7Ao3gBQ7be7RRVemSd2xlGYUDWiXZteVyuj//0bF9YaGnxLo1wQluGxGqeaoGYbubhru5G6bLmhCmYKTs2RCtKhp95K/plnyz0z2/NR8TChLUaq3Yqq2AJooD8z3gZkyzY10Ym1r+Ab4cyyRpaQsCgGsXtnYqShAsC7sP0QvFuhD85ghCqKS7KxCfsAcs3MJ78KUroUgtAauyWl8dMqAXLABHdmZp5qM6oQYDgJ6c4AEe8LYJwQisGQgdQAG/exCc8KebdqVgeml1ihMuFVIQIr5qAZqOVgIZPAgFMK49zME10aLExmkQMQYgSgEUEKIL8QudyqntWo4XwX+sJRx0RqJ4pcVogbaiWQQbAMZ7ehDm6xIn0HM+J3cO/1GkUxCnGZYRC3gQ9nnCfJyFF3KKBTDIRcEJ+1bCAecQN5ugbqxDB/GHFuN6CuGDmTu/UyyBFrIK80ZvS6EGiLxpjvDJDVG/Hjq3pFwQ6cIFB+e9M2JndpUtD5iklSwiyfwVrbAKMFYEEpCiRwHHjhB6/Hay6zmjTdwn2lMch6nKVZQpMljFALbMUTGgzUxmZsZkb3kUfBCqowrEjvBm7+oQHWC/7dnLbUMcTmcQC2irntONenxT5vwUqClmg0CaAmoQqCkUeNAHkOABwKoGfRBnD43LC9EC67DR69ACXGompBMzB9eNgutLQERTERq/8WqnngGeNwDISMa2i9YTcv9gxCOwsoU6xxVhl69oB498mWYoEjwiJERd1EZ91ODR0iEGoDPGFIewoQORfWyK0ReRC+soBbnw0wUhBoYy0jVCfupBvrLMFJpWzyOgBhpq0xOhCLWw0Ve9Blp9OsRB0voM1qrRzBYozTeh1gdB0ScAqJcaBtUsxRbB1pEQCQjgDuuACFddCyA9KXMt1HYNFoVMyBWBoWKmzqbZzjjBqQ+BB7UsbB5A2BRh2JFQC/DYAbzwCowtm3ZACmtAn9xMOiN9cF892V3R0Ayh27stpQRRASmp0L3K2zTRojptEHJA0YcQ2qJH2gmxCLEZCZQgEKaN2gORqCGqCGvQiGsAj9D/HQk3OdsIYdskUdC4PRGc3ds29xBvaWs63NTmiRN4oAZ84Aqb5gF9oAafzAm/0AeHPACF6gq6oAb2LWwqINsKsd2vmAuHbd0EoZ60sBCUgAixUGMHsSgOdcwhdN5HUdkBptcJYX5kfBDmZwRsKcYjy9y23HM/1wcDTtiLcAEAvmkEgJcHsQh2kOOxcNVSEN4FwQu80BB2gAg2/iwIkZVlu+EcThTE/du2FssbEOVSPuVTDuUbAAvzNE9pG8v4oBSgHaSuwAfHXRC4EAMEIAXHQAAXIAXuOJOOmI48jhDY7RCvQAqkgOCM+nGYcnC7MsCjsuRM7sMDUQEoWQKItgFb//ZiIF5+LHkAmfDokA7pvlAABdCjG8wUQCxsirwQrxCb65jjOe7jBMHTr3gQjEAHq/oQCIAIoo6q2AO5vYfFBQboQWF+tmDoGZzomTyu6c18gu4QvW4UeHACVfrcuFALpMDmVx0JDbEIrQ2LBzEGvTAROz7dRyR0SzOZsH4ktP4TYk2eKM7Qvs3e407uIz4UcuABjiCqUm0QdoDsbH4HPj0CCu6I1s4QivDssW0QpgCipU3keM7Kw5TSj93tOuFoGEwDi64QHj7TFNHwPMHJrsAJ2t2IMgCPinAH200KtYALCA7djSjdELEIuEAJrT4Cp57qE7EIa0AKr5DnB1EFYv8gBn4u3gavEhgangk9CDwc7IIBpNfH2q+ICIiA2LEQ8CMh7RlRC4gw79RX23Rd1zdvEqiJ8AIgY77Atk3+F4T6ybXQ2C2xBxSwEbGACJQQ3ffeyr6DtNw+9Sfh0jvPwwkB8Xcx7EU8EPX+5ixxClOwzYV91Wmv0oASHFFfYm5P9UuN9TL9GOl+AlL8Cm7uiFm9EhRAuxqhCMsugKBBBbV924c/EmJN94Uh8QRR9lb96Ssh9h5xB3EOgULL+V4t2Z8PElav8JeuGkA/EIuQC00/ApTwioFvEnzv9xdB6o6YYsc1HIVv4SIi+vHmEzl/A3FfTz7/GF0/ELiACLlAn6//EAux8PIqkaWL6hHOfpfIbxzLb/McsvU0V+6gj97lbvWKXxDsrxh276aLwPS4QBO9ABBjRgwkWNDgQYQGFSGS0nDNIoMiDn6gWJFiQowZE0rU2NHjR5AhRY4kWXLkgh0pF5gMiVIly5Y7VsZ8WeHGoA2DblTIeADmT6BBhZaUU1COhxN4BtqJ9HDoTzN0GD01uAgXJUUIOR68AkCECABXqEYcW9bsWbQJXaaUKdInTbYzz66V23FtShoCbPlqldbvX8AYw6gZyMmRK4J3EFEKrHFqIEumGpNFSOLrVw1ot07m3DnwAbahB5VYxVMjyroZM90IzfZt2bs7qm2gXdu2/+3WKV975t0bj1KRagaEGcFnAJ+BikiRetW74Ck6gXoJ5L2ZYBURVChSEVHlrHXn4cWbNNK6QKYCxARsKGLrRqaDdBFmWlVg0HoBg2y1Zl/AtNADViEmtx12wyi21MZT8Kw++gCJEzX68GCAAU4YQBel7pDijgXHmGKM6HoDbwQuRBBrhCtE4EKjKzT4CouDqOgBrI0WtPFGjFoZpIgS4jKoldVsKWIDAYg5r4DWFqDPPvwGKWAV+AiSzxdbYBGgBF80MvAgm4Yk5gYkQ0vwQB9xNHMoPBxxBLiOjKPwzQE8mGYNUrJSkJYp8pRMRIRSJEEMMSw7EaMHHiBRhA8Kwv9CBBgxGvFMSHnLBBZb+kKtI/pKGITA/J6MkszUKihBAEpX6cugSw/yZVRK+ZKyTJBSjXRWkeRQQxcLB0BBFzWKOkiNX/o4JAw4KTRhG0RqgUhByPL80LlHubuMio56WHGE7grSgNqMHqX127QKgGWVgrY8LUm3MDrgBi9XeUu+EVoREBYe/0O1rZHMBddGXz0yrNgBHOGEk2CHdSTOMPrglZoY4GQAETtu3MPZPGnhM6EqAPWuo2yxbXQgEWakcSCvLvN2X5QB3NHekuB9Sl5i2NsvNCFzukHfclPWWaPBHjz4TUcYIMCEGAhQAAlu7lB6aQRMcFgKG83wkOIpLLn/+KAqrq1i44ysBZnrEXrw7ooePi7o5J3TFskXWEo49SdZy5KXwBveVvtukIQjDiMI+3AlDEgaflMBKSJZ+nDEcxnggmMUMIEAqMeT2pIOxrD88jEs9mzEFA0dQQwTNSr00A9S9O6BLVD0+iC08XYdoRJgyXIonJ9C8HXc+Y5wwgFc4UMN4P0GfABIwqDHAQYYuABOyNfoaJpjGmromEjEk5qOPXAcscRruWfRRUZRzLbFr8SoMXf0ETqgiCJqj9Tl9NN3E+DiXelDDU5GwAUBREih5JUwxCB5MYiBFBjTkTVIryEH5M319hAIM20vOwPhzrXK0rr4pY1tJcBb3DIY/yk59KsjciAWnDzAJv3xz3/NKQwppHcMUnxkEQhoSCQY2BkHQvBMj+pBD7awhR5q5oPoa0WVPnU39w1RQYc4REc4ISFHnAAScOrGQPaHCBuy8CCUWMMabogjU+hwIIzoAPbEuMOESOsr3DLLo5KotjeqrzGvqUARBmE3JeYxPHKgkAgLwglXQMIRh/jFCOzgtDcxIBdYrIWd7hYI7I2xjA/8lrcyJgawXRAhHsQdJ+2Cr5BUQBks88ilVgGLAuhRlWPxo0YiJEUKQeIE9xvILw4BCUi4gjAEURzjHEeASDjSdR3IkxmI2YszzgqDaQEP/F7nzHO9BCSi3MEo4VIEWP8ccZXb/EnPPoIH3sEJEnw4hCNy6Q072EFpXZTCMaL3Qufh7hQU68BUULZMIRbkduky0z4/KaaPUDMl1iylebh50J/oLSQfQKSxHKcAGbhQCl2sxR1wYYdX1EKBDamF6xjxiQ5YgmJm0Bl4EtWYzYAmN+6KFShBEkeYqJQ/+RlETW1q0xL0KDc5vWlP77MBAt1GqLUhEEwRetQR9I13vlMDCgeCB+DxoUEqIACcCKe0dGLkFQyRHiK0eCNGkBQjpzAFL+hAB15MzVlWS5l1AvUBMQyKmfcKjQQGAYuc2KIAviDlQKCZEU++rAjoqkAmDHtYxBagADNji17Pg1jI8qT/PKExwkf8iVTMZmR+xbLfCcJQwuGEYZZ9kEHDfga5jygigRMV5o3GwFaCBMIMe/AQ5T5xihE0i2p72pdbNZAiLlgkn/qEFZBuoCm8FsFIfB3BZQELq7FkolPQ/adLOzLZHVS2pdLMbHcxootiybJBv2tqQV6hGFIUrZ0EuED1cmeGPO3ho72gwBQo0Ata2DO2ZuBvf82A23saRI0mQ9R3NmndgyzppwQqgWId/GAHM5a7Q2lF7G7gVwR/ckwaKY92Y7JhpHLRi395RSxi8VWzLIISd6DEsjKCBz5Y6GcUyl9C7EBDBERstdL7It5Emic6jGEPYlUieEpG4JNqUo4i/wlTYyH85ALotDVG9QjbiLEbKhMky34tyZY/uAiJNiSGaKGEAnv8lIVIgQFSQERrCQJjC52AD3iY4pt2aZBYkAIRd9DiDGt4ZrWZgp7bHNEHNFAF4RpYKH89cGjyQi6gtIIYsvMu3sq8UUAjJBZKczNG7LBRKUTMLJFo5wCi5943x7hCcybIAA4hBz5AwkEEOW//YrFNSFINwHo82UXmOpTAqsVHqxCAACBtkhtQCo+Vrsod9JyLTmu1FmvIhag/QglSSwEBLk6IItSZbQUaLp3crkqYN5SRRaTT2aAmBS6ibRARZ1ohDVneBRqCixHAedVOxQM3so0AaiwFx9ZWJf8j6ks16vA6IV35SliGC6CTuJTYxibJAe6jTWYfxNxtTi1XF3jtjcYzOeqcNqmbUgtwSy8S05YoKdaAgDvEwg5Z0dBGs+LtTSOATmJeA8pB3RRSkyIXFnWzucd8kFfYYcVrcAABBDeAorF3cQrYxh3GXZBLS28Ned4zivUYlV74t7+rfJRlLpMZRTvHXBM/tkfE5baMZyQWoM7FR3YsPa8jJNvv1PYaTN5zqwuzzI3jsUHSueJc+P2FhAs3tVmc1YJoVM3S6+hSYjFthrzc6pJf8wK9vXQXIkLzsagBwFY9DTvg4g7TXq3LEZByMd8aoaagwycyOyLsaOcD3MnkU/D/6Rm2L3kgdSxCX+NekJqDWvnLZ37zG8KAAjpk5h0hBQEcEb2ja4TU1n8nhzqyVcc1xKsJSTclMC+F8HdV8xc1CMFAS6EaaETdypf3BwMR0l0jVYInAm7aIRX8V1mJViiADUil4+s2Slikn/sI5ZM9jWiIhuk8fPOINBkAHKi/gsiFYzgYyJECB9QIRXAaBViDdzOIBBJBh2i/YDmBCSmePoATRwAJ5ZtAXKMACkimo+IcEfiTQAmdNgKX4FuLURkEL9umEns9RECAWMAFUPM+BAK1vCsIqKIqYyEABhgC4CmvgyChOnuThEkIqFIDPhgeOImBQ9BChJADYeEdR0gY/+TICDWMB0RyhKJRgQgZloAJA6YiCE6IJQpxKoygIQVCBHLLI+joAGaLFpNhIyUDQgGggdbwMMxaBGdDBGgrCFyoBRfyImFKPikghULsNo8zoBGaMTj5rM8KL1Q0xTfxgFUsFlR8v1hKRQppw8+yH4UJJ6DJHwjJQl8EFlasRT3kFUCspZ5RA2/qiEXYMY7bpk+YAttLRIy4pN6jit8bD5kKjSLEnY1TvQQihVogOIVQmg/0iIyiNnE0CDnQBWLxAF08Dt3JQlcwoV9sJYIAr1Z0KlsJngYZlnd8k+KJRYHsg1ypxRpDC0WwulAcojLKP++6xkbcF+dCqLnbqCTEhf+FDAo5aKKEACQPiCJWE443OYG8OcWS9MKTpBCS/AiRVMkDDIpAsEEc7C6IHIuaFA9G4yZPFD+/OIQBECE8sCVzcoVCKojN2huPeEFI8ElIAAmlZEqQwMcp8oCo9EOqfEmYOAXKmUmaDI+bxMkMO6hFyIUFPAs5+AWV7BVciRNdOEiD6INx2sgBiMo33Ei6HAi7/AhXeLXiaEq95MtYw0qW+AQ64K3j8xaLSDKMIJ/wURSTqcavFI9tfB1K7J8mDAk80AWQkINgHA4+sMc/MgrBrLRASLheoAMiO8BH2QIkEx1DKRHFxAIS0IjIHE2/qMw1iBhPBMWQ6IM18QhbKcj/N+FI2yxOg+gFaCxNCtCvl8Q9AiuwrrmWjhmIRVmj8zFOBXkFHPuqhIw5kajAWVPHOyyhMGAik8RO9GQEIKMAXuDKjHNO3fO1btmYxjSIRdECrUBP8dBObYvCkOBCWDwEYSFPAe0VgkBLlNRP41SrhBvNR9mWRIvOr9mIjTmyr0AIb8tIjMjQDCqxE7tNdRKmG0tC/xyJzfLCAgXNEXjBQ4i1GFRQbqKF7OkIRpBRXvgxZ2FOrCy051RMhBgd2DSdEXgAGMGCHvBRkFGIbFsMkFCEJcVAglCEXIgEw9FQ58g6UjyLNHOIdFuDPbPSEVBRdSQnUzyhj/iFfnlDGF0l/0uQCoQwg0+YjikIsj0gTIQrTh5tzYxgTBgRUmkpm+scgUUYRSmgQXQjVEPd0FHMvgX5NPR7p3TUKowCiUG1yC/1CGSEQ3ISpBPQBXykEKRcU6ycmClARNnagw6oL0vghSHTL0GjmilIzeZMiMREUt/DOlBzHm9LJ17lVdUjy40ynIvq1V7NCmBVoHIcD7LcwA4kBYuyg4wcS+nJBTDVH+Wr1oEgljt7qk2tkLYkiKckHlEVzFwDsg/pBVOQ1XEliF6zVWtEvuVrii6aV3q9g7uTHnulV32FPXxdkEWIBf6Rgqq6vsLJV56DOZlrjmNtiLorCF5dsdVTPFDrCKjig/95jJP7+QVXmJCE2dZ7rEviXNeMowW1sq+MAwCSEYpHYTiwkCubxNWQ8wgsTUHqk54ORID9TMBPdICnM5YYECF1u4PEG8XomyhwcznNw6qKDDeK/cfhoCWRVdBAAKmzgtVofMgkDYqyMxm0+0GCqFQFSlTyQ1SPqDkGGIA1a4pI/YuEdKFciAWIACeA8QAD9bSGUIABYDyseEIzA05WVNOoxc6p5QX7MgVGKFkgS8RgCIbaPBuEyL3tmM6XLQgnFT8oTY4nlSEXapgY4JBYUNuywIUEWgMatAOUu8iDoDM42UsCvR8ReoVjYACnMQEGOIYS/VpBtCGN0DddXMnAPT7/GTUIRjAFD+GFT9DRl/SEkJkRlUWIEuE/FfG/KNUHbKVcaAUJFiwWpBiBWBC9tTWJma0F/lm5aMMD4RyAO7OVAQVVAe3MqwTO3VU1OYOx8/zduGvTqSCr+jJe9zy+OrAMT1AFEdAAVAAKHeRBQZHegcjUtPgXGKwx3PxekQBbBbqDEuQEWaKQW4LHhFBfPNTeYkyIZJRC+WW1gYDLz/RJ+407UqWANu0AzcFOT7iFHtgFjhCBNuiBS/gJRZyWhyMIbUULPPBNGHS1fongn1haBZJg38QQviwOwH0xgGnDPuADt/yV4SDhODPh0CQIMV1hbirXKZjRzIICMz7jjkAF/w0AAFUYgTYYiDeugx5IBU9gCZMagQ/ggh8KruGq2Iv1gPu5YqAY4jbsQziRyycWVMUgwZH41/FVvmgjIQ8QZMwslqQKluHxgBRNqt2hEN8p4RAG45c8XIppUKQ6YzTOiDbAYYz4AAAgYJNwKxPp0bSTW4CJ4p/ggzYkDOEYpIMpCkQ+YsVAABayVymotoNQBErYxL2FPVQziF84jFBmSc8kFkG+lb8JGPflYlEuzkAgVaq52lNGZSiAg1lACFXQAAImZyg4iBzehZKQ5RTR04i05eEcilhLxghRiiE+yGD+2mEWROmZwP2JhIvkti1lMzfDg3IqSpiAEIKoW4w4y/+LzcduRs9PsAQQgVU6QKphKIYEYGc2AAYzbgA2MIYyOIEecAQ4GAF2Roj/fYA6Fok7rtUfbsmA+UhCmmYvTohYG6da8clE9rN2UjmydNZ3UzEWK0ROcEWeTov3o+SLTpswKotTeK0Y/qCXPghhgIMyYAMoaABjKIatHgg4gIN8IAcSMAc2aAB2bmeE8IQHIAH8DIkH3Rgt+C3pPcow1YUJmd+MGOERQEagJgqh9pUygz5kvV2NAK/w5I0uRN+pfh1IImOhuD8z0qOyHgYDSAC3ZoMyMIBzHoiyHohg6IFbmGnSJucywAgbhmeQ4NHgKp3o9VpwjUsV9uK17NRWUqj/BQ4DR8BlkghmJoxA6WEJPAAcqZ4MI461x57stCGmKUBelqC9eloldv5qYAAGlG7pkJDrHgiGg2BnYBhthEAFEgAAd2WdgwAfAqvG5u1ivEQI3tUFOVAqT2ZHR+iDp/7POKsqqLNCJAiJUFWDQepvv8ADEfpi6J6VecoTXggKM7AEClDXbyntgzhrAyiDMmDnBBBtj6iDgRDxEe8BmUYID2eDjPiAVOgBEqfN9n7O1FFgkAjKcjK9OEHw73Ra4fZpDnYFR3DoBrff4T04IOMFU3BIjLhugjjc2lMbdj5rDk8ANhjpkq5yDsdwGMeWEZhhHQYJYQAGA9CIS+iBOB7x//yciEOriF+DCVsCYbOw51hqEOB5MTWYIkj4BXdk8CFPT1NQVaqpvZBCqyHDCPiijm+eAmRSm2EQaTZIAA4/a/MuCC3vFpBBbzYWCQNoAGHQCDX2iqyljIPgApel8ZKIarTA6TCQKn8EVT3sg1/oFad93z5HGXF2jiKfAuNlBBx1lj35qJD6kEIviIOjBcIcA+rmjUofga4uA88O62W/VWyp4ZJ49I5gcREQ7xHhIfP5i8YliMj2WKrga4MIwwahxbnV8VpXkGe08MYocjqAYR2SLbH7r4OYr/oSMjilGEvI6vEo61nY8LaGgkcvBu+OdoRA2RFQ+IxQhTq4hDa4hf8B/ooCLolZAIZh8IiQkfg0Pwgx2IIIjUiYaG5ZQwsUlssHgUF1X3fxyDVT/ohk7wj5IohT6IUX9veSCARaoC+qsWwFSXEoAAbQNoCMH29ytutQH4E6qINdaIMHAADL6AEAAIA2WGURr80yaACNT+dtR4gPoGXbhgkFF82zcEs+fypLZvl9Aech46+PgI7+TQj17ICav/mxAGcgi/sR8GoOj3SQ6Pu+74hZ8OrshoNO/8FLAIuSSe9UaINLqIOKd1wuh4kGKAaOSXp29XqwF3kl0psxHIDlVnsbeXBnoYAxMHKNtpxe2IM9SFf+8hBEJIh69y9TYP09ODjKwXmhUE//WI39jOhwVG7tj8DwwS+Gr3ZroQ/po2cmErCMYKgD1QYMOCjvLe96r0/MH1YiiF7gsxd93kj0njeIU+gv26+c14JV+8Ic9e8A1ifcPHl5jAB8Dv97+f8I4D9j4fcIdt5wYwCIBlCAsUlQxgCcEQpHQGnocCHEiBInUlR4iYSISyNEVOzo8SPEBMZAVuRY8cMHkiopmlzp8iXMmDJn0nQZKFDNnDp3rgy0hw6FKUKHTmEEMpCloWNWJh36iaTDh1CjQgEpLAFVNmW2GmPj9etXgVShGDsIRxhPmRdJXDLZMi1JYcAMyHwL8QoAESIAXPl4RYNeLBOriKDCEi7ixIoX/6vcw4sx5MgUfdLhxYiRmcyazRj9uIfoFFokTYG2hPPj2K1m4bBuzXoYQ6qti21N8BWYQ7EOtW5F6Pp37KiSSa7VOKKNQuTDJxpogBam3YUY9YrQ8PHBgxFcRKSEqKVH4cPLx5MvP5ERnSlmzLOvSXnM+pnoSx9ND3qPRzhlUm8F65+NblF9ZdBWrc2y0H5RlaHSWO1BVJyDFRUUU3QjEEYFSlSIUIVHPXCh0IZ39YAFCYZNVGGEKaoYEy9CUbAijJP9BF9On4xxI45jiOZRIGaw8COQp0gkjAFlCFRQg1MJB5J+qpWREElObhUhhDFCNAswsL1U4XZ9jXCFCB92FP/iRoIpdEWJI6SpUF7UoWglnHGaQZQpcbZHC34QmUIHjSkmOcIwBiRw5JPP/YkaVXYiVqWiIxgJ3URgkiCGGBh5WZGHIHKoEBZuhifRm42Kyl5QRFFgSmejeuSQCyxUpSQUzCTT2SeW9KliasYAA4wxxUAZkZQLRimlqjUxOmoDxWxJkYbUmdgRdtpxB+amCq0JarHZsvcJaFNQ0OIYn5zG06GIOQQCM6+C5NAKQnVQ660rjpWAAQdqu6JbIxyrKhzA2KvSmySSUG1HfwX2JZnWPhtRqPc6zNMpQOV44wiB2DgFLztCVO6qia7r8UfDNMSCUCuo5utvrgnT0DLJDGX/yVMr6mdMgA09DKNbJLB1s0guobgFdT0sjFjDNxsdU8R7lMuIKRTQ0UF8wUkFq80fRzVLa6rZBmBuDTEjlMvdij1FQzYQVQ9Ci3Ec6KBQNECvyCAf3V5GGBl3s1x0ATyYXhoA1kN3iRU9N+EfRfwUf0+6FsQ/zFjSyymsujoC1q0VqTVYY2m+OVUEeUUgyr8yAoUORHUAFcmgcSBQA1r5+txCHHfU4CxFsuF2Wb8WDmMwD+zV1qhuPNJRc7B/VCFhZmoopuC7O+/SJ3TEzN/W/3FgDx3npjsQWGWd7JrsE4W/0Cm9ON0yaEKiBkK3dCgUaBk0c5+Ar+OLTxWh9T4f/2MdqfSgwS7y1ahKRCEKpeiIVvY2EQ1g6ANdChxcBrc/50UvZnCw38agkLoVpApRS/Lg1CJSPks8TTQd6NZS0oK1Mtgmcf8BC240p6UJrggVt9DZLVABoh0qChMFjMImOjILKMzQIxX6gKeow7y0SJCGc4uekGbBhhh+sGNfm0LYxtCBPXDmIx304DKWoS6F0KIDdHic+hSymc0wJnG+SRkc7IVBJ0pGFbvQQA9SUYeI7HEEfYRMIsAQBTAkYiUZ+GEUhleRMrCBJEdMol6WyJMm0vFhPzmFMPaTgJXJzSOkGUoHemSKXowhPd/aAy3SuBCYvcQxCglEGYECOVx1sv9jVazkR/r4R5IoRzkj8MQl8vKAYFQEA7IoZGT88EM/qCQRBPyhGzySLJCgCCXWtKZiKInLbJnxFM1hw79gEgj7DEWVFTODKfYwhqScEk9TMM1K5uMYb6EqRnPcZk0EqECO9O53nuiIGwq4CWSSJBGsiIAsXPLMKFSiIm4ohR8yIMgoRACR0exIv4wnHoqgJDLaxGdHvmieDlAgGgDS20xOCJoUdsQMn9hDqcYmU9DUE6Q2PREP91YHEfxvF6oAyUITqpJQQHMliIyCQjAAUYlWtBJg8IMshDeCQ/5QkR3pmREpghe98IUxH72pRFj5kpvkJBAdgAc/gCGsmqxRMyr/6cVQ6CBSisxpKHUCK15BpIo2iKANfk0FAAIrWMECxk0Y0WFBEQmGlVS0gBkoaEARuQkggiEUUbVqRHz4Q4JWRC66w+lEptM3r+Y1JqSBp0tcSZNAUAAEyzBGONnDCNCcDiQxnQIdxlVafHpCL6noq193UYcq1GG4xSXuH/UJksgWMAJgAAMr/CDdUrhBqhDBgGIXkojqYkK6rHjuD1OwhB8uIRsreeYmQgGS4o2Jbw3UEMEiGKF7mmecQsmTSuYTNXFSwAZs+Gx7xtCt/VKEW6DpxW552wbw/FSbyvWIGyZawEpwV7p+eC4YGjtIMCyUohJ+bnT9gInqIvMLOfgh/w66QJIJSGIEwnPGES7qkQSWZCJdOlOYFvPVtNC3PHAVilxX0iJvMYgq2qAAEZS1IkZM7Eb4rQgvmszSBNPQEwsGACoe/BEAsAkkmNjEJmSBSFZ8ZLsPRSSFOduRIfywCXF4syTe8AZRFKLOX4DIF8ig4jwTYaAfGWIRGRYpEUyqUiK4FNEkgpnl9JjRLihNjra4h0mboq10ohoUnqZRKnN6VJfoAQB2qZhE+GETlcCEQiSMapVoWL0g6cQoINCOIwgBFHUuhJzf0IU3xwECvhbEm8kAgVHoeQSVBWHVIIKiZullaPKNyDqHY4BGy2SuEoGl+aDAvvtoJp2T3kMHcv90W9zuodLmjEhDdCBGKDy50+5W1EVCrZNHqBkijwiFc2U8Agw01SXKLCBmJwKKNwACEKIAhZ6L/RFb11kSEACEQh4RAX3f75YboQgXsECp+CYaInVdQQh5MgsjicUGLmhIAmILF7Eq+hMdSMoYuOgCENC85vVod4G7ZYlwJ4VPMeeiGeIHhZaBfIzvPnqM9qWQ7dbbI0SduETccMgMBFzX2x1BF96wkgsfsCKwhkAXCjGCPO9Z4SAhO9gVUooIND12tURRD8QwHLs0JRnrhgscjAGFBCREg1MAAcr3rnKaNMkH74zGQhjhcphzEQ62G8vtoOCVMvhq8DCoec2nzAn/IHBgBSsAQamgYLYpnBzppl9RHQCws4lInKIB7wh2BQqRUmTYD68fe7G7QIY75wQUkhCEwXk/AhYv5AsqPnuxY318VpC5IhxDkRi2cE3SLuSTQrFBQ7SxEjxRRBjFaEADyoCWHpmhVDuaBVZSvpP9oG8KHTDFyyvzBHUwknVambbHhOF4Fk7Rba6DwzAkyG6wze0QxEHMUCA8mlAIgdGdngNmU06lXg/czURQVRQ8Fkn8WwFhwAh82SZgQtspRJ4BgiB0gvDJRADEgSCE3U4Q3wgEACAcXyJEQNdVXMhdnEQgkadA0LNVDDkJxckB2Y1IGi1kRlgF2UJkBhCcwwoQ/8GN2AcFNIVQ8EI9oZ/g5cR+tMtQgIAO+IP9mQW61RJE7J9tUFFUNEDuDJ5CCNhQENgDIgaXjUAculu+oAIA9EAb/FNHTJbskYSERcFBgcGqdUQn9JqvGWIcjMIbBEAhnCBECEIAiCAZBMDvTaIj8sQXQAAoLMTatd3zTYQOugkPMtFCqBRRAB6gBAEPmIMOeB4IjEGp2AoUaCH2NQUzvCKlZUZn2NdQfAs9MYIVql9EdIC1SQQtcIACDgURgGFiCGBDNNJHGNjLvCH17ZgTuYX/5CFIHNXSVZc3fqMbyEKpKRbFScQXiELBCQIZINyeFUIAvMEoIKIiMuKdBQAEBP9AnkHACk5AZIyCKEAE81EIR13TKJKiGmUGkPyI0dVO29zfBJiBC4TNFLCAEgBDAxjApi3EZxBFbllMi5wKJ6Tfv8zJlEnEKZiCgDEDC2wbUbhhWjij5H0EUnTLXcGJLtGQliWYCKDCb92CHm7jURUQhg0lhmXAhVlUR4BCFwBbJ0jC7uFei5mjO8IjIgqCPlricAQAGUBEInwgpEgEF4iBs0FgTBAJI7nN6AkFCCRAoCma2NQWGZkRBfiAElzhtrmKuiieGSWDDegAP5QBD2AeCMBAzDGGAfhHAshkW5nBueFLTu0OKrTFHYpAKlzCTyWYHfHULTRRhL0AeZGB2H3/hGZRlNepYBds4vAJ3xfw49kVgij4WiQuxxcIAmoqhBtEwO1lVUSIAXVYh0fphC50S8zoRCwxg8kdwlBsDy2Yz9+dAw8Uwww1iWoAGDWKhzVKBgAkwiPMoUR4Qh20QSoABgn4TjCoggjswgP0AAmkQjD8JE9gwGS5mkrEIXemBTDlxW89ZkXQXgT4ASv8UDwcH1AVEDNFxDkWnChcYkyQnT3G5nB0wT9CRCgsls9IBAnEXV6YCfXVBBtyJGLEEmiAHAjIAxDoT2KUwiByWm/pzHVGxg8UUAhAhCoEQxuo3l6kgnAthD59Z15owC20p0Tc5EpIWDmOSSmwwg8gRjD4/48GXMI/CWlFeCAIjsA7jNcSNIEk0JmCRgQ6yMKqhaZSMmVaKJw9dsJydMJWcmWYVShEINEWIIzcgYTBiICGKgSzjSUO5gS1pRZo2F1GpsW/NV+C8aReBINkihqMNMMPYcMt5AWotcElIJZE9NJE1MEtAAYAtEFy6adHJAIiySdISMMP1WBBjdhE2JDOtMFlFlSpndoXBMBSksE/fAPY6VqvAVuWNqJEkCkESIJp1iZPhKZCmOB40GZE3GZubpRCIJEYoIQINGtBRkS0bEdBUitoZctsdYsNABIicWBeARMe3YJ5gsiVSSocdhlI1MElxAMiXYCmuidNeEIw3JAIPP9AAHEqQGVXRHhncV2CX9UoABDAD70AANyCpq5qRTwDjC6EHeFRKphrRMgCK1DcI/iBcw2BKMQaGRwcg97jQtgaPAobIMTBIopdxz5cgjoRhEqEHzSUAi1EKO5gh4hJwkAEFZCAsmrLnr5EKSBSgd6UKtwCqN1NvlhZHiHsJOGrd+5CjWKEBjyAA/jsYqjCJfxWD/jOv2at1mYtu5KXAzhACvwAMowt2f4ANJxtMNSBwv7QdwIWeGhApgoXwvZsATWDvvjOMHVEIYgZRY1DxB1SDmSDsI0CPi4Er5rpRExAJ4TswwkbBMQB4tJRJ0CcRFTCzx5PRMSsKBrRptBpRID/ScK0CXVUp0JoYBRcbuFAKUQEwx0+7EeoQk/Ca04UbR3sQqO+7QO0QTBowUKYLqhmU2ZurfD6FTQI7A9VwjyIw4UR5VDy4VE511A6AA6EAPWKLTigQBLsAyIhAwBFK0SQgWcWEApYQwbgQD8IwgpGLkQI6wgQK0hMQKzFID4JAmteVxR4K+ZmLkF21MxqykRowaFdK3uoLpxYIENhQrK2B32y6VtYmc7sgux2BOziYQTXRdXy1I0e7EQcaVBGQAaQqnxhQMM8AiYc1CZkgKIW0DyQQVR+hIYl0jdClIUtL4a98D48VyhIV1SRWEQ4AyK9wDcAnyTUL080KNltUxe0/zBEtKwj6cS0TkuIAACHbAfvYouD5KSKuEElIMOYHVQlhEKRsgcWY0ooZEA6KET/1CuiRgTTVeod7kJN2BBg5K4IIG1E3FsEhFnsbSAGhMImeDAIS8QjyEICnwgBvUDTuUEoVEIEsAICK0QIFNASzICAfoSEBZFK/GESVJeFSRR4NRcYOMGJhZcoEDFcQKIksi8NTS5FWC416cScCga1jMCd5mx5jHF7PMJByUIPaJgiKTIjO/Lt4RsGqgQB5y8lJYLxPsNaqOpHtB5uUkTqrd5KAJP/kMCPjjEmZFgG4C9RDdJ1tSwgT8QMbqBKBIAK/FAOxCYJe3Eo1AGu+SogPP8cPaiAVQqCP5ryRIwm6npEOreZKk/AVO7aPEOAPOgr6a4E/U4Ev+FvjUVIi8YxoWGElVhsBhSSCERtFPzuCLRzBHyxjNHt6a4ELvvRd7bBA4iumwwWSweWX2EDIoUANqiEBRbzRKxFHy2wRKDCHe3FLkgqNFTCJkCDRGBABnz0lGbWMbGeLDByBiT1CHwzIJ4zDpBXOYRCDuDAEYTDDMzzyMZZIbDmCIJmxqJvPlcEURHSSjDXC2TdG7yZVY6sItJZaAYAIuVAQrtEElOELPhZe0G0eaDqYR1qFptaNAVtdYCDNLCnQy1yI2/zD2FyE+OgKtQBjTZqm8BtKkDqTvH/EL8iF2hbdhuIgfEKFB8+l3TxcEQ4r2RXxKeFmnIt6YWyp+w+E9stHSYwcig49EsMMgE5sjMhEkg8QnUdVVzHAVjrsySqmO7x3gSUNT6XskLo2kJknUcItCjY6gUUEBMgd8kCq0QIwihHgRCocl53xARQ7kQc219f8XgIdg7hYF8dbS4fFKr1U35uRBvgkB0vRDtzI8CAJ6FxVaZqah1EcEmr3SE570h39EP5wYROlFMZ5WgWEEgYbR1vhB35jga0AcTa7w+N2CEJIk/4dlBWlwz7J4b9kHNVNSIpN0V0gYDKuEQ89yiY9RusINY95fBNpa8aolzPWSF0QRNQsksE/9JGn7dLAAKMS1w0WZegAXZkwLe5Fm3slofFhoIz7DcJQLB8ozGTOmlFHNUXl0LbWTN4HAFffXhHoICI+RLr+XGYDbLUApQbeNdRheC+6oXvXK1lfgTfRrbtva9qwjgbHxWGWdiI8TCLAZ/2/pBi2HhcQwAZqKA+JqKc2ZlEGLHZKbliSIISR6ypFVAgR/Ts7oQIoOhbUDlJqEJ6wjlkuMEmgEES/NYD7JLqApPvMLZEMHgpLDJDhYKZj4Ad5QUA+NSLRkGMNlNj9fMIJMI2e7CMMVcUpOhHMPg4H89eUZLp2vRHOOWd5VmoV4SERUBFgAI6CsIQB8B2FxAOOKhi3P9qJxQCeHcEKuOeeXs6T6R3R1yyFbu3TkRyFBDACLD6S0wzBe6EQz8CGDQDDuCRM6+EHeGQua4tQ2nXryvsEoQAOGDBT6ZwIqlEoJs7REidc0H1QvDhbdP0D1FdqUXAbv/14GBAyx6Vs3eE7rGjSmigt49dCoJd5AaADzQWO8A7YuR8p+u7lQBCviuEAQecqeeTFSczIv0ANrO5SwQDCWjAGseENVRUClwCqSk7qNVpRFC3QtD4TjOpl3NxAa0amk/KrxNQmYt0FAgVSPznD3HgIINZKCQrfEaAtT9zRUVzUuHbJgz6pA4yCnTEr//xB++xAZEEKCyuIfaqll73BxD/UAQ4Q/12Qhc8buEKsh+EMU+AO1QqfZxIQiVHxB9SXNTTRHT0wIhFByoU10mDJzjgQAog0j6UfiEnlVCb/mtDLIq+hN5HQQ5swjMgg+t2BNnpGo9TxCXgbaqDQQgUu08jbSLM/VFlwDfytut/6n9+8GK0sUSUwlFXwlJrV2PxNrQfdXo59ES1tlS+tVWSbAAAn7oDRBcyEADFeRNgwgiFCyWR+eLmAxlJEyQJAiQK1EKNGzl29Pix44QvC78kBHkSZUqVK1m2dPkSZkhBH8FEsRnFzUYRMXly3Lnxmc0QAABoEHGURFFkIQgE3cSq5k0wocBEiAImg59SGDpWshkh/9FHT216pFKlMIdNJy1vRmkW45KnlBNGQbArqEunkR9V7RJR9m+quCj9tN0EBjGYTW2jVEpctW0lWWF7nizkUGGAmRsTYWIVhRWmsKFuslL4yHNjWY84FppxjRUGzSQLvRkFCEIcSQgVfiHTZYTAvRM6vYmDm8yoN50yCgRFxqKgiZWpV7d+HXt27SkBdfKYoS1rjT+3rySvsNTNZlXq1HlUyo/iq6z85FRY+KafhYncyKJqtRL6tsKgLUxOUiUVEdpwpi2uPuLPDT/iawuMRVIqJA5BbIOgiwlEGWiUADLySARU2jgPpfTyA8mNFlsE76aICilvIeECgCCAB2WpJP+CDBa7aUfQRAPJRg5tw0033jjqAjiFmPSokAAkyTA3uzj0jsYstdySyy5ZkqRJjjC5aROfvPwIRdJKqykCMPzAxEGO3GhLFhYxie9HqUpx0Q3KNlIFgB/a0m8EDNy4MwMwvGpsKj/UtAkMlAI47o0vnPtNIVACqIsMUUwaTyEUT3qkwZXmtCmF5LT8ohBAcMsRpUfwuymDUvw8iQzcIPhNlBm1+6ITgjA7k9hijT02pgk268qmUsxENtSNorIpgz5TSsQqm8RLadarHpvWpsMSW8KwcMGgT5YWOUqEQpACcBXWhkbyTRKNgO3CIkl8DaAJhdoIANaU1IxUpS8CiCf/iheagE4Qg/T6yFeFIvaIOOOQFAQCDfdCibGC39BVkI3L8w044aA9GeWUiyUDy47c2BbUk1EE1z6VxowiFJZutolQjwx18TNaYT4pzzo5+uLjOAIeQSSSPt2oEEkAwauuHG9cGiVMJkPJw4Hi8PTVETSdkiDlCtm4EBydJGMjVkXpIg6CHE7o6i7s6mJEkKaNACVQ7B7F7gBMpvFJJ8NUGfHEFa/sbZdELRbFbuNU6ZHJUyLwJmdVOtUmo1VSEay232h4Ypi6vhuCN7DrpIup85r3t6s3mkDKuAExu26HKj4uty56FXmEYGHFt6I4Wu5o1gxA6iRDSUARfu3FpZ+e//rEQVnWPJRR5LzMLaPqXiVsbxoaJWv8EE8vvzl8mjpQ6hIE4zi6eKOQvDlqurdPQRGF0zfYx3QENzre7N42ECsNpCDLYd/RjjejL4gCXsBTSCK8EgHyjcBgrhLFXoClkdJVD4QhFGF5WNaSxxHrPJe5hk3ugb3yJCIDsWnJzXLWEgDeCDd4086NAue2KWEsOQpkCGboRREQiQhKGnlYSnLFIQnGZFLSsd9CrLURUIxOaSPU4ha5SKPGseSEZ0KRQN7xBLVRr3IvIdmNNLYd2cnOXoUQhcV2pRxAkOE5GQOEJAZonSJhrTITsFsXPgi1QS6wi4lU5CJVAgoIPBFN2v9b0l34mKVKMQSR2hGFXS5ZHoAt5JOWCQAdO5XJ6lxmL7PJzhUbFgBUZkYQUXzDFBlZS1veUiFkACRIwuglUeEwaq7rY3VMNriUdHIE02lNlN5gHN7ZBRCHS5xv7gjJRL4LOQaD5i5x2U1vbpF/YJSkRnI3EooIMztkSA4EJNFMd74Tns0UBBmaWZd2OlNXBTHIQQoRJRyRbHEANeYtMUSQ3BTymwlVKPUcac1nQes80AsO2xayP+jkJSasOtKu7HLPeH7Une+jpztdiVCFxLI3ZDDpsd4QpsJ58w0EcehCaVrTk+kyezKzVwM7YlEIhMic9erN4Z5nnPjtZkYCGaj/SnBDS5vaspxPlepUj7WpnEI0Jj4dBQSB4xtdkq1hQtRIMYelEqWWlaqLlKhA0tpWt47skSrpJUuuYBQRYGEjWOjBUfDakbmmZH912RVubkc/py4EmcpMCVln+tbpdXAhK3XsZCmLkhDJtToPeMAIuCCCD2hEDHilQg9IZJ0HynRLiTVlZVnbWtfW0qop+atKesCFUFWhI1wgrV9N+xsAvha4wRXucEkSV5TMVra4HcFdOXIFEtiWt9QBKECJW13rXpeqW5VtdWp7241ooQd9VQgAjlLe6lCEJNLE7nrZ295rUvQkyEWJZjnr2SuIALdUIIEWeOle//4XwLb8wySy/6CJOaDkCxA4bMwqU1e+juC+uCVBeZn70ABfGMNttUAerPCHhFrBC404wyS8cOCTaDe+48zwilm80D94gRBWQEMWWJKHLGQhD9ObQxoMsZBJaEJS8I2kTltcZCPbMsQKmYMecpySLOjhD3/QA40X9wc0aEIPabDAGagMki8IYsHRIvKRyVzmnszhDD3O0hn0MIIzWMEKk9DDGeh8Bgt4xMomngMaPKwlQ5zBxB8xRB4IgYY0pMEKZ9BEFhoxicWKIsVjNvOkKY0SK6QhC2jQg5q1YwFNeCENetBEnL1w4xuD+tBpKPWN0YAGOHc4xlkyhB5mjGiOvJnEaJhEHnqsB/9CjGDPXujzSToh5OhitdLJvrAh4MzplLxYzYRo83Xm8IdCe4HEVlAykz+yZTpj+dVZ8EKpNdEIZ3dkDo2wQiMCjRJfK8QQwq72okNNiEbcWSOzrnWJVQLm/kpa2QFfL4g18Wltq2QSjdAIGs7dbQ4PO982DrUV1PziGM9YJRZI8gga4YUz/MEKmcZ0uc9tgRmHHA34Pokh0KAQCzQiC4fOQofb3ZE/z2HmZoX0kJEtcJ9bN95qDrpH/gxyKxDCC1lWtbgJkYc0g8TiMqZyupGOBnvXfAQb7jBLXqwHPQh7I2iOs6Gz0PQR/1ohhHD0QtBMZw5bYdFfBzW2pf0SC2j/OSWdAMS/e/5zv8fk5t+EO9sn0XQ4s/rQM565FQithwMPGtGEEPmq4UxnhWx8DqXOMo4bXh3Ln0Tscq433DePakzfOMaVP0Mahv1jmCy636aUL41m/3fbw5vWMT84LuOM5UN7wepw/sPT0Y3tM3R89y4/PtyfnOqZkxj4EFcZ69/+hzTY2dIhHjG/X5J56XukC0I9NrJqf/u/v3sE8f4+4j4PknkrfRJ/mMPQVTKHRcdfJWfgM+Mt8IcuJ67wFkLtVmLACgzrWKIR0OAAN0LveI782mvLVO7vCtDAaszQ0KDJUILlNKLRtMTGcIzrku7rvu/lCg3TEm0ECM7gtATz/7htcUxu5jJNArsk51BCEDKp/LQjB91qDkhM3CZhARUpDy4wAxcHxESMxIJwI/LA49zMC4rw1t4M6cQt1ORMCSvjyaJsyjJu4zruzkqQ7FBwI5iN4rYk6jBOx9SN3YzFEPDuIygi/DBIdRjsAbELyw5syYAMl5jwDJwQCrdD69bPI3aM01wvJdCgDxVC/7Lu45gv5kKt7C4tDywAzYAvDazu3txPDa9wIfJMyfgsJQhtIWaN1rCN1xAnEO3w/45GnQCBuhZiB7EjFtPKC+6sEf5A47oJERdiEVmi/VTiDFfxIxphzl6t0F4NGZMRzhANziTP+RaPzmruCLfvwHAN+P92reROTgZT4uiMLuRmTvJMTRwRL9VUTdc6z/y6D+w+wjcIQr1m0TrgcarSIAFbLea6KQ1GYMAuMQ1GDfugTgTXMSVasMm87e1uTOlArcAOTw+U0SFlbBLgjMNaDhgJrALHMA8mAQ2wDQUDMO3WbiG2DOTi7vcWEiIZr85Sss4MwROBDRTTsToS8CQcae8s7Fjk0abm4NJ2EedszZburtUmcQiPjgqnDCVVTuMUjuNqEfTOYAjfTiNND/WEr/3QT/1Ugg/9MDvA8NA0AdD6L/JE7vRUL+u6kCmdDMqkTBhhkidqsCNI5rdgUcWEywKQbtcQ7c3SwMZ2MZHSTdzErQ//z+AJN6IRJQ/U9GASCAzQgK3AnBLOFu3UnC/LUk/dHC8l9E33LPAS/xA7dkzaVC3LUBIdFaLrRrDGbowz2RLwzrJtMOUVxazvXqsu04AQ8M0QJI8Q1KzjJmEGQeg2k24Nh3AzUQLNYK7WEm/GUi/R6GwGCZIlAm96PHIEBnAlflE1kUUTQFIj0GuodGIuR0A4MZBLyHA0ia7ZsIPLvEATepMj5gDpku9krFPJ8uDr1rMyWnLPBJEjgvGbYBDl2PM6QSjzElGcJC0rBTM1r0MFvQA+QWJBGxQm/I9BOVEj2GzOTqY0BdLa0iDhriML1ZIlUjGh0m3dKDRAF0cmTWgu//nSzSiyPOiP/lbOC4RuRjNuEg6NNxeiHpXyJZiQEEy008zyzVrNCgC0Jz4wQU9USVXCLTFL0vJxOkXNDbcD7hzTCozyIZHxyZDR1wj0I/bsR90z5WRMD3g0JnpwMItFFBUiAWnTS5cUThMn3ox0/G5y4foQzUjsEpuuPIGN+E7i5TThAlMPS7OUIZGx1ZRO8SQyGjmuy/YM0960J/QvC9RMRGkE7v7g04wyTjtVerKzQBvMrsRLIzSAChzwQAdz0KJy5iT10jJt09rzzcSt1NatRtPvVmWURjmt6JrxxlJtxjSBEC5RD7OD4Dru4tbyI0BuEjWQ0AytIQ0hPz2VWv8RZ0Cvqifoq7M+ayGq4ChOtbQ0Ijz/sAQ3TxPkD9rSbtqc0gQLLBMX4kFXIl5TIgHfrEgZrTwsIObWbsmSVCMy7egEku1m9RJ3jcvScgurVWFRJkW3izq6a7mUSyMAAFzrdCWqLeRkztxeDtP21OlAgjxbImTrz+rmQEyB9CX0b8buzP9C0TKXEt4a4TMLDBeXEDUXFmdPpiGdtDLwK1RIdbwq1iZhwtegL9PyAGW7xAJulEPplDrYTCdTbdWm8tWcjs52VhGTbtwiUlJz1mvZjzX5ricg1mc3gmInlsJwElThLQ2SdqFa0Cvr7O189dRMLzSd9mvz9mSoM9IqQ1v/7atsR+Bsw/XMjA/5XIs/XdbEOk5vG1fHmrBve8LBmCvCRsBbkYJwz+z+9POtLtXJXA3pONdxR9dYhvC4vvM6mRVvSZd1vQRrHdBOW1d2Zzc7BJNOcbJnaVd3d7cnCAHtMjd2eVd4h5c4+VE8vRPgiFd5lzcPLlEr6TB4l1d6iRcRua0X5TJ5p1d7ZzcfBfPAoBR7Y3N7x5d1d7HDrhc265B815d0UxUKcbcn4Jd95/f2xnVoIYd+81d35Tcm+Fd//9f8/PclBBiAC9jnCFhFDViBvRaBQ3WBH5haGxhbIZiCl1SCebaCMzhAL9hhNdiD2ZKDT/eDRziAUZeET1jZ/0I4clGYhStNhcW2hWO4zF4YdmXYhluMhoH3hncYwy54coE2fHlYiAPsgv+WW5F3iJPYvy6YbCUWepUYiq3rgsu2wsgrba8Yi7NYi7eYi7vYi78YjMNYjMeYjMvYjM8YjdNYjdeYjdvYjd8YjuNYjsVYS5rYYkV4gPMYJnYwFnOwj/UYkB3YcQY5kAV5gg8ZgxE5kRfZkBm5gxX5kR35Ooz4jle4kfGYkDNZkyEZkznZkiM5gS+5kz25hiX5k0eZlCvZlGE4lZF4k0E5O35Yh1F5lWe5lm0Zlmk5l095l1lZlEu5l305mIFZl4V5mFX5mJHZmIm5mHHZl165lV05lP+nmZpv2ZmZmZeXuZmVGZu7+Zq9mZvD+ZvFeZzJWZqT2ZzTN3qtOZ3V+Ze1GZ7bOYij+X63OZ7PmZ3xGZ312Z7reZ/nuZrz+Yn7uZ1zuCPawCUQGiYUuiUYOqEXOiYceiUkmiUoOiUsWiUw+iQ0+qIf+iU4GiRA+iNE2iNI+qA/OqJROqVV2qMreqVdOopjWqZnmqZr2qZvWmXEACn4y3LtCiS0wK62QCEm7CgA4CN0WgT2q1tFQGjzaq+Y6wOeWgOuACT06sGA+iiEGiSQWqkVQgyMeqt3GsJG9SQ6q1snLLzKmjyo4CjSGiTMGsLSlqqPGqwVYgu+9SS+eiGIWgT/6rojrqAHnNi5/JojTFUhovooplqtF4KreRokDJuxCdsjAFu5ZBkl2FoENMCxL7utgbiqKYwEWGK0+pol7tq8WmKwW+JySVslPsCKNeCIVQKyV6IK9qqrq+cB+Iu+7kurq1oMRkALRIC/SMCzNyK3R4C+gHuvmhq0RGu3FkIDfvuonXsEsOC3g3uzOeK4k7uoT2K7N4uSPcKKF6IHTtVbY9tsj+KwRcC2xCC0P2K8N0K/eIm1R2ALbhtN6pu4OTtwP8AoJFshLpe5oxsk4hu5dXuzPkLAYbG+PwKzlSu8PwK7R4AKNKC12XsE3BsmHqC3UQILKqy0O5wl/LvB6Qpi/1HiCgDgAz6ABJhbwfGaJco7wy18hMRgs/R6JT5AuEeAqBU7rzcLsLGgxVFCtzSCxYt7I4p8IXQ8uz3CxheCCgC8I57cjl98vcH1xDvCW/f6AT6AChLcyo3crR0crHXciUEiyvc6secaTSRWA7ZgC6Q8aDfiyE9iyzfiyU9icBUizZNLIar8IzqLv4IbvT+CBLr8y1/CW9kcJWa7tJHizBsdzuX8JIKb0WXbxQs80z2C0C3XoGGitqkaAKT60jsCAKT7sDUAzD0i1J3rVIccJJwLuuy7xCf7uSYW1UEi1KGc0ru1B6iaipHc06G8rTE8zClcAwCABCJ9I+6csWkczf/B2lufetP5nLD9e9X9SrmIwr4pfc9pvdeHXSN2Xc+Fts+PS7mCfb6KvdA9osKVndkbPdeP66nDvSO24LlTgtvj/CUmrNrdHdpX4ttR4s4XPYSEnKcfAFzfHCT8W8QpnNIRvrrTdtPBC4g5vNLH3OFTQuJ53cO7GtC1XFQmPMw7/bx1/Twq9yT6PLgVorNKXSPO3eN5Cbfui8LkfOCR++Gb/Tw6vtxj3t4j9s+hK3AvO99/2rM8vd2rugeW3iMCG8LGnLbly+bLK+jpfL9XYgtg2yVyHuk/y9mppyiOuMI/i8BZfcyrQMX9e9PHniNgvSP0y7GxIMFVHc1vu7aFfSH/3B7o9ZzrFSLCRX4j6qrX7zy4bevDnV7cAd/ezz2ttzXaA3ztHV3bN4Lf4Rtc6V4h7B7l9/7vUeLbZZ7mAX+zID8lavvfF+LwJ17xOYLFU9+4hRqwZ73R+evyW+L2VWILThWwYX+sd17ffZ+8T1UMAl56qv4oqPoBitrpTTurJ1fFJ1uu93rT+fqusDqzYV7NywsLnF8EgD+uKQzYy0v7kV8ErsCyxZv7J14EurzA1x+zpZ4jrJi5vLXJfYL8LRethV38AeKKBhEiAHwYgTBhQioERWxRuAWAQoVVGpIYoWWgCA1XJk4E0BDLlYYEO3pEWJHgxREkTZ4cwZDgQ4EE/7G8nLiFIJWbJ2P2sMnTIxUSB4NOpClCjFGFDwhq0LLUY8SoCbGQIPiAKhaSK5emFNHVaw+wUKmaPYs2rdq1bNu6fQs3rty5dOvavYs3r969fPv6/Qs4sODBhAsbPow4seLFjBs7fgw5suTJlCtbvow5s+bNnDt7/gw6tOjRpEubPo06terVrFu7fg07tuzZtGvbvo07t+7dvHv7/g08uPDhxIsbP448ufLlzJs7fw49uvTp1Ktbv449u/btowfuNApSBJe4HwiWReud55UeJFy2Tc+Ty0bu9OsHlk9yoxYRPdzC57mVRHKVJ8J5RokhQlYj/HfSQOPBxeBLCH5nX/+FFuLl4FwRnoSgUgOaRxWCCm6YUEUCQigChTd9wN6FLr4YV4YY8QfTRiBpwMWNHX3QlE4TDfTAVQZhFB4JXOBHoxbhPTUCggCA9IGSKj2YUEb8gWgVQQB0pJF+MRHEBZADaVDUQiIAxZBEAY6wVVZZFtSRlGCN590HV433ZX8I5VQFjH7+eZaM+/XHkAYj5GRoUzuB1OdVfSY0kFIgUWEnUYM2meAILBa4Xg8fINhQpVHSqJCjBGphYo0n1niRiAhFumCKHxWI0KUg9ZcTFqmmKeql3k1ao6ETMaQioMYeq5CgNDKUlasijpSfiumluVV+Wri61UoDYeEqm/nRipD/fBedmhNJ/WERHo3dpteUh5CKUKajPYBklaflNvTTt1aOJWC1GohxHrHIDjywsoRm6myC0LqXrKzUgjURthDHym2m3oalkLiampfTQyXyp4V8/a0ra7uznuekCFXMW9ChDimU7Y/4mkTFvTTLSnDOfxpcY7MIZwokQg9QGetOdY610xUGubqpFp1+avGmSQ+JUNPQhgzyCFwMvWzXArKb1LBnfkxjjzuJDNXWUo+g9AeRIigsQgvvqbLOdr/IM7OY+pzVB/du2fBYYRPZEN+1LglVt4RjNZG/WHa5qFM0IhVmyYN/rCBCV7lZEkJYQL440LJeRQWoYAHFIsZ3r876VWwy+jVh67LP/tp67fklX9y07857777/Dnzwwg9PfPHGH4988sovz3zzzj8PffTST0999dZfj3322m/Pfffefw9++OKPT3755p+Pfvrqr89+++4jFxAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Proportion of cohort reporting severe to moderate Edmonton Symptom Assessment System (ESAS) scores (ie, 4 to 10) over time. Number of assessments is the maximum number available among all nine symptoms. Missing ESAS values for a given symptom were not included when calculating the proportion.",
"    </div>",
"    <div class=\"reference\">",
"     From: Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35537=[""].join("\n");
var outline_f34_45_35537=null;
var title_f34_45_35538="Lipoma trunk";
var content_f34_45_35538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple lipomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 367px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFvAVADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0ZrZyUdicdfl7ipQwYZd8Y9OKhMu9chiB2B70q7JJED4cqf4RXKz1tWtSwjeYwCjBzzx2pREUJ2MQRx/kVIQpI2nn64oLYYMxODkfQe9BN+xSjSW5EkgxtDFT2yB2pZ7SBWikcOwByTkgAVMqlchGKxN296fKHwpOCgGD7/hTSvuap66DYHgiuWiiRQeWAA9asWy+WrRhcjkqfX1FUbQRJc5uV+cZVOeuPSrsiLJu2zSZBBXnG1sZ/wDrVVrClpoRW0qRzzQgF/l3R5GMDHINZkYVNReSbDJchY5s8BSB8o9u9T75JZpjald2AQDyDkcj61Fp8Ut5aXccZjHnOW3MM4x1x9MU077j5epmzRQxTSmE5nScpHIoyR0wB9c965LX457Pw/dCeNo7yEtKk8QIKlTnH6YroLWCaz1iRYrpmXHClf4scqCe47e1al4gubYxOhMkihCkzY3jpuHrSUtzbbc8pvpbTXrey1WBt/nh1YT8FDjkMD3zXG31vJaQKttNHMGI+RQfXnpwevWvU9b0+DTpULRotgx2TQiIHaR6kdOPzrEv/ANvcrFdWcyiGVtqqrNhPrjoKqz3N41VKNmeZNrE/wBpa0Ym3ljIYuMEMewP4dqqac9zql7Ifmd5OhI+ZiO3sK9cj+FciRyzSrbCFfmZh2H4nrUD+GxZ3JS0gKeWVbzZeEIb0x1x1okpb2CMU9XLY5nT9OjgjjjlDTSkjeUGcdwo/qa9E8GaMkLyXl0A8gBxChyB6AVPHoTWF3am7nikgkBOyFPlQjux9D611Gmq/wBtlSTyo+hRY+m3HYVPLrqTVqrkagZmrrKttBIX8slhuwmdh5+Yj8cVyLPeaVfeYLeS4iY+ZHKsgKgfxKRwc9wfwrrdeC26IwlZImk2O/38Mc9x0FZOr+HvtNltnltpF4IBy349etTOzdjzZq+q3MlNc0yaS4doL64uUw7zCBsY6YOcAY9O3Wk1L+1DAEskhkMxztkX54U6k5B+YdPzrDl0aTW5Wjs7+6h1C1fdgrhVB/vDo3A/GtJtP1a1cQy3KvOyFswoUZ1z91Tn5anRMzs5dDW0VYYEtPPl+1T79rSyKO4P4Y+la91YxLG7x/uHIyNvRu/TpXOeHp/tupi1SN4RbwEGF2yytu4Hv0Jz71u6hP5czQssgtyMZVc7fals9R6NGG2k+bZGWS5uJI5PmMG/ChWOcHHU0+822FmwRGeJV2ld3zJ+fWs7U57tovs9hJKsyMQZnjBRVz0yOvsDWTcWct6Yr7ULlhEhy0KDaXU9z34PahLuYS8itbRq2oXRspFYsTJGjZBU9enoaqyrKYZXvLZwQDIXVt3b7ufark8EKXE728r28KOojUph06AkZ5K+tWZXO42t2nJGAy5IYdvp1qrmElbQyrK1K20LQjCMo2nqD6kVMdNEbRsdpZgSABzjPT+tXreBoI1hBOxfbmp4IyJRI8wc56Y4FUmZOJTlj2SwBQVDD5h6H0pl3eR2soVgzXDLhAOrfh/XtV542RlZny2Ty3GB1x+VQLFHLIJCR8pyueuPSi4zmdRimWOaa5ZzIj7QqDeI1boMjv1rckV9RRp/sjMhAjM74AQfwsB1OP6mteK2U7JCgdJHVWXgZ61ri0Ty3/s/auEw0bcq4I7Dt3pX0Gkc/pM8mhQRAKJYrhmhYbhuEg4AJ7jHQ12Mb3U1vBlERmUZLdPpXHvYTSxataQSO03ykuQCQxXK49CMVpLc6jpmkWSywfaI4Y/38nmYK4A5HrUy1NqaaOqtERvLjRmjA+8oPFXxjJAUbRgntn0rOs5UdRLC2QyjGP4v8aiu7poIGVMu5zj6VjbU64q+5clVJUQY53j+dE0anLLkBeufSqlnJK8ETSKY2A5PXNT7wQQ2SoGSKTKaabMy5ilgk82HJUj54x6eo96pfaojK5L444RlwQa25WJjbucdKxpwZLghVDFVwSOxJ6VUe5z1FY9SUKSZArhc4x71YjdEAZgAc88YqgyurKp+Ud+ev0q5Gdwy20Y+7z1NbXudrJwo8tvlwQexp0XWRwhJbjGcgVRuZCuwMz88jbViN2VflycnOF7fWmOztcuBMRDLbR1wPShCqtwPl7+g96QE4wuMYwTTARGq4JII6daZMbsUtAJyrbmkI6gcYqFiquC0Ksp6hfXtU8W4OWC5BH44/wAalCBVYctngZPSnuO7RTtUn8qZXjRMyF+O4OOBU76bJFblLeRYzt9f4qmX95CrqQM4wR61KiZPzgH1GepoXcq5hQzPHdiG/tcyyg5KkESYHVfQjFJqGlvfaeDbzMLiI70MnEiEHPBPtWxeWsOowBJDtw2Qy8cjoaihtpvs8Za5Mj/dzgdRxzVFNp67M881bXGsNRH9sWbBHUL5iL8knPVweQemD+FSaJqkaXU8dkJGtJl5jjj34J64U8r+Ndpd25ug8WoabJIuCElQrk++M8CuXs9Jk07V95Z4fNBWPeNrL6845GOx6UXtqNLSxNodxb38Nza6xdSKYXKGOePyyy9iRTJo00pLh7GXZZu5HmtKHMY6YIPb0rQubRb2e4ubjy1Uny4pQmMlR/Fj3zz7VEWR4bm11C0idUj3SOqAg5HykH0PPXvQ5Ct1MnRdc0uPU7i2upVuSE3W4hXPmDOGIHYdOPrVaTUodM19bhluI7OTMbs4x5eRlfqKpanajQ7611vRLMyfZlxOEGRKjYDLjtggfjWxHrVvqsLahBDG20hlhYEcHjaQe/UVHNfRmTi07XNLVwt5Z5imtZYZBgkIAx/EE4NZNo1s2+3e3dnB2xsJM7l927GoZbGCSQ3dkjWjsQTBCMjJHfNYWqx6zpmofaCieRJySq7SGA4yecj16VnIai4q7NmGwuLO5uLuAqvmyBWhdt2xQMAds+v40X07xWxukTcYAdyIRk9+M9aSx1sXNiZriKIzSFVI3jrx0z60+9SKWSERxqPMDNJ/dK8Hj86i+oOOlkZehxIl0Zp0kWdosmRzljkk4yK39oMAHmbs85zyfxp26Nof3cLDZ8oQVnXVoLlROriOVRnbH3PcN60nd6iasrIrRW0cVxdNbAKWIJXsTjnP6VSliiltpwyr8uSu0fMo7/1q+8WVSS1Qb3+baXKgiq8on/5bRRAdB8/P0JIppmElrqc7dQ7o4pBGXEXzqXOSB3Gfcc1IbRnit52Ul9uAAex9a1rvZPavEwkifBA5x7delVVhuI0VZJMqyjAK4PHHBp3MJR1Kt2Axj3Kd2D93ufrVAB1nyPk3A5GOfpWq0nmhljUhhwVPDKaztRQ7WKdQu0nHI9T+VWjJqysUppla5YM7HjAyOPenWZUMuz7m7H07c1kyTvHiP767Rgnr7GrNqzMCIwBvIGCOvPApvYlXudhDbqbJg4yAN3PfBzStdw21yJFPbkAe3HTqKS2mAgjTJZ2OF5zz/hWiLBWtIok3B4wAjEY2kev+FRsaxg2Z1tGP309uylzMzt7gjof6VPbXEV3Zur4wQQMgHINVdIeOOa7tZnEE28iSHIyMjggnqCOlZ1rKtvdx23Bik3Jgc7XzyM/hmhjjo7G3pe3TVYrGzR7SVK84PpitO2WOS2i3nEoXcTis+0kO6SNQMIR1PQ46U8gy7zyCMhWU85qGjaMi9K+VVGZgFbAI708BVG1PqxzmqUMpSNTccSEDKipPM+YYBxnkdMilYtssTossZBLDk8jg1luWiLLGoVVORu71emIZflJw3J55FQTRqyhAWJbv61UTOSueiruK7eD2x3NOjVs5yFOfSpRGVZcYVu/erCWiyFWC8jg9a0sdTkkVXtyQHYjPb2pXVlJZeeRwBmrxh3Pt+YADnHeiS3UDjJPqOtMSqdys2M9GPHQdamj+SPAB4HUHP506NVQjceemcdv8akRIy2Ywc8dKdyk+hBEZMtk4IA4NWuibnDE4wMDigqkjEnCyDjAHX6U54WLAOG5AHWmDae5BaAmI+XwQ5U+owTVyMSq64UbepPQU2CIRSPhSVzkHNPdjvcFfk6g0Jivd6D0jXDMyDPHXpVQRzw3Ja1UGN/vA5PPqMVejVHhY7sHGSfSntwGRSTgcbRjOOtVuNSsxyKqxK5cEtglm6n/61UNV8oRKxVdkfLIBjjoav7xBbhmjIK/nmsuSGa5aRpSscT5G0NyR2ob7Cjq7mVcafHa6XKAjhPvKVkIwM8AD1rmX0e6/tGJ5bhkjVfKlR2O3bkYyO46V3t0sUqqGcLgduOR0rAmnfVL1vscOBERvcjKnHO33PSol5HRGTZUudOdbF5bYIY0AXy2yVdQ2S2O309q5uPSfIiaUkOEnYLGSVA3EnGfX0z0r0C8aCG3JRvNcjiAHk/h2Nc54dKTpNJeAKwmfbG656HAJ9DxUtW0FHXUq2cVkkEUgkm89RhSg3Mp7ggCi+vL69gaKC2hQDrLcPsyP93HUiteaB/3uPJjDHIZV+YVTt7BWuxtcHZxub1/GpegNX3OSuoZXi5tljkVg25RlRz2wAa09DtgbeFmm82U9WJyCORj2rpriGMQruf8AeHgADGKyr+zEEDNC3ygfMvr7+xpPyJWpCkZidkRgwGVOeuO1U3QQTNlyyPyQBnafXHvWzBbosYkGOQPu8CoL2OSSVYxgxAZbHGam+gWMpNpiI5xkkhe3PpVS72wQOwjeRMEmMEsW9gK244ULAJheMbelQeTHHOcYDnkA8UkzOUOhz8EvmxMksTIu7Chxhl9M8VLMGELsQA+MjP8ADmtW4t1lcs6hg3OahCb4GSRdoBK1WzMXGxy10zFrfduEjvsJA6jHWq2qWrlPLJIHByD1HpXQNHmclguxD8nHOe5rG1Z3FyCEDDuwHArRNnJU30OZvU+aVlUfn0AqfSLZZlSQ4V1OAQcYqhdWiTTyTOsrKTwNxAUVp6RH5bo6/PCMBm3fd5702YQ3OssrQJEhyN3JJ6mtq2kkKA/KRjBVuCCKoWEiLEBk4P3W9fpWnbYEzqchcDg+tYs7YK6MHXLW4muBJFHFC6qcTsN23nIDeo9+1cjrF/dX1pcm0tfK1GEqcKepzjO09vQ16NqaiBTIpzCy4kGeMeoriJWVrp1WZd/m+ZbSg/eQdj9DwR6GtIsznGz0L2g6jDdaebqPducbpA33g3Qg/jWoHUAqo4z9CPeuZ06aO5t42hhMIYs7DPylgema1baZXvWWUFFAAwf4vpSasJSNJpVZQBwegz2p2RG5ffyAR16014wSqjBUr2HWquoTC3kgjbd++O0FVyOnc9qS8ikzRUlADw3Qc+lPMgVj8uSfu+lUfMbKgcYIzzVmKRQRvOeD1FNIo9RzucEtyBkjHSrkDA8R5Oaq3MPn4w7Ic8Yp5uHt8BELZwOOtWdfLzLQtrGowoyD1YZpMOmQPmzzx2oDFmTKZz6VO0LKqHd+XegztZ6lHaZZmJTp93/61TkYwdvA64zQyFZDnBUZOM96mdt8Df3sbSKC2yCKMlvMG4ZHGatMHMR4BOOuf0pkLHzCGPygZ20+4AD8KwkYZyDTuDd2TW43bQcbsYxnOKmY5JwcDGPpVFEwC/0yWyPyqzExyRxtBJyG5FCZLj1IWjaOUbdpyBnd1+tS7HLBmH6kU4Fid4JZcYA7g96lZNzKU3HPGelMdyJ1yAJCAQMAAmlKKxASE46kAbefcmlnMcMbSSMx2jln5/SpI33onYMM46UytUrlW5iikyJEO/kALzn8aiFpHbw7baPyweW75NXFiyMOPm6jBwDillDMAqgBNvNDDma0MG8n8qJhGES5kO1cLyffPtVRrCG1giZA+9VwMclh3yPxq55X+mjzOgTK7u3+cGomEkkjSFGOfccis27s6FZbFQv+4Z1Vyw6krwPoahZyw4Q/NwPl61YaGUkAhVBHKDkfX61XUESsk5LMfbk+1S2UlcgityJHd3LOTkgnIpl4C64RS5BwBkYPvV77KGRiFCtjBZT0PSoBFjAZyQOM45qNgvcyvP8AIYrKkqoG+XI457ZFOO/eWAxxzjofatMIMlQVA79qY8aojLubGflGB/kVIm/Ip+WRgqOW7nj86p3AYZAwzY5rRVThjkkEcDPameQdo2j5u3tQ31Iem5SjQH5m2jHUYwB7n1qtcIysRjBfmtIxMoy4AfGMjpWfPGCHdzu7irTMZpGLcxlIhnG4du1ZF/GZkKtsCdCB6dxW1dYOTtBOMYJ6Vh3KguedozyM8VpE4KtrnPzwLLdhVLGJeML24rW0axCYVQAh5/8A11FBbZuAQMLnJxXRWsIVWI5JOP8A69EmZqOo2G1W1ZZED+V0ZB0BPQ4+tbscO2LLEswHLdTUdqo8vGASOpPerqgEFd30rE6oeZTnijeP7u7cOVPINcR4h0WTek1moSWOTzUXd8hPdT7MOPyrv/LlSUtwyAdhyD6Vl6nAvlbSAd3KjPU1cXYdRJrQ4y9YMqIFNlJIcsrAZJx19CPcU66uXSAyQwxhhgssWdqEdSPTP9avak9vNaKSFd7ZjjPt1H4ii38gWm6EHBBYZPHNWcbuiWO+LJG8ZLZUEcjkGpw6yS7sknqPcVzNlHLZwQXMZ3o2C0fRQB6V0VqI2mdUZPn+YKp6ChotO5NM0alWQnIGcEcfSqkt8Yyv8YzjOPXpUtyHM20qvlnrk/lVO/B6pgkjPHf3osaJnu0ac4J2juB61ZijiCkhQWA7jIqBJsHDnpVi32swyeD2xVHVqL5bEbtoI9AanRGEGGypPp2FAC7sAN1x7f8A66VmKkhWBP8AdI9KXKLcYbcKzbvm4xyKYuA4LAY7jJq3FuZFzjB5J9aZKoBVs4GScHv6YpWGm+ox1XbuU85ycjmozt8wsSxbHUdqnjUohY7iT3IokXKYH3yRhhTSC9nYht3Z1AdTzx0p8hCNhMAHrSypIkeFUMe/HWmYLDEq7eOaNUG+qETcrAMxGPfPFWGcAEEgZGcZ5AqONWYnvt6j1pM8uAWOeScfpQVcnMkcuFlLD+ePelL7FZY+dvYck/jVNSm4j7pHTnmnu4XkP7E4/nVJjsWg29/7ueBznFMml+6jDcM84HFQRylGJxmNT1j4xThdCZtiK2M8knt7UXFyu5DNEkkchcFHKgdecdqrRK+MHZs6Bgf6U+7uD5v7obvUHjFMYmVdpYqOm1ByfcmpNUmkMlKtG6Q4L45Cr0qsluBDslyCw5O7Pf8ASrMqFEMkgBj2ng5Jx3ziqM9pDNFhVbaSD+7Y8CpauaQXmSqYYo3XepC8den+NMVGfJfAU4wCOajjtIZ2VPKAWIncfUjp/jVkRIZgqb9q84ycCp5ewnoV3tcoHAwQegqKYYmOEJYjqwq/OQWyGAHtTBll+YDYP73elYnmfUzDHsUufvH5QaUo6qCVBzwMVZumcSqkUZdCMk54FJdPshAwNx5J/pQlcU3ZJsyrp3VCRgZ6A1jykgsuTz1Oelad0CWwwzjoB61m3CiQhujAHn1o6nM2jGu2ALKc5H3jnr7VhXUZM+9AGGeFHb1zW7dxOrHJxk5IrGuATOfLxwPumtEck3qOsLcBvk6t0A7D0robaMCPLY3A+lU9Pi4QjGSO4x+FascAYbQPmB6Cs5PU2hGyK6LtBKEBc5NXIZFKFwCG6YqIrtBP3McGqqSstxhW+Xqff6UikzQacNkq3AHes27LvHkcEH0+77ipZrllkG7gEYyo4/GkMiv8oUHj5jmmgnJWObmiWAPHOd8NwSoDj+LHP5j+VZEkFzaWkccbtMFUAqeGAA7Hv+Nbkki3UMm9ciElSpHOR/Ksu68xLiHy2LqS2TnoCP6Vtfucsrt3IrKZNStEhgLCJFG5SCCT3BrZ06FIEPEYAGAw4OPSs3TrdYdZmWLOdiu3oc/5NdAqoEJbrknaBmkxpFZF2LJLLnplVbpj/Go/L8yJm2jzBxgnFaEw/d/MPukY9xTpYm8vou4HjNJMqyPUo5fMG3d8xHp+lTxM23DZBHPWsuEmGUBhkH+72rVhZCpLDc1NHZexZRmkYHqFHAqzG0aqQQB3zUMBwG2lcHjAPf8AxqZRgHeNxBGAKYXT0GXRnZSyIT6H/wCt6VgaVJ4iXVJEvI42tt2Q4xjHoBXVxyb1CMCT29/XpTy5DhODnOMLxUuN9bmlOryJx5U7kCIzMVz8o59f1qQoirydzLzn/CgKQDtORTwySkgKSyHDfj0ppmL7kSSALlQxOOe2KjkK5woxyev8qlaI4yT06Aiqk9uzlcyDcBztqr6Dik2KcqwUcH0GPxpRkMFDkE84PYUhJjRSyk9qcy5VsHJK7snjFSmUVbhf3gCHG7+EnpSPHlCytiQfMQecippYyh3NyeB25/xpg8oOBv59D1p3LT00CJ22biCR0IXjrT4h5jkqu1h0w33frUjruwYxj1zSQfuVIKggDgg9adwvdaEE0IxguEkHAJXqfeltnaWNgV+cHay5FOluYhK0PmRGRwWMeQCB6+//ANeoFeFbmNgJER/kJZeMjoc/pSehVnbUS4ZWj3NuBPJA7DNVZIfLLGFZQg+dkJODjv161rzxZcqrKGI5PXIrPnsy25RIxjxtwGwCKVhwkiO0ZWjLLlUdvlwKleJACFJAJy2KgjhEeFRNwHyqTnj/ABpGEgfGMgk5GeBU2KkrvQm2hucADoKqQDLSK2498ntVtnAjLFgABgfWqzFQztgc+lKxmr6iSZ8phH932681nSq3yqxzt/Srm8NkEncarSRYbCNxjNLyRD8zOuRyRgqw79ayLsmIDucEHB6Vq3LNllBD+x4FZFwdyuCCzDjFPYhozJd7szbfl+tQCxxLvwCWHftWo6gsmRzjnjpT7WIuGLj5fbikzOML6jLKH+IqMHoBV5kYIPLBXjBJ9aFCxICu046g+lNYEgglvXOeDU7s05baGa90ikh1Zeoy6kc/WqUZkicyqVliPPuv0x1rRuAPLB7dcCsy53RMHjGPUjt9RVLU56mhLc3SmLdHk7lyoHc+lQO5toADlIggDMP4femWv+sbztodTwo6AH0q5wz/ADAkdD6UWsRfmOUleaK7nx87MocqDw+OOT7jmr1ugYiUkSHYMYHygHsBU89qtpdebvzbOMZx9zrj8OfwqDRpCpngmbdLFkY4+dTyprUTG6cQfNnAUYIiODyoHQ/nXQRrjCOB93BP1rI04rDJLC2ACQSvtitK1hkSJo1kc4XCbucDt/n6VEtRonmKkK4AYrwcfWkZeCCG/wAmmqjKka72IOGPripHLM2Ao5PXNSU0drHJvlCMuBgc4zWjG5JULjsDz2qosMiAlR1556gVYXy+MjrzkU7nVdPYsoWEyspBUdq07WQkKCARnvzmslGZYwyDJ7Y6irVrcA4Vhhz68EVd7Dd7GrkmRQOvUjNSmQqcMeB7fnVWEgsVXn371YXZkjBdyPpxTvczuSIoVjgk7ueOcChTtB5wPc9ahKyCf7o8srg/Ng1ZCo8WFGWA9RTshshcF2DgglT+C1G3OEZQHPOQO+KtIiIhKL85HIpxSPC7Bhmx75+lKw00ipLErJkvkJxu7/hTgihAATtHHXP4mp0gEIORuBzkY6Ggd8YIJzjHSlYTkUpRkYLEgcjANBjDxtIoDj+8vr3zVmQsMMo2AdT1qJ2jCEIEQZPbrTLTEdHKrhvmHrz+A9qexJBiUYdTgn1pWLoANwwwyAWIz/8AWoUZUyuBI2OoPGf60wuQG2ikmA8lTIMFuMkY7U+5CyQPGn7sAcAY+U9qlJIXhguPmOBg0zhULcKvf3oC9ypGrAcSLyAykL09qa00kQCuFVR0Pf8A/VUlkhe13FgQe2eOtPnZpDtQnCjk+lKxV1ezKs0wBYIAzMN27rg1TkWQ8sSoHccZq1OGUblUEZHU4zUExZ3K7CAfxA/GpZcdNhF+aMkLkDn2NQSMHJ3D3PNOLeU20M4XGORVRWUSMdxLdio/nUvuS0IkeyR3djhmyF/+tUMjY+QMCTzkUs+VjLfKO5Jqs7JgvvBO38AKVyHrqyrcncWxz7d6ozRbUyzBmHUDtVx5QTtRssOoFDwM8YEa7cnnPX6mhj5X1MpGaWUhRk+3pVtYgrBXHBHQDpVk23luSpGQOPemxSE4zGy5GTxxipepajpdEEnlksUbPODjg1UnZoULgsRjlTVq8dY38xAQf4g3Q1VlTzo2ZSCV9TjNFrENFGVhIWVSN2M47g1C6O4B2nIPAz3qWaKSRUITY/JB659qYshjhL+WzYBJA5I/xpo55K71KhjWKbeUYLsOe49astwqlRuBxnBHNSIu7a6DcG4GPeo5bPEitGzRlTxx+hFN7EKLuRXAxG0rKCh456H2rmJ5obC/edlcbF2Y7lTjr6gdQa7JRJLGYLkLuA+UDhTWFrNhFNDJFNErI/y5J5Qn+XQVVN9xTiktCnLdhJYnjI3SLg7j97uMH861UvN8lqV3bXyCuOR6Z/GuO/sq5tw9rHPJI8J86FJDkHB5UHrx/I1vaLeLLd3I+fMiqVU87McEfng02uxkppnR4Khcr0HOe1SYweT8wHHvxUJYyKrbuCKXzcxqvp1aoRonc9Gkj8t9oy27tQsHzbzkLjBGKuvGCoLA7h2PWkADMcnIIzntVctjpTdhq/MgKHjGcilQ/d3DqfxppDZLHAXpz2p6AqPoKoNi/CVMeAc9/wAafG779oXIHHynkVUDxljgA8DOD0NSo7ZYo+XHDe9DQJF0OQZNzdDxxjHtU0ewdCV7jnp9KzklwWzhR0ApVnTJjAy+ei0x2ZoJJt+baxB4xnBH0NM85Y1UgYOMlT1FRwyrGojkxk9Bu5qV1jlcLtIOOhH600GiepKrtKq4ACr3Jz2p2DtJXIbruGOKjRBAucjYB25ApiuxfBXjsOoNMl+RI7MykLgH3oYEYJ28cEEVHuJVmVkHB5FKvmF+PKMZXgAZOfWkBZSU+WM5b0B/wqKQN5eURkBHHOMfSnmR1wxKqdvOf6moGdXkYByykZAB4/lRsIFLb/3mNzcEZHFI8ZViPl9hioDFGGUMMgnPPPP0qYS46qwB7Y/rQX6DGVFAXkA8YPU/jTSjEYxjnue3+FPA3g7iGzx6UmVYAq54OP8A61TcdyCdTxvUdOmDUDkEM/AwcDP+FWZtnlkM2G6kZ5NUbiSMDktnrgcZpbFLYgupFYZQHAAHTrWdNH5dv8q/e9KkkmeTGA3XpjgUKkkuFKYXAJPTNQ2aKLW5RuHKwoudwHX61SkillTgMqkZ5GMCtRoPLUKVyDyDTHjyzYPy98+lLyNErbFK2i2RKUUNkct6U8ZYA7lA7cVajXDDav3efrVRjMzMiROCDx83rRcLXY94mORuB3DcDVNkCRk7nDE87T0rS4MKBcbh8rL6VlXSsgL+bK3qMcZ/CjoTsrFC8aUZijTfhQCTwKUuFBhETl+wHIyPep8M8W6V/lOD8jYqojvBfSW6yCQcODu5xnn64ovcxluMcFlLMDhRz/s+1ViTGy/L8oxkHuK0JlJjLcHPUAVVnjRxIQ7AleM0JuxElcls7fapXJGcsuematyWwMDMDiQY696S1R8RqBynOB/Or10JSzeXEzLjJ3fKAfaluyY6M5zWrpoUSRAoPGAwOfw9ao34aSAs0WGdSGBbg/3WB+tdP5QaJLiQqHUAAdh6isHVE8q8kgZl8mdC0EnQK3938xWkUZ1mmjnZ4zK0MsYxMyBhnOCe49jUOqwQxTQ3cMZtpmyA6nGWA6EfTNbTBSlo0YGGG7B5+o+tZviSNbi3sJoyS32hUIHpghsjsRWiRyNOxds3ckHc20/wn35q4shEQ8vbkcnPPFUgdkcToMAqEwfUcYNNSRo7tVYAxEEZH8qlpDUj3PlzgDk85NQ+YFbYAvuMfnUkTBcA9B+tNRQw+Ubfm645xQ7HekiOZgoJ2nHAGaYp3KAuVHrUsn+qZWJC9s9KqNIkUgUSLk9ickimwSuixEFzknHvjmmHcJGYHg9v60q/vE3EHpgc8ChQASrgk4/KkUtNxUlbkqACOp7EVZRxtLHpjjjofeqLqGkIzyO3qKktHdZG3E4x165oLsmro0UcMqbh+fXiplL7WCEgHnpmqu5WcM+M44qYuEBbJVjzmmmQTi4QR/MAQBgEjGaR5C0YYquOnyk4FVEfzYhly2Ou0ZNP3/6NtfoeeAMmqGoktuY4HVFXJf5uuakieOeMbVLckgZx+VVlCkK6jkqeD3NTxBmH91sc4BC/nTsEkiO8a4+zObZI/N/gWXge+cU6LckALIFfA3KDwT3x7UQzrIGDB1I7AZp8kZI3RhyCDxRuLyZCVIPmLI2DzuJzUoDKp3yAsBxjof8ACoyfn42nHGNvAp7nkgEKpGGJxUuyGxxfC5Zgeew4qKVo1YjJUZ3fj/jQyqV5JC5z1wfqKiaKFSGDHKnHLUgViIkO+0Ec8bvT2FRPHHGd0gBlHcen0q8VDbWJIU89OpFIYuZCAAvBDH86XTUrmKB+ZSFUDdzuzxSG3AULw3BIxVwRsqfdAB5HPH1o8n92SCMjqO9K1yk7bGTslaXDruCnselHlKoYYAI7irpAy20jr9arswQZYgc7R8ualxL1ZTkVYY8ug68YHNVWJGWJPYYxjIq7OrO5YKzZ5PQCqFyqSqVl3FuOSTj9KmxSI2k2AgLvPbbgZquzb925WUNziop4hEgwWdD94k/dqrPKssQJgHlR5P7xsceoHp9adiZ+RGiCK5l3ptgzuCE5xn3qpfvHPOBBBE5U4ZlcDH+NZsGo6bqaTz6YJ5kUlG8s7hkdcc81d0+4t8RyPGY/Mj2lDGflI/rRynNJj7LzZSyt8o6bVOQPUYqe7gaSMIkgVjjHyenSqEbX8V6zQpH5bYZmJIOOc8flWhE9o0zCfrjBZzkZ+vahqxCk2gDTzRRm0fcFJV1aPaRjg4Pv2rXE0jpGEYEFfusuBn0NZU6HG61LMV/hQZHFJBfhZkSQvE0nI8xcBiOoB9aVhc1nqW7qUNPIqoED8+vzd/0rmfFVsi6PMV+WQcqjMQM4/Sty8iDQOwIDnkj0qlcvHNaxrMu6EfO2ecYHA9wTVxdmZz2sjE0BzPZWU0nyyNGA4Bzhx1H49a0rqxjup3VTtM0T7eOkmPvfXH8qqaNata+chbdErsVKn5lHB2+4HODVhLs3FxbPA6s6FpuOn3SCPxqru+hnay1KCMLqzjdcr5kf7wejKcH9QaWGFXlhVv4RlWJzn6e9Q6XP5+pXflgiJjIVBGOS2f5c1JDmPUIwC2xoywHof85pvQyR7HDMWXAwCTyc1ciZFDHJyKy4HCuVG0rwOnerhHCkgbT6NVHdvoSMN3TAGM/WoWgiKiRkG48Z7gfWrg/1QG1cn1NRzYABY7lIzkd6llRZWBJzsI5pAX3MJQDhsCnyIFIUZB7Z6U0jZhgR15FTsXuQSxtE5dnZ2GQSOhFSpcOmGQnBp8p8yJFUZbnleQTVYxssjFhk4B5P9Km+pS13LCuzAHDbs8gd6sICXxkquSB9f6VSw+dwAxjt3qwsoBAPyuRx7U7jfkXod658vBI5yaJFGMnI6/dOSP8ACmC4SOMKxXdnbhjxVuK4AUhs5YdjgVonoRe2pFDIRw2WHTAOP509p4skYJZuxGce4pAgIZlDYPIBOCfwpfLCv8wTGM/KMc96q43YEVyT8jMvYdOPqf61IX2sqHzEbHyA88VFtEcmFcPnjAOcfpTv9YrHeTg46dPzpCY2Taq/vQD6kk/ligBY1HlBQME5b+g7UBiwKDYrqM8fpUUW/aPO+c5wdvAHrSZSTLBjDMWChz0O7qKhMRdxiMqgOeR1HtTy+9SFX5hjr+maq3N49vJElw4Id9oKL0H0/rSQRjKWiLaR5Hy7myeBTJmONqld3RlFSW7blLF8j6ZNOjkMjM4AHHy570Bs9RJISYlIBDdeeaSSMR87eq96mV18wqxJAGABxUcjRsxLtlRzhu9DEmykThicfKSRzVeXG0lcbc42mr5Eco3RsoJ6LnNVCxjYiUqRngjrU3LvfYrSL5aMqJkA5O7uPase8aMqPmUsM5BOOPWtmR43ZSgbce/oKw7mbbdS7SnzANnHTtUtlwuZlxHHNG7OrxRAZJ6Fj9PSsu98i70+W2u7x1NwGVtp2HGMYHHpW+Edi7ySKxHIxnaKwtYiSaDNw0rktsSEHjngEgdR9aLkzd9DA8O6Eum6YLDQrcLa7ixubht5OTzhfwrYlnk0+4hElw06gEbFTbknrjHp71etLSO1XBnIgAwVB249+KtC3jDBrXYiE/e25zQ2Y2RR0+JJ3M5l2ySYCKwyNoPY1K8Ys/NdpAxBJY7P4fTFQW8UwaYv5UtrLISU24wDgZHpzUpSSzufLklc2UowBn7h6Yz3FL1MWmxi6jGZtlk9pLhfmIfBz7Co5TFcsVlA2HBZOo9OD/nFaElpbizSCUI4QYx5fb+lYF7pkiFZdPnKkMS8bgEMPY9RTRD0L8C7EeByZIh9wuTn6ZqBF+yQg3WNgciM9id3GaYl35qRCbEciMTtbuBwcGnapfrY2oQoJXkwPLH8yP8AOafLqS5WVx8nlxxSEoixbjnAwc/X8elcos0mm6mAFWS1SEOrDlgcndg9x04rThmuBtt3JlsWPmxMT+83Dkq307Vi+KFkO5LaQ5SVCCOm1nAw3t6/hWkUY1HfUks5jb3UURjKrsWdGX+6xOV98Z/Kugt7cTh5l4CApH789fpXOapJ9mit3jiIuLSb7OA38SEgbc+2R+Vb4m221xBHlS0YK+2SRj8waTV9UTF9D0y0ORuGC3T61eQnHbjuKybaTGdpXaeM4yQauWxcHD8he+ODUnoNWZeAAIPY1ZjUmPGeTxweoqtG/mgrkAnvVqCHKLtPI4p3C5EF+XH3ecnI602VFyVABz3arqx7VOWyx/KopIw0gwe3QDFSVe7KKQvHM25l8s42gDBH+NLLGiScAZA5yc81adX5BRW28jviopgisWfhuB1zQkVe5AoRVL78enpTShZydgA9c4/SmqVac8qVA4A7GrKLnb8xYv3wBxRaw7W3K4DKdwwwwRgjpVlSCu5Ww3YHp+tSzxxlAFyo45FQ2mBNgSBlDYO7rVKSDfUmtsqGMYwpyx56k96sRjzFLMGJzk7unNPQIWKbc+gIwM/WnTbY1UEFRnGRzzTuK92NUyCJtsYSXGD24qVFYR5wVJHVRzUlu27Cuy/UD+lXlQiI5w6egHXjp1p2uKUrGROhOSqncO+MnJ79KQQyFvnSNRyQQecVrtF+6VSpIJJ2Z/Ss6UqrkAhccBRRJDjO+iIYCWVt+4+uVxx/WnXECSEFflI6cfpUaXSvJhdxyD25qVnIXJJUn1PU1KYO8XcbFGY4iBgED+M4/wDr0+Q425bg9McECq7Ers3EE+456+tTbowrMdvzevOf/wBVFyn3B2UBiwBDcbiefzqNd6xHaVJ7A9ahkRlYEs7gnG0dvpSTJ8rEJhgchsdKLlWQSKyZDeWnf1J9qrSBJvkjkbd3I7D+lTQlJYt3J3DncO/eo5HWMkRlVU+vU0XuriuZ8yFXMYlbgccknpVNJEjZvOQfPwH6g1pzkMM7gN3UnjNUZyhLrtGFGOKh+Q76FKZVDFctGmO3f/69Y95G5uUUP5eW3EgZYgep/KtcI6BgMHPdjzVN7aMOziNWkYDO4E5HpQGlyKYzRJgRpKANuXfHX8Koz29xcygS+bFGeSIzuBx7VpRxqSsm2XeeNoOcVMrSkmV4DhTgDcCcetK5Lt1MtUlW2kjA3xDqT95c9D+nSp5UkntWSU4ZSVJyePSrbQJPF5uSrN90qxXI/wAayr6wWGN3ik8zb8pZic+vOeDikjJ+hdSefy0ZnjyRgk5zgVRvVkjUGDYzEEkE9vwqla3VrcGOeYloyCi7l2n3O3uM9CKzrmXT7m7dYZZ45OcSQyMg46gf/Xq0jGVzRluENuy3apCdyskudyqTwee341FqEMFrayiJctKCJFTkMOny+nHQVyOqHUbMTfZbu+lDEBy7B1Kg89jnjP41fsNYghlhtDIpiuVzEB1DZ7e3+FachzSbUtRJZ5La3la6ZyokVkmjX/WDIxn0YdD60utpNYzQXLSRTaTdNidtoBRmPyknoBkAexqzZO7ulr5qXO1m3diQONp9/wBadqRjXTL/AM5PNjdNskWMh1Pt2YHrVIh7aFHWdLubtL8ozMryxOJEOGVlAPfjsOlaOirJc3N87wlEinEQ5zzgFjn6k1Bol0I9DeN3aSRYSQzHlxjj9OPwq9oSmGHa+4GWFJDx1bGDSkxqLWx6BErK2DgL3Gavo7fcYAgCqR3FBknI/wBnNSWysCA3J71kz0muprWzlANxG45HParUc2Y8cbAMNx/Ks3dgjYSW6mrdrcBl2ZGCM5PBov0JS6mmrJJtVSQRRBAo3/6z5zn6fSo4kDxjBIbqW74q7FgIOe3Q9Kqwr20RH5TA5OB6cZNVLyFl3svz59un5VoJyzbWDoSAec49vpUb4lDKDlQccnrSsNNpmItupkAwAw7N396tpbs+xnQMi8YX+fWrDRfMVGcnPzADj2pjzOof7qgnaAO/49qGl1NHJvYGB3GNl+VuAc9aY8QVGAyo+9kcFfWlhGCTvIAI5Jp8rEq6rkuBkLkDNFidhhLBoyPmBPLAngVOW+cl2HlgbtuO9UnLoyso3DrgdsUySXKyHZncecdvSmmVa5ppOu6L5CSD97AGD+dagm3IABnK859R71y0FzEsyxpnPUDb19s1fW52R5eReeB8+KafQmcDSuJ1iTDPtQnJyckD61lSSojN985PBPB//VUKTKzsfLY44G45/nWfLM8kuXG8DIyDim5IuMbF83ChWCjr1Iz19aIpNzJluB/e7/hWYZRlgg/LPFWZBlAwk2nAKleorJMtLuXVJYsztnA4GM/jimXD7UCoRvxkcYpbeTKEmQMwGAMfypocRiRpVK4GB3yKq9hLcQSssIBl3E+vJp1xM72eFJLjkkL/AEqjaRoHkUBucsSwxnPSrXBJQMQB2PSjmRUkk9ChHMXVY0aTnrt4I9f51LEkyynzsOvO1uMj2NKfvnzChfsFqPz1GAH28455zz61Ldhy12G3TR/NgBiBjFU4kBjGG569amuUVmJzyecZ4FQMfMUKv3h1FJslbDG3M525VcZ59e2KjKssYwpyeuFySakZgpByNo68YP4VKWzy+7b6g0txPTYyZDPGVW2iyS2dzdvep13xW6eVPu4ydy5zmrEylADhVT+VUjdQWzASTIQTnIyaaDR7kS3DRhTNE4ySBJHnGfUjtVa9ceXcNe3qGDOfLZPLDcDvnmrV7e2pjV8szbxhdhycVnWjwXcPl29uBO2Q8hXHynk7Sf6U0tTCd90cibk37rELcmLtI0O0KM4GCfm6+g9KS6RbNLc+VvmMjpGyE5wBgluK6ldOM7pNcNGAg2AduuePfioNQtprNxcWyRqFBBMrYz9B2rZSS2QpWSscrNpAt0jnimuWjuAdsIkypfrjPYcEVm3uiWEMLA26x3buhkuEyDCexwfyB6GtbWLLVPKlvrKSITKxaPcwC8emOnfrVHT9bF9qiWerW32a8miMbAtvhuB1wrevXANVr3OKclJnQWNrst1ACiZTkOq8E84J/rTdXSPz7eTZsmc+XIFOF6ZyfyqeJXsLW3EcxEIdR93LIR259qfcXMI3w7cSyL5ikj+NTgjPuD0pLUl3INIhX7I7yKsbPEAoYcbs9PyFadtEGTYRsK5AX6dP1rMUSxWDnaPIdUkTPZ15x9DgfjWrZ3sU9m9xEQULk8Hp3H9RUyV9irpaHY7iJNqnOQMkdqdG6qwVzhvSmYDsowfXBPNLJEodWwQBxuNQeirdSWKbdIMn7x/KpVb5wOVA55/lVUL5TuDgqevYrU00gwoOVxycDINAnvobFvdN8wjX51OM+1adtKpQKOCeT9f/ANdcxbZLMpLAHpn/ABrR09nhhAlJYg9xTTE0jeiRMMc4PXp3pQwHAUYPU579qhs5Q6sJH5HG3PFKg+cBUX5Tyc96ogSbazH5uQOR6fWomZCoVgNrDJJ6CmSBYd3yF2PX5tvB7Ux0zkPg45AXrjtUsq2hXlSV5FaORiqtlkIwDUu8BN6oQ54OOeP61CwkDj5xjjquCP8APpRbuVRkQuCM8t2z7VJTd0NLnBYZHGNuADj1quWUhiEw2RznOPwpLh1EvMhLqc49R798VC0x2Eqo83jgj9KPIuwJcYBZckAn5qZNdS+ScPhcgfOeveqczLLKyoCHHG7GM1SmkdAxMRLA4DdcVN+hdjUNwFVwZAVPOR/iaoz3I3giR2XpgngZ96qSvKUDOAuBhemM1ZhQyYViQo+6CPahuyKiupZglUqoJlLEZyBgH8auQ3G/k/MQSNmPyqEIzKEiOMYwWGf0q1DbhMhC4YcfNjikgdralmGVcjf8vc9iKc20Mx25wRxyQPeoGDJuyQxB4461P5cSwnBxjnr69apitYr3EivNEsbHcSSSPT0qN5LhpFMbr5Srg7h1/GllubeOTYJkyPvLnn/OOarTSGcnysBGP33P9BUt9zSKdti2+1huZo0xnB4ANUmddwXy9/ffswB9KfbRIsK+azSkE43DkfgOlSuwDElE5HIJ5/Kp1ZD0diEncrFmKqOMqM0xVVcDgkjv1qd2Hltl8knIVRioAQCsbZJI+U9efemt9SWRzIQo2qOOMk9arf6mJQ5TaeMnkqc/yq00kcahSTvJ43dD9KcVVYGDAkt07k02J3tqQtErgby8i9V3MTg/4VXlEEaSKij5cjaq5JPpirbQp5fMe1lHQH2qk1rtgP78qzfMdz85ppt7k7bDZIXl+ef5ZVA2IMEp+J71VmIuAILgCORDnGcBse9WRImwx3kqlQOHD8H6+9UdU0uJj5kSxnK5ALf1600yHYuiGKO2AgAjTHKK3GaxdYvLqC1k3pHcLzhQMn8fb3qvJ9nhObsxJIOFLyBMfnwR+tUTf2vmmGVgJGOVFqC+R68dK0gvI55q6IbOb7VdrBb3bW7qm5AUB3j04649Kp+JfDUmsaVNG6W8lxsbymJKMG7YP1HTNUNcsLa9u7VtNu5UmtJRKXkJRwRzjDYyPWt+3lN25hu7UxyBtwlif5XPoRng/wCPFaNW1RzqLloyho8zjSI01NJluYgA4OSWwB2PUj69qd4kuv8AQo9QiT99DJHOUA3GSIcOwx7ZrRZJBbNLbq04eQgoz4ZcdPyxXK65dySCOytC6X8I3CB+GDEE5XsVOMEdOaIrUmpFxidTZSxNY3UDurxuhMcjcCRCOMe4rmPBWqC10O/0yaRHudMleF3PSQEnaw7mrPhWeK7mnt4kZEMTOsTPzC+Vyv4H+tcWGkufGF/eqPLSIG5VMAFyq4/EHB/Gr5TKUj6WZdv3RjPPB/lUa5BXAznqB04qGOTfGCp5HGTUm7DbQcDvjtXOesk9i2GVVGQOQTnqAKgYuGUNgqvpxx9KfGqyoXGQVIHB5ppyVbDcDkc+/alqIU3Aickg4JGAT1q9FONpAPHv2rJZTCM9APVc1IJWVsswQY5/z3oYnHsdHp9weASOeeeavSyhlKIdpPf/AArmrWJjIrKOf4iD1+ma2LcMwywIz0PU0J6A1Z3JJSXIbO4rxyuAaYdqpjOFPLEnGKJFLEtJhMc8dKqbgp25Vmzk57ik2yrNoexQcAZA6cf1qpPKvHlqzKOQR60+aVgSWZl28Yz1oLL5QUn5f5fhSBaEEr7gAAoccHLk/nTmUADaxHr2x+FRPGokG0vkjIJGBx3OO1EOw7iy84+Yk8ZqTToQPIjjMW5iBkk9fwFCRiSPeWCZ524xu+vvUssZK4jZIwD8wI6+1BjcLzEWfsBS1RVhos1zkPIM9mFXfIG1PlTA6DvSKClsp2/XjkfnViHZvAE5GR8yjqKpJisyuiIzlwMMvHI4pyDM+1JN2Plx2q5DCdu5VlbORuI4/WrJgwu8FXPOeMZ+tNpjckimbZXwWZkxyV9fzpLiTyo227SoXJPXmp5RM/BwcHBzzn6VWkt1WTAygbG4duKWxMZdzyzXbXXri8uQtjlZGGXQ8EfwnOeK6Twxp1zp2nKmpSl2PzYJLAZ7Zrq5bVN21eR1qrJhSignGeQB2qHDW7O+eMlVgoWshAiQR5hUAEfePpSps3tuChk6MR/WneUJhI4HJOAWHQ1JJGphAwrN3zxTS7HG33KMsxaQrAg7A1JLEqI/BVuB06Hvip28lIlIBPA4FVpVkLElcAcjHQUxXvoCr5oIlQ7Md+p9Kqw70nAIzGOhByfx9a0lIaPBPbkY6U1UgEZDIpz03f40J9BN2M+SRzKwRiZT1GzAH1pN8g5khLMe+MgVPCsYmdyxALcKOeBx/jSl9suFAK7sjPpSEzJlt3uHEkVvsIB+ZlH6jvVNjJaR7p5DHuwHSNdq56fhn2rbuFkdyNpTjJ+cj9BWTeWdzcpJFLMVt2UgAA7ycf3j09u9UjOT6spzwWs0Wz+z0ulQ4ZgoYZ75J5/Ks3TIDbXQSH92q7m2upUBem1c+9dMIvsdnHCjBRGNuXbILf1NUJ7y4tJFD20BUg7WRi/6dvxrRS00MpSSK8z2bkwxMhEgJCTc89wCay9V0sCMtaH7NdKN/mKdySY7MP61bktTqbMHhtd6kyKwj4H159e3vUUeoyWMoiv4hHaAldwIKpwOM9QP0rQxU1azRQbVCLW3aT5Flk++uSo46Mf4fY9Kh1PT49ZkMDp5dzFExjnA+dW/hbPt+RroDaKN11bJE1uRjAPyuvXpWR5U8BWWAYeCQtEdwIKn+E+1NPXQmdTSzPLNI1SVPiP591C1nPjybqBDxJIepX2Y4P1NaniLyzqtvLAW2/aVtnwP4JjuB/AjFZHxNijh1aLVrJGgu2LSSIzYYjPGPp/IisfxB4oN20f2ZiqyOZmRPruUEjuGyPpWpxO7asfT8MpLBRjg4yKtfMsbDPzZ4INU7cqzEoqkexq0DudBjaq9+tc10e1fUtWpdRhjycnrnipHUmJtqo23qoHUVBHtUhfmIHJwOfr9Kekn3EzwRnmkDVx+8tHiI4IGQCOlVZ2lilBYo4AIx/Wr6hQNw+YdfoadJEjJgcE9ueaQrpdDO/tq3iZQXdAucjZkfnW9Y6rZSRkJNE2OOTt/PNcze225mAUbc9xjH1rPniaGVQMMj9c9RVPQacZK2x2LajJHkkKYjyu3mqTamzSHZG4yRk7f84rnUsjI28vKvoASAfyq5baW8jK8l1OxA5Xe2B7iodnubwVPqzWur9PLcTOwYk9VJOen4VWS4il5VweRjd3qtLZXsaMiXjOuN20n1+v0qKNrsKC0VudxwMqAT+AosmjVUo2umbEjK64G4hOQAevvTIiHYMjENjkMOR71BH5kaAt5Y3AjbjOD+dS2kUyS+ZnchP8Adxjmgy2W5cgkZicgjGA2BU+Ns2OcdSP5f/qqKEvl0cqHzyAOn1qaVOM9/apsRezHmHed0jMQTwoAxx7VbjVFcMcEDjoOPaqSEQ5Jyc9TnrT4pirkBMhuDTTE22bK25IzHzgfdY8GpGQlQQQR3LH+lU4LmHaCM88HPHNVr+8YthCoXGRhuasxcm9C07KmWXaCDjiqMzsseSc5wTx+lUWnLbw0gkIHGBjHpUMs7hXzlm6Db1FZtlw1ZMblwdwyTnChe/8AhTIpjJcY2bcjoait33llXdkfMd44z7VMhG7CEZIIHGce9TqbXRZVlVR1Y4zSAfLwcsOxoQ88dQM9etPRi7ZOAe+BVIhshBRoySMYIU7vWmMybNr5UdvWpZw54J285HrVZ4A7/MC68jntzTaKSvqSCKMx7dp9QexpJNoX9387KPu9Nvual4C7Y+FXjJOKp3gfy8rgDPYcH3pbiWpC8sRVUUggDAAPU0YQoNquXxyVJGPxqr9iCS78A5PXHWrYUgHAYx4xjrgUalzSWxCsRlkOEdSw7PkiqVyMSx/aZp1gVuFQHIbsSRWqZ7eOAAPtHYsMVUufPKqUlBHZSBjHsaLHNJNsyppPLZ5YGebqCkoOT9GI4qrt0yTa8tpLHuGcjAwQcHkGrN7az+dvjvBA+NxZsmuZnDQ3jvquoLIkmFET7VVvfb68VaWhjJkEqwNq0c2mahdKqFkYSsVIU8fdI5GTwa17oTWkJluj9ot2+V5Xw3yn1IGCPc1X/wBEuIxEmx2BztYYKe4bNR6bfC6kGm3waLerkQxtuEmDhgD6d8VqtTnkmjPa8lsMtoJW6ss+YbaSUYb18tvX26VY0/WrTWI2eFJIJ2G5opl2NkdeO/PerGoW7C3M1pDEEUZfkIR7getcvqFjcwzefbmSS4GXDt8rqD97H88dDVJXZi3oYPxgs43023vrYb8vg7eqjBzkfhXl17D9nkiZGUhx5quM5+h/KvRvEWoJqmm3CXJZpVlW3mkRSrIR1fb0Izj8M157qMIhnn2K4hUmLbJ96M9cfp/OtehEJan17aj96do6cVb3LtUMu3n86giKhfl+U5qUuM5HAxnrXJ5HrqKvdEsZZcE7sAVKCXXIBYjqOKYr7kBGDzwcYpyK7PgHBIyT2/D0pGiRNCXdcdAcnB4xVpUy24dMYx3qC4litrR555AkCrl8DNTW58wBkJ2EZGeMilcHqriSwoWJIIOORjGapi0V5OWAZvvBTxj+laEsbENhQwADAHnP41FatI67mg8rccbWPX3obJUNLldbVARscMy8H5sjP0qzJESMopXjsep9KYYkY4KAZP3cf54qyhMa4DEEfT8qQW5RqWu93CjC4O7gVDdRPbBmIidj03gEDtxWlCyohUKOec45zUUzJ5fBHIziloCm7mbFbl1XaWLD+LHf61aUtEnzsBlu3epflDE85YZLKeKYqnzHXI3DnHoP5UdTS99yUSImMqqv6Ux2BCqHbOM46d+aj/1iOGOUGRjpipYsHG9ct03556duKCXG2oM2U+cEn1B6fhVSaTC/u22scnGKmfDvKVDZUYLdv1qqINz7ZEypxjn+XvTGrLcqC7mXMjqTgbcdP0plxe7yqux2AdM9/atG4sxLEwVAcDHH+NZbWbn5d0YA4K45FBLXNqhqXirKqoSVx6YB/Cpd5aUFkO1uQ2cDH0pkcCxkshDcZxxwamk3ERb42GcZYEUn5DSsx6uolZMld394HH5VZtyzJgEDbwMZpLdftH3VVDyDkc+1Wvs7IhWMbyT1JHH4U7FvsSo4DqDjfjuKTO6YKrHd6envSxxscndyOxNWUVhncVAUfj9KBXIGQMwDsSMcep/GkM2I9qAZU4wBj61MY5N2YlBX1b1+tV5o5QMs67iecdAKNgTvoSO6rCdrFuOSBVSXBQuWZVHGRVnyWRA6OpOO47fSqMzTZO91C54UJ1oRK8hV8tIASTuCDBJyarvLcRpkGNk7h/lJqffHjcxO/sRzk1TnuYVAadXOW4zxmjQa03CSUwxnzVIHQAc4/wAawb0LJkNYjymPLu5GD6Voy3LyPhLd4oVPUtyT/SoLqWSa3xHIYVX7ykc8nv6CmrGUn2MZNU02CfyI1uklfJ3RqXU/VsGq2oXcd3tguLTLTEcqocsAc8g8jgV0FxFFJCIisc3rgcD247VmS6Vp0syhYYWmiHLL8mw+xHT6CqVjnd+pVNpFYxF7O3iELArKlwoAYfQVmTaffT20s9rHpjshdotocEE4xz61en1CLTGktru3hniiXcGhkG7B6DGPb1rk7bxNpk800drNdaZM8jF0eM4z0B2k9/atI3MJtImvdVvJ4Sl1ZRpc24VbhBMcgd+MZK9wRXO65cahokC+XfXCWh+aEzHzUyeySYyOOx7U7X9ev4JRcSx2Vw8SldyPxIg6qQfmVu4yD+Nc3HdTazbixsVurUSKZRFJHvicf7I5wM55Fao45XYXesQNbxmWGOS1uYj5RGV5H3kPowPT6iuTuRK/2hhK8ylxEXYfex0+hwK09MsHvfEDWUsixuUZc7MAsVwDtP4ZrK+0vbR3tpKgO9wSAfuup/8ArkVRUFr7vkfXcZlJQo3C8EHv/wDXq2GwobAPt3qikhjIwwYe1XY2APXIYelch7cZXLKvujGzn3qzFHtBBbaWx0qnGdsecZ565q5aSKCoxtyevY035FPTYcJGUKm0EE49qtWwAPzp046Ux8gbwgYY6gDNJhkfORtIzj1+lTYWjJ0IH3lyAOOM49qH3GTOGwedwbgVDL8pU7ySfmB9PrSwuqRMQTtdjkjoDRaxSWly9HGGUly2cccVAVVWZgzbm79en8qSNn3cEhSMcjIpzF/l6AdCe+KTRHUj2scMhKjOSPWpU3yA+WMqR8xPSpXUsoOQcckZ4FRQMEkY4J56ehpCuIjyRBwQSwPAHfFQPc3K3yK0G+ApkuMDaas58xG2pgjPY8+9EYZJBnpn8vfpRqjWLS1sNeDzGLxllYjg/wCRUKQhWIG4OCMso4//AFVbkCsrBMqRxu9KaQCG252jv1pNK4czIPsxLDlskZyozSzwozKEcGRP4SSTn1qzK6+UkbFVO7gGqys4dgm47R06Afj6UrAtdWTpCsm1ucjPtVeW1gf5toKkEk5xg+1Z93fEDfJJHAFJABfH5461Qub8kKLa4R5ScjZk/mMU0rGkaMuhqOkMQUqgYqOSf5n1o3K00LIVGCRwOOcZFZSXEj71nkYEdNqnBFU7dZUvtpjmKjJzkAD8KvlujSNFyv3OkcqjktMFDdjyPY0+0Kkbd+ZFPJbjP0rGt0MrATJK5xwiLgde5rQghtoidiyBh3Y/oKOUJUuVGsDsiLAxqSOecU+GZio8pVJxxzWLLcFA5jiuHkYYGVHJqSNZndJGVUlAwFz1OOpxU+Rk6fc3nLsPnKhQMkLVSeVVI24PPGWx+goOWQhiCw42j9aoTbWkxDLgA5KrjJ/GkZRiXJpkKcOF4ycVUZI4UDZbeTwevNV7m0iZAdswbrkEkiq8Uc0GNjtLGMZBHzD0+tMpJW3LkzoUKsy4HJCnGfxqjLGryM0S4A5Lsef1qSWNsAunyZ3qQueap3Uf7nEkswQn5iUGB9TQRJJCs8KqAXLS9thycVkXOJrhTc+fGBlkbG4E+9XcW6RRy2xSYAAAhRyfwNRy3ss4eHyZohzvL4P5D096aZk2ugxba5mVfLLqoHIOFP4AdalhMtvbMsc0bufvRyrgisqa3ljZVNy7qem8FT9CRz9DWN4ns7p7OVV1C/2vwUC+ZjP904+U/WqSuYybWpuajeRxud8IincEKVYAN/iK5u50aG5tJ5tTvFkYkuiLErmLuDnGayJ44dKtTJbqZ5jwDeTEysenKn8OnFZcfj4yFbPVNMng+fy1mtXG8tn09c+9bJWOOUrkPiO1uGtYJLe5tpPIEjAsm1ym3I2kZyPY1x2k6vLHpcaXT2shtQwUPuWdAewPcfqK6rUL20muLsacbxL+BMbLlVVW3ddyngEDuOa4q7mnsLm7dmieV/lkaOQFWZskEewHFaIxbvdIzLy7uI71p/OBZ027lbdkAYwTWaTnHFW7qPZGPMg8snlCp4IPeop4yoBYBWwMgfTig6IWR9dWpBBYdM8Air8TKxzjJ9qyYuHJ6qKtxAKdwZ+ecdSM/wA65T1ILqzVU8Hk7sdqfE5ViTn2B71WicshUHDZ5JGKlGSfmB/nkUJ9S0aatuC4JHGSCODUyhR0TDYx16VmhWUqd7FenHrV2ORmTbtDH+VJicbCNE0gZd4CnkDODT4o8hwSGII4HTNG9c/Oq5HUgf41YhzKh4O3PUihO4+ZoSBBF8zfebrk/pUuAOgz9QcUmxt+GKlB/CeaRygYH5sfdwKPIT1ZLL8ik7QM9M/4VCwGPkAZiSWI705HEgGOCCcAmnIynO3bnOOPX0pMWxWVds+eASOeSRmpkXLFvmIB9RnPrT3UF1/eYQfLjFPFuiKCshXB4GaOthcwjOquPLDFl4LCn/KwDh8/TFJn94GZVQH3Iz/9emiNw5KsFHBBJBHWkBE8SLKCu45GADkiow0BYRybGcfwnkj8Kt3ML+WMyiM4yXxge1QRafDIhd44JX67mQZ9/wA6Nti1JNXuUL6C2LL9oCKh492PoBS2NvaHIhK4GflKYOBT/sJWeKQDc6kgBznaD1xx/kVNcWgljPl4Vh90txg+uKOaxpztK1wOxX3ACQDjG3of8aqyIZ7hZSdgHULjNaItGYfMyIuOdhquYOf3Zmwp52r3ouwhNItxOCSkYLBQQR1x9TUAUBcLGFySx5yx+pojK4JAnVgctx2pH+xyyZJCkcgOxGaL3ITG+WwIMSHLHBKjpSxW8rSElWwOCzEHr3q4gHlloVhTcfrSooKlXIkPByBQLnKN0sqRsq+WT0+tV4bchjJNIHYgcKOlXJLYtjZLt7AlckD2zUD2eNxa4Llv4S3B/ClfsHPZWQ5Z7WMtiSRzn720tj8cVnS6lBDM/k3a5K52k7jn6YqV7x428m4KQIPuuDkH/Cs67khhukY+RLuUn/WDPX3ouSvMpPq9yjyxSTRquMqY0b5QfXPv3qGSC5uWIW/lAI67AR9R7UajcXcRjksbSGEkkM85IU5+g9q5863aPdCDUDObj5gqwBmjYeoOMH8T+FWjJuxoyWM1kHe6iluI8f663J3Z9SOn5VmahrdzpxjkjBntU+95pKuoPoSOR7GpL++lKRxxXFtGZRhVkIdse4BGK5j+0ddUvY6LFYai6kie6aFhFB6ru3HcfpnFUkc8pWeh032m41CWORNLuFjz8xEwAwe+c0pMUy7UgdXTOA8m4Bvr0rHsda1aytCNdNrBAp+VoGOZB6nHQ+3SrB1XSLi2zHfW91E53R5n2/iT2HBxn0qkmZOfclvtKaaIiWwi1DZyBu8phn0IrzbU9O1SXR9U/s+3xZhz5kFwwaSLbzlemCPqc109/canHA76VqlxFEQziNo/NUD/AGXbBArzPXdXur+KaKc3LTNMVBaT93gd85GT17dDW0Uc89XoSz3T2dol3bara3SSwr5sMyguWb73HfB9wa5oQN5gniKNGGyCxUdPbPFPtIzEUma3SZQQpRgQvPTJ9acsvmXzSyWatEmQ0cS4Udaoa929hNQukuhvEexzxgfdH+76UjwxRxxKx3EsDIy84XAyP1p00yX90pbEcYX/AFaLgA+gH5U65hWK1YjJcuV5OCuOnHfNIE7WjsfUFs4VG5wCPmAORWhC27a2/wCfp1/WsqJcYBUBm6mr9uVyFYYGevXmuRnrR1RpKWwcjI9+c1YhBBDrnI71WjZsAZDKTwWPNP3bT8ox69s0Jo0UuheWQlAmePUjk1KuxhkEhTjGD39apwyYQFUXGM5/rVlZMucDjqFFHQL9idLlS+xSQAehPY981oxyru2nA/mazYWHAVdmMduTVlh8mNrA4HOP8aFoyZ66E9xJubgksvBGaa7NHIufmXHLe1MjZXBztBx1Pf60+RgMLtXAxwT19qT8hx7CJBlixXAYZwG/SrCBHA4YkAk5H+c1BE2XIHBHHX/OasRyHnY2O2GFIJXDKBAHOAe54x+FRqm5TtLeX7j/ABqreretPvimiWFR8ysp3fnVlTKUcFV5XnmnewuW2qZYzGVCtGr7ejdcGkfdgHnaeMYqqqSJiI4KqMZ6Z+lKZQhWMOH54J6mldjsTvMm3yuSyYJ7n8aPMSSINzgccc4phuEAxuTJ68YNJ9tEIKB0RT057UNoT8h7sYgGAA56ZwRSlyx2q6gAfMuKqSSF1GZF3j0GRTZpTgbi5LDHoT74FRfUa1LYmAUCNSxHAX7opTckPtlUfN3B4H1qmgYtukAGBwu7io5d0hChShzwFbANUvMdrmv56RrlmUIfcA+1V4JbMKcqoU9WK9eaylXypCvzdMybGz+Zq5vUEIls5kK5HYfXJo5mNQSLUNzA52wbGkU/dzgn8KfdLMELGKYEdldefwqp5RdydoF1xk7Mqo+tUL6O9Ri63ReNV5jwFX65p+o+VN7kouIYpAlyJgWOAWGMH8KluWT7MHE8CjOP3rZB/PnNYhmu55PLheIy53ZVeFUfw5Hf2xVWWKys7l5bpLr7Tg7Zpnzke2Tx+FFiZaFu8upzEzRGJ48bSGjGfwyc4/CsX+0IdPuEae1Rg+QQsIVlPXI9foKhkv289i8EEkQ+7IHKyfjj+nPtWLf295rksKzmObSA4IWBSolI9WPO0frQo9WZ899Ea+oaykwZ7OX7XNwIrW36H/fbov8ASs6a31mS3CXt/YWswOVEab1Htk8+3Sl0u20/w5II7WzuY7O4bcqxoTsc9QOehq1qOowzsFa6gs7cn7pcrJJ+OOKpES13OVudSeXbZ/Z2nk3ATXEabYzjqN5HXtirN/rljYWdva22k39wdwjjt0XaijuTk4/Or13rtoI5BG9mph+QSCdWKgdcBupqrp1z9tkMiTybgu4C6A7ng4HX/OK1ORq2zOb1zxmbq9ksLPTIlunTZO84BWKP/ZHc+9c5PqVolx9m0uzTZbTqWAXzGncZ4wew9eldXfeD4b24l8q4u4kB3GeGIKZJD1I9ucZFUrTS7LRrm5S1hcFVzKZCxYcjkP8AgTjFaJowmupyWofa7ueeS2Y2KfMZAV2DIHTaT79qzXs7B7O3hn1OV7wufMjZTthHfPFamoXGmy37SXTpPBjzE2u+A2cDb6+pJFZCLNqE8sFnpalmO4tuYfLn36A1ZjqV7+7tY7QWlsZZogeJZPUf3cdvrWehWO0f95IA5H7rkAjsT7dan1OzuImEkkKxB2ISOM7h74GScVAlrLJA7s+GBCrH1ZifQewo6msVFLcZAxjkgdP3bA5DnpnPX8K1rSNZrCBk2G8Zm25OSxDZNV7OSRXjS3WN3MJUKBuLAnkH3qePQ70ILqzADRIXZQfmQr1znp60hSaej0PpKMn5SBwOx61ZWQq+CDnrgcVDb/LICc4xxj19KtAoQGAG4dvSuQ9i2pajuE2n5QHI5A9KmjIkzuzheo9DWaSoc7hj0GMGrtmeCw2jkjA70NFcpMGVJCMlQRn2qxBIGjyCCvbFRvkgqyg579BRaW6wNtTODyBnIzS9CtGrl+GUblwSSePwq2ZGUDcw65OfSs4IDGzEY5HPAIqVST90DcBjJ/rTJaLqsNxzhRnHy84qZHO/OC3HYVUgO5sDHoQe9SPJEGIVCo7DHbuaQutiyQVySPlOBnoR9ak8skEq2eeM4yR+fFU3l4wh3ZPGe/4VNHKSF3Nzt6AHn8KB62Hho4dxK7iTlsCmRPBISqxFSTwxNJKUl6qQF556fSolYCQnLhecKOlSO3UmaVVbaMpjvt7fWleBZiTvcnPrkfnVcrIeBJhW98/pT4mKn5uDnjHb3qdB20ugkKRqcRBmyQeASfzqJyUYb0AyMgAdPyqWRywbIVYyOx5zmobcFlO8KQTkHqKTdgS0uyQhnTeeCB8oI61XimkTJcCQg4G0VI37wjy8DAxnGf0potyOWb5M+uB09qGzSEVbUjEqtKfkKE8nParLSnygsLLuxxzgE0Q+UJC6ttB6gjqfWmGMjcQ+WP8AAORQ3YpjrUlWy21T6gcH61ba78tdrghQc4wfzrNuZkQFZDgkDHyk1n3kqBQJJCyN/Dkru/HrRzEuN9S7qetW6BlME1y2M7V4UfU8D8Kw5dRvtRCxNELOPGQFyTx78DP8qX7Vb7NtihJB/g4qC/RrtFjeZiP7u4ow9xmi7M+lg8m8FvLHYXRhjDb0Eqlgz9Tz15qa1vkY+TqsDxSbQ28uZEYH0PUfjUAvbS3tpILnzAQpILqSSPXI71ha3qOkm3ST5FI25aV2jIB4OO5FXF3M5vqdLfm1ul+zQLESOdwO3Z/9esDVr+axCyQDNwkgPllgvPQjOeB359a87uibTV2j0jVhGtwhBjjTeR6sobkflmsldJ1HTWnvbTULmORcrKbuISMTnOcHOK2ULo5vaSvZI9GtPFtreW8ttfD7HfoSVilkBZyD1Tsw/LNdWl5HdafDM8USzMg3B13YPcV886tr0TxC11ayjbVrd/MS+jY/OeuGBwenv+FdJ4M1vWtTs/J0ud55ldiY52ykSZ4y5GSfp+lN07ajU+bRnc6toumiQXU2mWd1cdF3Lt5J7AD9aq6PHe2cglltbcW7qxXa/wC8UDoBkDjFVrSfVUea21NIzO+FQxS5DMfQnn1ra1mfYsdrEI5TOfKAfnacd6bWpEoJbMsfbbgxkx2TbOCpDryD3rjPFGqqlwkE6zsr7mkhjbkovPz98E4HYVsS3sGgGC11eTeQhWKcdiByCT1A/OubuI9JmF5qM0kkDlx+8uWx5gByAB02nFOCXU5qjvoc19mE98HTTzbed1uCmfmJ5K444A4pL/R7ezkSScu8DfIXZjETn+8eCcEelXbzxOY2aeO0kuLDBCYyjR55wTj+Vczr2ry3g3+QiI4JU+YxI/OtrnO4tvQtX32Kzske3jkkZ84kGME9hnnge1ZGj3EseoNduVjWP72OCARjAFabJb6d5Et7O77IwY7fBCoG5OzPpWHqVzHeX4kjTy4iAoGAOPoKbCnG6a/E6eGGys/s15ZXLQXGzJZoicMevbn/ADzVeW5vUv5GniJtpEIlkhztfuWPpxT7OK+dYU1F5DblR8sfJx6kdR0rakktNQb7Ers6LuaUgYDMPlUHv07VOhOp7fyWxn2ohJ3gOMr14pqZXeCOD0PpTkYbgDj0z0ArjufQIsKodiGHUdxxUtuu3pvAzz+lQ4IjLADp681JbrJIE+YBetFyky/GVkA2k5HPNQ7N0wkYk7e4PbvxTk3KCzA5x1NJHy2xVX3LHqO9NAi0mx4l3MuB3z1xRJxyh2npyKp6baW2m2pt7aLy4AWZUBPGTnqTVwEqFwc46Ac0Cdr6EkXy7QvfnPr/APXqUFlYOWJVfUY/CoN+0jPTsR61IEU4YpmQcZB4/GkmF+5YLK20lwG6emKOG+fJ78kdfwzVQAhwzD6g0smAigsxOeVzTYJFtJAEZCOSOWqRZFRNilsj3zmqUUankDqO5/WnrIG+QAqRnt1NQxuPYsCVJFAxuI688E0hbdHkgY9MZ5+lMRwAPMUgHqQOae5+RVjO1hypY9allqISJhdjOFT0znFPtY2CqmDg+vOaIdu0q+WdeCBycVcSNRCfmYL2GKloqTsrFd02yNkNtIHP938alJVQFKDpgADNSqrv95Sq92P9Kia2cMcsxBOfp+FCElfcJEKqoRQOcZAzmq/lb2/dDywOtW7cF8JHzGn8a9/arBhYocc8ZIo16D5nHQx/JcHB+ZicbutRXVnA6kXAUjbwWXJ/D/Gt4QMzA5AP8uP0qO8XACR7dzcA9eO9K3Ubnc4yK3NtchVcsXGUPRs+lDWs8s7KywkYHzlc5/z6Vu31q8zuMKYUwMgYbdn/ACKrzQxvcLAsroEBBCtjr2qQaUjkNftIzcRIyOx5Je3LBv8Avkdaw76we5gl+z215bmIBkuZNrsOf4epHTkV3wsSk8ggkdcgKN2Dnj86qXeiTZUx3CKgOWjEZKn361ak76nNUhbRHB3Wn6dp9vJNe2vmyuwf7U0g3se3HUfSsvR2ur2WaF9MRopJsRefKWxjk7j6c5A9sV3Ufhw6ezXZEUzoCUkny5XPoO1cuW1Cy14+YYJridwwREKJHkH5nx04/OtVUdtDJxMPWfAmmQJO8zm5umfeImkKJHubr/8Arrj7SK98OeI3k0SGS7si+EELh2OB82MZ9+oxXrNxpN1fIyX8nnFgWVSMIx9MDk9e9OTSzZQbFeAXLYVobZPKCoOoGOQO/OK0jUvuYThrocRqV9qXiSBZrUyWTwlnSOfaqggchjgZz6dveqEOpsLixittSF/IoX5TL5CoegQgdevXNdM+lWsOpSgQPcRyR72RIi4ix2DH1FSw2mjW8cdtb2cX2e5O4SEZYAHkYHIGelXe5zu/Vmbf6CmoXAh1CeOZ3C71t8tFEgP3VJ53Z5JrMt5IZI0t7mylurvTiyW9y23Dw7jtOSQMjnmofFmuReHLhrXRL4yYXJhKq6humDjpgc9651tfWdLaDU45lCx7NpjCg5z8xPU4PSrimZu+6LWtahqGoERWtvcQ7sCToAR7beSD1rm7eRHtprCRIIxvMjXbA7sL2H19PWugv9csLXTpLe0kaabAIc5XcT13fSuKZixJzV3CEXK9yS4lMztJJI8khPVzkkUlsoaZA5IXPUdauaHo17rl8trp0JlkPJPQKPUntXWN8NNZtgZJ2QIuDmMFjUymlo2dCg2rIdCsxiSIXKhZlyAHXzGxwAT/AJ6UTW1vaXLzKWVYkAlWLku4Gcn9K1tI8GrbSBZLe4ku253SHCgE8ZxznvVnUNKt7FIRaRq87ttLkZHX5j+A6Vmp3Zi6NlqevAEbSrA9iOxpjYcKAuAM8/zqREbYQOccEigQKX2BsN161gmj11a4iy7EX5QDjHzVPFMuPmB3DqBSeWc5cZA9uKgZOCBxz1FF0VZPQ0d53swOQeme1Pc4TA5Y/wCTiqaTxqypkB26c8GrEbKz9B16H1ouJKxLLJtwMYI5x2qSFncHkBvU1WMqljuL46emKcZVUbiXwe1O40i7HwNxBwe3Wo9xDEckehNQRzZPB9wMfpT2kOz5UbI65PX8aQ+VokRgMYc5PA9Kc05ztyOR0U1VRm3Z259PypVyr52bif4s0XKsr6l2NyVG4ZHY96mKEDjjjoapHcrMMkADJpyzOQGJyvoaLMF3RdR9xIHQDgk9aCQnzMvGemOvpVaKRUYmNQwHUdz+dSiQb8AAc596mQ0+xoWbI5LqD74HFXVIH3Q3BznH8qyo5hhUJABIzjpVmEsGYKVzjGOelSKVjVjkRiVAwCAcHqTRMqqhK52t0Oc8+9UY5gG+VuAct6VYkuFJCnnJx9Kuxne2w6AKi+WhCsecAYFO8uMthVUHs2Ohpk00flZBBcD5WVc8VEtwShKFWYccH5c0+Uq99SWdfLJIbcOnzc/lVeUypAclNo6HvilkkR4JSTvbb0zjH+FUJrl5IQgGIyACB3/+tQ1oUtSOaSado2LqoB+SNRt3e/0oEMakqqZYDkE9+5qvICrjEj7gMEjApAz8nzJBuzyWGfyrNxG3bYkktlV/MYfN6Ke/rVKX7auTFIFTkhSc1aUrsGN5bnk96pyXPXzI3RG4yOo9agh9mZWsXNxAFE7yvcP/AKpYQMA57iqljo0gXfcXTrcMfMcuA5ZjxzngD0ArYSe2WZjEVB6FmHJ+pqCS9nQSOkKzx524DDJA6Y/+vVq/QwavqUVvxaymC7MMDKcCaP5g3p9D9aZcJZpOSoLCQbiepYjuasfaIpAz2b28M2MvHOvT6j0rl9dvNVtNs8kFg0YlAJgk2+YDxgqRx9a0irmM2E+s3kE0ipaGe1P/AC9SZSNfY9zj1ArkdR/sho59Qcw3c867Zbe3kKIBnjk9Ce/rXaxXs9/bFLa28t2wHMx6DvjH5cVX1hLgIY4JbSSfAxGsGQMdsk8VrE55o8ovrb7RGH+wR2dm837qONWVixXjAOOmOvf6VQu9NvFYJugSQL5skuTJIxyevHv2rpPEMV7JNFdNdQNdcjyhEGEZPGCx79ct0FcjLeXNzIWeZ1lLbI0gG1cj0PoMiuheZytu+hj36OlwVnm8yXGHPJxjjFSaNp02ralDZwcPIcZI6D1qG8VUmZY5DICck5zk1e8Oa1Lod8LqGNJHHZuKUm7XR0w1SPofwLoOm+F7OK1yftTBpHlYfrmug1WZnt2ezIYqBtJ4DE9DiuD8O+NL26sUub+GDaCd6KD93t1rrbjGpRWhSQMhxIOegAzn+VeY5Ns9OKio6GNdyvbblu3mV8bpCFBBJ9W7VwGvXN29+DYmFGSRYVbdkdMsxNdR4gisBctCuoXUFzkEv5vDnGcYPBryvWmk0/VDFNczSwZMoVSCckdfY110odThxE1sj6PWTcMDgg8H+lTFVDjfjPpms/OVRl6559RVsFX4JO888iocTtjNMshSCmB1/KnzqgO7dtwOgHFUjMwl2kkjsfrUqDeVGflPB70vU0tezZJHsGdyg54wfSpmhzHxwuenvULxl8hMYyRzUqO+zY4G5Rgc5yaTK8yRVCoQW3+x600xpGikbtoPOeeaACAHHGRkkd6mYOJVOAe/HrT1FsReYuxSCOe2MU+BdpYFnKk9+lNBUyqFUDaOM0u4h8MRkH0plarQcwQEMCTz2NMUhZF2jLAevNI6nzycj1IPQ0iJ8pIzwPvDrQJMsj7u8Y6cjtio8u4UjAYHkqeMUmV2DByxPORVZ7pEufKAYY5Bz3NJsSdi3v2lVc89PZTU1uMKArgkc5zz+NZsd0GU78kZGeOTTkmUzeWco5HyuB1FKw73NEM3IZsn1FWY7jy13buvXNZEhkSTcWwo79eKeWLbAD3xz1osKTuacVztjUNySTz6Ui3eJMgBU6YHHPrWLI74AbIRuOD3p8U7Lb8ZI+8aqxm/dNwXPARZ3UHj60rXRbARCcjB8vkt71gLLsdWcksQM+2e1SNqLI7YX5RxnpQhc1ti816xEqRyfP3JU8D6etI10UtlG/aMfNzjisT7e8pcAFD9c1LatvYF5GIHLk8kikCqpF59UjY7YWBI/iAqy0hkHIB685xj8ayp3SWdY07fNnpUx3GJv3rjHAxUsrmTsy1cXTRR7By3brk1AxmfOGAQ/N8o796qbDJsYu3Qf/Xq3sdkIjfbgdMcEenrSIlJJFSR38wIUVmH3Q3GR6moX86OQ8AB25CNu/wFGoyTQWQcBQVORt9v/rZqnNcyqi4TzVbjghSD75q1Ej2iYXl6YWW4lt/KSMjHK5fPHP8AQVUumS+s5SkKxll5VyMHvjiqd9IzzMk9uAiAHl9xJPp29Kzn0u3nZt0UVu6qAqJk59ielbRjbU5qk7rQe19prah9kmSQJ/rUJlwBnqBz2P8AOqviCS+hiZ9JuLeJUVsq7bvl+vY+lZmqPJPcjR7Yxw3UahlFuu0Bc8kuefwFcj4h0QabDJNqCQsUAAWF2Adjzls8k9a0UTllLQzNQ8R36Nc2gMEJnYNM5TPOOQOSMHrx3rDhe5cnyZAuAfmDbeD1/Ou00PwrbpZwXl+Ekmn+byT9xVIyOnfH4Vi67p9ot+3lx+TAhAbaOeegAHHbrV26kc0U7HMlSASfXH1pMHirN1HEj4hdmHYGmwxJ5TSyMQBwAOuaVzdTVrnUeHtdWy06aC/nlVWODGI8/LjjJ+td7oHimyt9CWbUGaNwmNqqdx/LgD2rxiSTzGABbbwSWOcn1rciuxp9lGEUTySL5spk5C84GB61k6SvcJVZRSRa8Va6dUur0pJPDbEq8Ubrksfc9vWuXErgkh23MMMc8n6066uJLiVnkZm3HPJqCtUrBGOmp//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has multiple soft, flesh-colored nodules consistent with lipomas. Scars are present at sites of previous excisions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35538=[""].join("\n");
var outline_f34_45_35538=null;
var title_f34_45_35539="Rock of Gibraltar sign";
var content_f34_45_35539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Subpulmonic effusions with Rock of Gibraltar sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral subpulmonic pleural effusions, larger on the right side: Chest frontal (panel A) and lateral (panel B) views and image of the Rock of Gibraltar (panel C). The elevation of the lung bases with an abrupt drop-off laterally on the frontal view and posteriorly on the lateral view has been dubbed the \"Rock of Gibraltar sign.\" This finding is best seen on the right side on the frontal view and bilaterally on the lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35539=[""].join("\n");
var outline_f34_45_35539=null;
var title_f34_45_35540="Valacyclovir: Patient drug information";
var content_f34_45_35540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valacyclovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     see \"Valacyclovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/35/3638?source=see_link\">",
"     see \"Valacyclovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valtrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Valacyclovir&reg;;",
"     </li>",
"     <li>",
"      CO Valacyclovir;",
"     </li>",
"     <li>",
"      DOM-Valacyclovir;",
"     </li>",
"     <li>",
"      Mylan-Valacyclovir;",
"     </li>",
"     <li>",
"      PHL-Valacyclovir;",
"     </li>",
"     <li>",
"      PMS-Valacyclovir;",
"     </li>",
"     <li>",
"      PRO-Valacyclovir;",
"     </li>",
"     <li>",
"      Riva-Valacyclovir;",
"     </li>",
"     <li>",
"      Valtrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691885",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat herpes infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3652586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat shingles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valacyclovir, acyclovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Raised liver enzymes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pinpoint red spots on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for an infection that came back, start this drug as soon as you can.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11133 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35540=[""].join("\n");
var outline_f34_45_35540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232799\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232800\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016213\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016212\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016217\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016218\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016220\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016215\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016216\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016221\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016222\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=related_link\">",
"      Valacyclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/35/3638?source=related_link\">",
"      Valacyclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35541="Approach to dermatologic diagnosis";
var content_f34_45_35541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to dermatologic diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35541/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/45/35541/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 7 percent of all adult outpatients have a primary skin complaint, and 60 percent of outpatient visits for skin disease are made to nondermatologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with common, chronic medical conditions, such as obesity and diabetes, have increased numbers of skin conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The prevalence of skin conditions is high even among hospitalized patients, with many previously undiagnosed conditions becoming manifest upon a thorough skin examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/4\">",
"     4",
"    </a>",
"    ]. Over 12 million physician office visits are made by adolescents and young children for skin concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/5\">",
"     5",
"    </a>",
"    ]. More than one-half of patients also have great interest in skin care products or use alternative treatment modalities that may impact the skin, such as herbs and food supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some research suggests that the training of primary care physicians in dermatologic diagnosis and treatment is insufficient compared with that delivered by dermatologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/7\">",
"     7",
"    </a>",
"    ]. Nevertheless, patients trust that their primary care clinician will accurately diagnose and treat the majority of their skin conditions, even while they have higher trust in the diagnostic acumen of the dermatologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, primary care clinicians need an ever increasing base of knowledge, awareness, and diagnostic skill in dermatology.",
"   </p>",
"   <p>",
"    Being able to speak the language of dermatology is half the battle. Once you can identify the primary and secondary characteristics of a skin lesion, you will achieve far more success in formulating an appropriate differential diagnosis. The art and science of dermatologic diagnosis lies in utilizing all available findings to assist in forming and then narrowing the differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35541/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Unlike many diseases, objective findings are present the majority of the time in locations detectable upon physical examination.",
"   </p>",
"   <p>",
"    The initial approach to the patient presenting with a skin problem requires a detailed history of the current skin complaint and a complete skin examination (",
"    <a class=\"graphic graphic_figure graphicRef61227 graphicRef52494 \" href=\"mobipreview.htm?36/5/36954\">",
"     figure 1A-B",
"    </a>",
"    ). In many cases the patient&rsquo;s general medical history may be relevant to the diagnosis of skin disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important initial questions to ask patients with a skin problem include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How long has the",
"      <span class=\"nowrap\">",
"       rash/lesion",
"      </span>",
"      been present?",
"     </li>",
"     <li>",
"      How did it look when it first appeared, and how is it now different?",
"     </li>",
"     <li>",
"      Where did it first appear, and where is it now?",
"     </li>",
"     <li>",
"      What treatments have been used, and what was the response, this time and previously?",
"     </li>",
"     <li>",
"      What associated symptoms, such as itching or pain, are associated with the lesion?",
"     </li>",
"     <li>",
"      Are any other family members affected or have a similar history?",
"     </li>",
"     <li>",
"      Has the patient ever had this rash before? If so, what treatment was",
"      <span class=\"nowrap\">",
"       used/response?",
"      </span>",
"     </li>",
"     <li>",
"      What does the patient think caused the rash?",
"     </li>",
"     <li>",
"      Is anything new or different, ie, medications, personal care products, occupational or recreational exposures?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional questions that may be helpful include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the patient have any chronic medical conditions?",
"     </li>",
"     <li>",
"      What medications does the patient take currently, what have they recently taken, including over-the-counter and herbal therapies?",
"     </li>",
"     <li>",
"      Has there been any increase in stress in their life?",
"     </li>",
"     <li>",
"      What is the social history, including occupation, hobbies, travel?",
"     </li>",
"     <li>",
"      Does the patient have any underlying allergies?",
"     </li>",
"     <li>",
"      Will the patient's education, insurance, or financial status influence treatment considerations, such as compliance?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, it is important to include characteristics such as distribution (extensor surfaces in psoriasis and dermatitis herpetiformis), lesion morphology (wheals, macules, papules), and secondary characteristics of lesions (thick, silvery scale, thickening, or lichenification). Knowing which conditions are more frequently diagnosed can assist the practitioner in arriving at the most likely diagnosis for a given patient. A table shows the top 10 most common diagnoses for patients presenting to dermatologists and nondermatologists for skin problems (",
"    <a class=\"graphic graphic_table graphicRef65404 \" href=\"mobipreview.htm?20/48/21260\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The physical examination of skin complaints should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type of lesion",
"     </li>",
"     <li>",
"      Shape of individual lesions",
"     </li>",
"     <li>",
"      Arrangement of multiple lesions (eg, scattered, grouped, linear, etc.)",
"     </li>",
"     <li>",
"      Distribution of lesions",
"     </li>",
"     <li>",
"      Color",
"     </li>",
"     <li>",
"      Consistency and feel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two most useful characteristics in terms of forming a differential diagnosis are the type and distribution of lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lesion type",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to always accurately describe dermatologic lesions. Many diseases are more easily identified when the appropriate morphology is recognized. As an example, isolated macular eruptions are rather infrequent compared to papular or papulosquamous conditions. Thus, if hyperpigmented or hypopigmented macules are seen in isolation, the differential diagnosis is much smaller (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29831?source=see_link\">",
"     \"Approach to the patient with macular skin lesions\"",
"    </a>",
"    ). True bullae also occur less frequently than vesicular and pustular eruptions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14186?source=see_link\">",
"     \"Approach to the patient with cutaneous blisters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=see_link\">",
"     \"Approach to the patient with pustular skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Primary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lesions are either the first visible lesion or involve the initial skin changes. The terms used to describe primary skin lesions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macules are nonpalpable lesions that vary in pigmentation from the surrounding skin (",
"      <a class=\"graphic graphic_picture graphicRef58169 graphicRef61452 \" href=\"mobipreview.htm?40/34/41512\">",
"       picture 1A-B",
"      </a>",
"      ). There are no elevations or depressions. The differential diagnosis of macules is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef61066 \" href=\"mobipreview.htm?36/18/37164\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Papules are palpable, discrete lesions measuring &le;5 mm diameter (",
"      <a class=\"graphic graphic_picture graphicRef73398 \" href=\"mobipreview.htm?26/27/27060\">",
"       picture 2",
"      </a>",
"      ). They may be isolated or grouped. The differential diagnosis of papules is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef61037 \" href=\"mobipreview.htm?21/12/21709\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Plaques are large (&gt;5 mm) superficial flat lesions, often formed by a confluence of papules (",
"      <a class=\"graphic graphic_picture graphicRef54581 \" href=\"mobipreview.htm?32/28/33219\">",
"       picture 3",
"      </a>",
"      ). The differential diagnosis of plaques is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef68549 \" href=\"mobipreview.htm?20/15/20732\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nodules are palpable, discrete lesions measuring &ge;6 mm diameter (",
"      <a class=\"graphic graphic_picture graphicRef61498 \" href=\"mobipreview.htm?30/27/31154\">",
"       picture 4",
"      </a>",
"      ). They may be isolated or grouped. Tumors are large nodules. The differential diagnosis of tumors and nodules is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef70150 \" href=\"mobipreview.htm?20/38/21100\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link\">",
"       \"Overview of benign lesions of the skin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cysts are enclosed cavities with a lining that can contain a liquid or semisolid material (",
"      <a class=\"graphic graphic_picture graphicRef68396 \" href=\"mobipreview.htm?25/38/26214\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Telangiectasia is a dilated superficial blood vessel (",
"      <a class=\"graphic graphic_picture graphicRef71614 \" href=\"mobipreview.htm?13/22/13667\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pustules are small, circumscribed skin papules containing purulent material (",
"      <a class=\"graphic graphic_picture graphicRef67402 \" href=\"mobipreview.htm?28/0/28677\">",
"       picture 7",
"      </a>",
"      ). The differential diagnosis of pustules is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef56796 \" href=\"mobipreview.htm?18/51/19259\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Vesicles are small (&lt;5 mm diameter), circumscribed skin papules containing serous material (",
"      <a class=\"graphic graphic_picture graphicRef81443 \" href=\"mobipreview.htm?5/57/6039\">",
"       picture 8",
"      </a>",
"      ). Bullae are large (&ge;6 mm) vesicles. The differential diagnosis of vesicles and bullae is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef78295 \" href=\"mobipreview.htm?23/31/24060\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Wheals are irregularly elevated edematous skin areas that are often erythematous (",
"      <a class=\"graphic graphic_picture graphicRef50151 \" href=\"mobipreview.htm?20/36/21058\">",
"       picture 9",
"      </a>",
"      ). The borders of a wheal are sharp but not stable; they may move to adjacent uninvolved areas over periods of hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Secondary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary lesions of the skin represent evolved changes from the skin disorder, due to secondary manipulation or as a result of infection. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excoriation describes superficial, often linear, skin erosion caused by scratching (",
"      <a class=\"graphic graphic_picture graphicRef73387 \" href=\"mobipreview.htm?18/30/18916\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Lichenification is increased skin markings and thickening with induration secondary to chronic inflammation caused by scratching or other irritation (",
"      <a class=\"graphic graphic_picture graphicRef80745 \" href=\"mobipreview.htm?8/20/8517\">",
"       picture 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Edema is swelling due to accumulation of water in tissue (",
"      <a class=\"graphic graphic_picture graphicRef57090 \" href=\"mobipreview.htm?34/19/35121\">",
"       picture 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Scale describes superficial epidermal cells that are dead and cast off from the skin (",
"      <a class=\"graphic graphic_picture graphicRef68198 \" href=\"mobipreview.htm?21/54/22372\">",
"       picture 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Crust is dried exudate, a \"scab\" (",
"      <a class=\"graphic graphic_picture graphicRef82281 \" href=\"mobipreview.htm?18/22/18787\">",
"       picture 14",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fissure is a deep skin split extending into the dermis (",
"      <a class=\"graphic graphic_picture graphicRef50615 \" href=\"mobipreview.htm?3/54/3937\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Erosion is a superficial, focal loss of part of the epidermis. Lesions usually heal without scarring (",
"      <a class=\"graphic graphic_picture graphicRef57242 \" href=\"mobipreview.htm?39/15/40177\">",
"       picture 16",
"      </a>",
"      ). Ulceration is focal loss of the epidermis extending into the dermis. Lesions may heal with scarring (",
"      <a class=\"graphic graphic_picture graphicRef72285 \" href=\"mobipreview.htm?36/57/37777\">",
"       picture 17",
"      </a>",
"      ). The differential diagnosis of erosions and ulcers is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef74110 \" href=\"mobipreview.htm?7/19/7485\">",
"       table 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Atrophy is decreased skin thickness due to skin thinning (",
"      <a class=\"graphic graphic_picture graphicRef60332 \" href=\"mobipreview.htm?29/9/29844\">",
"       picture 18",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Scar is abnormal fibrous tissue that replaces normal tissue after skin injury (",
"      <a class=\"graphic graphic_picture graphicRef81039 \" href=\"mobipreview.htm?37/7/38006\">",
"       picture 19",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypopigmentation&nbsp;(",
"      <a class=\"graphic graphic_picture graphicRef60866 \" href=\"mobipreview.htm?32/30/33262\">",
"       picture 20A",
"      </a>",
"      ) is decreased skin pigment; hyperpigmentation&nbsp;(",
"      <a class=\"graphic graphic_picture graphicRef78119 \" href=\"mobipreview.htm?20/25/20885\">",
"       picture 21",
"      </a>",
"      ) is increased skin pigment; and depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef72369 \" href=\"mobipreview.htm?35/34/36385\">",
"       picture 20B",
"      </a>",
"      ) is total loss of skin pigment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lesion location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain conditions have a predilection for particular parts of the body and are seen in characteristic demographic groups. As an example, tinea capitis is a common scalp eruption in children but is rare in adults. In contrast, tinea pedis is seen frequently in adults but rarely in children. Thus, when a child presents with foot lesions, diagnoses in addition to tinea must be considered, including eczema or atopic dermatitis, drug eruptions, and contact dermatitis. When an adult presents with a scalp eruption, do not assume there is a tinea infection, but consider whether the patient has seborrheic dermatitis, psoriasis, or an allergic dermatitis.",
"   </p>",
"   <p>",
"    A table lists initial differential diagnoses based upon classical distributions of common skin dermatoses (",
"    <a class=\"graphic graphic_table graphicRef59080 \" href=\"mobipreview.htm?20/44/21197\">",
"     table 9",
"    </a>",
"    ); this is shown graphically in figures (",
"    <a class=\"graphic graphic_figure graphicRef61227 graphicRef52494 \" href=\"mobipreview.htm?36/5/36954\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26223450\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial approach to the patient presenting with a skin problem requires a detailed history of the current skin complaint and a complete skin examination (",
"      <a class=\"graphic graphic_figure graphicRef61227 graphicRef52494 \" href=\"mobipreview.htm?36/5/36954\">",
"       figure 1A-B",
"      </a>",
"      ). In many cases the patient&rsquo;s general medical history may be relevant to the diagnosis of skin disorders. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key questions for the patient include the time of onset, duration, location, evolution, and symptoms of the rash or lesion. Additional information on family history, occupational exposures, comorbidities, medications, and social or psychological factors may be helpful. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type, shape, arrangement, and distribution (",
"      <a class=\"graphic graphic_table graphicRef59080 \" href=\"mobipreview.htm?20/44/21197\">",
"       table 9",
"      </a>",
"      ) of the lesions are cardinal features to be identified by visual inspection and palpation. Primary lesions and related diagnoses include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Primary lesions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Macules (",
"      <a class=\"graphic graphic_picture graphicRef58169 graphicRef61452 \" href=\"mobipreview.htm?40/34/41512\">",
"       picture 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef61066 \" href=\"mobipreview.htm?36/18/37164\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Papules (",
"      <a class=\"graphic graphic_picture graphicRef73398 \" href=\"mobipreview.htm?26/27/27060\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef61037 \" href=\"mobipreview.htm?21/12/21709\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Plaques (",
"      <a class=\"graphic graphic_picture graphicRef54581 \" href=\"mobipreview.htm?32/28/33219\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68549 \" href=\"mobipreview.htm?20/15/20732\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodules (",
"      <a class=\"graphic graphic_picture graphicRef61498 \" href=\"mobipreview.htm?30/27/31154\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70150 \" href=\"mobipreview.htm?20/38/21100\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cysts",
"     </li>",
"     <li>",
"      Telangiectasia (",
"      <a class=\"graphic graphic_picture graphicRef71614 \" href=\"mobipreview.htm?13/22/13667\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pustules (",
"      <a class=\"graphic graphic_picture graphicRef67402 \" href=\"mobipreview.htm?28/0/28677\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56796 \" href=\"mobipreview.htm?18/51/19259\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vesicles and bullae (",
"      <a class=\"graphic graphic_picture graphicRef81443 \" href=\"mobipreview.htm?5/57/6039\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78295 \" href=\"mobipreview.htm?23/31/24060\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wheals (",
"      <a class=\"graphic graphic_picture graphicRef50151 \" href=\"mobipreview.htm?20/36/21058\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary changes are due to spontaneous evolution, manipulation, superimposed infection, or previous treatment and may alter the morphology of the primary lesion. Secondary lesions include (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Secondary lesions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Excoriation (",
"      <a class=\"graphic graphic_picture graphicRef73387 \" href=\"mobipreview.htm?18/30/18916\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lichenification (",
"      <a class=\"graphic graphic_picture graphicRef80745 \" href=\"mobipreview.htm?8/20/8517\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Edema (",
"      <a class=\"graphic graphic_picture graphicRef57090 \" href=\"mobipreview.htm?34/19/35121\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scale (",
"      <a class=\"graphic graphic_picture graphicRef68198 \" href=\"mobipreview.htm?21/54/22372\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Crust (",
"      <a class=\"graphic graphic_picture graphicRef82281 \" href=\"mobipreview.htm?18/22/18787\">",
"       picture 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fissure (",
"      <a class=\"graphic graphic_picture graphicRef50615 \" href=\"mobipreview.htm?3/54/3937\">",
"       picture 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erosions and ulcers (",
"      <a class=\"graphic graphic_picture graphicRef57242 \" href=\"mobipreview.htm?39/15/40177\">",
"       picture 16",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74110 \" href=\"mobipreview.htm?7/19/7485\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrophy (",
"      <a class=\"graphic graphic_picture graphicRef60332 \" href=\"mobipreview.htm?29/9/29844\">",
"       picture 18",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scar (",
"      <a class=\"graphic graphic_picture graphicRef81039 \" href=\"mobipreview.htm?37/7/38006\">",
"       picture 19",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypopigmentation (",
"      <a class=\"graphic graphic_picture graphicRef60866 graphicRef72369 \" href=\"mobipreview.htm?26/45/27348\">",
"       picture 20A-B",
"      </a>",
"      ) and hyperpigmentation (",
"      <a class=\"graphic graphic_picture graphicRef78119 \" href=\"mobipreview.htm?20/25/20885\">",
"       picture 21",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lesion location often provides a clue to diagnosis, since many skin disorders have a predilection for particular body sites (",
"      <a class=\"graphic graphic_figure graphicRef61227 graphicRef52494 \" href=\"mobipreview.htm?36/5/36954\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef59080 \" href=\"mobipreview.htm?20/44/21197\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lesion location'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/1\">",
"      Fleischer AB Jr, Feldman SR, McConnell RC. The most common dermatologic problems identified by family physicians, 1990-1994. Fam Med 1997; 29:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/2\">",
"      Garc&iacute;a-Hidalgo L, Orozco-Topete R, Gonzalez-Barranco J, et al. Dermatoses in 156 obese adults. Obes Res 1999; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/3\">",
"      Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998; 39:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/4\">",
"      Nahass GT, Meyer AJ, Campbell SF, Heaney RM. Prevalence of cutaneous findings in hospitalized medical patients. J Am Acad Dermatol 1995; 33:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/5\">",
"      Krowchuk DP, Bradham DD, Fleischer AB Jr. Dermatologic services provided to children and adolescents by primary care and other physicians in the United States. Pediatr Dermatol 1994; 11:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/6\">",
"      Ernst E. The usage of complementary therapies by dermatological patients: a systematic review. Br J Dermatol 2000; 142:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/7\">",
"      Gerbert B, Maurer T, Berger T, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Dermatol 1996; 132:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/8\">",
"      Federman DG, Reid M, Feldman SR, et al. The primary care provider and the care of skin disease: the patient's perspective. Arch Dermatol 2001; 137:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/9\">",
"      Gropper CA. An approach to clinical dermatologic diagnosis based on morphologic reaction patterns. Clin Cornerstone 2001; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35541/abstract/10\">",
"      Federman DG, Kirsner RS. The patient with skin disease: an approach for nondermatologists. Ostomy Wound Manage 2002; 48:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6838 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.196.66.12-1617F87D8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35541=[""].join("\n");
var outline_f34_45_35541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26223450\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lesion type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Primary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Secondary lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lesion location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26223450\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/6838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6838|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/40/28296\" title=\"figure 1A\">",
"      Physical exam skin front",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/28/14792\" title=\"figure 1B\">",
"      Physical exam skin back",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6838|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/60/31685\" title=\"picture 1A\">",
"      Viral exanthem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/10/6306\" title=\"picture 1B\">",
"      Solar lentigo hand 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/27/27060\" title=\"picture 2\">",
"      Dermatosis papulosa face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/28/33219\" title=\"picture 3\">",
"      Psoriasis plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/27/31154\" title=\"picture 4\">",
"      Lipomas multiple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/38/26214\" title=\"picture 5\">",
"      Pilar cyst 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/22/13667\" title=\"picture 6\">",
"      Telangiectasia nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/0/28677\" title=\"picture 7\">",
"      Pustules in pustular psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/57/6039\" title=\"picture 8\">",
"      Herpes zoster vesicle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/36/21058\" title=\"picture 9\">",
"      Urticaria 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/30/18916\" title=\"picture 10\">",
"      Excoriation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/20/8517\" title=\"picture 11\">",
"      Lichenification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/19/35121\" title=\"picture 12\">",
"      Angioedema lip 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/54/22372\" title=\"picture 13\">",
"      Actinic keratosis hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/22/18787\" title=\"picture 14\">",
"      Impetigo crusted lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/54/3937\" title=\"picture 15\">",
"      Inverse psoriasis gluteal 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/15/40177\" title=\"picture 16\">",
"      Toxic epidermolytic erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/57/37777\" title=\"picture 17\">",
"      Pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/9/29844\" title=\"picture 18\">",
"      Lichen sclerosus on the chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/7/38006\" title=\"picture 19\">",
"      Dissecting cellulitis scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/30/33262\" title=\"picture 20A\">",
"      Pityriasis alba 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/34/36385\" title=\"picture 20B\">",
"      Vitiligo segmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/25/20885\" title=\"picture 21\">",
"      Acne hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/48/21260\" title=\"table 1\">",
"      Common derm diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/18/37164\" title=\"table 2\">",
"      Macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/12/21709\" title=\"table 3\">",
"      Papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/15/20732\" title=\"table 4\">",
"      Plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/38/21100\" title=\"table 5\">",
"      Nodules and tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19259\" title=\"table 6\">",
"      Pustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/31/24060\" title=\"table 7\">",
"      Vesicles and bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/19/7485\" title=\"table 8\">",
"      Erosions and ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/44/21197\" title=\"table 9\">",
"      Distribution of skin lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35542="Cherry pit with secretions in the nose";
var content_f34_45_35542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Cherry pit with secretions in the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 425px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGpAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelZ/wDwlGr/APQieJP+/wDp3/yVR4y/5GPwJ/2GpP8A03XlZLHUtQ1nxjcXHi7VdI07SLxYUitYbQxxxCyt5mYmSB2J3SuevTHFAGt/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXFfC7xBH8SdMvLzQfHHjCEWkwhlhu7XTEkGVyrYW3YbTzjn+E8V3/wAPdQutX8A+GtS1CXzr280y2uJ5NoXfI8SsxwAAMkngACgCr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVVa/vrWwgM15OkMY7sev09aAOe/wCEo1f/AKETxJ/3/wBO/wDkqquo+OLvTbZri/8ABuv28K8l5LnTgP8A0qrA8UfEuUb4NBgCdvtEwyf+Ar/jXl2o3d7qczz6hdTXEp6GVsgfQdB+FOxajfc9If46aShw3hrxJ+C2h/8Abik/4Xto/P8AxTfiXjr8lp/8kV5FLF8x7rnkZxUEkJVecAj+VQ3Y0VOJ7IPjto5GR4b8SY/3bT/5IpR8dNIJwPDfiTP+7af/ACRXiSKACqgBR+lSxS+Tcbxt3AcHHGaakP2SPa5PjhpcYBfwx4lUHplbTn/yYph+Omk7C3/CNeJdo6nbaf8AyRXjM0kk3D4OemaqGQqhhXIXqd1Fxqij2z/hfmiZx/wjviT/AL4tf/j9Rn9oPQB18P8AiT/v3a//AB+vCpRnIwME+tUJVwX2cAc5xzRctYeLPoJv2hvDyjJ8P+Jcf9c7X/4/Tf8Ahonw5uI/sDxLkc/6q2/+P18+JIIZM7FZe+RnNST3O6F1CRKW/i28gelLmH9Wh5nvj/tG+GU+9oXiT8IrY/8AtegftHeGT00LxJ/36tv/AI/XzVMrbcKSee3FRhFbJZQwPG6i5X1WHdn0yf2jfDQIzoPiXnn/AFVt/wDH6b/w0h4Y/wCgF4k6Z/1Vt/8AH6+ZnUqgDDoc56H86jKBgcEjnqTzRcX1WHc+mz+0n4WH/MD8Sc/9Mbb/AOP09P2j/DD426F4kOen7q2/+P18t7DvKKGHfI71bgQKFOSD6+lO4nh4I+mj+0b4ZBwdC8Sf9+rb/wCP1PbftBaBcrug8P8AiRh/uWo/9r18uysyKV3c/wCz61oeHroJIkY5fvnOBUOdtgjhos+nl+OGlt93wz4kP4Wn/wAkVKPjTp56eF/Eh/8AAP8A+SK8WsmG7H8R/Ktm2+p3VDqsbw0F1PU1+MlkxwPC3iT/AMk//kin/wDC37XP/IqeJf8AyT/+SK84jQ4yAufUirKKOc5K9c0vasn6vE74fF+1P/MqeJPzs/8A5Ip3/C3LfjHhPxIfobL/AOSa4VUxt4y2M88U4R5ySMt7cZo9rIl0YnpOl/EOXVc/YPCHiCVh1Xz9PVh/wE3QNaP/AAlGr/8AQieJP+/+nf8AyVXlCho3DxlldfuuvBBrrND8aajYlYrwG9hzj5ztcD69/wAauNW+5nKl2Or/AOEo1f8A6ETxJ/3/ANO/+Sqqat44vdI0q91LUPBPiSGys4XuJ5PNsG2RopZjgXRJwAeACa6DRtesNXT/AEWYeZ3ifhh+H+FZXxY/5JZ4y/7At7/6Ietb3MWrGh4n18aCunKunX2pXOoXX2SC3szEHZxFJKSTK6KAFif+L0rP/wCEo1f/AKETxJ/3/wBO/wDkqoPH91BY6z4IubqRYoI9ZkLO3Qf8S+8FcdrPiyYaX418UXHiXxDZ6Jo99HbRWmm21kzbDb2zEjzoWJJeZjy/TFAHYX3jW+sYDNeeC/EMMY/ie404f+3VYw+LcBOB4T8SfnZf/JNcv4f0uz8Z+I7/AE278Q+OrTV7KCK5kivxpx/dyDKsrRROvI7ZB9qwvCUk1/4X0e8uXL3NxZwyyOABuZkBJwOByapJMD0T/hbdvn/kU/Ev52X/AMk0n/C3bbBP/CKeJMfWy/8AkmuPaAAEEfXnFRmHn/dxjNPlQ1Y7MfGC1PTwp4k/Oy/+SKa3xis1xnwr4k56f8efP/kxXEvFu9yT+H41BcRDBX7v4HOal2LjFM7k/GjTwMnwv4kx/wBuf/yRTT8a9OHXwv4lGPaz/wDkivN5I+SehIx061VnX5V+8COPr9am5qqMWeof8Lu0zn/imPEvHPS0/wDkij/hd2mf9Cz4k/Kz/wDkivLBEeuQcDuf6U518tQMFmHA4pN2D2MT09vjjpS/e8NeJBj2tP8A5Iqtc/tAaBbLun8P+I0Hutp/8kV5FfPt3ZDccndxiuL8Q3JxjdtBPoahzZpHDRZ9ByftK+FIv9ZoviNfTMVtz/5HpI/2lvCsgymieJSP+uNv/wDHq+TbuRp5fSNP4Ox+tSROjbQp3juNucVXMyvqsPM+sz+0f4YABOh+Ixn/AKZ23/x+oj+0t4TBIOi+JMjg/ubb/wCP18uvJmIhQNw4XuPxqq7q0hQs3A4JHJo5mUsJDuz6vX9pLwu2MaH4k5GR+6tv/j9Kf2kPDAGToXiXHT/VW3/x+vlzG4KQWIIHXt7VZkUGMNnj1B4FTzsp4KHdn03/AMNH+GMA/wBheJMH/plbf/H6aP2kfC56aH4k9P8AVW3/AMfr5ht/3keed2eT0/OmMAspKY2nrjmnzsawUO7PqL/hpDwv/wBAPxIfpFbH/wBr0D9pDwwX2jQvEpbr/qbb/wCP18yAb1B3En+HkdKjjUxzKXAGc/PkYH1o52P6jT7s+pF/aI8OsQF0DxKSf+mdt/8AH6kH7Qfh8j/kXvEv/fu1/wDj9fN9muUAHyjHB45HrirpQdTwaXOw+o0+7PoeP4+aJL/q/DniZvpHa/8Ax+rsXxnsJQPL8K+Jjnp8tp/8kV896cq71yPmHHOK7rRQu0L8oB56j/GjnZjPCwj1Z6snxWjcDb4R8S4PfNkP/bmti18Y6jdRCS28E+IZYz0ZbjTj/wC3VcDYx/KOQewwK17Oa4tJvMtHeJ/bgGri7nHOKjsdb/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlU3TPFXKxaghz08xB/Mf4V09vcRXMYkgkWRD3BqiDmv+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KrqqKAOV/4SjV/wDoRPEn/f8A07/5Kqpq3ji90jSr3UtQ8E+JIbKzhe4nk82wbZGilmOBdEnAB4AJrta5X4sf8ks8Zf8AYFvf/RD0AdVRRRQByvjL/kY/An/Yak/9N15XH+KNB1nxRovxN0Pw7cWlrd3+sQwSTXLMqrCbCy8zG1SSSuRj3PNdh4y/5GPwJ/2GpP8A03XlWtU8FeFdXv5b7VfDWiX17LjzLi5sIpZHwABlmUk4AA+gFAHFeBPhlqHgf4hS6lpWqLd+H7vTIrO6iutiTiWEBYmVYo1QqEAXnnkk5rq/hP8A8ks8G/8AYFsv/RCUf8K48D/9Cb4b/wDBXB/8TXS2ltBZ2sNrZwxQW0KLHFFEoVI0UYCqBwAAAABQBLTZHSONnkZURRksxwBWP4k8R2GgW++8k3TMPkhTl3/DsPevKPEniW/8QKRM5hts5WFDwfr6n600rjUbnYeJ/iFFbl7fQ4xPKODcOP3Y+n97+VedHUb3Ur5ptQupJnJ6uc4+noPpTETMJI4A6YGabaIROucKOmPWrSVitEiC9jHmZ28E89qzlQAv97PvW9fRk5PTmsmWPBIUjB6ZqWOLM2SMM6gbuTj2NWr2w8u3MxOI1GB2qS3TNx8zfKvpV3xJcRi0toYx8xXL98f5+tYznbQtN3ONdcLlWDD0qCQEdMBugwO1aMqqR95gxHBNVJ0+QZBAPB9TUxZuiDeThecZ701Bv3hThvehhjOMY9uooi+ViuR61aGMuoim0NzuHI9KzZgqjnnnoK1JJiYmPYng+tUZwGXPVlGfl5/OndMuJQbgbg3BHI9ary7RGFBcnuc9KlkBJAAwegx/WkCY5A/M/nSsaXKZTqAMn0/wpr4DY3nHpVlsY3Z49AcZqu4G7aD34xTC5V+aRznqOp9qbJt28MxI6fLx+NWSuOdoJ9+M1CeC2GBPXA70CbIogByz7T6D0qym0KXIJIqCMO7bU3Z6mq2o3scKMsZ+6eSP60myWyLUr9bdSQT5nbA4rM0bUXivfMlYgls89vx7VlXU7XM7OQD6UseRjBYj2pqGhKnqe56NdrNbxspABHHPWuosiCByCMcc4zXlHgTUyEWJn47Etn+vFep6fKGAwQenJrmkrM2l3NiIDvknvgcirUScZx789ahgXpz7HJq5EATjr+PepMWCqoHIPbJznFSrGdxHzH6GpEUkcN+nSpFRjgdR3NMhsgCbuwGelOEY2sD1HGB1zVgJgg/z7VIq56gDB64pktleFWjYPEWVl6OpwRVnxj4qux8NvFVjfD7QsukXcaSHhgTC459f50oQYbC8Vh+PkI8B+Icf9A65P/kJquLs9DOSvud18cP+PXwln/oNH/0iuq5Kw8M3vjL4Z/EfQdMkt4by91aNY3uGKxgrbWTHJUE9FPQGuw+Nn+o8JYz/AMho9P8Aryu64C58N6JqFy9zf6NpdxdSY3ST2yO7YGBkkZPAA/Cuk5ztfhv8P9S8O+M7rWprfR9GsJNNjsf7L0eRnimlVgTcSExxgPgY4Xoevrw/gSMHwP4czgn+zbf5fX92tSx+DPDOQD4d0XH/AF4xZ/8AQa2oYI7WKO3toUihiAjRIxhUAGAAB0AFNIlsjkjyOQGHTioXiYBiVB7Zz0rRZON3AU8EH1qOWPrjIXr9aYJmXIgBzxhT0qvKOMhQR+lac0QyQOOOlUbgEdicnpSNosxpYjkBR+XWoPJyvIzz1xjH+FbEsJdSWbnrux2qMQbRwuCeg/xpNWN+czjEAC2FK/3jz+NZt8wQH5cj1zgVs3W1EZuAenB61zOoyiR2UN8o6kdD+tYSZcNWYurXLCI4wT2B5/pXEeJ2Kqi8eYw3EjHH6f4V1t6TJcbNwwnT0rhdfm8zVpEHIUY4Pf8AM/0qVudK0M5FzGxBUsO3+FWLZ2wSxD+oHWmgDKA8c/N8vSrMKbvMLEEDv3Bqy0icowjGB8vYVUk+VwRnnjd6VoLuaEYI98iq11GA4JByeBhsUiiUsPJjkDE4ODjqfrV2TKorJkdvm64rPgbCbMsAPzrRtYw9uqkjAycDmpKKqN5cqjkoeCBzz9KfNtBGVYE9yOgqMIwk+/gZPHQe1SD5sqOvUg85plIlttrL3GeASMg0SIUxgAAHaSB1ot0KHLHgDkHtViVQV3bThu5PFBRYsXBUAlgSeuOK1BgnkE554rBs3aFmO4pg9eufb2rVhfODuwpOMZqXuOxsWGd4ILY6E/5NdxojElSfmHTAJ/xrgrH/AFoIXI74GP6V2OhuMqACMjsP/rUXOerE9A07lASSB05zWsiAgnBJ75/iFYukSblXg8jrjj+VdBb4ZQWGR71pBnlVVqIEywBHBHAFWLKW4tZfMtnaM9+4PtUiKTgDAHWpI4xjKDjt6V0I5W7HRaZrqTAJeARydNw+6f8ACtsEEZByK46O3JBGMsOcY/8ArVqWc01sQFy0X9w9voafs77Eqrbc3a5X4sf8ks8Zf9gW9/8ARD100MqyrlT+HpXM/Fj/AJJZ4y/7At7/AOiHrO1jVO+x1VFFFAzlfGX/ACMfgT/sNSf+m68rqq5Xxl/yMfgT/sNSf+m68rqJHWNGeRgqKMkk4AFADq4bxl44i07faaSVmvBw0vVI/wDE1j+NPGct15llo7mO1+69wOGf2X0HvXCiMAcd/T1qkjSMerEuZZru5a4upJJp3OTIx5P59qniVigPT361Gse045yecAVbiT5CASB6kd6Y5DY0+THXuMGo4oiJ1ycH9DVqNPQYz1zSuvzgc8c80zNsL6Plffr6iqFxBu3AYxitmW3YqPukAZJz/WqLeWHy2SaiTsCOectF0I69CKo3bGVzIxLknqe1bGoxZZ2LAnPAHGKr2mmTXdndTKARFyeckVz2vdm0Wt2YsnzsAg5/2jVS5ByQAAM8jNST5XJPJ9+1VmDSZIP4k9qzTdzoRC54zjHpjtTVC4KKOvWkk4JPIH6CnRkg5Jx/s1qmUytdfuyM8DtjgfhVR5NsLrkKT0ArSmjDowA4HfOTWTMChxnn8watFJkHoRx7ikONoIyMdM8VKAchs89vQ1E+RnPJPfPGaY7leQ7sZIIH6VC7nngYHcCpJSBhec/WoG4z82PSgREzFh5Y+Yqecc09IkQGSb7gGeTj9aN6QBpJdqKozkjNcjr+ryXjGGEnygc8cZpb6ImU+Uta1rwybexHyjgyZ5rMs58yZcbiOoYdf6Vmp17DjJ71IoGVIBGOwPWrirGDk5as1ZraO4G+3IjkPzFc4H5VSAKMVOMd80qSMQAxbPXGOtXli+1FQSofsc5NUUjQ8OT+VMPLZlwRzz0/CvZvDlx5tsDnK8DgfzrxjT7Oa2u13cZ7g5/OvTfB8207CB8x6jiueqjqg7o9JgyAp4HvV6IHaABWbYEbQRjryPetWEHA5Bx61z3MmTxjgHggdRVgKMk9/pUcS8DjIPXnpVhAcAY59aoybBVGMDJxUmw9TyfWnopYduR3FSrGe3fjNMhkIQ44yT7c1h/EBM+AvEuOMaZc/wDopq6XacfdPXnjpWF8Q02+AfE3T/kGXPT18pqtEM674zKWTwiAcH+2W5/7cbuuWRc85JHQe1dX8YOvg/P/AEGW/wDSG7rnmQCT5SckdK6UYDYchVBzgHg4xVnYpHQeuTTY0GeeMjp61Mny8Ec5weKuxDI9h6DPNNK7iWOcnjFTsmScYK54J7UxlwXKgkY6DoKARUlTBwdxH90VSlicknjk+n9a1GxuxzyPwBqGSMH723jsKRcWZnlHJCr0689TVeYeWvOWx6ZrQuCoGCoO08kd6xdSuQgJJ4A7d/0rKcjeCuzJ1a5ZUYLncR+Fc9NnyGZjnvjB6VdmLTzmU7Qo79Py6Vn6nJshf5Qw6cf4VizthEyE4aSVwWYA8Yz/APX/AM9K8wlnafUrmQOx+bAJPb8a73W7jytFunyMMpABI/kQf5V5rbMAUO4nv7URRbepsRjGwE8njHY+/wBavRD7zlgvGGbHIrOTLKPLXA9T2+la9vnyDwQP++sVRqhU6Zyx45x6VDOgYeXuPTOPT3qeAbV2Akihv9YqPypbBxxmgpFCLcV2lu+CW6mtHT3HnbQ7c8kkcGqkylOArffxgDt71bt8q6t1VT+IpMaG3q+Xch+MY5JH9KBuwrKM9Bj1qe/TlXUAhhkHFNsgMc5JPYHmhFIfgYbkYYd+oqTIKBs9RjinyRmMfIq+4JqEnBJyuPboPb60FIdGoSReAMggnGRVy3YfLuLZH8VUcnJBQgn04zV63Yq5BLMQMYJxihjRq2wG5cqSPw5rotKnCFAe3uM1z1uQCnI3EYHFX7SQxnBG3nOQcVJM1c9K0a6VtuWbafcV2GnzCRR90qPcZNeYaLetkfOxUYwRnP8AOu60q5J9cHvjp+tC0PLrwOqjJKnABz2NWYV3YHJwfwqhbMxweQMemDWnbdQDnJ7etdMDz5KxfhjVgN3XtjAFaEcQK4HpUNorbc85+tX1XA4/nW17I5WrsiVNrblyD61z3xTk3fCzxkG6/wBi3nPr+4euo2+tcr8Vh/xa7xj/ANga8/8ARD1Ld9y4Jxeh2NFFFZnUcj44ljg13wPLM6pGmsSlmY4AH9nXtcv4u8Uvq7m1sy0dgDgnoZfc+3tV/wCNI3ReEVxnOsnj/tyu65QxbFAOCe4xVLuVEoeWc5A+nvQYyM9+OMVZKrvwdx4yKRUyPQDt7+9O5dyHYc5GOg5x1q0iApgKp68imiP5jkAHHJPapY1xGR8wz05pXE2Inygbz06f/romXG3Ppnb/APXp+OMc9frSzldo6AngkUXMyJZ3J2MflxwD/SooYCzsSoyBnnvTCCJFOOM4966CziRbVnwA4HfvUTkkhPQ5DUlzE+cs30rW8M3NpZ6LcG7kUwyIfMjB6nt/n9KpakgDyfLnOcgf4Vzl3MxQx4YL6ZrklPSxtGPMjFunBldsDDMT6ACoicqQSCcZzU15nqO3HIqrKQQOPxxxQjrSIJVywVcAemetTKGEYUDaO4zmmNGSSTnB5zinKCvQEn0HStFoDYpGB0GR6dazb2P5txBIHU4zmtUAhOAOvYdKrTpvDdCSfpmtEJMx5GAIGFIH8qqucDI7dsVYvxtc5wPcdaoynIIAOccGmaEbFvmAKkjqD1pjmOGMliAMVJghSxGSB+FZmoSM6FV2kDk+poZMpWMTXtSaZikJOP4qwCG3AnJPXrzWveWzebucYLdOOAKjS3ywAHOMZ65+taKxzttmaqnDHaD9O9SRqew4A5wKuLaYIB+8OOvSpFgOQTyR0VeB+NOwIqRrnO0ZHoc81chLLjBGSOwxTktjwMO+cnA44+tTx2oY9cexHSixaZbtbjO1fU9K7Xw5cMskZU5xx61xaREDJwQv90Y/Gt/QZtjqoc5HXrwKzqLQ2gz2jSJfMhUlucVvRdQCBjr0rjPDdxlFXP4ciuxtiSoxuz14rj2HMvxDOTuBx0A4q3Gp4z17ntUEagkEj+uatxKOMAYHp/hTMGSBf94/QcVMB8oPHtSRqSTt49Ae1WUUHpgfQU0ZsjCYIDLyR3FYPxET/i33ickYH9l3X1z5TV06qMZHf0rA+I6Y+Hnig8H/AIlV1/6JarW5mzofjB18H/8AYZb/ANIbusBR1KjocV0Hxc/1ng7gn/ict/6Q3dZUSBmJbPTkAV1IxbHRgkY+XgfpUZUZzkjPqamC4jGAv1qKQNzxj68U7kiKwAJXv1zUTn+7nA65PSkHOdvOenP86a0iDD/n7UXHYYx6CoZmZeeh9zwaV5Fw285HXgdqqSF51JQFyBjA71LkXGJTvbkIoCsRgc8//XrAu5TM3U7eavXDSNuV+g/vdfwqk6DhVTdnoM4rJs7IRSM9o9kZJbAPYVzurSeaVVB8tdDfuUUg/KR2HWuduFbeznJ3Dgk9KzOqBzHjA7dDdflwO5P/ANcf1rgUUqo3Fcjmu58bSlNKActmQ44yAP6VxQUFSoAww6jqKuGxMty3Gd8ZDMTxwCMVrWTOkSHacDp0+UVjWvAIYH0yelX7M4G0j5zyBQzWJrsqsVZXZtwx0olXGHI2jO0YIohYyrtlD5PYd6kuF6E4XIwFPJFIsp3a5CMTz06U6wwXKSALkc4FBG8OmDjvnr9fekt8ednBx0+YYxRqVFk8xIgRJCeASOePrS2ZJ2ggEn1GeKnu498Qx+eM5FU4CUlUMo9Bx1ouUjRmXC4Byeq5qE/M4OFyOMEdKtTgMm5RjA6YPP8AjVeAbmJ2554zQrlEZG47iwP1Pf2q1Cd3HAGMjn+dRPGA7ElVHTpmp7ZjtIP50wRoWnMYX7vc5q9DgHAHArOgO2QHA6c+5q/H0ViR6/LxU2KaubOmy4kXknv7fyru9FnYhDk56ZA/+tXnlk21h8xP90bcYrr9DlUBcYxnvgfpQcdaJ6XppLqCOcDoR/8AWrftV5BAAA9uc/lXL6LICBnHAwORXXWKqVUAA8ZOMVrTZ5FaNmalony/d689P/rVcAxUcKgAYBHFTYrZs5ooSuU+K/8AyS7xj/2Brz/0Q9dWa5T4r/8AJLfGP/YGvP8A0Q9IfU7CiiipNzzr4ydPCH/YaP8A6RXdcvPznGMZ6V1Pxk+74Q/7DR/9IbuucdB/D+fvTRSKrJ04HH4UqoTzwd3p0NTSR8jI+XuKUAY6Dr+FDZRXZRhR3+nNPThdoA/D1pWBwRnBPOMdaeoOGweuM0riIyCVYYyf9mnQW8s7mNFJ9AKmS3Lvtj5OPpWrokX2a5DhscY465pcyW5nKVtjCa2eGdVljO/0I4/Op9Una3AU8Aj8q0tYlM1yJDtDA9fSsbVpvOUKw24GSPX3rnqTuC13Ma6JZ2yxDEZrnriImSSRz06DPStu8Zgp9SOPWq8iKLDEkYDS/MrrzkjsT2+grLzOmLsc3qKYh6EDrz3rNUZYBiOCMgnpWpfnKMp44+pFZseVI2lee5FXBnQnoW9q+VkZ4/WoZcgDO38eKl3koeeaQQFoWkJBIYArnkCrvci4kSbgFB56nn+VV7mM/MV5OOx6VdWMLt28n29KimKkEYyD2FHMSnqcxqDDeFXk+lUMYGGwCDWrqCDcc8DuelZ5BTJ7Y9M1p0Nb6FS4YpC2Cc9j7e1ZswLAEYOOmO1XbxvmVTgEc5A4ojjDw7tuT1xmpbM5Mx7mITRs3Vu2R0+lVokyMEkH09a2ZYl3sXIJ74qhJE0bjaQB1IFOMjOxE8PBIUBfQHr+NOWH5UGBkHp/nrVpUV1y43fQ9qesZGM8L1z2rVSFcrCADooA3Z4PFPA2/dAIHOKtMgH3VJzx0zUbRnoWG3HpVpjTIwN6jCcnuO1WbKTy5lPAP0xUBGGBXaBjGP600swwck4GQG7VMtTWDPTPDdyF2ZbJ9T0NekaXIHRe/H5V414dujlPmIJ5yP8A9deqaDPvQHOeOxzXFUVmby2OqtsELgZHqavxcdeATVC35C5z+PNaUQ75x25pI5mWIQScAYNWlUEDvj8zUMS7hjOAauRLkY4yB0pmbDHJ3Z/HpWB8SFA+HPikbjzpN2en/TFq6VUwQQenbFYXxJX/AItt4s6Z/sm7/wDRL1S3M2afxc/1vg3/ALDTf+kN3VKJQwGMc9eau/FobpvBoxn/AInLf+kN3VSIcr357jiutGMxHjABIA/HioHTOdoTJq6Acc4HOM+lRTY29Fzn8KGSmZbJjn5cZxx1qCRMDAGQT0q9KCASCAR1NZ8ykFtnPrzzSNYleVdqYIBAPQnoai1C43W4UR4Prngfz/U1M4+XHGM9qoXJAYqAWPp6Vm2bRVzIdSzDjnP5VXuTgZB6e3NX5yoJY7Qe2f5Vm3pIOBnJGf8APNZtnTAx7wsR2Hrgcn8KyroDAwwCj1HIrYmDlgSR7begFZV8yvMqhQFJ+uTUs6InBfEF1DWkSg7uuRjj9P61y4GVOVJwO9a/jO5+0eIZFUgiJNowcgH8yP5VlKARggEjvWsVoZXuwgJVh8gOey54q9FnOQM54xnrVIAZBA+Yc8GrkeWyBhV6+/4UmaxNi0YOFH3B67uPyq9Iu5eFG5T1rK02QiUIF2k9Nwz/APqrYIyoyTzzhu5pGhnupQqxAxjgNTfmI+Y5A5OfSrk8e9SQRu6EZqsg3RhSSQOpPOPpTY0XoyZLfC4K4wRmqI2qxD/Ljoas2RzE2SMA/hmkkXkghcgZIA6ipLvqW7d/Ot/LPDDpnnPtVeAYuVH3RnoeDSwSfLkHJ6dM06VwJw4A6c56imUWr2PEgPyHdwe2KhiBXjBJzhfYVcn2tbRMxBGM8d6rFSp5UEHuKfQEWI2AccEEcH2rRts4HO0gce9ZaH7uGIBrRtCM7VC4Izj/AOvUl9DStTtOOQT1APWui0ibDgZ79Nx/xrnLd+QQx+pGa2bIncFGCM54FNmFRXPTvD9xllAbBI9T/jXf6WxdRjoB1Jx+HWvKvD85DLxyOR8uf6V6XorlhyAc45A4/lTjozycRE6eEEKPpUh6UyHhakrc40tBtcr8Vx/xa3xj/wBga8/9EPXV1yvxYH/FrPGX/YGvP/RD0wsdbRRRUmp538Y+B4P/AOw0f/SG7rAONvHUdDXQfGHH/FH56f2y3/pDd1hwIcYOE5700UtiNhgDGMnnmmjgEkjpnNTzJhcEjGajRAeq/jQMiZAQdwyP5/4URLn5QpyT69Kk2/KAoGc/nVm1jUqRgHPYVm5WFJlm1jWEFyCfrwKVmZV3A4ycdMZH0qe0QPGyg4x3/wDrUyYbR5aEH6cGspMwvqZOpEBVOcMOTzWPcsXXBwGJ55ya1dRChXjblweCOR+PasN5CpIdgSeF74+lY2uzeARQpcXcYKsybtpVep/GtDx74fTQorY2zu4dNzb2yQfb0H0FdHpvheGysIdUa5E5jCyNDgDJ9zk/yzXMeLdb+3ySYJ8gkkIwIwfqeTWtS0I8vUUZOU9Dzi9fL/Xr6VVQZJKkdOauvmec4AxnGBSfZiqBhtIzzx/SpS0O29kVnUb1GSARnJ7U+ViY9oxjqccbqfIChOBnaOpOcVBnc/3hmgkN/wAgGcDGeBVeabnP8PYjr+VLNIF3Y6+3NQSEt1PPfFNCK9wvmfj03dRVC5i2IxA/xH4VpS4GSF4zyR6/WqkuGQ9faruO9jk7uRvtDKclRznPStqwVZNP3DG7OOetZ2p222UMCOOvPNOtJiECjIA5x60X0JkupPPARKy46d/eqUsTbju4JOflHArRU7pmMgCnHJ9KjePLAjkjkA8VNyUUoEAAOQF6cVYMRKHL5x044NTxQ4UnAA9uKmEfA5BY9utaREyiVwobBHOPlOD+NRMuABxzx1Iq9JGoY+/v+lVpUPT9cVqmJFKT5CRv25GNvXJqM5L4X2JY8ZqZ0JJBGahYBTg+vIGTQ9TWLNbRJ/LlHX2r1PwvdbsHOMAAV49asUdWRQT/AJ616B4Vu/8AVjPPcD1rCpE3i7o9j085ReeO9asIJ7jPaue0KdWRQWBzzk10dvzg8Ln8qwTMJrUuxrk9cHGeTV2JcEErnj8qqxA9Me/NXYlyMD1qjJksaBsZ4rB+JKg/DXxbhgT/AGRdk8Y/5YvXSKuVyFUDuawviWv/ABbDxb8wx/Y951/64v8ArTjuZMn+LP8ArvBvOP8AidN1/wCvG7qqqZUZXc3YY4H0q58VxuuPBgHJOtN/6Q3dRIgKEHjnoe1dZlMjVQOuAOvFQyj5ioLH1GcAVZdc4JGB0yKryAgFWFMSKTDBJzn0FVpdoONx+hHT3q63rkY689qrXCnDEcr2GKTNIlCfA3bW/E5JHvWZKpYliSWJx83NaNwAQucHtWfKwXgnkk8VkzogZ1wpRTyfTOe9ZN0u5CA3zcfhWtL5RciUHGMKPf8Az9ay512sAVB56qetQzpiZl6SqEckkce9ZF1mGF3cjhewyRW1dhi+EHJ6YArmvErCDTbgoDu2+n/1qRrfQ8t1J2n1G7kdgdzYXJNNQDdg4yACR/hUcY373Qsed2c9PrUn8AYnex5BAwBWplEkVAQu84yT3yakiX5O+zpnH8/SmLlScrk46YxnPpT1Qnpzj7pIIoNkWVx+6YZ3oeMtjPvXQWUplhwSBjpkd6wUOASCSBVy0k8mUZPU/pUs0TNRAc7HBHt0x9aq7FEjq5BBHBHarMrfvkIOA3fH3vpUTBNxlBGQcnjtQMZaqIm5I68Ajoatj/Wpk8E4NVRlWJx8zDc3uKnYk7CCQB6f1pFocY/LkwXVB7DrS7G5Iwe4J7j6UpUf3g2OpPP5elOCgODghsYxnFBSEjkONjE5B+UDjNTHBBJ+UY49c1EY9rBwNoA5OcmpFB2DJJ74xnFOwDos8kEccepq5AVypcZUHOR1/GqiggHnaB3/AKVaibPIxgdSOtDLTNa36Eg4btnvWtaYB2/cYDpmsW23bhkH1wK17MknnJz1HWkZzOu0KRFkUHAJHOcCvTvD0wKqCRjvjFeT6PIVkQA8n0J/xr0vw5Nwg5P1zz+tNHnYiOh6Ha4MYIxj1FTVWsW3RDJPHr/+urRFbI85IK5X4sf8ks8Zf9gW9/8ARD11Yrlfix/ySzxl/wBgW9/9EPQUkdVRRRQM89+L33/B/OP+Jy3P/bjd1jKBGcjNbPxe5bwf/wBhlv8A0hu6xFIJAXOenFA0SSE7fQe1ECYyMlV96cqbgeNxx0qQ8EL+JFJsLlQgCUMoJGeD2/KtmGFEh3hV3N6mswxhpUDE4zz71u+WogREO9s5yMn9azkzObKtqPs8wf8AgbIJ9KiuYUcEjbggnjrVi9dUbbjJBxye9ZmrO1u7glvnGfSsmTFXZi3d2samMpu5/KsiWUb93QZ+lXp9pQyHOTwcVj3rFQcZLY4wOtQ9DqjHoXv7fvraJoYJ2EHXy1bA/HFYWt3DzgAAMZOoGT+VKZE53Hlunr+Vafh7TrC9lm86+EFwq5i3biN3sAKIQUpXbKdoK5DZeH7u3S1nuIgiSjKkjH51TvbdVlkUbSCcetd7q+uK+ixWs3lSTxfKHCYx/M/rXFOQ43g5UnnnFXOS+yZRm5O7Oc1CMplscAVlO38PJ5yK6a8i3xEA8/SuauY3ikI+Yg9GHas1I6YtMps2G7+h+vpUi5I+7j26/jVeVBv5PQ8nNWIn+TvWiY5CSgk89O/PWqcvJIYnHarkwG0lQCB2PFUZRhuQRx68UXIMzVBvXsxxzkVlwnbjBJz6VvuvmKAx4PRazbmz2gsoI9s4FK5Q62G4kNkk9jU4jDEllz746VVsn/enIKjHTJq+ADnk496LktDo4sLuyuCP4jzTlGQflDD36U+PsMhvqKcoOcEqwXg9q0iySCWLGOFAx196qSwlfYDpjvWq0eQNnHc56VVljySVAPp6itUxGLLFgkEDaOmartGxYYxuPXNa00e7OR06iqk0RCcevbqRVJlplWNCQOeQceldDoFwYpFUsCSe1Yqj5s7SAP7wyM/hVm1dorkbCA4OT6Gpkro2iz3Pwtc71QA8Hjrmu6tG6ZYEdemCK8p8IXmVjAcgnGTmvUtPcuit04/OuRqzJqI1oR0OTg+p61ehQkY9O4qpFgjPOcdcdKvwKcAZwOvFM5mWYoxglgSfbpWH8T48fDHxfwARo13x/wBsHrooQMD5evPJ6Vh/FBV/4Vf4wxt/5A94eOv+oehbmTYfE/8A4/vBfGf+J0/H/bhd0BkGdykn26UnxR4vPBf/AGGX/wDSC7pgHXqfr3+ldhnPca+ApwpGe+ev4VVkGS2V68Ad6u5GcANx69Priq8pC59+MigSKEgbGQODxzVZyRGwJA7D3+lWpc7tpPtWfcPt4APp9aiTNooz7t/mOcZ9c9Kz7mTdkEjpyR1qzeHI6nrjOM49qqIhIJbaMe/OKjU6oqxSMUrH5F74HFU7iNomKMFUqa15gCNpyB6Dj8Kzpxk7lGFz3yfwpGqdzIuAFDMqr15rivGcm3SLsltu75SCeT+oruL/AHFCAMY9P5VwXjpiNFkZWYITjJUmpWrNJP3TzeHLQ7VTp/EDUi8ZwQCOPpUMLBlbcw+g4yfrU6sC/UkdMEYBNbsygyZN2AwOce/WnofQgKeoboajUnCnIznHOP8AJqU7j/EoyMdM8VLOhMsRbjgZI54I5FWfvLwBgcHt+VVIup27s9Mf1q1GWC7mBZc/rUstGjFMJIVU8AH5SfX/ABoDZOWC7iecDk1WT92R8x68ZHA96tAkIPlLK3Gc/wCcUih0qjILDjOc9jU0DZjcBcjoBUUQVo2RhuC9GzmnW7cH5idw6YwSfb1oGieIgjYQGCdOOfz71LGASS6t6c9aiQAOAVKqpwcipk243gHJyOc5NBQ94gR90AjrmmxjnAHy+oqyzCSFDjkcYqMpg8qVz6d6YxFBVwRg8cY5xU8a7XHb6d6ais/zbDux1z/OrEa4IclmPTkUwTLcHQcAHPToK1bRjlcAnsazYhlfUjp71btgAV4wc9c9qVgbudNpr/Mh5HPGOB/KvRPDEhKqQN3HOAf8K80sM5yV7cc133hl0Lx52jnjkDinY4q60PWNMJMC5z07j/61XaztHb9yPU/StGtEeYKK5X4sf8ks8Zf9gW9/9EPXVVyvxY/5JZ4y/wCwLe/+iHpjOqooooA8++LwJbweB/0GW/8ASG7rEVSW56e1bvxbz5vg7H/QZb/0hu6xCAT6Y6EcZNFykWUCAKxO5vp/OnRKc7jwo9+aYmXX5yPp0FPiJQ4X7394UrkMilGTx94nsOKu2kjhfLCcflVXbhyTknOcnrVuN1+UM27t9KykTIhuywdSq/dP3euKzdZbe6OTuOOeK2rwMqqVIK9dvr+VZd5saDDHD9cdqh7BB6nN3b4TbjjOQOnP0rLvm/cliCG44FbtgkLeIrMXSh4N3zKehH5jj8aTXrG2udTkt9MaNd7HZ8wAH5CoktDoUknY413X53dR83CgDmn6cFkWRi2Md6deWbxI6s6hlJBAbGffpVW03JkbsgjvxURZq7NG0xDRkc59SMAVJbwFkITOB09fqKr2ki5PVvXNaUckhGYwAvt2oZztmbcwsu5Sv696zpbFJIWkYA5PX+lbMigzDefx96W5twATDuKkYyRWd7bDjKx57qEIEhCrgEZ9cVno5jJAGST1Jrq9QtsM24gtjg4rltQj2SnsPUcGrhK50J3EeTd8rKcfXn60wKzKADgHnk9vaq+/LjcT04IrT0aS3W5CXUIeMg84yR7itSJOxR8vIAwee9Sx2LG3MxX93u28nJH4davXkUIc+S5ZR/exmqrO8ULIjBfYVm5E3uYt9aG3nWVfuMfWpATgN1PYgVLMDJGSTk55PeolcqgGdrYwwFNO5puXIx0JHHc9/wAqlVFI65JPA9BUNsOQQM4H+c1bUZww69OOa0iyGMUAcckZ6Acmo3jBJ+U/0qbaWPOODjgVOIsr+8B9PWtUydjIlhwe+MYyRVZ0A+UZHc8da2ri3ABOAAOntVGaI43AEk1aZSZjzJ5bZ5GOOKSI/NkscdM+lWp054AAHQVXjU7iSPmHT0+lM1izuPBdzgrjHHr/APqr2nQ23wDaDjHavBPCMgS6+9jP0wK9u8KzbolGc46k1z1FqOeqOxg5xyPQgnpWlbqOhI9CKz7fkDncK07YdPbjNQckmXIc4yowOnXgCsP4ooB8LvGOP+gNef8Aoh66CBcnBZvoawfikP8Ai1njHr/yBrz/ANEPTjuZtkPxO/4//BWf+gy//pBeU2F0R9zYYenOKf8AEz/kIeCv+wy//pBeUOCcknFdZE9xksn7xmVQF6Af5AqjMRvyQBmrTlgQTgHGMdefWoJV49B34pMEijOSynacN69hWfOhywyzDGc1ovgZ6KensaqyDqcdOgFS0bxMiaFcoOo6jioJQoQ5AAPUgYxWjIucnaBjniqcqqBtABH0qTZMznQkZK/L2Gcj61Rny2ec/XoK0ZlwfukH1B4qjdgfKQN2TzntSZqjFu0+UKB34PSuD8eKw0tww43ZP+z+lehXQUMBhse5zXn3j4gae25lBJ4GecfnUx3NJfCeZRHbIwYgjruPUCrHO7LA88jAzmq5HcZI7k8VKoOOOCeMg9a2ZjBlhfm3E7Bx6YNPViCM53HufSoIt3IJBZRjcW6VKTjaSZNvof55qTpiy1HwSDjBHSrMGQFPOcfjVRcZyM5PTHU1ajJEi7ienQcUjVFgAqeGw4GBip4SRF824MvXHNQYLowBI+Ycg1NGCp+XBOeBjj8aRRZjyCV2Lg/PkdBTsEkYIw3OM800KzEdiPToakjT5sFR65PakCJSTtyeSOoNToQy70JVR1B5qKNDtIf8DjNWraMAgg9uMjJFA7kiY4G0kdR6CnbQGO5Se+7r+tORGVFPPHGWHrTogN4VySuDjnNMZJDGTGMKcdeuak8ogA4Oe2RyKIQ553D6egq0sZwRkgHrjrmmiWwhAGMkY/rViIgEBVHPqf51DGpWTGD147irMYO7LMN3rjigdzYsnyVwDu7/AOc13PhuY715IGecH/69cFZn5wT1xnGa63QJMOhyST164/LFBhVWh7NoMu+FfmJwPU/41tVzPhiRmQdu2OcH9K6YVpHY8p7hXK/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD0wOqooooA4H4rjdceDRjP8AxOW4/wC3G7rLIKEHaCO2TnFbHxRz9s8F46/203/pBd1nzQYYhQctznHWpY0QxIzu4PXqOKAcyEAZI4yDwPxqaMPbkSKhYjnpuA+tNkme5leRxkn8qVxDHwVbIYk9hViyUAh5A3sBVXlmCgfTnPFW4UAwobv3XNZtmciV8MHIU4J781R16INp6TBAhHHYf/rrStlZ7jA6L1+lZniWdLiMiFNqrxyx61EnoKF+Y5/Slxdy3JkhR44zsWRS2SfYVUhuW0/VILyQRyCN8lUThvUYOB+fFWLaMMj5DKuOR60kKorklVZhU3a1NmdFLYaXrmlXl/BYTRyff2uy4H4AYrzC9RYrho1zgHtXWX+rXaWbWkbBIT1AUZNcjdcuT1z71kpNyuXTTW5c05wEO8c/lWrFIGgI3KjAdu9Y0AztwvPXOelaMQIjAA2jOSfU1UtSJbjZtzrnqR7da1LUGa32HCnpjHNVhH8pPAPbI4q9pkot2yy7uOcHvULzM2zD1Sy2IGKZJ+hrgtdtxvygwB1Fesaxcx3C4VQhxjFcHrlurlmUf/qoVkzWlN9Tg3QxEBchW/hNWbVwCGJOB0HQikvIvLkGce/NEG5MAEFgeAeK13RvIu7SfvcKe2f61HOnyHae3AHNWI855xu6cUjRs6nHIB4zUMi5mBVYBQw3dDmoHhZZMMD1OSOtaTwfPwFyO2KQwDO45U44B5oRSZXt/lIBySeOOtaCDOGweT9DUFrEVZM4471o7MrnAIznNaIlsgCEE4x9Kmi+8QPlp7g4IYbsdCKBGD0U+wPf3rWLEyOaM55GcDis+ePdxkHAySOuK2WiZhnb3571TliyeV4z2q0xJmHPHn5hkH164qm8eG7H26Zrbmj5JKj6j0rPvUVHAQ5J54FUaxZb8PuYrsDGR2wehr2fwdNwoO4+/NeHac+ydWxgk/jXrPhC4BaMg9cd+/5VnURo9j1u13ZUbTk1q244zgg4+uPwrH01vMiRgOnccVuWY9G4JrI457l63BxgKwHqawPip/ySzxj6f2Nef+iHrooQeM8471z3xV/5JZ4y/wCwNef+iHqorUzW5B8SBu1PwSP+o0//AKQXlOZWDZwcDrzS/EMBtW8EAnA/tl+v/YPvKnlQHngkjqeOK6SKj94oygAk+vI5qrPnaB/e9DVx1GSS4JA7VTkAVxnikxxKEvzDk4yeAxqs6jPGflOAcVckVioJH14zVORl5bJx9OKRsiGZOXJwRjOQ36VQmjCryhH41dZ1AYbsZ/h7GqsnBZgTjPPFSaxKE6fKe30rNuE5Oeh6EnkVq3AGOcnuxxWZdbcZGevHFSzWJj3RwH5OAM/LXmPj+5+Xbn5s5288V6VqcwVmycrivF/F9yJdSdR9zPKj/wDVShqypvSxgKNpJ5AAyx6Z/CiEHy8sFUknoP60j42jjA5+Ycn86liAZQPnHrnrW5nEDGAwwFMhx0/xqffsBPGM4bipLeMsQAGA65xTmj3SgN35+UE/jUtG0ZDYiN/cAdMcmrcW0j5SME4K5wRUIi+bLbSo7461ZjhXYMfd9vWpNostQ7sqOTjqCelTQx4kwSoAOaS2QqAGyP4WB44q7DC7sQIyM8A5zipLuLHGi8MD83QZzUwjbONylscc9BTLdBnawHPBxVgIoYBcgfp9cdqQXHwKeMrux3q4ikFdvJ9+jVFGgVTliw9ev6VdjXMQIPQfN64/rTBseQWfGUBPUDvTIoMZBBGO+cn8KnWMYDKeQMgDnNEYGQ+eDxwOlA0xkKZA6njHHAq5bRnDAZP+znke9QIAHdcsPUVZtm2SdOO1MGK8RXnAUn+L2pyxscNwfQAVbXaRtG7nkjrSCMbhuyRnpnmgSZJa8MDtA45B5/Kum0XhlOFHOAMDiudiAVmx8o6jPFbWnycrkkE85Lf/AF6ZM9UeteFJ0whO0duMV28ZyoIrzDwxdkMMsRj0P/169JspN8KnPNVE8uorSLFcr8WP+SWeMv8AsC3v/oh66quV+LH/ACSzxl/2Bb3/ANEPVEnVUUUUAcP8TQG1DwUD0/tp/wD0gvKivFRGyAcHsDnFSfE/IvvBWME/20/X/rwu6hu2ycnGfp0FSxdSCe4k8p4Q7mLGdmcAH6CqUR6FiRgcgcVO2XXgnjn3qrI/l5AIK9ee1Zt2KsSIADuxyT3ParsfLYXkDjI7VUtWUtGGA54z/hWuBDHF0OVH3iRxWTZlLcRpRp9k0qYWZuM9Dj2rlNRnf70i/KTuzu/nU93cyTTuhdmwc8msm7l8wYzwOg9KSd2XGFi2iLHpTXBUgMx6H+VTfYHh02GV0KpKu8Z4zQ9s17LYadHK37zlickAd63/ABZbm1SFI1m8tUChpHz09KqppG5DlrY4HUgwjIAGDxu3GufuiDuzxnhfeul1PmIsV5z+GK5xYzPOCoLYP4gVjT1OiL0L9pbhLdTIeM5IJrQtd12rFEKgenYCkmiDiC3I2E43k8YFadhLFb3DrCA8RXao6ke9bWXUxnIrNA0QUEswbkHPWmsCrZBIbHNdNeXFpqM0a+WLcRRhegG4/hV2XwxKUhfIBl9QeKzdO+qMfaW3OBvFZlAJI/GsS9iLbt4yOlekah4cZbeeRQpMRwa4+4sjtf5Rx/OsZRaNYVE9jgdU0/r/AFNc/NE8TDOR9f5V6He24BIxx2wM81h3lmk7rDtCs3c1cGdClcxrPBVgwGMZFbFhatLuCKWcJuC4JzUGk6cVnu7eZkSQLlQ+TuPoBXdeD7aGK3e7nWNZEGxR13n0rdU7q5lUnY4YwgkxsvI6nvVSa3xwAeBgc9K7W+gS6W4u4o0jbeVYIMAn2ArlrtcbgVK/UZ5rBqzKhO5nwR8jjLetaUcBByOB6elV4mTy8EncD1q3CwI4GG7jrVplNhtJAX5s9xmo8kHq3pVlkLZJAA9O31NMZSEUkjB/OtYsQscTPwqMT6DmnS6VqDqWjtJXXP8AACxNS2c/2dhgqMHBJre03xLdadcRXEDxSbTna6EqfwzW0eXqRJtbHCX1rewEm606+jUHq0LAfnWLekSPyQMDgDt+Fe0eJvibJqfh2ewksLf7RN8rS7QNq+w55rxu7JDuwwi59MZounsaUpN7kFudskbbMkHOM9a9b8M39jcaXGsFpDFcJ95l6n9a8ii6jH4mur8LXLxSjYx5b1xQ3odDVz37w7MJYF7g+9dXajgZI/GuB8IXG5UU7jkfrXoFiNwwW6jNYdTlqqxoRDHQfL2xXPfFX/klfjH/ALA15/6Ieukj6Z5/Gub+K2P+FWeMf+wNe/8Aoh60gZRIviCcax4I5x/xOn5/7h95V+SI4IZgwJ6YxWf8Qjt1fwQcZ/4nL/8ApvvK033upwSAeuRW6Maz94z5lVAQuMmsy54c4OSOOOtbN0gJOByO+azZ9hHTOeBmkyoMypBnk8n2PFVJVIcDP0HpWlIikMTz9DnFVZ8BgVyWx16VJ0JlCbKrgDIPUY5qrcLtRchs+vXNWZR045BzUbFgpwOAe5pGiZmXJG/O0j8ay7uXcrHPvjFadzjaefyrEvC4XoeRn5TUSNYnN+IJ1it5GHJCkk56mvF9RlM905LAjJbkjFeq+M5tmnO3K7uMKSK8mZDJM7FeT0VeTiqpombIVGTwN2BjKjofpVuGDIUYZu4z0qa1ti0gG0kn04/Aite3sRkhuCfugcZrVsm9jNSI4DE5IBPP+NP2bkOcfKccVtPZZVFjydw+VSvIPeqklm4OQpBHynIwc1LKjMpmNoixyDxgt3NWrc7iNzNuPPC9KmutNvbRVe6tZFifkS9QB9RRaWE1xKi28kSE9CxwP1qWmbRncspH0CtjPp1H41aEZAALEtjv3+tMEDWztFM6mQd0O4fhVuFQRgjOOgBqGaKRHGuc54B6D0q1GhDcqc46k9DSRAhiF445wKsvGCm9TlTwd3Wlcq42BTGcFmyOvrVuLIUlc7T1NRwp8u5SARxn1FTxjrkDBPFA0ydBtBVMhcfhUqKcgFWJ7AdKiT7uDznsT2qxbYA+U4I6Y5/OhMVxjpmMtuAZTjAo2kAEFfxqwUL8FWKkcEdM0loN6GNwqnBwematMpMWIccFiG756H2q3syAy/exzgAce9Vbb5WKMcKPukHj8quRtgFWxnpmkDJItsiqOntitC0OODuH4c1nRgI2Mkj2GKuQHGMnAHYDrTRLO18OzlDkEZ9gT/SvUtElLw9+BznP+FeM6TOqSA5xjHSvUfC06+WFG0E8845q4nDXXU6quV+LH/JLPGX/AGBb3/0Q9dUK5X4sf8ks8Zf9gW9/9EPTMTqqKKKAOF+KGPtvgvPT+2X/APSC7qtICw6kL6GrfxNAN/4KB6f20/8A6QXlRvEx4xn0GMYpML2KByrEqM8daSdIlgBBG/Hfr+FWWjDAschh296yb5thIC4HWsJvsG+xJZvh14PXHFO1K6wu1Mk4xg9aLYoI0lPQfwn+tZ1xIrTSHAKnovasmCjqQAsiSP8AxbepNSNbD7JbK0bNLKwA565Pr/8ArqtKztG2MhTwW/xrc8MGTU/FFjC7ForaIyEueuOgH41pTVwqX6GzeaXptjfo0EZjeJV3EOzcntz/AIVieKLyG4lKW4OwYG5ia0vEEsV5rMNkshCTTYZo8E/0FZvjKK0spI7W0tvKVeCxU5Y+/rWNaV15HPDV3ZxutybIhGrck8nHFZ1iBFmQjjPQjrUupytNqJijB3DjrmmxKEZFLF3HGMdKIaI6+hdDmMFpgSznjnnFSW8h8x3fgnoBVEDz7h3k5jXv6VbtY/l34EUWeWHU/SjcyaNmz6qznIrqYNek8lIcfKvT2/SuStmUFSCxHpxU0UjDn5SM9Ov4UudowlFSOxbU7cWb27E+Y/LNya5m7tYhbuyvgk5AIzxVRZy8q5ycnnFSum+TClmJ9OeKiUroUY8pzGqRYYlWzx2GK5zULaR8SKMsvpxXY6nb4LZBxnoeCax2jCN9xCD/AA7sis07HVFmFrcyvaWd0AfNT5CAMZqbSL+SXy1fCwAHaF6k1Q1pcwFViRVU5GM1U0i6liljCyvEo4yCOK3hK6KlHQ6EXptQ0W07S2eRWZeSFjuGce9ad7bzMwMz70cZDBsj86x7qMxkocY9c8VEm76kwKTqN5z1B7f54qzbg8A8Cqm0A8ggZ6k44q1ARlByc9Ca0Wxoy9EVO49O+D3qwqZUbgvPPWqiOdpBBHPI6/rVqOTILHHrzWkCGRXEQQ7lPXqc96rMSAcg49MVoOisFKjDH071SnidAuWbrzjmtkCM+44G0ZHuRWHqCjI/vL2rduRg7SCR/e7Vi3mQMDGM84qkawKIy3qSBwfStXSJglwpPHvistAAxwCT2brirdq/zIy5wDjJ7UWN0z2/wVdbmT16Zzx/KvWNO5Rfuc9814P4IvMTICwJH3RnAr3HQpTJChIHTOOKxkrM56y6nQIOe1c18Vv+SV+Mv+wNef8Aoh66WPoK5r4r/wDJK/GWf+gLef8Aoh61gc8SPx8ca14HPP8AyGn/APTfeVqSAbsMc98E1k/EA41nwOcE/wDE6k4B/wCofeVrEAkHAwK3iYVviKs6sSu1Vye57VmXERZvmkBQHkCtS4VixZm+TrtAzj86oSrGyOdhYH14zSaCDsZzxkuArKo6jsKoyRvJI6oQpHrxn8OtaFwCq/u1IUfw5/z+VZ05+VQoYA9Qag6IsoPIQdo24PUkck1G6YYDn1PGasEYbr+J61FKzKpdSAVHbt+NSzVGRfODGcHjOBx0rnr9gqnn3JzWzeMXc5bGaxbw5OARgdhWcjaOxwnjwl7SFcklm9OP5Vx1tZdd4OeCDn+ldt4vjE09tHnJI4PTFUILPAUYBVRnkcGqi7IykzMhsxndg4GOoroho6rowvEZQ6vtMX8QB6H6UsViUjAKtk9q0riNp1gR+DEu07ehH0p8xm2YZhbKupZXHOQao3cbu+XLbzweP1rpHtcZ4BGPvdMe1U54AwyxwcdKLlJmDczXkkAhaaV4k6KTkZ+lZoHyruYls4ANdBc2xB4Ay3aqMsAcYxwPXvTvc0TsZ8DFH2E4OeCOc+1bVlL2zkd6x7iJ45AeMAZA7VbsZ92Qcqw5walo6Iu5r7TkAn5W5BPerEZ4AJ5HFMg+eLcNpJ6KRUsakL5eAcdeOtQaJj4UK55LHPQirCruRcfxHkf57UiAEfLnI4ODUh5tsArlDwfWi47kSfu3IbA56HtVsAI5JJ6dqjuIB5UU0Zyf4lqy0sZCSohRgcdefy9aBj4GKvg5Ck5JJxSGJvNyBgHlT/Q02QecnmZ5U8BucD+tWbciWMZHz9KpMNitIhDLI42N2DcVcgG5MqckHkjtT5YllXcQGZepHQVDanEjKxPB6jgGq3He5ZXLSbTlQOmDVqDGeC3y9SKYseQNqjGPSnICf4c44HPWkiLmrYyBCp3DPvzmvRPCt7tKAyHrjGeP/Qq8xhfZtC9cc98V1fh25ZXwhIx161aMKsbo9lhbegPrXMfFj/klnjL/ALAt7/6IetTRLrzoFBz6dDz+lZXxY/5JZ4y/7A17/wCiHqjjR1dFFFAzhvibxf8AgvjP/E6f/wBILypCP3e4ADHvmm/EoZ1HwUMZ/wCJy/8A6QXlT26kAjAwRSZEilcAq+cgKenasrUIwWzyTW5drtUDJJrMuBtcEluSPpXNUKizKtfLaaOO4cpAX+Y7sHH1qLVoorS+eK3JaMHIyxJx+OKTVz5N5jPB5XHaqqFbm+QzHCMeeai91oaJdQWQiHyhjk555rX0SZtPaWaIKJZE2bvQe1ZGwG/2RjgZANa7KAg7hR1FK72MajFghljvrS6QHML5LZwPx5FY/iTUJLzUrm4k6L0HSu70IRT+EZpbgqoDMS2McD6YrzTWAGtrhkAVWOMt0P61lUi4tRZNPVmDA3lo0+0h5SQozkgVLbnZlzu3Hj8ajjTJ4ICovYdPwrc8M2kJhvNUvM/Z7ZcRg/xv6Vslobydih5ZULCoxzl/r6VY4faMbUUfIuevvUTO06+dL8gkbIU+lTRIpJA7f5zSszJlm3cEhSxyx57VcJVmKx5VQOSxrKB5OB+GKtRblTHryd1ZSJZY3kS5Qkr6gdacLp43DZXOcc81D2wcgnk0x25yTxn061i2ILw+e7nGSB+VZc0O+PlRwfmrRB+dg3ccVGXGw4I60Fp2OV1a23wy4Ax/SuXtlG7C8j0Nd/qNsTbSHOTjFcHbbRcyI3HOMitYM2i7o2LS9kKIjBnUHoTnFLqS7mUiIhgcnJwKgtAA42t06gjg1NeurZ25BA5GetF7kWszHkBRj0GKnic5XALenaobhj5hDZ+lCcHjp6nvW0TQ0I3HJRgfUYzU0ZK8EdfTt/8AXqvAPUYXHarMZB284HtWqJFEjLyCcjg80u5HTB4x3zyKZKAFAxnqQfWq8r7RgkrmtEIhv0C8ryvbrz+FYN9nZvOPcHritO/umwylXJH90E1izOXJGyRfXepH5ZqkaRKytwQuCc81NEx3JuPI5GOlVFb5xtHGeCB0qygyQFX5icYPeg3Wx3vhC5KX2AcdOc19A+GpPMtYjgNjHXrXhOneDtctbCPUwtubaNQ8oMyBlB9icn8q9b8C3fmQIOo4PTp+lZ1E0Y1GpLQ9IjwABnpXM/Ff/klnjL/sC3v/AKIeukg+6Dx07VznxX/5JZ4y/wCwLe/+iHrSGxzRIfH/APyGfA//AGGpP/TfeVqEMCVfAHoayfiGQNW8EE/9Bl//AE33lawO8A7SQOea2jsYV/iGupUkDjA4PpVS4bCk7vl9cc1cbg7WL8jJ4zn8aqvhiMdD/eqmRFmTNu2t85Y9OmOKoToQCQxb156VqTnGVcgLnp3rLuQu5Ux1GazaOmLMydiDkA49+lUJmZflHU9Ah4/GtC4jxywyF6gc1nXe3Z/CBjtxUM3Rl3uQ3IOeh5yKxr4ZBGOR6cD8RWneNgH16Y7VkznLnLYyOhrKRt0Oc1iPzLuHI3YGORTkteQx5zzjOKsaiFF1GzqSoGARzmpoFDFWdQR29qrZHLLcZBDglnGW9AavRwHaCcYPoakig3npweR6mrSxMMADaO49Ki5DKbW42nIxngZ5qpd2APIzn0xW7sKpgp8o4GBmopbbevIAyfWncEzj57YgEFSrDnnrVC5gwRg7pOnI6fWuxuLEOg+U7fTHFZF3ZbeFGQfbNJSNU7nKXNruGzaNw5AJrOubeezuNzR4cHncvDCulurYqV+Vic9c9qfPJ9oj+z6jHvTPyy45QVadzRT5TO0+cMynerDv6A+lbC/Kf4dvTNc3PBJot1wBJbMMqw9D3robUie2VkO4Y5xz+lRLQ6YyuTohUbiwyevoKktojcSNA7fK3IZhxx6mptGthfXRs2ZIyVJznHQVWILxKknzCMkAUjRO5JBw3lZIQgrvByDTtuFaMbgOq8ZFMQYIXcWxycHpVhSP7pOOSehpjuNaOVAp+9jkEf1q7BcLE28pxjjjikNzE0qK6kptwQpHNIVcg4Ab+7u9PSkO9y7bMXXJwD3Hc0SIA58vqegqG2kAAIHzZ6DBq3ncxLE4zkDsK0TI2EX5lG0jPp61IqsX6As3b1phBXJznjqD2p8b7eA+7Iz1/nTBk8ZCDYAC3JPbFaFjcmNgGJIPAGBnFZBcEnrjrk+tT27lW+UYz37U0S1fc9U8L6iMKpwpHbIyP0rS+KMgl+FPjAr0/sW8/wDRD1wPh2+8nYoIyO5b/wCvXU+Or37R8JvGG4/MdFvB1z/ywf3rRHDVjyyuei0UUUhHFfEcZ1PwSP8AqMv/AOkF5UqEJKCOP6U34hAHV/BAPT+2ZP8A033lTlQJwXGFPQA80mRLcgujvJCjnHU9D+VZFwpZTtyB0IBrYmXEg2qeRjkc1nzKFY7wAOnrXNUEjn/EqESW8mMgrjJ6f4VRACWhnOM57Cr/AIjYMqk4449xVA5bT4kUfnWXQ3v7pLan54S53M3JOfX+tb0atcwC3gTdOSSDgk4rDtRmdRgZH411Xh2SOxu7u8ncrFHDgA92z0FNJPd2Oao9Svf201jpEdgQVB/eyKg4/GuE12b915YTALcAHtXW6zqss6fOoDSt8xwOnp1rhNVnM+pN12ocAYrD4pXKpJ7jDEfJwqnc3HHIFXdQm+0R2unwYFtAo3gH7x7mkUBYNqkFiM596giwsh459xW610LepIE8y5jiCHaOQPQVb29SuSQdox603TYn3TTEAswwtaemxqb9lIHl20e4nPBY1pYylIryW/2eNQcF2HIps8LIFLgAn36irTjfcMT3OOmearXrh5VCZIXjjrWbhcm5E2QOAQOuM0zk4xgnuCegq/dwLFCn99lDNxVBcFSFzt6HArKULDTGkkDgY561HMeCuBnGc4xUiKOrD8OlMlGCVA474FZtFplWZN0GAQAwye+a8/1GIxahIAO+cE8mvQiQAecccZ5/XtXHeIrb96ZR8rUbG1NlWxkBcZJ9+as3IyARgd+DWZakI4A/Hdxmr8cgZtpQFcYzmrSuOS1MyaQmc5zg+nap7dS2OST3B5qlf4iuchiffFWIJBkYJz+eK3iU1oalugJGTz656Va8tQSSMe4qjE+QMAY7VeRlAHGM9O+atGbBwCwD8Z6kHFF/baSmnrLHdTm6HSMKNuaCBKoAxn881m3yyRMBIhX0yK0QLUfoWvvod2LhLdZ2A4EhPX8Ki+IPjKfxdd29xc6bb2jwReWXhYlpB759KyLlgSVKknrWRdNtOEXJPU1pfSxooK9yAMA+VAAU5OD1q1G5BjxwwbPWqeMMW+XnvjH41OgbzASCe2QcgUjotodWup390xee6kl8wAMWI+YDoK9Z+Ht2EEYIGMdM8V4xA/yLhT0BbHAr0jwFdkNHsYYA/OpkrohxSWh9E2RDQoR0Irnviv8A8ks8Zf8AYFvf/RD1r6FL5tlGfasj4r/8kr8Zf9ga9/8ARD1VPY40VviKCdV8EY6/20//AKQXlacTjYoILMPU9azPiIcat4IOSP8AidPyP+vC8q66YIbPHfHrW0TCt8RMWwu4lg3TjmqsvGSWz7etPLFTyOvrUMrAMAxJOOMVZkkVJsYPAPv6VQlcv/ql+9wSOM1enYjJAwc4B9ao3e7eFYtGQc4PWs2dMDKmX74C4x3POaydQxnLEMT6962bjJ6nG7oc8msi9QsMqzYHGfWs2dETBvtxBCqOOnPQfWsxslepyOvNaV9gEgnGOMY4JrLx98YIPZj3rKR0JaFHUgpa3YY6EZxzVqGLEY7sfyzUV2qo8QP3c5yen41P5bFNyN3+7U30OWS1NTT1UAFgMj05NXTDuck/M3rnpWTZT+VcIsuFz35rfiBztBO09OKVzJqw1LY9epx16VVMZXeGAJHJGOa14SfKCvgn36mq8kXmSOCOnWi5KKMkatjGDx2qhdWhBJUYb1Na80JjAZdwx+GKiLB8jkknnNJlLQ5e7sS64ZVHoKybq0VVAbIAzgg8/lXem3DKSuMnjrwayL3T8NuVPfHep5mjSMkcDeW0jKpyWG0gcdKZoG6CZ4fm8o8cj+VdZc2COGIX5uud3+cVhXlq8WGjDKy89aq9zeEy48QWc+W5WQ/dwCM/WooiEWVcnIz0PerBBuLWOVW3HocjpUMEf+lFB8xb+H+tCOqLuOtizSRueg69Kmly+ZA565ANDbIYGQnc5PJ6cUxmYxjK8fTtVFFq2kD4JTEm0ryM49xVi1Zkh7t6kjJP51loyIVZSNp4+Y/yqzHMZmGByOAWPU0waLEziJywz83YDpVnzgy/LgZHfnP1rLUMrEgNI+cYGasoxKMzDCjjA/z+lCCxeiJK5YgZH8JyPxp+75cBuDxnHWqay5bcDg/lViJt4/2WHVR3q0Kw705AGejc5NWLU7ScgrkVGnlKdypnH8Z7mnFySTgZHPB6VSFc17KTaV68Vs+J7/d8M/Fa5dt+kXY7/wDPF65u2bBUbh6gAdqPFs4HgXxIFyVbTbkdB18pq0Rz1YXR9JUUUUjmOM+IQzq3gj/sMyf+m+8q5cIdzHBGO4xVfx0M654GGcf8TmT/ANN95V6SL5mOMc9c9almU3qZ0pDckH3JqncsI0BOck8EelaF1GULLkY9x0rNm+Z8YyPTNY1NgRzPiA7gijkk85qPTSDKyHghOBT9Ygdrh3IwEHA5rMs7oRXKvjLDjBPP+NYp6WN2vdNWxA+0SEjJBCitrQoU1DxXDaTEtHFEblkAJBOcDJ9M+tYumZClmILsxOK2NLm/sqHVtQQ7r65VYYvRVHv+OauDgk3I5nbm1KXjK/Fzq9w0JUwRN5YIHXHXn61wcqP9rPHJOee1dM6HyliO48Z5bOfUmufmCyXLDHyA9K5Iu8mzaGxZhG5SzAD3qOJA74GfmNWITgH7vTj3ohBUqwz+gAreJLZPcS/Z1IiBPRR71p2kXkRzEjGcFj61j7PMvUjUkAuOvetzUt1vAUOFduM4zmtHsZSKjOVcPjauO1VsESb5CckdhViOMTXcMYwFVd7H6dqr3Vwrz5GceuKhOwixqFz50kYJ+bYBjpgVUgVjG7cjJ470hATe5HOOCDWlaW/l+HmmkA5bjP8ASnbmFsVorctCzhQR3NVXi3ORnJUdM9q6/TbVI/DlzPKQCwGM1zBmASUDknpkdqiUEgjO7MWZgo5B+90PesXWUzuGCeMetb2rKvysowD1Unj8qw7vMq5OBg9awZ0wZy20xSHKqce9Swsu0nuOnYVYuAGlK42qOc5qqQy5UYx2NXA3epkzyF7gjJHPOOlXLJCWHylc9iaoSt/pAAIJHb1rb0tE6n5c8g5610xiKTsjTt4VGCeuOhqUjqCvAGev8qeNqqw4A7etQPOok2lsD2PSrsjK9yrcOVAKcdxiqF5fSFBHJ8yD25qxdTBfTOe9Yt3KrMWVRuzjOe9Ui4ojuGUjuR9cVS2Jxluvr/KrG0sAxUNk4I9ailkVPkGfbGOK0SNEQSlT8uOf7pp1uAZcHJH1qpJJvkUjOfSp4gElGB7nH9KDaOxsQ7jHxkt2Hauw8FXOyaPJZR3z0NcRbPgFRtGcnNdL4WmVb1A23BHf1o3QM+nvBsxlsF9MemP6VF8WP+SWeMv+wNef+iHql8PZt9oBuBxxV34r/wDJK/GX/YGvP/RD1NM4n8TKPxNbbf8AgsnoNZf/ANILytBHEkY6kdjmqvxEk8rVvBL7d+NZk4/7h95SK2dwH3s5Iz0raLOeqtSwOCeMY9agcj5iByetPUgjcD061XlOPlTO01dyIogMhWQOOAvOOtUL6T7Rc+e8SRqF2rt6t9T1P41POfvK5/KqMn+0AVPIHWoepvFFeQ7kI6Y7HpWTdyARc9zxxWndMdpHmbeeeKzbgEEBc7fTFS0bRMTUhuh3EZPYkZrLuYvs0sar92VN2SOn+fxrWu03GQbRjsKzZG34ZwCVG0E+lYzOmOxnajlo4jnp3BqxbFsblJ2k8dxUMiq1vtcA7Wxge/vVmwXyZBG3zZ6Vzt2MppFlrb7QgZWG/rWnpFy4zHLncveqcSPazj5QynuT/nFXFi6ypjcfXvUqRnJaG9Cha2LquUJ25I6Gs+6n8h5MjAPc1Y0zWHttPuLFo1KTsG3H+E+1RXFutwQw6445xzVt9jGMddSxCYrmKAmdElkU7g3HSsgp/pG9H2ofU9aCAsrdPlHGat2VxZxaTewXNu007EGCVDt2+tRzdzTksPiZSMD9ajmiDrjqPWq9ohJyGY47VpQoJTjgHoapO5nKNjn7u0znIPJ7jk1z+pWhy3TZ3LV3d1CNwGAQeKx9Qs1aMttXjPFLYqE9TjtLRkS4tpOfl3KB6VNahYryDKhmKk5Hf2NJcD7NqXnEBFxg+h/CrOk2B1PWI4Yp47dZUY+a54Ax/WrWp2RloU445CzySxOmcsA46j1pWIeFgFxxkZ4qTU23XEYUttiTyTznoeoqoGwxAYfXrVHRF3KayGOQqMZHJJ6VJBcEsCGDD+Eim3MZwXCAMeh6VVXgF0wG+7xVmisbdtO+4NGVRjww3cNUxPLbflDc7R90VjQzBWXkDPOK0oZQXGW3A84I6e1LYlqxoRNv4whGOai8xhIytlQD/niltoi/nv1VF3Ybr9KYSJY1yUDdCCO1UmSmi9E4I+7kn35+tWCp2jGzI9KykkMbFS/SrSOpB3Ejvx1zVITRfhkCj6VF4tkLeCPEAOATp9wcD08tqijchiGxnuTUHiiXHg7xAuOunzjn/rm1WmRJaH1XRRRTOE5Dx3xrngb/ALDMn/pvvK19mGwMAHnnvWT45ONe8Df9hmT/ANN95W23C8E5PPNSznqv3ihfopYsSMDjisuyjMt5gKvy9TWvcIJcgdQPyqtpVtveZi+1U5JNZyWgKWhga5ZCO4dgwIcHoK4q2tydRl3yKiRjdgg5NeieIZBNJEvCqq5GM1xOtxfZ43kwTI/cHAA+neuKMjaEm1YsWMu5d+046DjgVYu7j5FUE8D061kadLi3Xjk9RUk8ucZ+n0qZslx1Emds8Y+bgYrKe28p9ucseuBU7zATx7jhC3OOtWwvmztIQFQDj2oiVexVRMEZHBqcxhlIG1cDt3pCO479PersyBLcE4HHatEzKTMtJTDcwScko3Qiuv8AFdqqw6fKnBZAXx6mucvrV4DbPJj58OFPpXRa5LJcaNBI3zYcH0xj2rZ6xMpPVGRJA0M08KYBWPcxx2PasxUOzdwcn0qe41BptQuXOP3mBnOAcDpToVVosAAEc+2Pas3oWtCK5UiPB4Jq1LOz6dHCGyqDOM1Tu3DytyCB6imPLuUDoCaFKwWOlu7rGiwxZIwm4g9K5fcFVucA+taRZp1csVAWMAYPOKxruYLzkcds1EpBCJBNNkMG/DHWsu5G2MjaMk56dqkuZSAmMgCqzSL5BZ/fGe1ZvU6IowZWBnYbgAOcmq0zLsY5AIPA7UXc4Vyuc9wKovMSrYCk9yRxiqgbpFKRt1z1OR14rVs7jYP88n61kSpI84wzYFaFpbTABm4yMjmupbBI1hcnChGJ+tQSSyH5uFHv2pqL8pG4Z/OmuAGbcA2RgDPWmZopXkiDJZuCMZ6nP0qj6dQucZ28/hWtcMpyCBuArLmIQkL9SM/rVRLRXkmKnbyPfuaqXJyfvbc/rWhaxW103lySGNjxu5q/rPhKaz0E6rHeRyQCQRbRgNk/jmt+XqVdJ2OTR97HGcjopPSrkWd6ZHAHIJqgMh9mTu781o25UTIXBOOeOMj0qTZbFqByGQtkE9MdK39DYpcRMSfvcmsGPDu2M7c8Z5x7Vr27hJEKggDoaY2fRvw1uMwYJ+lb/wAVTn4VeMf+wLef+iHrz/4Y6knyqcLkYwP/ANVd58Tm3fCfxif+oLef+iHqI6M4Z6TKvxRfy7zwW+M41pv/AEgu6cMCTg9R06Uz4qDddeDBjP8AxOX4/wC3C7pkcoZAQ3y5wCOlaJmNRaloybc5zjHSomb5Mcj/AD1ppYbiBg9vrVd3yCTknuDVpkqJFdnPB/8A1fSs93O4fwg9Se1XJGOD7elZ07FmO0jAHU1JtFEEp5bg4Izwc1QnILHBYZParEzryAQOPXrVKY4BPQeooN4ozLslgWJI6gEdKzFON7dQo5HrWjdPgFfX07VlO/75gZDg9O2KxkdMVoVxgtkjCluhNTWTb53RiFZB3FRSDaoIJOGyR3NVr0m3uUmUbUkHUjvXLLQznG52lqqXEKpjcR+hpiA2rsh3BQcZAzWfoV1ucktuzjrxiupa1WWAMMZz3HWoemqOd6OzKAgWQr1yRUiSNAUSZCoPGRzRZxyQzEMrAZ474FXZY5LkhFUsw6HHSqT0IbM26j3ncELbujDkVSS3dJ5EdSOw7iuhsrC4EyqUDY5PX+VaMUVuY2MjL5qvtPTGKThcFV5dDltLMH2x49RdoIVQlWVd3zehp+9o5A7DbuGeBmtu90+3d5grqRGM7/Ws+awW3jWQFmRh8rj7p9eaSuhOSZF5vmIDn5+gB9PWoLhQsbD+I/rWje6RNawwSzoyxzj5GPGeKz2jYKQJchT2OeKvUjQ5jVLRWYlkIUjGfSsKOeKKSaCUlXRMIVX79drqELYwnC4wcjrXOajpMZlDkHjpn+VNOx00prZmT5ySsSflG3j1pgXe4JHBHb1pAFtpWR1RkY4U9Sp/lU1xayQXM0SZZVAYEccVaOyLIkyQVGDjqc9/es2QmCZ1YYGeO+TV5XZjgkg/zqnfAtHwSCDgk9cVcWaoYc/Nnk/ex3xVq3nx8jZCk9dtUVO5Mbcjtt5qQ9fkyccH2q3qNo3orl/KMa8ZHOetOjcbF4YE9wOlZsM2SJGfBUYz3q8j+ZGpVs85AHQGpuRaw+Tk5BJHTce9SwScggfd4xniqom4YDj69DTBL1A4bpu7U7jsawkOBtB3dcVn+KpwfCetg9Gs58Hvny2pUkwWGeR696oeKZM+GNWwSv8Aoc3B6fcPSrRElofZNFFFWeccl44/5D3gb/sMyf8ApvvK25ByOPu9D2FYnjf/AJD3gX/sMyf+m+8rcZCCzOpx69KTOeruQzAKMk9OmT1qK0VA8/mHMZXO3PJqS5yW+UgYHGaqCRYn3SICCOmOP1rKa0M0YWoAG48w/NgfdLVzXitlks9/Qg4GK7Iwfa5ZGEUhgUHJUgAn2rhPEMjyr5YXCoT1xXE1ZnVSV2YdjcMgwzAjsM1amkwCQwz6+tZEjGJtzFsewxUxuNyqCdpPUmpmayjqSq3mXcasoYqN+fSttVU2xCJwDzx0Nc5bzBNQ+ZlwcKAK6e3+eARq/BPOe1C2MKhCybGQEHnqCOBVm9id7bJVtoxyOKh1AeW4A6g8c9K7TWrCCLw7bSRtGAVG7d1Yn0raCurmEpWMvxPFHLYafJCV+SEAjNZiXZOjvaMRjO7Fat9YXN1ZW88KuYCuMntjvXNXDKrMEJLLweeKG+jFHVESRq0fKrleue9WIojDC+8L83T2p1pCQyPIdq9Wou7jzl2onGe/Woky7mft3uxfucU9hhQCAPQHirEVu7y7WUAIQGHtUF5KPPkJ/wBUv3S3apirsdzY0KyFwl40gXy4gM5PB964zVp0N26w/wCryeRjmu2h8yDwvMwDIJSXZge1eaSSbnIBwM9c5qpKwUtWx8pzBuPBz1zWZdXCCNgRgfpUl1NwM5IXuOg/CsDUbhp28uMvs7motc64ojmkE0hOBwOePvVUkIYfMMEHBxT3Aii29e+G71SnfCnOM4yOelVHc1RIt8IpSsaD5e5P9atxX0jjdI4xjJGa5lrpknZVjQgdDnk1aS5IPI2kjoa7FsS0b4ucYyOD3B5H1pZLtVUEffA7ntXPzXLAK3zYxwc8CqT3LMWUE4x3NJi5TbuL5WYDggenWqcspHDck+/I96zJLjb944Uds81WluxhcMf+BCqjEZZup8PgMTj06GlS+keDyXcAZzjArPa5BPALnb26k1ExkRSVBBXqCea1V0i0rmmWJY7CBnqSKswyFZE24wOM5zkVm2s3mgENjIxV0Hp90ehpGqNO2OWIXoehFa1vw2ArYPU56VkWxI5256GtGBiuGBAPrmhAz0X4c6h5d4BnjcOeK9m+IEnmfCHxcwI50W86f9cHr598FXLQ6si7sAnOBXuvi6bzPg34tycn+xbzH/fh6JK0jkrrVM0/iNF52p+Co8Z3azIMYz/zD7yswFre5kgYjK87QAf5E1t+NhnX/Ao/6jMn/pvvKrX1lK+oSyIOF6sx6fqT+WKG7MwluUJGHGCBxz9agkYk43EnGRmlmO07XPPrjrUJzggryDg9yKpMSQ2U5BIzWbcuFfI6nqK0JSpGMYXPY1my7cNz1PpnNBrAqS/ORnb7GqV3LgBRtx396uxwxzTFpyUtohvkKnBb2BqlrXmR3EYNuLRWAPl5J+U9Cfek2dEdzOu2UAYPLegrLkjK79qlhn5sir9w2+baCCO+BVG7wsbNuIIOB6VmzoREGAHXco4qK7gMunSAAhozuUnrimqS0TZJyR0J71LaTbWWGRcgj5smsJoiaLvhmcNHkqNxHIArsrORlRYnGB1HtXnXh2O8fxMum2UZluCGaNFOAwHJIJ6/SuqiuJmQicMkgPKupBH1zWUpKK1OWcbs6cOqdRvB7mrCXRQFYAEY9WNYtlfIAVlJU4G0DkGteAwmBd7ETE54pJ32MJRtuOXW1tJN0Mfm3JBG49Oe+KoQLe6hc3cEUPmPGnnyYwML656evFasdtocW661eeRY43H7lEYlvrjnFVNT1TT38QQ3XhUT2kiwNHPMYmRXHG1drj8c4rZRe8hK26M/7NKLZZba5STfz5TE5/Wr82oy3kMEOooI7SL5SkajI+hp1k1s+jXTXjyLqKP8i7fvD1rOu96oJo9xQcEgZH41LVg+ITUrsvtV7mWaGP5Ylc52iuXvLiaGc4bap6Yq39oRrhvOJCt0Pp9ag1C1CBc7svyjMDiouzeMUtyVLoSjDMzf7R6/lVe8jL4bPB6egNM8ryl7FuvGc0okDYPB2j+E521oiGrPQ5e/AikO4nyienv6+1OR5JgVLAbR1BPPt9Kt6tGG3u3PtjH61iQS+TKqtuOSMZPbuKpHTTloJdbkBcHODgjpxUNyUYA5YBhxjitW72tI+zcsbchWPT8ayZeMJklc/jimjri7oqxSCI9yP4qnZgvO8qCM8d6oSswlZPwz04qwjgjGS390dK1RrYlWVlALcAngAcmtK0nHB45HOBWMcZVcndnj1x7GpbWdopjG4wP72aGiWjYbauCOVaod7CQ/wjHA9Kj84MuFPamlxg4yQDwSM5/+tSQJFsPwRnk44Hes/wATPnw3q2eQbWX3/gNTK+ck4HsR1qh4iYHw/qhwADaS/d6fcNUhSWjPt6iiitDyjkvGwzr/AIFB/wCg1J/6b7yumm2tGR/KuZ8b/wDIf8C/9hqT/wBN95XQSHBI4zQ3oYVXZlGZc9gQT1I/rVG7XaPujg55NaExDOOVye3Ws69PykD5u9ZNkRMq41DyLG4gwD5vQZwV/Hqa4nU1wJJG5Hriu0kt9sMjOMl+mP8ACub1SzR4yiZU5z8o71yTkrnXSsji7onnnJPT2qnHKwfBIPPPtWlqELWjFZg2T0PTNYbsGcsg+Ydqyepu0Wc7ZmYnnOenNdRo9wHMeGBI5JrkhIZWTkAdDV7S7porsIWBXuff1qraHPUjc7PVpkmuV8pdoI/M10GjyRappcVrcS7PsxLEnJzXKzMRbpIGz6Y5qMF4lWRgFHXJNEJW0OScLo9KS+iXSLhLUr+7XbGWXIJ9cH+VcLrN0928XmKqlECEAAc+uBVyxhmuLA35hfyEG5XCnDfTjpWJdzeYxLcZ7Yq5vVXJhGxM820qpJCIMcHrVrQLaS7tr9kACwfMWI/SsrazoWyWP861NMvpLC4mRGWOOeLy3A7/ANaFqWya0kAhneTGVJJPr+VYysv2O5lc87wACKkmmENs8Y5578ZrEubtRCkbY2Btx9T7UluOMWb3iW9+zaJb2Izvdd3XHH0rzy6uUh3lsZ9D2qzruqFleadyHPCkc/SuQmne4lJbPHIptXOilCyLNxePOxWPKqRyelVWHlqRtOcdc4FSRABlJwPY9qZdy4jLFdzep7UrG2xTdgXwQcZ9ckUk2BGwKg/hRYLHcybZJWjPYj/69Jex+Uzx5D7OdwOaahYq5yV/Mv2s57HsOajMxK5Dj6nmq2qXixXrq64Q99vNQ/aoiNwz8wweMZ9v/r12RjoK5ZkuZBt2kkZ57flVWS7IdhklvQ1BLcqVbBPsM5qu0u85xgZ5GOapRHcla4kKruYZ9h1/GkErkrlyW9cZqAcYCjd196kJO0D5cEdh0rRJATRS8hT69c4q4j7h8zY/U1nDkgAgeuTU0LmP5d4UL09zQNGhA5jcK5OCeR1q+0nODtx6kdDWcMOnPJPPHapo23hcjnP3h3qWjWLOktGZokyevXtWlCy5I5UY4HrWVZEGMZOeOfatCJuM9xwM9/pUpFM3vDbFNUibgZOcele569OX+EHi0YwDot5/6If2rwLRyVvoNu4NuxtxmvZ9VmLfCrxYD/0BrsfT9w9VNHLXWh6P4148QeBf+wzJ/wCm+8rWntgTJsCjevOTWN473f254G2Y3f21J1/7B95XRXK5tznGW6momro5Km557dZiupUL7gTwRxz9CB/KoWLb+c++TWpqFmDOeQCvJOP5VkM2PlzyCfxFEXdFIjuXGAoyePSs+4beME54796nncqCFGf9nNUpjjIGc4znPT2qzaKGea0Ibyz168ZxWbctLPOJLhy7Dpkkn/PtV5wBkbmAA6Y61QuG+UjjGfwH0pNG0EUplLO5VT8nJIHT61RuyDHGAowecDnPvWiXMUDpjJfuVyCP8fes6T5uMNgjgA1DN0yiA6Blx17Z/XNJGoeVIxtU8lSeKdcKMtyST2xUBbCKu75xyvsfeokhvU0mF55ts+nl4dUtWLwTxpmUccqPYjtitjwsmo+K4NTuGuUm1K2+ea3Y/vXH94KMk+nasA3J2rMreXOnzZJyDjv7ii91a907XLXxBo37u8iAM6p8qTL3BUYBrBxU/dZyzi1qjqNOZJgSAu6NsbWH58VrWMgSaWORWbjKZqnr1/o9/dW+paBOM3UYkuIRnET8cdAPypkF0JAGc7SOARxk1xtOm7C+JG/pV3A98n2s5hGCQvt0q7qWpx3OoSXRj3joykZxjpn1rmGMLK4QmN2IwpOQa0rGwAjeO51OCEyAn5gTj0FbQqOWhhKmlqOvLieaR5AipnjgY4+naqkd9JHaSWhfMedwB6Zq5fXkbwwSLEkTIgjZRzvI/iqtYaVLrV2LeHZHIwYhn6HHOK1TvoJIxJdOmZ9x8uaIHcQhrb8SajDq72ci2skEsMAibjg46YqKKJXtpEG6O4Vtm3IwcfSnJDbtaM1zdbZSPlQIc5HY1S0QOV3cwbqEnAyd3c561murKGIJBz0ArorqGUKGMeFf7vrWW8TgOvRjzg9x/jQi0zDuNzN8p3Y5yR0rmtTVicqcEc8CuqntxGWbHzd8npWDeJjLcAj0qkXF2INNulurdQww8ecj19xUV2hzwdu7rgcVmI7W84nXJ+bHynrWxNiaJZIm2hh0XkGqeh105GLcfKMyLnP8QNLC5V1wwOPmGO9Lespyo+bI6Y6VUVtrquQGxnOcCqTOpamiNrPkZK9QM9PWmtjzMqQD71DbSkjJzk9MjrUu4KwZwCememasCa3l3qUBIKnr3qaR8liCR2wP8az922YlCwXHrip0bdxnjsM0rCLCuCV6fhzVDxCSNB1NQSc20pP/AHwasByq5G0Ad/eqGut/xItTbIBa2kxk5P3TVIJbM+7aKKKs8g5Lxuca/wCBf+wzJ/6b7ytxwx3YII7cVh+N/wDkP+Bf+wzJ/wCm+8roTUyOeruUF2oG389+RVMshDSHliehx/KrVwj+YQjDHfHUfSqd4gSI4zn0z1rGb0JRAUSHfJdxffGEUqOn48Vg6naoriSMrtPqf/rVq3UTHbvPAGADyKgu4jmNSrOSMDJxXBJ3ZpB2OP1/TJL20aWJQWX0GePwH9a4CdDZzqj9HOOteyyqYM5UbCDkHBrm/FOgRX1gZIiVnxuBHBz+YGKmMraM6YVOjPOElUXAA6HPWrgBZkZSAe571jMJYJzHLw6nBJ/xHFaccu6PLEj+VbLYc0b9jfGSABvmKnBPYVpPMtxbSRluGjIGea5yy3IxyzAOM4A4/CtG2Yb1IJ2k8jNQpcruc8onoH/CRKfBtvYIv79UWJm6jA/EmuTILSooHzMc/hTUmPlFVyBnjHFIW2njn6dqcp87uzOzRaGFkYHDbRxTZZgZl2/dHUgVA0mGAz2xnPSq9zK0a8tVXBIgurgyzbFLFQccVzupXIWdlLDavLCr8twbdHnfI64964jUb2Sd3Cn755561UVdnRTgOvZmvJSzbggOB6VDND5cZwe/TrTA6hSvZR+XtUckjO3JxwMev41tY1tYmRyyngYHr2qpeXACEDJwcnPapclVAwAO2KzJnAYhsnJz7ms7ajEfaoMm7v34/KqzXbZOXyvc1f0vVv7PuTHdw+fYyjbIvCsB7NgkfhWVrjWUdxIdPdjEfmAOfl/PrWlmCOQ10hr+Qov4A/rVDdtIIOM9Kku33Ts5PJJ5IqANz147juK7IqyAk3ZHuT65pRjB5yM4PFRqckEE/XFPRxk4ZhlvvUxokGQAO3oewp+VwSGwc9h1pigln5Y/j1oU5B25H1ODTQD12gZ4AzkkDIqU8OmACX6ZOM1EnGMZ9/pUoPzbSAxPfuf8KALdqwKhd+D6YPNWYNu/A4YfjmqVqxEvU+/NX7VT9o5AIz1HFJmkNzobX5V5B4Xqe1Xo8YBG0/8AAapwHnB5BPOaupuxjI446/pUo1Z0fhmzaXUIJMHZ6+9eua1EE+Fvi3oP+JPeHH/bB6828BOBeIGULz1Uc/yr17xfGo+Ffix0A/5A94M8/wDPF/WlN62OSu7I7Dxt/wAjB4F/7DMn/pvvK6EklcdBXP8AjT/kYfAv/YZk/wDTdeV0EqkNx0olsclXuYWtRtjMQ+bp1/8Ar1yWswNZTIZZN24ZLEY/Af8A167+6hEhORzjjPNcB4qM7Xvzg7Qu0ZBP9BWMNHYVN3djJmPGTgD1zVR+Mg5GeuKczjaMdv0qB2ypx3HXua2OuOgyZ8IPmwcYrPkYbhxk56HjPvViY8EgkD3FUnkLA78cHn/61I2iiGaQHceNoPXn8qrSHjjBwOo5q00xNs4jAGWwff8AGqDkbQvynnpmkaEMrKUUdT6iqlwWQ/KAp9QeasyHdwSM5zx2qrKoLltoz3z3FJjQgIUqxYsCMGmgqd0bMemBx1qES8usiHGflNDyPEUbYGC84bv7VzziW0SWl2dOk8uTmBzhW5OK6ewuh97arKBnGcH6j1rl5za3dvI6MqnODH2FLpl6YZBDM21RjDHqwrCcLmDidvBMspBRsNjnmtOLymu4ldlMYHP1rltPbY77GyOoC9xWrbSBmDgcHqB/DWcVYxmjYvXLyF8oiLwMnjNJpt/5qSQJLgP1I45+tMMkc0Do6Fnx8vHeufhR4L4MMgA/QValZ2M+W6OsaFY49yADA5NQyOGVgTuyMDnmj7WWgCOox1OaixsXdEwI6VqmYFeRi/yuWIHT2qjcAJIPQ9wM4q07q7HJCsOKrXDbV2qBxyapMaMu5T5eSMVi3sBKluPn6H3rZnYvOAQRg8Y7/Q1SuCG3D8uOlWjRM4y9RU3g54PK1V0i6EExikOQxyo71razCWjLqP8AZyOK5NuNyrnI6eorSyaNoSsdBfoBghhuY5B7Csq5Ee5u5XsD196nsr3zbYLJncKqzSDMgGMr0x1qVozupSJYnCxhmBJ64xxVoybWBBwMdqyg+3IIJwPzqxG6MUBBz6d6s3aLfUcMcdQTwaRXO44OfUHjNJIwJHLYxk5xUTYyCMFRk9KaQrFjdliQ30A5qnrjf8STUB8vNtJx/wABPNOSXhhGAPfPJH4VW1sqdGv2X7rW7kAdvlNNCl8LPvqiiirPHOS8b/8AIf8AAv8A2GpP/TfeV0T8DFc743Gdf8C9f+Q1J/6b7yuh6DBzSlsYVdyrcE7cAH5qz9xM6A7SoPOeM1ozfMQorPugyPnGCeR9a5Zq6MkMtjHcTzxvsaU52ggn9T/hUN9bk2wuGISRG2spOP8A6/8AKpYnW3u45YvmZl2nJySfw/lmorsSPa3KttDebnAHGTXHNJDizHn/AHyhGUHg4wOKoXym0iRBkkck44rXggEcPmsp67c4qnqsfmzxgjdH1wOaxepumeceOtK+0Ml7ZgmXHzrgnPv3J+lcnayByVb5T0wfX39K9SuQqSOGBKk9PUV534o09LC/E1uNtvIfl2jGD+AA/nW1OXRm6d1YkS9dooVeUkRjaFPQVqWLxqpbILAZ575rlxIGjBOAwP1rVt5CYwvRT396ckRJHQRSHGeMds81IJRglQCPes6OT91jnryPSrDy5gU5JPTrUozsLJcjzQBg/XrVS+n3wkA4XvgVXmm/eFs4GMZrN1O/CWp+YHHoa0SuOMdTL8R32AlvG7cdTmsa2j3k7iOnPGKbua4uGkfBJBwOtPSTy4GxuJPHSumKsjpSsiFceaUxgHrjk5pyKPMI5LdfX8KgjZVYnP8A9aponUTDc+ECn8aG7jYyaTbnjCjrWTcS5O7cPXFTXdwFyVYbcdfWsHUL0RKynB4zkdaUYiRNd3KRqS2fqTXOaheM4KR/Kh7g4JqK6uXuDuX7q8Zziq0hG7AbgdMcc10wp23GROTjaAuRxx2puTkE5C+g7+9IcA8EHjkDrSAHGRnB5zmtRXHgnBI5UmlDAtwTxTP4RxgY796d3A5HYUx3JfvfNgjA60oJ25JGP4e4qPIcA/LkdvSpF9TtJHOFoC5LgjIGQD69qkzg/NnB/T8KhGcDAYHOeTUw68kc9v8AGgLk8ZYuFYoVHQYz+NammofPyxP1AxWXFuD5ZQRj0zxW1pcZVd2QD3A60pGsNzYtyP7vAHPFX4TwMjIYVRiAB+6TgZU9q0LUfvI9vftSRoztfB9tvdW2YPY+len+JQy/CvxWGA/5A92MdP8Ali9cZ4QtMRxFVIwefpXdeNIyvwx8UHB/5A93/wCiXqZPU4a7O38af8jD4F/7DMn/AKbryuklHp1rm/Gv/Iw+Bf8AsNSf+m68rpjyKrcwqalcgY4ABrm/EdksrhthweCRgZ/HFdKflciqd/CJYiOc9u39a5qitqYp2Z5Lq1s9lNjadnuwFZxkyoAzgenJzXfanZJPaOknysD09f1Arz25RoJ2UgjOQM8VUJ33O2nLmILhyThs57ZNUy2Su9hjrj0qxK5IPIxjBIP9aqFgFIwMjrWh0xILiXdt+bp+VRtKu0sVY9setRSyDIPOM8A5OajY7icnGDyewpGlhN6kn+DPB9TUcoCMxyckYwB0ppkyxDMDjuKlRlPyoAc9STjj1ApBYzZtrOAvG7qAOlVGkaIHgsvfdzir1yAkjhXyDxgdKouNwz6DJw1SzVILe43O0aD74yV7ZpSEl/csSJOzYxg+lVCxEnmL04O7HP0FW2IaIbSGB7nispIJRuTabqMsExjcspHAXPUV19nqdv8AZeGy3Qg9/rXAXMbShWiP72PoQeSP5Vd0vUEmGAuHHDA8c1lKJyzid3Fft5XmwYkhHUDqtPEkc4WWR8Hsprm4bl4zvtwoPRsng1Y85ZVx0kHOD39/pWL0epnym7PKwZVWTdgfN61bhnJhIY4btz2rnlusDawycdenNWVuQobnP41oncxlE0Lwq4fa3OOoqgl2xUiQ/P7d6rPejdhWOD1J71XMgDsdvy+1FyeUvStn3JrOu5NgODnt9KWWcDaCxweKoXlwNo25464q4yCxT1FY2RgT83XGa4nUHCXjcnA7DqK6q6uAY8sck89K4jUJQ13Ic8k8nriuqJpEXzTC4w3yk5xnNTvclmVg2HHX0/H2rFnmVlJYqRng4qWKfzYRwN2eOMfrTlE7KLNLzTnhQqng+mfapo32nDZyOBg5rKhcbtrEkH1Pf6VdidWHAPBwOcE+4qVodiZpCXKMGZQcYx6U5XblWxwMgDqaqwSbtynIPXpwPxqUNuxnJI+6zD9KaGG7btLDaDzjrVfWHP8AZF8CQVMD/XO01YbLHHPPQ46VQ1TI0m/xyPJfn/gJqkTLZn6D0UUVZ4xyXjf/AJD/AIF/7DMn/pvvK6Fuh71z3jj/AJD3gbH/AEGZP/TfeV0B44PPfNTI56u5WPRh1bsKrTco6tk4GCT2q3OCuWXk+mazbiQxWzMrZYnCru6k9vWuWbsZRKelDfqJLsCI+ncE1dnQSRSE5YFi3AwM1X06wmg160MrnHlO7KMEbjx161pJbrLA0SZVQxzwRn9a4ayaL5WykRCpjifcQFJPJHNY1xbkAHdkAnBx0FWNTsjDNmIcdzilh3vjcTwMVgnYqOhyGohVlJBBJOPUGub8RWXn2UoAC4G5WzyK6zWFCyyL1Knn2rMk/eA4QYIxx0Fap9ToTPJ1fBwxJI4OP8K1LKXa6/3cc561na7F9m1KZQWxvzhugpLe4UHOQPQV0W0LaOnDjKBWIxzUzyBoSQvyhc8j+VYMV5l8HAHc5qaS9xE24/NjA5wDU2IsMvbsxjBPX26CsC8la4O3JCjoPSnXFw00pAJ28/jTQoC8enSt4RsaJWKzLgMDkemKrTk4I55H0Iq1KcKSRz9f6+tUJnAXg4PTk1RaGFsSAZwMYwearvMqNu3bV6ZPeobq5WMHBUEfwisC9vzIRgn2HbP9auMblWLeoTqhIVhz+dc5eSszO27Azggd6tF8ZLuCc9AeRVC4Dc4wcnjnqK6IwSCxB1YE8j+6P601j0yfkHb/AOtTWbLHnA/u+tNY4wRw3vWhIj7hwQFP8WB1ph+XgjA7YNKTtOcqD7dKRSd231GaZLHfMCCoJ7c0AZGB82f50ijPA5JPI6UdufXj6UAiRTwB0HtT+hBC8joM1GvIBAye46YH9Kev3CWHTnI5xQUSrjDce5z0qZQ27GFA9jmoQx6owGOgIqeBQDgEeuOtAFiDKn7wJPrwTXQaauIlxyDzyMmsCFCWAODzgHPeugsyAqgg88+n41LNoGnGeQpOMdfatPTU827iA5564rNRiSC3GOldT4WhDSBiMMffr+FJaDk9D1TwfbfuV4x06d66f4gRbfhj4swoP/Eouyf+/L1meEkUqnc9DzWx8RcH4X+LBt6aTd8/9sXqE7s82s9TpfGv/Iw+Bf8AsMyf+m+8rp65jxr/AMjB4F/7DMn/AKb7yunrRCnuRTjAyKrsd3PTj8atyLlT61TYkkgnH9ayqIwmrMxNRtvLuN4zg/xdh/n61x3ifQEkSW7jIG0c85H8ia76+jSSHAHz9j6VyussbfSrl7ra6KCFDAc+/NcyvFmtGTvoeXyup+8wftxwBVSZ8Lleg/E02e4RpJNhIBOVHU1VkkYj5lIB5Iz/ACrpT0PUihsshdhlypzwMZFQSHnBJGRxjpSzs3y42j69voaikcgDC4x07H60jVIA6hQwIx79aXeFO2MfNjqe3vVfJOAPm/2hwKZIxB+Xbnpk0NlWCU7gVJBPrn9arTAhflkwQc7cdasttKMTubHGQcGq+QzoNy8Z5C/5zU3LREckOOD05YcVEZfKIBOYyewqQKpYD7ynJJPSoZgSBuRVBPrn9KVrjepMGDKdjHIOciqNypiuPOjGJP4hnr71KhELgY3L2xgfpUr8ZZhwe3Uj8azasYyjcs2N+LhCSSem7mtNJMSGRWyODz3rkJCbaYzRk+UeHUVrWt0CnJypGQR1qJQT1OaSsdE+qiRsCMZ6ZPGaieWUgB8gH7oHcf0rLaZXjJUfOvHWpIb4tsjMgyOh7/nUWaJ0L4kkjyWJx02kVHNcAsAeRjHr/k1UuLw8ADnvmqU9wSuFbBJz7ZqkiGjVa6XyWZmOenBrIub8MW5K/wBKz7m4Zc5Jzjkg5GKypbxQxyw247dqqMRcpfv707DtIz3xXKXMrNIdhznO/HapdSv2GOCfpWJJcEgnkjqMH/PNdUIgi08pZkyMrgjgfzptpOscqje+3oP/AK1UGuMMcljnJH09M0sdxwfl/IYrRo2hKzNaRlwA3zDtgYxV23l3qCG/Hp+FYUc42bfmKZ6HtV6xmVCI3xgnKgnOKho7YTubsTkNv5wRwegNWNxZcu2FHPFZoPA3MFxzjtViFyFIbt93HWkaotxnIK7jx19RVLVGP9l3wHTyHzxjPymrUTqeOrHoe+aq60rJpl2rgg+Q+fXoaaJnsz9CqKKKs8Y5Hxz/AMh7wN/2GZP/AE33lbxPGe9YPjn/AJD3gb/sMyf+m+8ral+Z1DLwOetZ1GctfcGcZI43Y4qBtO/exTu+WRshQ+F/lTrgAHIIBbjI61C0wk1KEM2I0Q/Un8K56llFszg7FlCv2k3JC52FTjqfan2Lb42bay5PRqr3RKr8gJB9Mf1qaykY2wOOegHrXlym6k0uxtTlaVmUdaXj5VypOWPpVCOB202WbONvK4P+ArUuCxLJs3N07CnXVqYtGaFeHbqOBVQp3uyU7ts86v1Z5GLjJbtVa2td13bqxAVmxn0rZ1OykSUvLlZMAsFHT8jisW5vhbQtnH7s5z3zVtaG8XfY8y+JLwf8JNPHbqgiTGGUDBNc3HMSC2RuHr6Vo+Ky9w89x8oYtngVy0d6Y+j49c10wWh1ctkbq3QA+XGeq0huWlG1TkZ5JOMVjG6DspduvB4wKkS6VEIzn8elaJCsaSgAc4JzwO9BkXJAGQBnj/CsafV4x/rGxxjnj9axbzXZDI4h2rkY6c4qlFsEjob2+TnlcDjrgCsG91HarYzjHU85rFmu5JCCWyx5yev41FvZ25Y56/MPlNaqBokSTXEsxDEAgj16moW4ZcYPrnqDR5eBzndngg5prMcDAXA4GetapIYgfBGMBiMZH/16qzE7jhQe2alPUg4PGCT/AE9KryA/KCNy9z0NUiWVSMg4wzDsO1Nbk/McD37miQ8YJyvPTrTTnqfl44qiLiE5HTjvRkkZPTtQ3XAA6fSgZzuP1zTEKOfc44x2pwzsHH4kd6QYJGMgjrjpTo1GfkY8jr6/hQNC8ZGOo6lqkSNhzj6dxToo8+49B3+tWoocMCNoJGBn+VK5aiRBMEKwOc5yvOatJESw2euCfSnxx7eV37geTnoakCqc4HIOc5pXKsKgCjBOW9RzWxZFyVICj05xWVGPmJAU5/Me1aVmNuNvAz3pMpaGxAd3U7u+PWuo8NyhLhE3YPXB61zVtkEcLkjr6fWtPTZBFeRtnILYyRRa6FI978KMVRSfukdD1FavxEfPwy8VBfu/2Rdjrn/li9c74XuP3EIbIyBn/OK2/iC+fhv4qx30m7PGcD9y1Zx0Z51X4jsfGv8AyMPgX/sMyf8ApvvK6auZ8a/8jB4F/wCwzJ/6bryumrZCqbi54qpcrt+bgHpVuopFyp5xUzV0RJXRhXTiNSxLEnuO9cj4v0ZNS01pQ7ccldxA/VgPyBru7m3BjbZyfrisaREfKzEJzjrx/SuWfdCpy5Xc8Dv4XtXClM/QY4qoW3DahB+npXrni/wpDLDLLZMJvlyQGDY98BTXjlxG9rctBMkisDzkbc/gcU4T5j1aVRTWhJLIzDjAxx64quSWyRjcO5wQKexw+FGc/wAJ7VAQq4J4ye1WdCEcE7u+elNUgg7eQOAemDQXx/fY+y1GMlD1AJ47igoFkyR8p4yOecmmj58vtHXAJNBDpgggDuO1NbJOGxn0z2pDuLMNoUYJxz1ziq7AD5lKbieM9qlbcqN8pwOMr1pvBG5ckemM5NIZDIOG3KUOOMHk0xXHmBGcAsMBvep2wUxlsnqCOTVe5UNGpJz6Z6mhq5LISnLBh+H9c1TWQ2dwwLHym4Geo/GrW/BKtyDxyKr3axyREcED/ZpWsYzjdFxZ1ZRtA2+pp0kvJwVDeh7+9YtrcGOXyZeQTwA2Bj1qe4lxH8hKkHrjNDhc5ndGhJdsqgNkAfxD1qk10W+6dzZ5BGAapPeDOwjPp6Gqct3tQ4cAZ44oUBXLV7cvt2OQAOeBWJNOxVsgAngU+eZXX5j06buf1rNvLkBT9MjB6VcYhdEN3KQchmBPHH+FUC+drFsMMjOOWodiCuThT2H9TTAxUEB8ZPQj+VbpCFBUj1x0wMg0oJxjOM8gnoaZu2q2TuLH0zS7ipILcH1NMZKrgKMncCcHH+NaNkcncRjHORWUGAkODwBz71paZhlI4x1xj9KmR00XqbMbebtKjHse9W42LZ5wQQcjn8KoqGXbtYLxnHtVkfKQFPXnJ9KzsdiLqSYBbGGHOSOtM1cn+yLsABf3D8A/7JpEkDbgMgdMkdfp6U3UmH9k3qgttEDkDGP4TTRM9mfoZRRRVnjnIeO/+Q54G/7DMn/pvvK3OwGePasPx3/yHPA3/YZk/wDTfeVtuR0yPTrWVQ5MR8RFcsFAZsFRWDdo7Zccrn5d3b/PvV6+kO8/McDjA4qEqrKqeozmsWr6MmKsaVhMtxp6q7BWAxzx/hVb+04bNFiQGTacEqjHJ/Cssy+SoYbRhuhzg1sw2aS2RVVDE8hiOp9uK5ZUWndFNsr2+qRNI8trDJJL0JaNgPzGacHupIHuZnZWwdicHH6UsTxaZprQOwidmJI+6T9KI55ryEeTbSBF/ikXcD9MGmqbbSWxPkjmbyWeSYOVLyA/Oe/8uKxvECM8uDH+7I+9knmupmwxuFiMec4ZQCMfhXP6wkiqFc4CDjr/AFp1Eb0nqeVaxYAvOrAbSMV5X4k02WxnMkRYoep7V7XqsHmSPsGQep9K5XXNMW+t2i2gsFx06fpVUpcrszveqPJxcS5AJZTj64/wqFrub5ctuyOKk1GCWzvJLebK46Z44/GqW/ksMYxgBeRXakiUBds7Wz19f0xSbWP3SB3Of8aQvtBAB3duOaVZBu6hU755qrFJjlQ7R82fpxQANqj5sA89xUbSA4Zm45wcdKYJMkBSAfUGmkO5JuYKenJ4qKV87PM9ODnGaGc8Bj97jrURYq2d+Mduwp2BsQkb8AnBGeBxn3qCVuqjdgdgaczYXJztJ6DkVVlYnO4/TimiWxjgBgMdOwpvOcH9aUnjHOKQdO+RwKogUHOfm+XPVuaQDLdTkUoHPJHH4VLHExYHGR3obBK4RqxOQASeBxVmGEknIOT0OcZ96khgKjcy5Uc8HirSLyMljjr/APrqGzaMRkajquR2Pt9PWpxHtGSRgchs0IPlA3deoxzipNoAGSMHpnqKm5YEFACwG3sRyTSkbt+3J4zgngf40YxIdhHTvTdu4bXBB9O1O4iaJHJUb+vUdcfjWtZoevTHXdzmqltHgDII/HpWtDGFUZAyOOlFxpFqHAAO75jzgVfsomlu4UQBjnr/AJ6VSiAAC7s+uRWnosqxalCx5z7U0Jnr3hkFWjCkfKOmK1vHcxPw88UqeB/ZV12/6YtWNoL4Khm6cVp+OgF+HXidgOP7LuRyOmYmqVuefV3PSPGv/IweBf8AsMyf+m+8rpq5jxt/yMHgX/sMyf8ApvvK6ftWiIqbiimSZxnilHFDDIxQ1oR0Kj453Y2n8q57WYwpLkDyu7LgEV0rLz7HiszU4ttpMq4LMDt9fzyP5iuWUWZrQ5d5JWs55LaJvsw4Ls3BPtnr+Ga848baMHtjfxqibOoUAZ9zjH8ya9XjeC30mPSbKMG4fMkzEnCjuWbjJ/T3NcddnfaXETAnJK5Df5/nXO17OR1UZcr0PH433KQgBPrSkAqCMlh05yBU2s2ps75hlsHsf/1mq6knJAzj+EnFdKd9T01IbMecA4YjnPQ00DKKBx9OP1pZGXAC4wfUZxTVYOvPGOnGcU7FKQ1sbxubOBxxjNRgfvAARgmh2z1OGx2Gf8mlO7O5cZx1zgikUmMZi5yuACdoOMEClYAHBIYDgepofJYBj8gH1qMthVC4B7DtQFyUAkAnJyeMdqrShdpYLtTp0+9Uytk9CcdeaglxjDHcQc49qLCKbZzwABjnnP6VVnBG0g4I9eQKuHJLN1GM9ePwNVZzlR0b8c0MbMu7UBRyS3XPqfrTrW5DoVlJyvQdSfapLyM7cgEA9s1lPutp2ZC4JI4Heqic9WHUl1AmLr0HTAyBWRdXmHAQrk8sSev0rZvCZ4QU5yPmGORXMXIIlJwAB14ySapIwQryFm3FtzL07VFKu/gjBP3uc01dqknhc9z3pwI+YA4yOeec+tabAVRheygY445pnIK/Nn265p0wx94E5HBHrUfbjAyOvWmIXgtgnHfP+FAJ52kfQjkU0HkZ6+p4xQSCByTz6d6ATJWbBUKOevIzVqxdUuRuzhvQVTVmwcMOPUU+J8ENkjBzwaT2NqbszqTt5GPwPUVNGAAuQMnjI7VVEu6ONz3A69RU0LfMI2OM/qKyO5MtkHJXeWIx0GP51HqRH9n3gZmP7l8A+u00BsyAkj+6CQc1HqC4sLzPJETgk9+DTQpbM/ReiiirPIOP8fHbrXgcj/oMyf8ApvvK15HJjOFGTxmsjx6rPrfgdU+9/bMn/pvvKsmQglc8A8E9qyqHJXT5kyKc5baOpOM9cVSmmMe5EfK5wWIqS9Y5+UgBe/eqKn5W2jLZ5GcVCBLQbdsTARlgeo5rS07U5ksAkW7zQOWfDAfhWTeEyTqC2X6k9hU8S4RpBtOB3OK0T0CSJQCBh23HOfmyR+RoN5erZrbWm1HmfaGCjkfnxTUl4PORjnmmxTK8ySM22OHnIHJ9vSklbYmxYkg8iFLe2cuyHdLKxzuP41z+viSNHeQA+nI5rsdFj+1n7Ux4J4QkHb/WszxhdRurwIVIUcsGzz9Olc04O9y6UrM8uZC6yPKy5PPIrIki2TEscA+vNdD9jmvHkMaMbeLl2wcKfQmsu8hSBWeZwuPfn8qiUTvjI8k+JumLFPFdqFDNww9R+dcG7FlwSNuONvFehfFbUVurtIos7EUDIHH4155KqE4GcjnHUV2Ur8upaImO0YbpjIPem7hkbt2R6DmnHG4DkZHQc81GCeSuA+ep7VrcqwGQAnHHbng02TJx3A5z3zQwOCSR0z1prHoV+9+ZP4U7hYUsc8kkNyVphJ6qQPoOlKQM54A7Z6Cm7Vw+wluOnvRdCsRzZ25yG9ulQEDnOe3erRU4XJ+b8jTfLPQqACOo6mi4uUrbTtOBkD0PNPWPce4+verKwZILEcdzxn2qykBA7Ant7UcxSgVYotpGOo74/SrKxbXUsWAX/OasrGVUKVGF6/N2qTyvlO1k5Ax3/WpuXZIjVA/BOCOR2qVQ2M7mU9McZFJtUP0yG9BTwAm452+p9P8APrSY0IcdcHb6HqfrRkDjbjcOcHIxTjGM5wMY4GevvQw+UAcHP4UFDWz5fHIx1zU8A2hThgc5IHINMSP5+GwfTFXIE5zjA6DPOTRcRcs41IJPHPrnFaCZySR07kVWgACcZ47gcmraqFJAY4ApICRCR0LFuoq3Zc30G0nO4Hk1UTBzg89hitPRMHUoiw6dD2zVpkyPXvD0ZaJXCgZwDk4q/wDEEkfDrxMvY6ZcYwf+mTVV8PsrRKRjkccVP48YL8PfEgAI/wCJZcjr/wBMmqE9Tz6mrPTPGv8AyMHgX/sMyf8ApvvK6YHiuZ8a/wDIweBf+wzJ/wCm+8rpPatURUdmOFGabnB5p3amRcibnPPIORVe7JYHbjOO9T5CsT/KoHQyttXGepPesJmTd9Dn71JGmJIKEDBYckD29Pwrl7zDTyLsdT/Dkc/4/pXZ6krq4jwQPXgE/hWJqVkrLlflfPOBjP1rlnE2pytoeTeN9LlUrcJG3XkgE/0rinfEnTPbOa9m1yxju7R4mAJPALY4P4g/oM141q1nLpd40U4YcnGeM/h1/Srpy0sz0aUroaX+XDdD6cZpd3y5XOOgxUAxwBlSOfQf/XpCSTzwAcY7/jWtzUfIx8wFj/hTGPDEqu4jAPemGQksfl46UjtuYZ3cnqetMpDmxlQG+bqMUhwTuJ+oPPFNJzgLhSepHeg5IwwyuevTPtSKuKo+fdhWUcde1NlJChe2c7u/4U0vtAYhcZwAB1oV8EcAn3oAp3IwwLdc8ZGRUEvB3d8YOeasXO4SHO4N3JqqQSMfIQB19PxpFEUoDoQcLjnisvVIFaEnkNnK1qyvtKgHHfp1FVb1RsBzggdRzx9KaJlqjEtZuTG55POfeqF4h84vyOc08ybbh2QkAdQec1Ndx+YAyjC4zkjp/jWhyNWZjvknqAx6DrxRkEEhT6kVLMMc9wOBjGarEg5ySOh4P6VaEJKO575JUHtVYledi/N1HtU820L8hwOg9zUL4zg544A9/egljWwWPfj9f60o55GSR1PvTWJAOcHtntS9+c49OlMQ4ZAG4En3pVOB97HqKaDgZ4yT0PTFPUgcNuI9h0pFxZvaZJvtwnBReCKshiGyu7d1HGcj0rK0eQByhOeMgY61oknIyu31w3FZM7oO6NCH5wRyD15PT6VDflv7OugwBAhbB/A023baSVGQOAM4zSXxB0+5wij903Q+xpoctmfo9RRRVnlHK+Mv+Rj8Cf8AYak/9N15WvqunfaAZIPlmHb+9WR4y/5GPwJ/2GpP/TdeV1VJq4mk1ZnCzO2x1K/vPund1FUGKxNkEf8A167fVtLjvk3LhJx0b19jXEXVvNBcvBcq6ODxkZBrJxsY8jRArDezN36D0qwshcgbsLjGO1UVOSw5VVPX1p5yxMhJCryDmqRLRLdPhwsOMDkjpUTy7oypOB9amO0xAqu7PJJ61DHCs80URO0ueSAeB9KNQLun6munaTcjLMznCdwPfrVEoZLc3NyrCBedxP3j+PFO1FY4r1YYyzQxHHJzn86fbXY1PUtkiKllapkDv+lJq+wkraoy5rm5tNCazSOMxTymcuoJOfbtXC+JraSW3LSgjYMncOtdhq+oNc3s8x27BxGuMfl2FYd5C81oxbBZs8YrCWmp10nbc8c8RWAuI2YL8/t/+quDuoXik8plPHHoa9i1iwaNCDkHOOo/SuG13TVlQsi4cHjoaqnM7LX2ONyQCRyfb+tRscnBIJI7elWZYmR2U5BHTBxUIXC7T29Og/8Ar10XFYjzhTxgrxk88UmQeQxA60/GABg47H/PegAgEAkdmz3pjGfKTgbcDp2/OkKgBckjjPTrU23OQwBAHY4z70qDnK5Geh70ARhDsLHkn0p2wAjBTPc+lSqg3YOQCc8dTTgO6BlBPPekMZEoJJ4x6Y61JGgKglDgA9+lOVWw20MUPc/zqUANkEZxwCtIYiKDGMjgn0waUgFtwABPB78VIAW/h3D0zyaMEDjKk5GaBETqQSQvHT1FPVQmdjlCR9fxpp+ZTu6D04p6ED7oIXHG6mIVR/EuDnnFNfBU/MMnqW6U4cgqcnbgnHTNO3AgZXg8AdwKRSFiQEjjOeAB0q7bR8KAQccAjnFQQKeC2SOxH86vQryR27AUDuTrjdg7lwOpqwp7gDafaoUAwoxnA4BqdD8uFOGIyfaglkqnHRgwxitTQ03XG8dQBwDWWCQCVwOxrU8P/LOMrj/dNXsiWz1nw+5ECAA8D86s+OmLeAPEecf8gy5/9FNWd4fyYYwSTnvnrWr43U/8K88Sg9Bpdz2/6ZNWd9Tgqbnp3jb/AJGDwL/2GZP/AE33ldJ7npXN+Nv+Rg8C/wDYak/9N95XS1stjOpuMcgDPbuKFcYwTzThxn/OagDFJNzN8o4OeAR2qW7My2JH5GM01WCtubAFSuPXpTTyh9R+NGwNO5k3+Z7gOeFA4Gf51SuYhJETgDjuf/1VoXEmJDuGPc1FtHku+3Hckc1yy11JUmcfqtszxEoBuHfPX9cVyWt6Ql/ZNHcoA55BDEfngjP4mvQb2N0iEkbkMM4Un/JrAvrKfas5ZDIwzjOcfhjFcs5NPQ6qdWx4zq3h69sPnK74/UkfoASawg7Y+YMT/tCveI2MihLgkr0I3H/61cP4m8D/AGkPdabtVgSSoOM/kCTWkK99JHZCqnueflwMBjgHnpxTd4OPn247bc4/CkuorixlaG8heOQdpQVB9+cGq8j8HnI6ZB5rpvc2RKkhzgFun3h2p3mnjcx9/SoC+No646t0FDEsCAR7kkc0GlifcGXCZyvYGkd8bT3Ycgj+lQLIuFKkYz1JpZSQhByTn72e1AbEU+7LNu7YzULYyBEp+UcE96kOCXyRn1zUb4Kj5W4HXOAaAuRMDnJPU59Afaqt+UWFsnLAZX6VYd12gBcn+7jIFZmrTv5bKcq2ccc00SznSSZGzzk8c1ehKsjIwzgZTnGKoQ7t+Ccj2ODVscOzKcjbknPNaGEirdxsrDI68gFsGs6biQtjnvzWtcfvkUYK+vHWsyVSiHYO+ck5xVIzICRgpnJPJ9aibA9PoRmpCGG5Tyvao846ZA9qoliHOOOnrQTnv8o6Uh9yfalHI6Zx0pAh6gt34xxxxVhI8Lggq3TGf1qO3QFs4zn8AKt4O0AglSeo/pU3NYobE/lTRSDoOOnBrVDh9w3Zb06jHtWUwLZCkDA7/wBPerFtISFAY+YoyDnA/Gk0dEJGhC4yB0XoWx0ou2Bsrgq7/wCrZTx14NQk5wMgEdCDz+VFxLu06bLliUbPHTilY0k9GfpXRRRVnlnK+Mv+Rj8Cf9hqT/03XldVXK+Mv+Rj8Cf9hqT/ANN15XVUAFVdQsIL+Ax3C59GHBX6GrVFAHnGt6Tc6VlmzJbk/LKB/P0rORy8MnOc9TXqzoroVdQynggjINcrrPhYEPLpeFY8+Sx4/D0qWuxnKHY5iMBVXkgY+Y//AFhUF1JtlVlyPQe1PkWa2kMU6tHKD8ysMVCDulHZh09hU3MrCzvtUlgN5HGeTVGQSW8LJj55DyoOc+3rV+NDJehSu8jkA1UklWG9mnkjDgLtT5eAfWobKizIvYPKyr439T6VHEUlt2fnKHA4pLkSSl+WJJzzV97EWWmxJIrLcycqrYyB61lO9tTe9jj9YhEiOJPvDpjp+dcRfQAbtwHHOQOK7rVMyCUsTtAxya5yeAPHxgEDvURR1U5WR59remfO0kS5OM7h0P8A9euZZMNtbjA5Nej39vuV1IPPbHWuR1PT/nJHy9wSOlbxkbbmI6hlLZGFOOn60GMn7zHBPX2qWZJFbdwe3IqMc5BBDdq0TFYaFywPRunA/wA4pypuJLFuOM4p+Q33umPmIp4XLKBggDgkUwIgF+UZHrk8U9FPGflY9DjNOC7iQSowcn3+lKAGJA2k8EAelFxCYIwcM3qc9aeoTO7O7jOMdKjwoLlQFOcZPIH0qYkgBWPX07/SgQ5QARz0/M0P8oIzgZyM803nbx6YOeTSthRwQAOMEZzQAxhjB24B9OhoQEj0A7E/ypp5bgY9M8H8Kci/KuAPQEnvTYD15OEPPfI609FywyMA+/NBDFQXO1R1HY0sanDfNnPTPFSWWIVwDkZz6GrkSrwBwMbuPWq8Shdp2/MehHWrcZIAJHB464x+FAiZTlmK849RUq5I68D0FQR5YNnI56dqkY7lJI+mOM1SJJIhufCqOemBXa+EtILASPnB/Cue8P2f2m8TI4HNesaFaLFCgHHrUTn0RnUlZGrpluI0j/Lnijx1/wAk+8TZPI0u679vKarsARc55HbHSs/x3keAPE2COdMue/P+qaiJwSd2em+N/wDkP+Bf+wzJ/wCm+8rpBXN+N/8AkP8AgX/sNSf+m+8rpK6I7E1fiF/CoblTtDc5+6ceh/z6ipaXP40NXM9xiBvKUN9+o3L9AOe9PVyzkdB26UyZiOBwfoKzlsRJq1yvJEzcqMt2NQXCMtuUC7sDkZAq2GIHTj6CmyScAsvHf7vNc7SJTRzmpRGOECQ4HB+XGSPasidjJLK0nmBNoCKW5/TrW/q9ydsiRuWUjoT0/AYrHWS0tL2H7SodAuWbccE/kT+grkqrU2i+pkTW+Dl/lzzg4pkXmIzJHuPuO9dddQW9rbB8uY7lsJG2V2f1/MisxNMZDI0jAufu/MDkfXJrnlpuac5wXiLw9Y6qcyRLHJzlowiEn/aO0n9a868R+C7zTF+0Wv723HUoThR7u2BXtk8HzOGGMd/6VXlg3MSyKyejLn8s1pCrKJ0QruJ82LMCWA2kDg7WzxUnmMTwOB6Z5r0rxr4JjuJHu7Ryrtyc/MT+bAfkK881DRb+0UtKhYL0bcMflmuyFWMjuhNSV0QszEhiMDsAaC5JUdcggk9BVFnYORICqjknGKTzFz1IY9yx4+laXLsW95Vcj7uMZ7D3qJmTLSFy2Pl65qEO0m7dwCcE56/hTZ51SMKrDjuBiqQhlzIcZ2gnjFYurSk5UbsA9jxmr91INgYOSMcZPNYF8++Xg4C8gHgZ9apESYkKgt9zAHepwwVQm4H+ntmkjUiHjbz1H/16RzlWA4C+lNGbI2YIoyW2ng8ZFVriLggqBjgd81OSQQN2fXI6f41WY5Ylhhc55PU1SM2U5M8N0J5APWoR1J6gd/Srk4PlE5HuBVL2yOelUZsM+oOPQGnLgHocdqb64JzVi0Q8tyOwoehUVqWbdMAZGVxzjmpAuedpY+pPenKpZlBJAPHpilIzuAGD2I4zUGwzAU4YEnH+TUT5+WQHn1A71O77c44G3btxmul+H3w+8QePdRW20C0zbow827kysEX1bufYc0x3sYVmJLuaKC2illuHbYkSKWd2PYAda980f4GS6X8NvEviPxkNt/DpF1Pa6ejcQsIWKvIR1YHBwOB3r2v4U/CLQfAFuk8aC+1plxJfTLyPVUH8I/U1v/Fj/klnjL/sDXv/AKIeixnOs3pE6qiiimYHK+Mv+Rj8Cf8AYak/9N15XVVyvjL/AJGPwJ/2GpP/AE3XldVQAUUUUAFFFFAFPUdNtdRj23UQY9mH3h9DXF6p4XubItJa5uYsdhhgPcd/wr0Cik0mS4pnlmllY5GWQESt8oHp7EUy50xry7ZUZUhXgsV7/hXoeqaHY6kd08IEvaROG/8Ar1y2ueHtQtlVrBRcwpzsXCsPw71lKnfYxcJRd0Zr+H1WydbcBpANxZuRj15rltQuHczyMRtjXywQMCuz06eW40+5S5Z7ZUB84soDfTBx+lcw1ql9PFBCzraqxlIwM49evFYtOOjCnNv4jjL1SIVUAqfTrWPcrt2DAOevNdZrMLSW5uUhkjgLFItwOGA781zFwCeF49cDPNKJ3QdzA1SH5iVAz0HNYF7b/Nz36E966y4QI2JBy3GcVk3lvycDBI5was3jI4q6tgGJXI/9lrPlt13YyXPU5rq7mAMm44zjBz2rHuIdjcZ3HocYwKabNNzDdGUtubcO+expqngkZ5446VoNGMkkH+7uxVdk4ye5x1/pWiYWIjjZnblegHQU4HIXPyA+nQ011y28GQsOo7U3JxlgmP8AZNUKxLgAfKSqk9x/nFKpG4BsHGSec/hTAfmZiWbGPbP0oTJcBdp56mgGiYHcOd3HZe1Jz8oUYbGck0KRt5Oeep6U7PQDG7+7nt60EkeD5is7AsBnNSRcKOnPQ+v1FJt2lgB1OeO1JGCcbCAc45PWgRJtUAAYz6qcZ9qkiUkfKV3A45pvGMnaO3TOanQBVXqAfQUikyVAPuBcZ7VZH3ehI6Gq6fLyCfUH/CnhgOgPTvTEWAxAww46dOKcr4PDHA461BkgkZyQM/N3p1sAzooK/N/DjkmqSJ3O68HQfLuIzjoT1Fel6cQqDGCfasr4feBtc1O1ikS0a2tmGfOuAUBH+yOpr2nw94H0/Swj3Oby4HdxhAfZf8az5W2c1XV2OU0PRL/Utpgj2QnrK4wv4etanj/w/aab8LPGL4864/sa8/eMOn7h+g7V6EoCgBQAB0Arlvix/wAks8Zf9gW9/wDRD1okZKKQ3xt/yH/Av/YZk/8ATfeV0RrnvGgz4h8Cg/8AQZk/9N15XSSRkA45/nVp2MqsW9UNyM0jMQc84qB32t0x9aHcFPfFRKojn5h4IM2RTLvA+bGeMetNDbVAHU9aZdOcICRk9OOlRzJoly0Y9eYxnHNEi4X2pLZiYVJ7dc0P8xOARWclZB0MbUk3MQcg44rDlhWUS/aJH2IMKigDP5/4GtzUsKxJOVPWsO7QFGJGT1z/APXrmlpqbQV0XtHuTfyPBM5FtBHkIgB/EDGT+A/GtC0mE1r5TyZ2k7G3ZP0PzGue8PM8sk1rG0e+4G3L8jHfjnP4itLToZgs1srufIPB6f8AswH4VlLUTTRV1aFIpmdB8vQkqRz9KzZx5hzwMDG3NdPcWQmtVmaMZbhsY/otc1qEbWkpDdCMrg9qytYaRRkhWWByThuhyeTXMXlt5chaMsvqa6GZ1GFBXaewOOay9VKpKqLgsaaibQk0c7qXhrTNTRjcQqsjD74Xcf1OK4HxF4HvLPc+nqbmIc4Iy+P91FNerXYENmGIwfQ96htLopcRgHhsZXJxj39auMpReh0RxEonz9M8ttM8TxGOdeofgj8D0qu8yBevAOenetH4i31nN421NtO2C3jYKDCAq7u/AA/z3rmJrpju6gY5wOtejFNo6lUurkl9cbpM4O4985qgoUsctgHgluKU88tkBh83zZxTkyrAk8gYBIzmrEWCRsyR82B93+tMYnacAKvoOp98/wBKVWHlgkHHQUydtu5kJEfAyw4z/ShIhlaQEPlUweuCePwqJnALEHIPB9adIwHRgQDzUchUKFJwzDp/9erRDElOyPjDDsQOc1RHJPU/jVl5zt2AcKMCq+wtzxz2zT2M7Ngg3EBAc+laUUe1SucHggYqtBHgD7ueucZzWlZwS3dzFbWccs9xIcJDEhdm9gBzUNm0FYazdgXYN1GasafY3Wp30Npp9pPdXkhCpDCpdmP0Fe0fDv8AZ08Qa4YrvxTO2jacfm+z4DXDD6dE/Hn2r6d8EeA/Dvgq08nQNOjhcjD3D/PLJ9WPP4DAp2CU0jwH4X/s3z3DRaj4+lMEJIddLgfLN7SuOn+6v519NaRpdjo2nxWOlWkNpZxDCRQoFUVcopmMpOW4VyvxY/5JZ4y/7At7/wCiHrqq5X4sf8ks8Zf9gW9/9EPQSdVRRRQBz/i3RL7V30a40q/trG90y9N5G9zatcRvmCaEqVWSM9Jic7uo6Gqv2Hxx/wBDD4b/APBDP/8AJldVRQByv2Hxx/0MPhv/AMEM/wD8mUfYfHH/AEMPhv8A8EM//wAmV1VFAHK/YfHH/Qw+G/8AwQz/APyZR9h8cf8AQw+G/wDwQz//ACZXVUUAcr9h8cf9DD4b/wDBDP8A/JlH2Hxx/wBDD4b/APBDP/8AJldVRQByv2Hxx/0MPhv/AMEM/wD8mUfYfG//AEMPhv8A8EM//wAmV1VFAHE6n4e8WanbPb32teGJYnGCDoM+fz+2VjQfD/xJbxSRweJNDjEi7DjQ5s49M/a69PopNJ7iaTPLdR+HniW/sbe0k8T6MkEC7VCaJL/W7P6VkJ8HNbVlYeKtL+U5wdEfn/yZr2mip9nHsNO2x4bP8EtZmcs3i3TwSc8aM/8A8k1E/wACtXYY/wCEvsQPQaM//wAk17vRT5F2K55dz5/f9n7Um6+L7PHp/Yzf/JFVpP2cr+QYbxjbY9tHb/5Ir6Joo5UP2ku582v+zNdPn/isbcZ5ONIP/wAfpjfsxXRx/wAVnDgdv7IP/wAfr6Vop8qD2ku580H9l+4IwfGcWM5H/EoPH/kemn9l64P/ADOcQPXjSD/8fr6Zoosg9pLufM5/ZdnyD/wmcOe//EoPP/kekP7Ls56+M4uuf+QQf/j9fTNFFg9pPufM4/ZdmHTxlCPT/iUHj/yPTz+zFckY/wCEzhA9tIPP/kevpWiiwc8u580H9mC5OM+M4ifX+yD/APH6UfswXAJP/CZQknudIP8A8fr6Wooshc8u582L+zNdr08Zw/8AgoP/AMfpyfsz3adPGcH/AIKD/wDH6+kaKLIfPLufN5/Zpuzj/isbcYOR/wASg/8AyRS/8M1Xn/Q5Qf8AgoP/AMkV9H0U7Bzy7nze37NN63/M6Qgeg0c//H67Dwh8Ir3wqwl0/UPDM10P+Xm70KeWT8CbzA/ACvYKKBOTfU5X7D43/wChh8Nf+CGf/wCTKPsPjj/oYfDf/ghn/wDkyuqooJOV+w+OP+hh8N/+CGf/AOTKz/EPhzxjr2ganpF54k8Ppbahay2krRaFMHVJEKkqTdkZwTjINd1RQBz/AIt0S+1d9GuNKv7axvdMvTeRvc2rXEb5gmhKlVkjPSYnO7qOhqr9h8cf9DD4b/8ABDP/APJldVRQByUmmeNZB83iDw39f7Bn/wDkyom0bxo3XxH4d/DQp/8A5MrsqKTimS4Re6OMGi+NAqgeIvDuB/1AZv8A5Mpr6H4zcgnxJ4eyPTQph/7eV2tFLkXYXsodjjU0bxoiFR4i8OY/7AM3/wAmUh0bxoRj/hI/Dv8A4Ip//kyuzoocUw9lDscPN4e8YyqQfEnh8Z9NCm/+TKpt4O8Vs2f+Ek0EcYwNDmx/6V16JRSdKD6DUEtjzm08GeK7VlaLxLoWVz10ObB+o+14q+NA8Yhyw8R+Hgx7/wBhz/8AyZXb0VPsafYHFPc4hNA8Zozn/hJPDxV+qnQZcfX/AI+81VvfCXiy8i8uXxJoQHquiT5/W8r0Gin7GHYOVHln/CuvE27I8UaMD3/4kcnP/k1VSf4WeIp5xLJ4r0suOn/Elk4/8mq9eoo9jDsPlR49c/CjxDcJtfxZpgGMcaLJ/wDJNVH+DWvGORU8Y2EZdSu5dGfI+mbk17ZRQqUFsgsfMP8AwytMSzN42UuxyWOknP8A6Ppf+GV5TjPjRDjpnST/APH6+naK0sWpNHzAP2VZRkjxpHn1/sjp/wCR6UfsrSAsR4zj5GCP7IP/AMfr6eopWQc8u58xD9leUdPGiZ9f7JPH/kemt+yrKxyfGqE4x/yCP/t9fT9FMOZny7/wyi+Tjxogz1xpJ/8Aj9N/4ZOb/odEz0z/AGT/APb6+pKKBXZ8tf8ADJr9/G4I64/snr/5Go/4ZNbnHjRRn/qE/wD2+vqWigOZny8n7KTqR/xWiEZ5H9knn6/v69O8FfDLUvBcATw/eeFLeXGHuG0Cd5n/AN5zeZ/pXqdFAOTZyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZXVUUCOV+w+OP+hh8N/8Aghn/APkyj7D44/6GHw3/AOCGf/5MrqqKAOV+w+OP+hh8N/8Aghn/APkys/xD4c8Y69oGp6ReeJPD6W2oWstpK0WhTB1SRCpKk3ZGcE4yDXdUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nasal foreign body (cherry pit) was placed into the left nasal cavity by a six-year-old child (A). After suctioning (B), the cherry pit was located on the floor of the nasal passage adjacent to the inferior turbinate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35542=[""].join("\n");
var outline_f34_45_35542=null;
var title_f34_45_35543="Mean corpuscular volume";
var content_f34_45_35543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mean corpuscular volume",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/45/35543/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/45/35543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean corpuscular volume (MCV) is one of the standard red blood cell \"indices\" (",
"    <a class=\"graphic graphic_table graphicRef64238 \" href=\"mobipreview.htm?41/52/42827\">",
"     table 1",
"    </a>",
"    ). It is the volume of the \"average\" red blood cell, stated in femtoliters (fL). Measurement of the MCV and its importance in the differential diagnosis of anemia will be discussed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/1\">",
"     1",
"    </a>",
"    ]. Control of red blood cell hydration, which directly influences the MCV, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general approach to the patient with anemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODOLOGY AND NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MCV can be measured or calculated in a number of different ways (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of volume-sensitive automated blood cell counters, such as the Coulter counter. In this type of apparatus, the red cells pass one-by-one through a small aperture and generate a signal directly proportional to their volume.",
"     </li>",
"     <li>",
"      Other automated counters measure red blood cell volume by means of techniques that measure refracted, diffracted, or scattered light",
"     </li>",
"     <li>",
"      By calculation from an independently-measured red blood cell count (RBC) and hematocrit (Hct), as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;MCV (femtoliters) = 10 x Hct (percent) &divide; RBC",
"    <span class=\"nowrap\">",
"     (millions/microL)",
"    </span>",
"   </p>",
"   <p>",
"    The normal range (95 percent confidence) for the MCV in",
"    <strong>",
"     adults",
"    </strong>",
"    is 80 to 96 fL. Normal values in newborns, children, and adolescents are strongly dependent upon age (",
"    <a class=\"graphic graphic_table graphicRef52224 \" href=\"mobipreview.htm?18/31/18939\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROCYTOSIS AND MACROCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, microcytosis is taken to mean the presence of RBCs with a MCV less than normal, while macrocytosis means the presence of RBCs with an MCV greater than normal. Since the MCV is an average value, a sample with an MCV in the normal range may still have a significant population of small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large red cells. This situation is best assessed by direct examination of the peripheral smear, although a clue to the presence of cells of varying sizes (ie, anisocytosis) can be obtained from a determination of the RBC distribution width (see below). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discussions of the various causes of macrocytosis and microcytosis are found below (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Causes of macrocytosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Causes of microcytosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESTIMATION OF MCV FROM THE PERIPHERAL SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of macrocytosis or microcytosis can be estimated from the peripheral smear. The normal RBC has a diameter of 7 to 8 microns, equal to that of the nucleus of a small lymphocyte. Thus, RBCs that have a diameter less than the nucleus of a small lymphocyte on a peripheral smear are considered small (microcytic) (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ), while those that have a greater diameter are considered large (macrocytic) (",
"    <a class=\"graphic graphic_picture graphicRef58820 \" href=\"mobipreview.htm?4/47/4854\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RED BLOOD CELL DISTRIBUTION WIDTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Automated cell counters estimate RBC volume cell by cell, sampling millions of RBCs in the process. In addition to being able to calculate the mean RBC volume (MCV), they also determine the dispersion of values about this mean. The latter value can be expressed as a standard deviation, but is more frequently expressed as the coefficient of variation (expressed as a percent), also called the RBC distribution width (RDW):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;RDW &nbsp;= &nbsp; Standard deviation of RBC size &nbsp;&divide; &nbsp;MCV",
"   </p>",
"   <p>",
"    The normal range for the RDW is 11.5 to 14.5 percent. There is no condition which regularly yields a RDW less than normal. Thus, in practice, the RDW is either normal or elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link&amp;anchor=H4#H4\">",
"     \"Automated hematology instrumentation\", section on 'The red blood cell volume histogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Significance of a normal RDW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A RDW in the normal range indicates that the red cells have a size distribution pattern which approximates normal. This suggests the presence of a homogeneous population of cells, either all normal, or all under the influence of an inherited or acquired maturational defect (eg, myelodysplastic syndrome, some forms of aplastic anemia). It is important to indicate here what a normal RDW does",
"    <strong>",
"     not",
"    </strong>",
"    mean:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A normal RDW does not exclude presence of a \"significant\" numbers of cells which are much larger or much smaller than the main red cell population",
"     </li>",
"     <li>",
"      A normal RDW does not mean that the main population of red cells is itself normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An example will demonstrate the importance of these two observations. In pernicious anemia (PA), there is an emerging population of macrocytic red cells, whose presence should increase the RDW before the patient develops an increased MCV. In one study of 26 patients with untreated PA, 31 percent had a normal RDW, 35 percent had a normal MCV, and more than 15 percent had both findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, the combination of a normal RDW and a normal MCV does not effectively rule out PA, and the combination of a normal MCV and an elevated RDW is not sufficiently sensitive for detecting either early or late PA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Significance of an increased RDW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hematologic implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased RDW indicates the presence of increased variability in red cell size, also called anisocytosis. An increased RDW is commonly found when there is a nutritional deficiency (eg, iron, folate, and vitamin B12), since nutrient levels available to red cell precursors may vary widely during any 24 hour period, resulting in variability in red cell endowment and, therefore, size. However, the finding of an increased RDW is not specific for any one abnormality, such as, for example, the presence of macrocytes, microcytes, or reticulocytes among a population of normocytic normochromic red cells.",
"   </p>",
"   <p>",
"    For these reasons, the RDW can, at best, only be considered a semi-quantitative measure of anisocytosis. Similarly, the RDW is not sensitive enough to be used in the absence of anemia. There is a natural desire to use the various possible combinations of MCV and RDW (ie, pattern analysis) to guide the practicing physician towards one or more possible diagnoses. However, the authors feel that the use of such analyses, including more complex algorithms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discriminant indices is potentially misleading, and should not take the place of more specific laboratory investigations, including examination of the peripheral blood smear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cardiac and cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having a higher value of the RDW appears to be a risk factor for adverse events in subjects with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/3\">",
"     3",
"    </a>",
"    ], those with coronary disease free of heart failure at the time of testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/4\">",
"     4",
"    </a>",
"    ], and those undergoing percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H37#H37\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Hematologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of these studies this relationship held despite the fact that 88 percent of the subjects had an RDW within the normal range and that the graded relationship between a higher RDW and increased cardiac risk was independent of the level of hemoglobin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, a higher RDW was a strong and independent predictor of increased long-term mortality in patients undergoing PCI who were not anemic at baseline (HR 8.6; 95% CI 2.8-29) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Why a higher RDW level should lead to increased cardiac risk is unclear; some pertinent observations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study subjects with higher RDW levels tended to be older, more likely to smoke, had higher body mass indices, and lower levels of hemoglobin and serum albumin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study in patients with heart failure, elevated RDW was associated with decreasing hemoglobin, increasing IL-6, and impaired iron mobilization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 847 consecutive patients with a first-ever acute cerebral infarction, a higher RDW was independently associated with poor functional outcome and an increased risk for all-cause death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     All cause mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to an increased risk of cardiovascular death, an elevated RDW was found to be associated with an increased risk for all-cause mortality, including cancer-related death and death from chronic lower respiratory tract disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This was shown in a study of 8175 community-dwelling adults &ge;45 years of age who participated in the 1988-1994 National Health and Nutrition Examination Survey. Results of this study included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with the lowest quintile of RDW, adjusted hazard ratios for all-cause mortality were 1.1, 1.2, 1.4, and 2.1 for those in the second, third, fourth, and fifth quintiles, respectively. For every 1 percent increment in RDW, all-cause mortality risk increased by 22 percent (HR 1.22; 95% CI 1.15-1.30).",
"     </li>",
"     <li>",
"      The relationship between all-cause mortality and RDW held even when analyses were restricted to non-anemic participants or to those with RDW levels within the normal range (11 to 15 percent) without iron, folate, or vitamin B12 deficiency.",
"     </li>",
"     <li>",
"      Older age, as well as elevated values of CRP, fibrinogen, and white blood cell count were strongly associated with higher RDW levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above for cardiovascular mortality, the physiologic mechanisms underlying the association between increased mortality and an increased RDW are unknown, although oxidative stress, inflammation, and poor pulmonary function have been indirectly implicated in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anisocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased RDW is the mathematical equivalent of the term \"anisocytosis\" (ie, the presence of cells of widely differing sizes), but is not diagnostic of any particular morphologic finding. These morphologic changes can generally only be detected after careful examination of the peripheral blood smear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most hematologists therefore do not use the term anisocytosis, preferring instead to examine the peripheral blood smear and describe the morphologic changes in specific terms, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microcytosis (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Macrocytosis (",
"      <a class=\"graphic graphic_picture graphicRef58820 \" href=\"mobipreview.htm?4/47/4854\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Red cell fragments (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spherocytes (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some automated cell counters have computer programs which \"flag\" for the presence of specific abnormalities, such as anisocytosis, microcytosis, macrocytosis, hypochromia (reduced hemoglobin content per cell), RBC agglutination, and the presence of a dimorphic (double) RBC population, as shown in the upper panel of figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef69210 \" href=\"mobipreview.htm?37/51/38717\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SOURCES OF ERROR",
"    </span>",
"    &nbsp;&mdash;&nbsp;For determination of the MCV via automated counters, the assumptions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The particles that are being counted are RBCs",
"     </li>",
"     <li>",
"      RBCs pass through the counting aperture one-by-one",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       counting/diluent",
"      </span>",
"      solutions do not cause changes in the RBC volume due to osmotic effects, and do not induce RBC lysis or fragmentation. Such artifacts may be disease, time, temperature, reagent,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      machine-specific [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If these assumptions are incorrect, an erroneous value for MCV may result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link&amp;anchor=H14#H14\">",
"     \"Macrocytosis\", section on 'Spurious macrocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following conditions are examples which can cause erroneous values for the MCV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cold and warm agglutinins",
"      </strong>",
"      &mdash; The presence of cold or warm-acting agglutinins can be the cause of extremely high MCVs, due to the presence of RBC clumps within the counting fluid (",
"      <a class=\"graphic graphic_picture graphicRef50522 \" href=\"mobipreview.htm?15/10/15527\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\", section on 'Anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Uncontrolled hyperglycemia",
"      </strong>",
"      &mdash; Severe hyperglycemia, usually &gt;600",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      may lead to osmotic swelling of the RBCs which were previously in osmotic balance with a hyperosmolar plasma, and which now are diluted in a counting solution of lesser osmolarity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Extreme leukocytosis",
"      </strong>",
"      &mdash; When the white blood cell count rises above",
"      <span class=\"nowrap\">",
"       50,000/microL,",
"      </span>",
"      a value that is more than 1 percent of the normal red blood cell count, the red blood cell count and the MCV will be falsely elevated, since WBC, which are larger than RBC, are counted along with RBC in automated counters.",
"     </li>",
"     <li>",
"      <strong>",
"       Interference from platelets and other particles",
"      </strong>",
"      &mdash; Platelets (mean volume of 9 fL) and particles such as Howell-Jolly bodies are too small to be counted as red cells, since certain automated counters will not count as red cells any particle smaller than 36 fL. RBC fragments smaller than 36 fL may not be counted, while platelets with volumes &gt;36 fL (ie, megathrombocytes) may be counted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CAUSES OF NORMOCYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, the mean RBC volume is normal (MCV between 80 and 96 fL) in patients with normocytic anemia. This is an extremely large and amorphous category, which can be narrowed somewhat by examination of the blood smear to determine if there is a sub-population of RBCs with distinctive size or shape abnormalities, which would place the patient in one of the categories listed below (ie, early microcytic or macrocytic anemia), and by use of a kinetic approach to determine the mechanism(s) underlying the anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the adult patient with anemia\", section on 'Kinetic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CAUSES OF MACROCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrocytic anemias are characterized by an MCV above 100 fL (",
"    <a class=\"graphic graphic_table graphicRef66772 \" href=\"mobipreview.htm?9/47/9980\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58820 \" href=\"mobipreview.htm?4/47/4854\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the population studied, the most common causes of an increased MCV are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of an increased number of reticulocytes",
"     </li>",
"     <li>",
"      Macrocytosis associated with alcoholism",
"     </li>",
"     <li>",
"      Deficiency of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      or vitamin B12",
"     </li>",
"     <li>",
"      Antiviral treatment of HIV infection",
"     </li>",
"     <li>",
"      Use of chemotherapeutic agents, especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"     </li>",
"     <li>",
"      Presence of the myelodysplastic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Values of the MCV in excess of 115 fL are almost exclusively seen in vitamin B12 or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency, or following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    . Even higher values can occur as an artifact with cold agglutinins, which cause the RBCs to go through the counting aperture in doublets or triplets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/17\">",
"     17",
"    </a>",
"    ]. Warming the specimen (and reagents) to body temperature prior to a repeat count should return the MCV to normal, and confirm the presence of a cold agglutinin.",
"   </p>",
"   <p>",
"    The specific causes of macrocytosis are discussed in more detail separately. However, they will be briefly reviewed in the following section. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reticulocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased MCV is a normal characteristic of the newly-formed RBC, the reticulocyte. Thus, any condition which causes a major degree of reticulocytosis will be associated with an increased MCV. Reticulocytes can be recognized on the peripheral smear as larger RBCs without central pallor, oval to irregular in outline, with a blue tint (ie, polychromatophilia) (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Disorders of nucleic acid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital and acquired disorders of nucleic acid metabolism in erythroid precursors leads to macrocytosis. This can occur with folate or cobalamin (vitamin B12) deficiency (",
"    <a class=\"graphic graphic_picture graphicRef74901 \" href=\"mobipreview.htm?9/45/9942\">",
"     picture 7",
"    </a>",
"    ), or following the administration of antimetabolites which interfere with nucleic acid synthesis, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , or cytosine arabinoside. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Abnormal RBC maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal RBC maturation, as seen in the myelodysplastic syndromes, acute leukemia, and aplastic anemia can lead to the presence of macrocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link\">",
"     \"Anemia in children due to decreased red blood cell production\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H4009103#H4009103\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Bone marrow biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other common causes of macrocytosis include alcohol abuse, liver disease, and hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=see_link\">",
"     \"Alcohol abuse and hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevated (ie, greater than 95th percentile for gestational age) MCV in the fetus has been proposed as a marker for trisomy or triploidy. In a population of 267 fetuses in which the prevalence of aneuploidies was 4 percent, the sensitivity of this finding was 100 percent and the specificity ranged from 43 percent among growth restricted fetuses to 58 percent among appropriate for gestational age fetuses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CAUSES OF MICROCYTOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of microcytosis (ie, MCV &lt;80 fL) usually reflects a decreased hemoglobin content within the RBC, and is often associated with a parallel reduction in MCH, producing a hypochromic appearance on blood smear (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ). The following are examples of the various mechanisms leading to microcytic RBCs (",
"    <a class=\"graphic graphic_table graphicRef59035 \" href=\"mobipreview.htm?0/26/428\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced iron availability, as in iron deficiency, the anemia of chronic disease (inflammation), or rarely, copper deficiency.",
"     </li>",
"     <li>",
"      Reduced heme synthesis, as in lead poisoning or the sideroblastic anemias (",
"      <a class=\"graphic graphic_picture graphicRef66705 \" href=\"mobipreview.htm?28/4/28742\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced globin production, as in the thalassemic disorders or other hemoglobinopathies.",
"     </li>",
"     <li>",
"      Rare and atypical inherited microcytic anemias due to defects of iron absorption, transport, utilization, or recycling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three most common causes of microcytosis in clinical practice are iron deficiency, the anemia of chronic disease (inflammation), and alpha or beta thalassemia trait. Since all three conditions may demonstrate the presence of hypochromic and microcytic RBCs on the peripheral smear, other findings must be used to establish the diagnosis.",
"   </p>",
"   <p>",
"    In two studies of hospitalized patients, for example, an MCV &lt;80 fL had sensitivities for diagnosing iron deficiency of only 48 and 53 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These numbers compare unfavorably with a serum ferritin &lt;30 or a transferrin saturation &lt;15 percent, which have sensitivities for diagnosing iron deficiency of 92 and 80 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Estimation of iron stores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important discriminating features are a low serum ferritin concentration, an increased total iron binding capacity or transferrin level, and low serum iron concentration resulting in a low index of iron saturation.",
"   </p>",
"   <p>",
"    Anemic patients will have parallel decreases in hemoglobin concentration, hematocrit, and red blood cell counts. The degree of hypochromia and microcytosis is quite variable from cell to cell, leading to the presence of an elevated RDW, often greater than 16 or 18. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anemia of chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of this condition are the presence of a low serum iron, low iron binding capacity, and a normal to increased serum ferritin concentration. The causes are usually related to the presence of chronic infection, (eg, pulmonary tuberculosis), inflammation (eg, active rheumatoid arthritis), or malignancy (eg, stage IIIB Hodgkin lymphoma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with previously undiagnosed thalassemia are most often heterozygotes for the alpha or beta variants of thalassemia or HbE variants, and may not be anemic. A family history is therefore often negative. Physical examination may reveal splenomegaly and the peripheral smear shows hypochromia, microcytosis, target cells (",
"    <a class=\"graphic graphic_picture graphicRef56728 \" href=\"mobipreview.htm?29/23/30071\">",
"     picture 9",
"    </a>",
"    ), tear-drop RBC forms, and basophilic stippling. In comparison with iron deficiency anemia, the RBC count may be normal to increased, and iron stores are normal or increased. While the RDW is normal in some patients, it is often elevated, but not usually to the levels seen in iron deficiency anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/45/35543/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Definition and normal range of the MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean corpuscular volume (MCV) is the volume of the \"average\" red blood cell, stated in femtoliters (fL) (",
"    <a class=\"graphic graphic_table graphicRef64238 \" href=\"mobipreview.htm?41/52/42827\">",
"     table 1",
"    </a>",
"    ). The normal range of the MCV in",
"    <strong>",
"     adults",
"    </strong>",
"    is 80 to 96 fL. Normal values in newborns, children, and adolescents are dependent upon age (",
"    <a class=\"graphic graphic_table graphicRef52224 \" href=\"mobipreview.htm?18/31/18939\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Methodology and normal values'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Macrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrocytosis is generally considered to be present when the MCV is &gt;100 fL. Macrocytic red cells have a diameter on the peripheral smear that is greater than that of the nucleus of a small lymphocyte (7 microns).",
"   </p>",
"   <p>",
"    The most common causes of macrocytosis are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66772 \" href=\"mobipreview.htm?9/47/9980\">",
"     table 3",
"    </a>",
"    ). Values of the MCV &gt;115 fL are almost exclusively seen in vitamin B12 or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency, or following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Causes of macrocytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Microcytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microcytosis is generally considered to be present when the MCV is &lt;80 fL. Microcytic red cells have a diameter on the peripheral smear that is smaller than that of the nucleus of a small lymphocyte.",
"   </p>",
"   <p>",
"    The causes of microcytosis are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef59035 \" href=\"mobipreview.htm?0/26/428\">",
"     table 4",
"    </a>",
"    ). The three most common causes of microcytosis seen in clinical practice are iron deficiency, the anemia of chronic disease (inflammation), and thalassemia trait. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Causes of microcytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Red cell distribution width",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red cell distribution width (RDW) is a measure of the dispersion of values of the volume of individual red cells about the MCV. The normal range for the RDW is 11.5 to 14.5 percent. An increased RDW indicates the presence of increased variability in red cell size (ie, anisocytosis). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Red blood cell distribution width'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The finding of an increased RDW is not specific for any one hematologic abnormality (eg, macrocytes, microcytes, or reticulocytes). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hematologic implications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An elevated RDW has been found to be associated with an increased risk for cardiac death as well as all-cause mortality. The mechanisms behind these observations are unclear. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiac and cerebrovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'All cause mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/1\">",
"      Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol 2013; 20:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/2\">",
"      Saxena S, Weiner JM, Carmel R. Red blood cell distribution width in untreated pernicious anemia. Am J Clin Pathol 1988; 89:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/3\">",
"      Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/4\">",
"      Tonelli M, Sacks F, Arnold M, et al. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation 2008; 117:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/5\">",
"      Poludasu S, Marmur JD, Weedon J, et al. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. Thromb Haemost 2009; 102:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/6\">",
"      Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail 2010; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/7\">",
"      Kim J, Kim YD, Song TJ, et al. Red blood cell distribution width is associated with poor clinical outcome in acute cerebral infarction. Thromb Haemost 2012; 108:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/8\">",
"      Patel KV, Ferrucci L, Ershler WB, et al. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 2009; 169:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/9\">",
"      Perlstein TS, Weuve J, Pfeffer MA, Beckman JA. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med 2009; 169:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/10\">",
"      Horne BD, May HT, Muhlestein JB, et al. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med 2009; 122:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/11\">",
"      Grant BJ, Kudalkar DP, Muti P, et al. Relation between lung function and RBC distribution width in a population-based study. Chest 2003; 124:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/12\">",
"      Garcez ME, Peres W, Salvador M. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 2005; 80:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/13\">",
"      Kobayashi S, Moriya H, Aso K, Ohtake T. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int 2003; 63:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/14\">",
"      Uprichard J, Dorling D, Bain BJ. A dimorphic blood film as a sign of the onset of iron-deficient erythropoiesis in megaloblastic anemia. Am J Hematol 2012; 87:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/15\">",
"      Planas AT, Van Voolen GA, Kelly LA. Hyperglycemic macrocytosis in electronically determined mean corpuscular volume. Use of three different automatic cell counters. Ann Clin Lab Sci 1985; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/16\">",
"      Holt JT, DeWandler MJ, Arvan DA. Spurious elevation of the electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 1982; 77:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/17\">",
"      Hinchliffe RF, Bellamy GJ, Lilleyman JS. Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration. Clin Lab Haematol 1992; 14:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/18\">",
"      Camaschella C. How I manage patients with atypical microcytic anaemia. Br J Haematol 2013; 160:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/19\">",
"      Thompson WG, Meola T, Lipkin M Jr, Freedman ML. Red cell distribution width, mean corpuscular volume, and transferrin saturation in the diagnosis of iron deficiency. Arch Intern Med 1988; 148:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/20\">",
"      Seward SJ, Safran C, Marton KI, Robinson SH. Does the mean corpuscular volume help physicians evaluate hospitalized patients with anemia? J Gen Intern Med 1990; 5:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/45/35543/abstract/21\">",
"      Marsh WL Jr, Bishop JW, Darcy TP. Evaluation of red cell volume distribution width (RDW). Hematol Pathol 1987; 1:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4432 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35543=[""].join("\n");
var outline_f34_45_35543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODOLOGY AND NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROCYTOSIS AND MACROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESTIMATION OF MCV FROM THE PERIPHERAL SMEAR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RED BLOOD CELL DISTRIBUTION WIDTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Significance of a normal RDW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Significance of an increased RDW",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hematologic implications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cardiac and cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - All cause mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anisocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SOURCES OF ERROR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CAUSES OF NORMOCYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CAUSES OF MACROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Disorders of nucleic acid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Abnormal RBC maturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CAUSES OF MICROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anemia of chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Definition and normal range of the MCV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Microcytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Red cell distribution width",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4432|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/51/38717\" title=\"figure 1\">",
"      RBC size sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4432|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/47/4854\" title=\"picture 2\">",
"      Megaloblastic smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 3\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/1/27670\" title=\"picture 4\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/10/15527\" title=\"picture 5\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/9/31895\" title=\"picture 6\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/45/9942\" title=\"picture 7\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/4/28742\" title=\"picture 8\">",
"      RBC in sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/23/30071\" title=\"picture 9\">",
"      Beta thalassemia trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/52/42827\" title=\"table 1\">",
"      Normal red cell values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/31/18939\" title=\"table 2\">",
"      MCV variation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/47/9980\" title=\"table 3\">",
"      Causes of macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/26/428\" title=\"table 4\">",
"      Causes of microcytic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35544="Labetalol: Drug information";
var content_f34_45_35544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Labetalol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/21/20821?source=see_link\">",
"    see \"Labetalol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/59/39863?source=see_link\">",
"    see \"Labetalol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Labetalol&reg;;",
"     </li>",
"     <li>",
"      Labetalol Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Normodyne&reg;;",
"     </li>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker With Alpha-Blocking Activity",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 100 mg twice daily, may increase as needed every 2-3 days by 100 mg twice daily (titration increments not to exceed 200 mg twice daily) until desired response is obtained; usual dose: 100-400 mg twice daily (JNC 7); may require up to 2.4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension (hypertensive emergency/urgency):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. bolus:",
"     </i>",
"     Per the manufacturer: Initial: 20 mg I.V. push over 2 minutes; may administer 40-80 mg at 10-minute intervals, up to 300 mg total cumulative dose; as appropriate, follow with oral antihypertensive regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. infusion (acute loading):",
"     </i>",
"     Per the manufacturer: Initial: 2 mg/minute; titrate to response up to 300 mg total cumulative dose (eg, discontinue after 2.5 hours of 2 mg/minute); usual total dose required: 50-200 mg; as appropriate, follow with oral antihypertensive regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Although loading infusions are well described in the product labeling, the labeling is silent in specific clinical situations, such as in the patient who has an initial response to labetalol infusions but cannot be converted to an oral route for subsequent dosing. There is limited documentation of prolonged continuous infusions (ie, &gt;300 mg/day). In rare clinical situations, higher continuous infusion doses up to 6 mg/minute have been used in the critical care setting (eg, aortic dissection) and up to 8 mg/minute (eg, hypertension with ongoing acute ischemic stroke). At these doses, it may be best to consider an alternative agent if the labetalol infusion is not meeting the goals of therapy. At the other extreme, continuous infusions at relatively low doses (0.03-0.1 mg/minute) have been used in some settings (following loading infusion in patients who are unable to be converted to oral regimens or in some cases as a continuation of outpatient oral regimens). These prolonged infusions should not be confused with loading infusions. Because of wide variation in the use of infusions, an awareness of institutional policies and practices is extremely important. Careful clarification of orders and specific infusion rates/units is required to avoid confusion. Due to the prolonged duration of action, careful monitoring should be extended for the duration of the infusion and for several hours after the infusion. Excessive administration may result in prolonged hypotension and/or bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arterial hypertension in acute ischemic stroke (unlabeled use [Adams, 2007; Jauch, 2010]):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patient otherwise eligible for reperfusion treatment (eg, alteplase):",
"     </i>",
"     Blood pressure (BP): Systolic &gt;185 mm Hg or diastolic &gt;110 mm Hg: 10-20 mg over 1-2 minutes; may repeat once. If BP does not decline and remains &gt;185/110 mm Hg, alteplase should not be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Management of BP during and after reperfusion treatment (eg, alteplase):",
"     </i>",
"     BP: Systolic &ge;180 mm Hg or diastolic &ge;105 mm Hg: 10 mg over 1-2 minutes; may repeat every 10-20 minutes (maximum dose: 300 mg)",
"     <b>",
"      or",
"     </b>",
"     10 mg followed by an infusion of 2-8 mg/minute. If hypertension is refractory, consider other I.V. antihypertensives (eg, nitroprusside)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. to oral conversion:",
"     </b>",
"     Upon discontinuation of I.V. infusion, may initiate oral dose of 200 mg followed in 6-12 hours with an additional dose of 200-400 mg. Thereafter, dose patients with 400-2400 mg/day in divided doses depending on blood pressure response.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/59/39863?source=see_link\">",
"      see \"Labetalol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to limited documentation of its use, labetalol should be initiated cautiously in pediatric patients with careful dosage adjustment and blood pressure monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Hypertension (unlabeled use): Initial: 1-3 mg/kg/day, in 2 divided doses; maximum: 10-12 mg/kg/day, up to 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Intermittent bolus doses of 0.3-1 mg/kg/dose have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pediatric hypertensive emergencies:",
"     </b>",
"     Initial continuous infusions of 0.4-1 mg/kg/hour with a maximum of 3 mg/kg/hour have been used; administration requires the use of an infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s recommendations: Initial: 100 mg twice daily; may titrate in increments of 100 mg twice daily; usual maintenance: 100-200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ACCF/AHA Expert Consensus recommendations: Consider lower initial doses and titrating to response (Aronow, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F186211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F186212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage reduction may be necessary in hepatic impairment due to decreased metabolism and increased oral bioavailability, use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 5 mg/mL (4 mL, 20 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 5 mg/mL (20 mL, 40 mL) [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 200 mg [scored; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trandate&reg;: 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bolus dose may be administered I.V. push at a rate of 10 mg/minute; may follow with continuous I.V. infusion",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     500 mg in 250 mL (concentration: 2 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F186254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      2.5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, Ringer's; most stable at pH of 2-4.",
"     <b>",
"      Incompatible",
"     </b>",
"     with sodium bicarbonate 5% and alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amikacin, aminophylline, amiodarone, ampicillin, bivalirudin, butorphanol, calcium gluconate, cefazolin, ceftazidime, chloramphenicol, cimetidine, clindamycin, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, enalaprilat, epinephrine, erythromycin lactobionate, esmolol, famotidine, fenoldopam, fentanyl, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, lidocaine, linezolid, lorazepam, magnesium sulfate, meperidine, metronidazole, midazolam, milrinone, morphine, nicardipine, nitroglycerin,  nitroprusside, norepinephrine, oxacillin, pancuronium, penicillin G potassium, piperacillin, potassium chloride, potassium phosphates, propofol, ranitidine, sodium acetate, sulfamethoxazole/trimethoprim, telavancin, terbutaline, tobramycin, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, ceftriaxone, furosemide, micafungin, nafcillin, pantoprazole, thiopental, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin, insulin (regular), tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-severe hypertension; I.V. for severe hypertension (eg, hypertensive emergencies)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4588984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension; management of pre-eclampsia; severe hypertension in pregnancy; hypertension during acute ischemic stroke",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Labetalol may be confused with betaxolol, lamoTRIgine, Lipitor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Normodyne&reg; may be confused with Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trandate&reg; may be confused with traMADol, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (I.V. use; &le;58%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 20%), fatigue (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&le;19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 5%), edema (&le;2%), flushing (1%), ventricular arrhythmia (I.V. use; 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (3%), headache (2%), vertigo (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Scalp tingling (&le;7%), pruritus (1%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&le;4%), vomiting (&le;3%), taste disturbance (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculatory failure (&le;5%), impotence (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&le;5%), weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormal (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (1% to 6%), dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia (reversible), anaphylactoid reaction, ANA positive, angioedema, bradycardia, bronchospasm, cholestatic jaundice, CHF, diabetes insipidus, heart block, hepatic necrosis, hepatitis, hypersensitivity, Peyronie's disease, psoriaform rash, Raynaud's syndrome, syncope, systemic lupus erythematosus, toxic myopathy, urinary retention, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other adverse reactions noted with beta-adrenergic blocking agents include mental depression, catatonia, disorientation, short-term memory loss, emotional lability, clouded sensorium, intensification of pre-existing AV block, laryngospasm, respiratory distress, agranulocytosis, thrombocytopenic purpura, nonthrombocytopenic purpura, mesenteric artery thrombosis, and ischemic colitis.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to labetalol or any component of the formulation; severe bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma; uncompensated cardiac failure; conditions associated with severe and prolonged hypotension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of labetalol use when considering eye surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic injury: Severe hepatic injury including some fatalities have also been rarely reported with use; periodically monitor LFTs with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope may occur with labetalol; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Initiation with a low dose and gradual up-titration may help to decrease the occurrence of hypotension or syncope. Patients should be advised to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope. Orthostatic hypotension may occur with I.V. administration; patient should remain supine during and for up to 3 hours after I.V. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms. May also reduce release of insulin in response to hyperglycemia; dosage of antidiabetic agents may need to be adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with extreme caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; bioavailability is increased due to decreased first-pass metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud&rsquo;s disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud&rsquo;s disease; use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): If possible, obtain diagnostic tests for pheochromocytoma prior to use. Labetalol has been shown to be effective in lowering blood pressure and relieving symptoms in patients with pheochromocytoma. However, some patients have experienced paradoxical hypertensive responses; use with caution in patients with pheochromocytoma. Additional alpha-blockade may be required during use of labetalol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Elimination of labetalol is reduced in elderly patients; lower maintenance doses may be required. Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Alpha-/Beta-Blockers may diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F186200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Labetalol serum concentrations may be increased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid natural licorice (causes sodium and water retention and increases potassium loss). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse events were observed in some animal reproduction studies, labetalol is classified as pregnancy category C. Labetalol crosses the placenta and can be detected in cord blood and infant serum after delivery. It has been shown to decrease maternal blood pressure without significantly effecting placental blood flow. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The pharmacokinetics of labetalol are not significantly changed during the third trimester of pregnancy. Labetalol is considered an appropriate agent for the treatment of hypertension in pregnancy; intravenous labetalol is also used for the management of pre-eclampsia.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F186188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of labetalol are found in breast milk and can be detected in the serum of nursing infants. The manufacturer recommends that caution be exercised when administering labetalol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Labetalol HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (20 mL): $2.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Labetalol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $56.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $72.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $96.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trandate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $74.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $126.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $127.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine, pulse, cardiac monitor and blood pressure monitor required for I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Albetol (FI);",
"     </li>",
"     <li>",
"      Biascor (AR, PY);",
"     </li>",
"     <li>",
"      Chenday (TW);",
"     </li>",
"     <li>",
"      Hybloc (NZ);",
"     </li>",
"     <li>",
"      Ipolab (IT);",
"     </li>",
"     <li>",
"      Labedin (TW);",
"     </li>",
"     <li>",
"      Lamitol (HR);",
"     </li>",
"     <li>",
"      Normadate (IN);",
"     </li>",
"     <li>",
"      Presolol (AU, TW);",
"     </li>",
"     <li>",
"      Pressocard (PL);",
"     </li>",
"     <li>",
"      Trandate (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DK, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, GY, HK, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Trantalol (MY, SG);",
"     </li>",
"     <li>",
"      Xin Yu Sen (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     -, and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptor sites; elevated renins are reduced. The ratios of alpha- to beta-blockade differ depending on the route of administration: 1:3 (oral) and 1:7 (I.V.).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 20 minutes to 2 hours; I.V.: 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: 1-4 hours; I.V.: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Blood pressure response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 8-12 hours (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-18 hours (dose dependent; based on single and multiple sequential doses of 0.25-0.5 mg/kg with cumulative dosing up to 3.25 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 3-16 L/kg; mean: &lt;9.4 L/kg; moderately lipid soluble, therefore, can enter CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via glucuronide conjugation; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 25%; increased with liver disease, elderly, and concurrent cimetidine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 6-8 hours; I.V.: ~5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (55% to 60% as glucuronide conjugates, &lt;5% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Possibly decreased in neonates/infants",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ACOG Practice Bulletin. Chronic Hypertension in Pregnancy. ACOG Committee on Practice Bulletins,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2001, 98(Suppl 1):177-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/11508256/pubmed\" id=\"11508256\" target=\"_blank\">",
"        11508256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, &ldquo;ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Number 33, January 2002,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 99(1):159-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/16175681/pubmed\" id=\"16175681\" target=\"_blank\">",
"        16175681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al, \"Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology Affirms the Value of This Guideline as an Educational Tool for Neurologists,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(5):1655-711.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/17431204/pubmed\" id=\"17431204\" target=\"_blank\">",
"        17431204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Breckenridge A, Orme M, Serlin MJ, et al &ldquo;Labetalol in Essential Hypertension,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1982, (1 Suppl):37-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/6124264/pubmed\" id=\"6124264\" target=\"_blank\">",
"        6124264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cumming AM, Brown JJ, Lever AF, et al, &ldquo;Treatment of Severe Hypertension by Repeated Bolus Injections of Labetalol,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1979, 8(Suppl 2):199-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/393288/pubmed\" id=\"393288\" target=\"_blank\">",
"        393288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jauch EC, Cucchiara B, Adeoye O, et al, &ldquo;Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):818-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/20956227/pubmed\" id=\"20956227\" target=\"_blank\">",
"        20956227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maronide RF, Robinson D, Vlachakis ND, et al, &ldquo;Study of Single and Multiple Dose Pharmacokinetic/Pharmacodynamic Modeling of the Antihypertensive Effects of Labetalol,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1983, 75(4A):40-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/6356898/pubmed\" id=\"6356898\" target=\"_blank\">",
"        6356898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35544/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9540 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35544=[""].join("\n");
var outline_f34_45_35544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186205\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186206\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186247\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186209\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186227\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186210\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186211\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186212\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186176\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186160\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186180\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472668\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472669\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186254\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186179\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4588984\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186256\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186245\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186184\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186164\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299562\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186200\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186172\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186187\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186215\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186188\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186186\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186174\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038665\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186163\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186183\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9540|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/21/20821?source=related_link\">",
"      Labetalol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/59/39863?source=related_link\">",
"      Labetalol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35545="Pelvimetry 1";
var content_f34_45_35545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72077%7EOBGYN%2F51127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72077%7EOBGYN%2F51127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Vaginal examination to determine the diagonal conjugate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     P: sacral promontory; S: symphysis pubis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.280.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Pelvic inlet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three anteroposterior diameters of the pelvic inlet are illustrated: the true conjugate, the obstetrically important obstetric conjugate, the obstetrically important obstetric conjugate, and the clinically measurable diagonal conjugate. The anteroposterior diameter of the mid-pelvis is also shown.",
"    <div class=\"footnotes\">",
"     P: sacral promontory; Sym: symphysis pubis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p. 278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35545=[""].join("\n");
var outline_f34_45_35545=null;
var title_f34_45_35546="Fentanyl: Pediatric drug information";
var content_f34_45_35546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fentanyl: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"    see \"Fentanyl: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/29/472?source=see_link\">",
"    see \"Fentanyl: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&reg;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Fentora&reg;;",
"     </li>",
"     <li>",
"      Lazanda&reg;;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      Subsys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&trade;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Apo-Fentanyl&reg; Matrix;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg; MAT;",
"     </li>",
"     <li>",
"      Fentanyl Citrate Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Fentanyl;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      PMS-Fentanyl MTX;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Matrix Patch;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Transdermal System;",
"     </li>",
"     <li>",
"      ratio-Fentanyl;",
"     </li>",
"     <li>",
"      Sandoz Fentanyl Patch;",
"     </li>",
"     <li>",
"      Teva-Fentanyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     International Evidence-Based Group for Neonatal Pain recommendations (Anand, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent doses: Slow I.V. push: 0.5-3 mcg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 0.5-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation/analgesia:",
"     </b>",
"     Slow I.V. push: 1-4 mcg/kg/dose; may repeat every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Continuous sedation/analgesia:",
"     </b>",
"     Initial I.V. bolus: 1-2 mcg/kg, then 0.5-1 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate upward",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean required dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &lt;34 weeks: 0.64 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &ge;34 weeks: 0.75 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Continuous sedation/analgesia during ECMO:",
"     </b>",
"     Initial I.V. bolus: 5-10 mcg/kg slow I.V. push over 10 minutes, then 1-5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate upward; tolerance may develop; higher doses (up to 20 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) may be needed by day 6 of ECMO",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"      see \"Fentanyl: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Younger Infants:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sedation/analgesia:",
"     </b>",
"     Slow I.V. push: 1-4 mcg/kg/dose; may repeat every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Continuous sedation/analgesia:",
"     </b>",
"     Initial I.V. bolus: 1-2 mcg/kg, then 0.5-1 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate upward",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Continuous sedation/analgesia during ECMO:",
"     </b>",
"     Initial I.V. bolus: 5-10 mcg/kg slow I.V. push over 10 minutes, then 1-5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate upward; tolerance may develop; higher doses (up to 20 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) may be needed by day 6 of ECMO",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Older Infants and Children 1-12 years:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesia for minor procedures/sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 1-2 mcg/kg/dose; may repeat at 30- to 60-minute intervals.",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses may be required in children 18 months to 3 years of age; 2-3 mcg/kg/dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intranasal (using parenteral preparation): Limited data available: Infants and Children &ge;10 kg: 1.5 mcg/kg once (maximum: 100 mcg/dose); reported range: 1-2 mcg/kg; some studies that used an initial dose of 1.5 mcg/kg allowed for additional incremental doses of 0.3-0.5 mcg/kg to be administered every 5 minutes, not to exceed a total dose of  3 mcg/kg depending on pain type and severity (Borland, 2002; Borland, 2005; Borland, 2007; Chung, 2010; Cole, 2009; Crellin, 2010; Herd, 2009; Manjushree, 2002; Saunders, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Continuous analgesia/sedation:",
"     </b>",
"     Initial I.V. bolus: 1-2 mcg/kg then 1 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate upward; usual: 1-3 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; some require 5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Moderate to severe chronic pain:",
"     </b>",
"     Transdermal patch: Opioid-tolerant children &ge;2 years receiving at least 60 mg oral morphine equivalents per day: Initial: 25 mcg/",
"     <b>",
"      hour",
"     </b>",
"     system or higher, based on conversion to fentanyl equivalents and administration of equianalgesic dosage (see package insert for further information); use short-acting analgesics for first 24 hours with supplemental PRN doses thereafter (for breakthrough pain); dose may be increased after 3 days, based on the daily dose of supplementary PRN opioids required; use the ratio of 45 mg of oral morphine equivalents per day to a 12.5 mcg/",
"     <b>",
"      hour",
"     </b>",
"     increase in transdermal patch dosage; change patch every 72 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Dosing intervals less than every 72 hours are",
"     <b>",
"      not",
"     </b>",
"     recommended for children and adolescents. Initiation of the transdermal patch in children taking &lt;60 mg of oral morphine equivalents per day has not been studied in controlled clinical trials; in open-label trials, children 2-18 years of age who were receiving at least 45 mg of oral morphine equivalents per day were started with an initial transdermal dose of 25 mcg/",
"     <b>",
"      hour",
"     </b>",
"     (or higher, depending upon equianalgesic dose of opioid received).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Children 5 years of age or older and &lt;50 kg:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Patient-controlled analgesia (PCA):",
"     </b>",
"     I.V.: Opioid-na&iuml;ve:",
"     <b>",
"      Note:",
"     </b>",
"     PCA has been used in children as young as 5 years of age; however, clinicians need to assess children 5-8 years of age to determine if they are able to use the PCA device correctly. All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual concentration: Determined by weight; some centers use the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;12 kg: 10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 12-30 kg: 25 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;30 kg: 50 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demand dose: Usual initial: 0.5-1 mcg/kg/dose; usual range: 0.5-1 mcg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lockout: Usual initial: 5 doses/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lockout interval: Range: 6-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual basal rate: 0-0.5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Adolescents and Adults:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesia for minor procedures/sedation:",
"     </b>",
"     I.V.: 0.5-1 mcg/kg/dose; may repeat after 30-60 minutes; or 25-50 mcg, repeat full dose in 5 minutes if needed, may repeat 4-5 times with 25 mcg at 5-minute intervals if needed.",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses are used for major procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Continuous analgesia/sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;50 kg: Initial I.V. bolus: 1-2 mcg/kg; continuous infusion rate: 1-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;50 kg: Initial I.V. bolus: 1-2 mcg/kg",
"     <b>",
"      or",
"     </b>",
"     25-100 mcg/dose; continuous infusion rate: 1-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     <b>",
"      or",
"     </b>",
"     25-200 mcg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Patient-controlled analgesia (PCA):",
"     </b>",
"     I.V.: Children &gt;50 kg, Adolescents &gt;50 kg, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual concentration: 50 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demand dose: Usual initial: 20 mcg; usual range: 10-50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lockout interval: Usual initial: 6 minutes; usual range: 5-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual basal rate: &le;50 mcg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Preoperative sedation, adjunct to regional anesthesia, postoperative pain:",
"     </b>",
"     I.M., I.V.: 25-100 mcg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adjunct to general anesthesia:",
"     </b>",
"     Slow I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose: 0.5-2 mcg/kg/dose depending on the indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate dose: Initial: 2-20 mcg/kg/dose; Maintenance (bolus or infusion): 1-2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     . Discontinuing fentanyl infusion 30-60 minutes prior to the end of surgery will usually allow adequate ventilation upon emergence from anesthesia. For \"fast-tracking\" and early extubation following major surgery, total fentanyl doses are limited to 10-15 mcg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose: 20-50 mcg/kg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     High dose fentanyl as an adjunct to general anesthesia is rarely used, but is still described in the manufacturer's label.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General anesthesia without additional anesthetic agents:",
"     </b>",
"     I.V.: 50-100 mcg/kg/dose with O",
"     <sub>",
"      2",
"     </sub>",
"     and skeletal muscle relaxant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Moderate to severe chronic pain:",
"     </b>",
"     Transdermal patch: Opioid-tolerant patients receiving at least 60 mg oral morphine equivalents per day: Initial: 25 mcg/",
"     <b>",
"      hour",
"     </b>",
"     system or higher, based on conversion to fentanyl equivalents and administration of equianalgesic dosage (see manufacturer labeling for further information); use short-acting analgesics for first 24 hours with supplemental PRN doses thereafter (for breakthrough pain); dose may be increased after 3 days based on the daily dose of supplementary PRN opioids required; use the ratio of 45 mg of oral morphine equivalents per day to a 12.5 mcg/",
"     <b>",
"      hour",
"     </b>",
"     increase in transdermal patch dosage; transdermal patch is usually administered every 72 hours but select",
"     <b>",
"      adult",
"     </b>",
"     patients may require every 48-hour administration; dosage increase administered every 72 hours should be tried before 48-hour schedule is used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breakthrough cancer pain:",
"     </b>",
"     Adolescents &ge;16 years and Adults: Transmucosal lozenge (Actiq&reg;): Opioid-tolerant patients: Titrate dose to provide adequate analgesia: Initial: 200 mcg; may repeat dose only once, 15 minutes after completion of first dose if needed. Do not exceed a maximum of 2 doses per each breakthrough cancer pain episode; patient must wait at least 4 hours before treating another episode. Titrate dose up to next higher strength if treatment of several consecutive breakthrough episodes requires &gt;1 Actiq&reg; per episode; evaluate each new dose over several breakthrough cancer pain episodes (generally 1-2 days) to determine proper dose of analgesia with acceptable side effects. Once dose has been determined, consumption should be limited to &le;4 units/day. Re-evaluate maintenance (around-the-clock) opioid dose if patient requires &gt;4 units/day. If signs of excessive opioid effects occur before a dose is complete, the unit should be removed from the mouth immediately, and subsequent doses decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Adolescents 18 years of age and Adults:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Severe pain:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M, I.V.: 50-100 mcg/dose every 1-2 hours as needed; patients with prior opioid exposure may tolerate higher initial doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intrathecal (American Pain Society, 2008):",
"     <b>",
"      Note: Must use preservative-free.",
"     </b>",
"     Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single dose: 5-25 mcg/dose; may provide adequate relief for up to 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous infusion: Not recommended in acute pain management due to risk of excessive accumulation. For chronic cancer pain, infusion of very small doses may be practical (American Pain Society, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Epidural (American Pain Society, 2008):",
"     <b>",
"      Note: Must use preservative-free.",
"     </b>",
"     Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single dose: 25-100 mcg/dose; may provide adequate relief for up to 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous infusion: 25-100 mcg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breakthrough cancer pain:",
"     </b>",
"     Opioid-tolerant patients: For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. Patients experiencing &gt;4 breakthrough pain episodes/day should have the dose of their long-term opioid re-evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal film (Onsolis&reg;): Initial dose: 200 mcg for all patients;",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another transmucosal product should be initiated at doses of 200 mcg; do",
"     <b>",
"      not",
"     </b>",
"     switch patients using any other fentanyl product on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"     If titration of dose is required, increase dose in 200 mcg increments once per episode using multiples of the 200 mcg film; do not redose within a single episode of breakthrough pain and separate single doses by &ge;2 hours. During titration, do not exceed 4 simultaneous applications of the 200 mcg films (800 mcg). If &gt;800 mcg required, treat next episode with one 1200 mcg film (maximum dose: 1200 mcg). Once maintenance dose is determined, all other unused films should be disposed of and that strength (using a single film) should be used. During any pain episode, if adequate relief is not achieved after 30 minutes following buccal film application, a rescue medication (as determined by healthcare provider) may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Determined dose applied as a single film once per episode and separated by &ge;2 hours (dose range: 200-1200 mcg); limit to 4 applications/day. Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal tablets (Fentora&reg;): Initial dose: 100 mcg; a second 100 mcg dose, if needed,  may be administered 30 minutes after the start of the first dose;",
"     <b>",
"      Note:",
"     </b>",
"     For patients previously using the transmucosal lozenge (Actiq&reg;), the initial dose should be selected using the conversions listed below (maximum: 2 doses per breakthrough pain episode every 4 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"     If required, should be done using multiples of the 100 mcg tablets. Patient can take two 100 mcg tablets (one on each side of mouth). If that dose is not successful, can use four 100 mcg tablets (two on each side of mouth). If titration requires &gt;400 mcg/dose, then use 200 mcg tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Conversion from transmucosal lozenge to buccal tablet (Fentora&reg;)",
"     </i>",
"     : Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Lozenge dose 200-400 mcg, then use buccal tablet 100 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Lozenge dose 600-800 mcg, then use buccal tablet 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Lozenge dose 1200-1600 mcg, then use buccal tablet 400 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Four 100 mcg buccal tablets deliver approximately 12% and 13% higher values of C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC, respectively, compared to one 400 mcg buccal tablet. To prevent confusion, patient should only have one strength of tablets available at a time. Using more than four buccal tablets at a time has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nasal spray (Lazanda&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     100 mcg (one 100 mcg spray in one nostril) for all patients.",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; do not convert patients from other fentanyl products to Lazanda&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"     If pain is relieved within 30 minutes, that same dose should be used to treat subsequent episodes. If pain is unrelieved, may increase to a higher dose using the recommended titration steps.",
"     <b>",
"      Must wait at least 2 hours before treating another episode with nasal spray.",
"     </b>",
"     Dose titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 100 mcg spray in each nostril); if no relief with 200 mcg dose, increase to 400 mcg per episode (one 400 mcg spray in one nostril); if no relief with 400 mcg dose, increase to 800 mcg dose per episode (one 400 mcg spray in each nostril).",
"     <b>",
"      Note:",
"     </b>",
"     Single doses &gt;800 mcg have not been evaluated. There are no data supporting the use of a combination of dose strengths.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. For pain that is not relieved after 30 minutes of Lazanda&reg; administration or if a separate breakthrough pain episode occurs within the 2 hour window before the next Lazanda&reg; dose is permitted, a rescue medication may be used. Limit Lazanda&reg; use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy; if long-acting opioid therapy dose is altered, re-evaluate and retitrate Lazanda&reg; dose as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual spray (Subsys&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     100 mcg for all patients. If pain is unrelieved, one additional 100 mcg dose may be given 30 minutes after administration of the first dose. A maximum of two doses can be given per breakthrough pain episode; must wait at least 4 hours before treating another episode.",
"     <b>",
"      Note:",
"     </b>",
"     Patients must remain on around-the-clock opioids during use. Patients previously using other fentanyl products should be initiated at a dose of 100 mcg; do not convert patients from any other fentanyl product (transmucosal, transdermal, or parenteral) to Subsys&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"     If pain is relieved within 30 minutes, that same dose should be used to treat subsequent episodes and no titration is necessary. If pain is unrelieved, may increase to a higher dose using the recommended titration steps. Goal is to determine the dose that provides adequate analgesia (with tolerable side effects) using a single dose per breakthrough pain episode. For each breakthrough pain episode, if pain unrelieved after 30 minutes only one additional dose using the same strength may be given (maximum: Two doses per breakthrough pain episode).",
"     <b>",
"      Must wait at least 4 hours before treating another episode with Subsys&reg;.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration steps:",
"     </i>",
"     If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 200 mcg unit); if no relief with 200 mcg dose, increase to 400 mcg per episode (one 400 mcg unit); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 600 mcg unit); if no relief with 600 mcg dose, increase to 800 mcg dose per episode 	(one 800 mcg unit); if no relief with 800 mcg dose, increase to 1200 mcg dose per episode (two 600 mcg units); if no relief with 1200 mcg dose, increase to 1600 mcg per episode (two 800 mcg units).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. If occasional episodes of unrelieved breakthrough pain occur following 30 minutes of Subsys&reg; administration, one additional dose using the same strength may be administered (maximum: Two doses per breakthrough pain episode); patient must wait 4 hours before treating another breakthrough pain episode with Subsys&reg;. Once maintenance dose is determined, limit Susbsys&reg; use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual tablet (Abstral&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     100 mcg for all patients; if pain is unrelieved, a second dose may be given 30 minutes after administration of the first dose. A maximum of two doses can be given per breakthrough pain episode; must wait at least 2 hours before treating another episode.",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously using another fentanyl product should be initiated at 	a dose of 100 mcg; do not convert patients from other fentanyl products to Abstral&reg; on a mcg-per-mcg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"     If titration required, increase in 100 mcg increments (up to 400 mcg) over consecutive breakthrough episodes. If titration requires &gt;400 mcg/dose, increase in increments of 200 mcg, starting with 600 mcg dose. During titration, patients may use multiples of 100 mcg and/or 200 mcg tablets for any single dose; do not exceed 4 tablets at 	one time; safety and efficacy of doses &gt;800 mcg have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Once maintenance dose for breakthrough pain episode has been determined, use only one tablet in the appropriate strength per episode; if pain is unrelieved with maintenance dose. A second dose may be given after 30 minutes; maximum of two doses/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes/day. Consider increasing the around-the-clock, long-acting opioid therapy in patients experiencing &gt;4 breakthrough pain episodes/day; if long-acting opioid therapy dose altered, re-evaluate and retitrate Abstral&reg; dose as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007): The following assumes dosages of 0.5-2 mcg/kg/dose or 1-5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     in normal renal function: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     :  Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis: Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults: Transdermal (patch): Degree of impairment (ie, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ) not defined in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate impairment: Initial: Reduce dose by 50%; monitor patient closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults: Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Although fentanyl pharmacokinetics may be altered in renal disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal (patch): Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate impairment: Initial: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Adolescents &ge;18 years and Adults: Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, for buccal application, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onsolis&reg;: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate [strength expressed as base, preservative free]: 0.05 mg/mL (2 mL, 5 mL, 10 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, sublingual, as base [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Subsys&reg;: 100 mcg (30s); 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s) [contains dehydrated ethanol 63.6%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as citrate [strength expressed as base, transmucosal]: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actiq&reg;: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s) [contains sugar 2 g/lozenge; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal, as base: 12 [delivers 12.5 mcg/hr] (5s); 25 [delivers 25 mcg/hr] (5s); 50 [delivers 50 mcg/hr] (5s); 75 [delivers 75 mcg/hr] (5s); 100 [delivers 100 mcg/hr] (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 12 [delivers 12.5 mcg/hr] (5s) [contains ethanol 0.1mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 5 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 25 [delivers 25 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 50 [delivers 50 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 20 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 75 [delivers 75 mcg/hr]  (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; 30 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duragesic&reg;: 100 [delivers 100 mcg/hr]  (5s) [contains ethanol 0.1 mL/10 cm",
"     <sup>",
"      2;",
"     </sup>",
"     40 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as citrate: USP: 100% (1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as citrate [strength expressed as base, spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lazanda&reg;: 100 mcg/spray (5 mL); 400 mcg/spray (5 mL) [delivers 8 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, for buccal application, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fentora&reg;: 100 mcg (28s); 200 mcg (28s); 400 mcg (28s); 600 mcg (28s); 800 mcg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as citrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abstral&reg;: 100 mcg (12s, 32s); 200 mcg (12s, 32s); 300 mcg (12s, 32s); 400 mcg (12s, 32s); 600 mcg (32s); 800 mcg (32s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, lozenge, patch",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F170661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access is restricted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transmucosal immediate-release fentanyl  products (eg, sublingual tablets and spray, oral lozenges, buccal tablets and soluble film, nasal spray) are only available through the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Enrollment in the program is required for outpatients, prescribers for outpatient use, pharmacies (inpatient and outpatient), and distributors. Enrollment is not required for inpatient administration (eg, hospitals, hospices, long-term care facilities), inpatients, and prescribers who prescribe to inpatients. Further information is available at 1-866-822-1483 or at www.TIRFREMSaccess.com",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Effective December, 2011, individual REMs programs for TIRF products were combined into a single access program (TIRF REMS Access). Prescribers and pharmacies that were enrolled in at least one individual REMS program for these products will automatically be transitioned to the single access program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Abstral&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239930.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239930.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Actiq&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085817.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085817.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Duragesic&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088584.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088584.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Fentora&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088597.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088597.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Lazanda&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263032.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263032.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Onsolis&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022266s000MedGuide.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022266s000MedGuide.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Subsys&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM287863.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM287863.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral:",
"     </b>",
"     I.V.: Administer by slow I.V. push over 3-5 minutes or by continuous infusion. Larger bolus doses (&gt;5 mcg/kg) should be given by slow I.V. push over 5-10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"     Apply to nonhairy, clean, dry, nonirritated, intact skin of the flat area of front or back of upper torso, flank area, or upper arm; apply to upper back in young children or in people with cognitive impairment to decrease the potential of the patient removing the patch. Monitor the adhesion of the system closely in children. Clip hair prior to application, do",
"     <b>",
"      not",
"     </b>",
"     shave area; prior to application, skin may be cleaned with clear water (do not use soaps, lotions, alcohol, oils, or other substances which may irritate the skin); allow skin to dry thoroughly prior to application. Apply patch immediately after removing from package; firmly press in place and hold for at least 30 seconds; change patch every 72 hours; remove old patch before applying new patch; do not apply new patch to same place as old patch; wash hands after applying patch. If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape; if difficulty with adhesion persists, an adhesive film dressing (eg, Bioclusive&trade;, Tegaderm&trade;) may be applied over the system. If patch falls off before 72 hours, a new patch may be applied to a different skin site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Transdermal patch is a membrane-controlled system; do",
"     <b>",
"      not",
"     </b>",
"     cut the patch to deliver partial doses; do",
"     <b>",
"      not",
"     </b>",
"     use patches that are cut, damaged, or leaking; do",
"     <b>",
"      not",
"     </b>",
"     use if seal of package is broken; rate of drug delivery may be significantly increased if patch is cut, damaged, or leaking and result in absorption of a potentially fatal dose; reservoir contents and adhesion may be affected if cut; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (Lee, 1997). Do",
"     <b>",
"      not",
"     </b>",
"     use soap, alcohol, or other solvents to remove transdermal gel if it accidentally touches skin as they may increase transdermal absorption; use copious amounts of water. Avoid exposing application site to external heat sources (eg, electric blanket, heating pad, heat lamp, tanning lamp, sauna, heated water bed, hot tub, hot baths, sunbathing). Dispose of properly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transmucosal products:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Buccal film (Onsolis&reg;):",
"     </b>",
"     Foil overwrap should be removed just prior to administration. Prior to placing film, wet inside of cheek using tongue or by rinsing with water. Place film inside mouth with the pink side of the unit against the inside of the moistened cheek. With finger, press the film against cheek and hold for 5 seconds. The film should stick to the inside of cheek after 5 seconds. The film should be left in place until it dissolves (usually within 15-30 minutes after application). Liquids may be consumed after 5 minutes of application. Food can be eaten after film dissolves. If using more than one film simultaneously (during titration period), apply films on either side of mouth (do not apply on top of each other). Do not chew or swallow film. Do not cut or tear the film.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Buccal tablet (Fentora&reg;):",
"     </b>",
"     Do not use if blister package has been opened or tampered with. Blister package should be opened just prior to administration. Peel back the blister backing to expose the tablet; do not push tablet through the blister (damage to the tablet may occur). Administer tablet immediately after removal from blister. Place entire tablet in the buccal cavity (above a rear molar, between the upper cheek and gum). Use alternate side of mouth for subsequent doses. Do not break, suck, chew, or swallow tablet (this will result in decreased effect). Tablet should dissolve in about 14-25 minutes when left between the cheek and the gum. If remnants remain after 30 minutes, they may be swallowed with a glass of water. If excessive opioid effects appear before tablet is completely dissolved (eg, dizziness, sedation, nausea), instruct patient to rinse mouth with water and spit remaining pieces of tablet into sink or toilet immediately; rinse the sink or flush toilet to dispose of tablet particles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intranasal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Solution (injectable product):",
"     </b>",
"     Pediatric patients &ge;10 kg:  If congested, suction nostrils prior to administration. Using a 50 mcg/mL solution, administer half of the dose to each nostril using an atomizer such as the MAD&reg; Nasal Drug delivery device or drip into the nostril slowly with a syringe; higher concentrations (150 mcg/mL and 300 mcg/mL) have been studied to prevent excess volume administration and decrease leakage, but comparative trials have not been performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Nasal spray (Lazanda&reg;):",
"     </b>",
"     Prior to initial use, prime device by spraying 4 sprays into the provided pouch (the counting window will show a green bar when the bottle is ready for use). Insert nozzle a short distance into the nose (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch or 1 cm) and point towards the bridge of the nose (while closing off the other nostril using one finger). Press on finger grips until a &ldquo;click&rdquo; sound is heard and the number in the counting window advances by one. The &ldquo;click&rdquo; sound and dose counter are the only reliable methods for ensuring a dose has been administered (spray is not always felt on the nasal mucosa). Patient should remain seated for at least 1 minute following administration. Do not blow nose for &ge;30 minutes after administration. Wash hands before and after use. There are 8 full therapeutic sprays in each bottle; do not continue to use bottle after &ldquo;8&rdquo; sprays have been used. Dispose of bottle and contents if &ge;5 days have passed since last use or if it has been &ge;4 days since bottle was primed. Spray the remaining contents into the provided pouch, seal in the child-resistant container, and dispose of in the trash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Oral lozenge (Actiq&reg;):",
"     </b>",
"     Oral: Do not use if blister package has been opened. Blister package should be opened with scissors just prior to administration; once removed, patient should place the lozenge in mouth and suck it; do not bite or chew lozenge. Place lozenge in mouth between cheek and lower gum; occasionally move lozenge from one side of the mouth to the other; consume lozenge over 15 minutes; remove lozenge from mouth if signs of excessive opioid effects appear before lozenge is totally consumed. Remove handle after lozenge is consumed or patient achieves adequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sublingual spray (Subsys&reg;):",
"     </b>",
"     Open sealed blister unit with scissors immediately prior to administration. Contents of unit should be sprayed into mouth under the tongue. Dispose of unit immediately after use, using disposal bottle provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sublingual tablet (Abstral&reg;):",
"     </b>",
"     Remove from the blister unit immediately prior to administration. Place tablet directly under the tongue on the floor of the mouth and allow to completely dissolve; do not chew, suck, or swallow. Do not eat or drink anything until tablet is completely dissolved. In patients with a dry mouth, water may be used to moisten the buccal mucosa just before administration.",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14472638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F170668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, acetaminophen, acyclovir, alprostadil, amiodarone, amphotericin B cholesteryl sulfate complex, ampicillin, anidulafungin, argatroban, atracurium, atropine, bivalirudin, caffeine citrate, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefuroxime, cimetidine, cisatracurium, clindamycin, clonidine, dexamethasone sodium phosphate, diazepam, digoxin, diltiazem, diphenhydramine, dobutamine, dopamine, doripenem, enalaprilat, epinephrine, esmolol, etomidate, fenoldopam, furosemide, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ketorolac, labetalol, levofloxacin, linezolid, lorazepam, methotrimeprazine, metoclopramide, metronidazole, midazolam, milrinone, morphine, nafcillin, nesiritide, nicardipine, nitroglycerin, norepinephrine, oxaliplatin, palonosetron, pancuronium, phenobarbital, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, theophylline, thiopental, vancomycin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atracurium, atropine, bupivacaine, bupivacaine with clonidine, bupivacaine with ketamine, butorphanol, caffeine citrate, chlorpromazine, cimetidine, clonidine, clonidine with lidocaine, dimenhydrinate, diphenhydramine, droperidol, heparin, hydromorphone, hydroxyzine, ketamine, meperidine, metoclopramide, metoclopramide with midazolam, midazolam, morphine, ondansetron, pentazocine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole, pentobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection formulation: Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 86&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patch: Do not store above 25&deg;C (77&deg;F). Store in protective pouch until ready to use. Keep out of reach of children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transmucosal  buccal film, buccal tablets, nasal spray, oral lozenge, sublingual spray, sublingual tablet: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from freezing and moisture. Store in original child-resistant blister packaging until ready to use; do not use if blister package has been opened. Keep out of reach of children.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Sedation; relief of pain; preoperative medication; adjunct to general or regional anesthesia (FDA approved in ages &ge;2 years and adults); has also been used intranasally for analgesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch (Duragesic&reg;): Treatment of persistent, moderate-to-severe chronic pain in opioid-tolerant patients who are currently receiving opiates (FDA approved in ages &ge;2 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transmucosal products:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal film (Onsolis&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in &ge;18 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal tablet (Fentora&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in &ge;18 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasal spray (Lazanda&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in &ge;18 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral lozenge (Actiq&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in ages &ge;16 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual spray (Subsys&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in &ge;18 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet (Abstral&reg;): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opiates for persistent cancer pain (FDA approved in &ge;18 years and adults); see",
"     <b>",
"      Note",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients are considered opioid-tolerant if they are receiving around-the-clock opioids at a dose of at least 60 mg/day of morphine, 25 mcg/hour of transdermal fentanyl, 30 mg/day of oral oxycodone, 8 mg/day of oral hydromorphone, or an equivalent dose of another opioid for 1 week or longer.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FentaNYL may be confused with alfentanil, SUFentanil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fentanyl transdermal system patches: Leakage of fentanyl gel from the patch has been reported; patch may be less effective; do not use. Thoroughly wash any skin surfaces coming into direct contact with gel with water (do not use soap). May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fentanyl transdermal system patches:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       Dosing of transdermal fentanyl patches may be confusing. Transdermal fentanyl patches should always be prescribed in mcg/hour, not size. Patch dosage form of Duragesic&reg;-12 actually delivers 12.5 mcg/hour of fentanyl. Use caution, as orders may be written as &ldquo;Duragesic 12.5&rdquo; which can be erroneously interpreted as a 125 mcg dose.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       Patches should be stored and disposed of with care to avoid accidental exposure to children. The FDA has issued numerous safety advisories to warn users of the possible consequences (including hospitalization and death) of inappropriate storage or disposal of patches.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Abstral&reg;, Actiq&reg;, Fentora&reg;, Onsolis&reg;, and Subsys&reg; are not interchangeable; do not substitute doses on a mcg-per-mcg basis.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrhythmia, cardiorespiratory arrest, chest pain, DVT, edema, flushing, hyper-/hypotension, orthostatic hypotension, pallor, palpitation, peripheral edema, sinus tachycardia, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, attention disturbance, chills, CNS depression, confusion, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, fatigue, fever, hallucinations, headache, hypoesthesia, insomnia, irritability, lethargy, malaise, mental status change, migraine, nervousness, paranoid reaction, restlessness, sedation, somnolence, stupor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, decubitus ulcer, erythema, hyperhidrosis, papules, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, dehydration, hot flashes, hyper-/hypocalcemia, hyper-/hypoglycemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, abnormal taste, anorexia, appetite decreased, biliary tract spasm, constipation, diarrhea, dyspepsia, dysphagia (buccal tablet/film/sublingual spray), flatulence, gastritis, gastroenteritis, gastroesophageal reflux, GI hemorrhage, gingival pain (buccal tablet), gingivitis (lozenge), glossitis (lozenge), hematemesis, ileus, intestinal obstruction (buccal film), nausea, periodontal abscess (lozenge/buccal tablet), proctalgia, stomatitis (lozenge/buccal tablet/sublingual tablet/sublingual spray), tongue disorder (sublingual tablet), ulceration (gingival, lip, mouth; transmucosal use/nasal spray),  vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, erectile dysfunction, urinary incontinence, urinary retention, urinary tract infection, vaginitis, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ascites, AST increased, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application-site erythema/irritation/pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal coordination, abnormal gait, arthralgia, back pain, Chest wall rigidity (high dose I.V.), limb pain, muscle rigidity, myalgia, neuropathy, paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, dry eye, miosis, swelling, ptosis, strabismus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, bronchitis, cough, dyspnea (exertional), epistaxis, hemoptysis, hypoventilation, hypoxia, laryngitis, nasal congestion (nasal spray), nasal discomfort (nasal spray), nasopharyngitis, pharyngolaryngeal pain, pharyngitis, pneumonia, postnasal drip (nasal spray), pulmonary embolism (nasal spray), respiratory depression, rhinitis, rhinorrhea (nasal spray), sinusitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, hiccups, hypersensitivity,  lymphadenopathy, night sweats, parosmia, speech disorder, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amblyopia, allergic reaction, anaphylaxis, angina, aphasia, bladder pain, bronchospasm, CNS excitation or delirium, depersonalization, dysesthesia, emotional lability, esophageal stenosis, exfoliative dermatitis, fecal impaction, gum line erosion (lozenge), gum hemorrhage (lozenge), hematuria, hostility, hyper-/hypotonia, laryngospasm, myasthenia, nocturia, oliguria, pancytopenia, paradoxical dizziness, physical and psychological dependence with prolonged use, pleural effusion, polyuria, pustules, speech disorder, stertorous breathing, seizure, tooth loss (lozenge), urinary tract spasm, urticaria, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or intolerance to fentanyl, other opioid agonists, or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patches: Severe respiratory disease or depression including acute asthma (unless patient is mechanically ventilated); paralytic ileus; patients requiring short-term therapy; management of pain following outpatient or day surgery, intermittent pain, or mild pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patches (eg, Duragesic&reg;) and transmucosal products [buccal film (eg, Onsolis&reg;), buccal tablets (Fentora&reg;),  lozenges (eg, Actiq&reg;), nasal spray (Lazanda&reg;), sublingual spray (Subsys&reg;), sublingual tablet (Abstral&reg;)]: Additional contraindications: Patients who are not opioid-tolerant (see",
"     <b>",
"      Note",
"     </b>",
"     in Use field) and in the management of acute or postoperative pain (including headache, migraine, or dental pain). Abstral&reg; and Onsolis&trade; are also contraindicated for acute pain management in the emergency room.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with bradycardia; hepatic, biliary tract, renal, or respiratory disease; acute pancreatitis; cor pulmonale; significant COPD; other chronic respiratory conditions; or those with increased ICP, head injuries, or impaired consciousness. Patients must be monitored until fully recovered; decrease dose in patients with hepatic and/or renal disease; not recommended if patient received MAO inhibitors within 14 days. Use transdermal patch with caution in cachectic or debilitated patients; these patients may have altered pharmacokinetics due to muscle wasting, poor fat stores, or altered clearance. Frequent use of Actiq&reg; or generic lozenge may increase risk of dental caries; Actiq&reg; and generic lozenge contain 2 g of sugar/unit, as hydrated dextrates; patients should maintain good oral hygiene; inform diabetic patients of sugar content. Use buccal tablets with caution in patients with mucositis (no dose adjustment is needed in patients with Grade I mucositis; safety and efficacy in patients with more severe mucositis have not been studied).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fentanyl is not recommended for analgesia during labor and delivery; transient muscular rigidity has been observed in neonates born to women who were treated with I.V. fentanyl",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High potential for abuse; physical and psychological dependence may occur with prolonged use",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; abrupt discontinuation may result in withdrawal or seizures; potent opioids have a high risk of fatal overdose due to respiratory depression. Symptoms of opioid withdrawal may occur in patients after conversion of one dosage form to another or after dosage adjustment. With prolonged use, taper dose to prevent withdrawal symptoms. Neonates who receive a total fentanyl dose &gt;1.6 mg/kg or continuous infusion duration &gt;5 days are more likely to develop narcotic withdrawal symptoms; for infants and children 1 week to 22 months of age, those who receive a total dose of 1.5 mg/kg or duration &gt;5 days have a 50% chance of developing narcotic withdrawal and those receiving a total dose &gt;2.5 mg/kg or duration of infusion &gt;9 days have a 100% chance of developing withdrawal. Use with CYP3A4 inhibitors may result in increased effects and potentially fatal respiratory depression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with alcohol and other CNS depressants may increase risk of respiratory depression, hypotension, sedation or coma; dosage reduction may be needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage form specific warnings:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Parenteral:",
"     </b>",
"     Rapid I.V. infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, respiratory distress, apnea, bronchoconstriction, laryngospasm; inject slowly over 3-5 minutes; nondepolarizing skeletal muscle relaxant may be required",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should only be prescribed for opioid-tolerant patients. Transdermal patch is contraindicated in the management of short-term analgesia, in the management of postoperative pain, and in patients who are opioid-nontolerant; should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids in the management of chronic pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Monitor closely for respiratory depression during use, particularly during first two applications after initiation of therapy or after dose increases",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use in pediatric patients",
"     <b>",
"      only",
"     </b>",
"     if they are opioid-tolerant, receiving at least 60 mg oral morphine equivalents per day, and &ge;2 years of age. Patients should be monitored carefully, especially 24-72 hours after initial patch application (when peak fentanyl serum levels occur) and following increases in dosage. Monitor patients who experience adverse reactions for at least 24 hours after removal of the patch (apparent transdermal half-life is 17 hours).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Accidental exposure may lead to severe respiratory depression, including death, in children and adults; proper procedures for handling and disposal of patches should be followed",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Keep used and unused patches out of the reach of children. Avoid unclothed/unwashed application site exposure, inadvertent person-to-person patch transfer (eg, while hugging), incidental exposure (eg, sharing same bed, sitting on patch), intentional exposure (eg, chewing, swallowing), or accidental exposure by caregivers when applying/removing patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Avoid exposure of application site and surrounding area to direct external heat sources. Patients who experience fever or increase in core body temperature should be monitored closely",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; serum fentanyl concentrations may increase by approximately one-third for patients with a body temperature of 40&deg;C (104&deg;F) secondary to a temperature-dependent increase in fentanyl release from the patch and increased skin permeability. Transdermal patch should be applied only to intact skin. Use of a patch that has been cut, damaged, or altered in any way may result in potentially fatal overdosage. Transdermal patch may contain conducting metal (eg, aluminum) which may cause a burn to the skin during an MRI scan; remove patch prior to MRI; reapply patch after scan is completed. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transmucosal products:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Buccal film (Onsolis&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should only be prescribed for opioid-tolerant patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in the management of acute or postoperative pain and in opioid-nontolerant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Onsolis&reg; is available only through a restricted distribution program, called the FOCUS Program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ;  appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another. Patients using Onsolis&reg; who experience breakthrough pain must wait at least 2 hours before taking another dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Buccal tablet (Fentora&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should only be prescribed for opioid-tolerant patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in the management of acute or postoperative pain (including headache/migraine) and in opioid-nontolerant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Fentora&reg; is available only through a restricted distribution program, called the FENTORA REMS program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another. Patients using Fentora&reg; who experience breakthrough pain may only take",
"     <b>",
"      one",
"     </b>",
"     additional dose (if pain not relieved after 30 minutes) using the same strength tablet and must wait 4 hours before taking another dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Nasal spray (Lazanda&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should be used only for  opioid-tolerant  patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in opioid nontolerant patients or in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Lazanda&reg; is available only through a restricted distribution program, called the Lazanda&reg; REMS program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another.  Patients using Lazanda&reg; must begin therapy with a 100 mcg dose and titrate, if needed; during therapy, patients must wait at least 2 hours before taking another dose of nasal spray. Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral lozenge (Actiq&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should be used only for  opioid-tolerant  patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in opioid-nontolerant patients or in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Actiq&reg; is available only through a restricted distribution program, called the  ACTIQ&reg; REMS program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another. Patients using Actiq&reg; must  begin therapy with an initial dose of 200 mcg and titrate, if needed; during therapy, patients must wait at least 4 hours before taking another dose of the same strength. Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products. Safety and efficacy have not been established for patients &lt;16 years of age; 15 opioid-tolerant pediatric patients (age: 5-15 years) with breakthrough pain were treated with Actiq&reg; in a clinical study; 12 of the 15 patients received doses of 200 mcg to 600 mcg; no conclusions about safety and efficacy could be drawn due to the small sample size.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Sublingual spray (Subsys&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should be used only for  opioid-tolerant  patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in opioid-nontolerant patients or in the management of acute or postoperative pain, including headache/migraine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Subsys&reg; is available only through a restricted distribution program, called the  TIRF REMS ACCESS  program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ;  appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another. Patients using Subsys&reg; must begin therapy with an initial dose of 100 mcg and titrate, if needed; during therapy, patients must wait at least 4 hours before taking another dose of the same strength. Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products. Cancer patients with oral mucositis experienced increased fentanyl exposure following sublingual spray administration; avoid use in patients with grade 2 or higher mucositis; use with caution in patients with grade 1 mucositis, and closely monitor for respiratory and CNS depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Sublingual tablet (Abstral&reg;):",
"     </b>",
"     May cause potentially life-threatening hypoventilation, respiratory depression, and/or death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; should be used only for  opioid-tolerant  patients; risk of respiratory depression increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia; usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Use is contraindicated in opioid-nontolerant patients or in the management of acute or postoperative pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Due to the risk for misuse, abuse, and overdose, Subsys&reg; is available only through a restricted distribution program, called the ABSTRAL REMS program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Substantial differences exist in the pharmacokinetic profile of fentanyl products; do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; appropriate dosage adjustments must be made; use caution and monitor closely when changing patients from one product to another. Patients using Subsys&reg; must begin therapy with an initial dose of 100 mcg and titrate, if needed; during therapy, patients must wait at least 2 hours before taking another dose of the same strength. Preparation contains an amount of medication that can be fatal to children; keep all used and unused products out of the reach of children at all times and discard products properly",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially consumed products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F170653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Midodrine; Naphazoline (Ophthalmic); Phenylephrine (Ophthalmic); Phenylephrine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of FentaNYL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of FentaNYL. Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of FentaNYL. Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: FentaNYL may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of FentaNYL. Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4432922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit juice may significantly increase fentanyl serum concentrations and adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Fentanyl crosses the placenta and the injectable formulation has been used safely during labor (Gomar, 2000). Chronic use during pregnancy has shown detectable serum concentrations in the newborn with transient respiratory depression, behavioral changes, or seizures in the newborn infant characteristic of neonatal abstinence syndrome; transient neonatal muscular rigidity has also been observed. Transdermal patch, transmucosal lozenge, nasal spray (Lazanda&reg;), sublingual tablet, sublingual spray (Subsys&reg;), buccal tablet (Fentora&reg;), and buccal film (Onsolis&reg;) are not recommended for analgesia during labor and delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate, oxygen saturation, bowel sounds, abdominal distention; signs of misuse, abuse, or addiction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patch: Monitor patient for at least 24 hours after application of first dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific opioid mu receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory depressant effect may last longer than analgesic effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 7-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: Children 3-12 years: 5-10 minutes (Borland, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Almost immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (initial placement): 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (initial placement): 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch (removal of patch/no placement): 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal: Related to blood level; respiratory depressant effect may last longer than analgesic effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Fentanyl serum concentrations are ~twofold higher in children 1.5-5 years old who are not opioid-tolerant and are receiving the transdermal patch. Pharmacokinetic parameters in older pediatric patients are similar to adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Drug is released at a nearly constant rate from the transdermal matrix system into the skin, where it accumulates; this results in a depot of fentanyl in the outer layer of the skin. Fentanyl is absorbed into the systemic circulation from the depot. This results in a gradual increase in serum concentrations over the first 12-24 hours, followed by a fairly constant concentration for the remainder of the dosing interval. Absorption is decreased in cachectic patients (compared to normal size patients). Pharmacokinetics of transdermal patch with or without Bioclusive&trade; overlay (polyurethane film dressing) were bioequivalent. Exposure to external heat increases drug absorption from patch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal film and buccal tablet: Rapid; ~50% from the buccal mucosa; 50% swallowed with saliva and slowly absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Transmucosal lozenge: Rapid; ~25% absorbed from buccal mucosa; 75% swallowed with saliva and slowly absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Highly lipophilic, redistributes into muscle and fat; crosses placenta;",
"     <b>",
"      Note:",
"     </b>",
"     I.V. fentanyl exhibits a 3-compartment distribution model. Changes in blood pH may alter ionization of fentanyl and affect its distribution between plasma and CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : Children: 0.05-14 years of age (after long-term continuous infusion): ~15 L/kg (range: 5-30 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 4-6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 85%, primarily to alpha-1-acid glycoprotein; also binds to albumin and erythrocytes;",
"     <b>",
"      Note:",
"     </b>",
"     Free fraction increases with acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &gt;90% metabolized in the liver via cytochrome P450 isoenzyme CYP3A4 by N-dealkylation (to norfentanyl) and hydroxylation to other inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"     <b>",
"      Note:",
"     </b>",
"     Comparative studies have found the buccal film to have a 40% greater systemic exposure (ie, AUC) than the transmucosal lozenge, and the buccal tablet to have a 30% to 50% greater exposure than the transmucosal lozenge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal film: 71% (mucositis did not have a clinically significant effect on peak concentration and AUC; however, bioavailability is expected to decrease if film is inappropriately chewed and swallowed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buccal tablet: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral lozenge: 47%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual spray: 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: 54%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients 5 months to 4.5 years: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients 6 months to 14 years (after long-term continuous infusion): ~21 hours (range: 11-36 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 2-4 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Using a 3-compartment model, fentanyl displayed an initial distribution half-life of 6 minutes; second distribution half-life of 1 hour and terminal half-life of 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: 17 hours (range: 13-22 hours, apparent half-life is influenced by extended absorption)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal products: 3-14 hours (dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal film: ~14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal tablet: 100-200 mcg: 3-4 hours; 400-800 mcg: 11-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nasal spray: 15-25 hours (based on a multiple-dose pharmacokinetic study when doses are administered in the same nostril and separated by a 1-, 2-, or 4-hour time lapse)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: 24-72 hours, after several sequential 72-hour applications, steady state serum concentrations are reached",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transmucosal products:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal film: Median: 1 hour (range: 0.75-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal tablet: Median: 47 minutes (range: 20-240 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nasal spray: Median: 15-21 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral lozenge: Median: 20-40 minutes (range: 20-480 minutes), measured after the start of dose administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual spray: Median: 90 minutes (range: 10-120 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual tablet: Median: 30-60 minutes (range: 15-240 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine 75% (primarily as metabolites, &lt;7% to 10% as unchanged drug); feces ~9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Newborn infants: Clearance may be significantly correlated to gestational age and birth weight (Saarenmaa, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/29/472?source=see_link\">",
"      see \"Fentanyl: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All products:",
"     </b>",
"     Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid alcohol, other CNS depressants (eg, sleep medications, tranquilizers), grapefruit juice, and the herbal medicine St John's wort. Fentanyl may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use; may cause dry mouth and constipation. Notify physician immediately or seek emergency help if acute dizziness, chest pain, slow or rapid heartbeat, shortness of breath, respiratory difficulty, confusion, or unusual symptoms occur. Notify physician if acute headache, changes in mentation, changes in voiding frequency or amount, swelling of extremities, unusual weight gain, or vision changes occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"     Read the patient Medication Guide received with each prescription and refill of this medication for details on proper storage, administration, and disposal of transdermal patch, as well as instructions about overdose management. Keep all transdermal patches (even if used) out of the reach of children; even used patches may be dangerous or even lethal to babies, children, pets, and other adults; discard used transdermal patches immediately after removal by folding in half (so the sticky side sticks to itself) and flushing down the toilet; discard unused patches that are no longer needed in the same manner; protective pouch and liner should be thrown in garbage. Notify physician if high fever develops while wearing the patch. Do",
"     <b>",
"      not",
"     </b>",
"     use patches that are cut, damaged, or leaking. Wash skin with clear water (not soap, alcohol, or other chemicals) if gel from patch accidentally comes into contact with skin. If patch accidentally sticks to the skin of another person, take patch off immediately, wash exposed skin with water, and seek medical attention for that person. Accidental exposure or misuse may lead to serious medical problems, even death. Do",
"     <b>",
"      not",
"     </b>",
"     adjust the dose or number of patches applied to the skin without the prescribing healthcare professional&rsquo;s instruction. If the patch is not sticking, the edges of the system may be taped in place with first-aid tape; if the patch continues to not stick to the skin, an adhesive film dressing (eg, Bioclusive&trade;, Tegaderm&trade;) may be applied over the system; do not cover the patch with any other bandage or tape. If patch falls off before 72 hours, a new patch may be applied to a different skin site.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transmucosal products:",
"     </b>",
"     Read the patient Medication Guide received with each prescription and refill of this medication for details on proper storage, administration, and disposal as well as instructions about overdose management. Patients must be enrolled in the appropriate REMS program; these products contain an amount of medication that can be fatal to people for whom it was not prescribed, those who are not tolerant to opioids, and children; do not allow other people to use this product (serious adverse effects and potentially fatal overdose may occur). Do not use this product unless you have been regularly using other opioid medications around the clock for your constant cancer pain and your body is used to taking these medications. Keep out of reach of children;  these products contain an amount of medication that can be fatal to children; death has been reported in children after accidental exposure; promptly and properly discard dosage containers after use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Buccal film (Onsolis&reg;): Discard unused film appropriately; remove foil overwraps from any unused, unneeded films and dispose by flushing down the toilet.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Buccal tablets (Fentora&reg;): Discard unused tablets appropriately; remove unusable tablets from blister package and flush tablets down the toilet; to dispose of excess unusable tablets call manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Nasal spray (Lazanda&reg;): Properly discard by spraying any remaining liquid into the provided safe disposal pouch; this includes any unused therapeutic doses left in the bottle (counter will advance to &ldquo;8&rdquo; once complete). Push down finger grips four more times to remove any residual medication and also spray into the safety pouch. Once completed, seal the pouch and place both the pouch and empty bottle into the child-resistant storage container and discard in the trash out of reach of children and pets. Wash hands with soap and water after handling. Current bottle should also be discarded and a new one opened if &ge;5 days since last dose or &ge;14 days since bottle primed. Additional pouches may be obtained from the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Oral lozenge (Actiq&reg;): An Actiq&reg; Child Safety Kit and OTFC (Oral Transmucosal Fentanyl Citrate) Child Safety Kit, containing a child-resistant lock, portable locking pouch, and a child-resistant temporary storage bottle (to keep medication away from children), are available from the manufacturer. After consumption of a complete unit, the handle may be disposed of in a trash container that is out of the reach of children and pets. For a partially consumed unit, or a unit that still has any drug matrix remaining on the handle, the handle should be placed under hot running tap water until the drug matrix has dissolved. Use the special child-resistant container available in the Child Safety Kit to temporarily store partially consumed units that cannot be disposed of immediately. Frequent use of oral transmucosal fentanyl lozenges may increase risk of dental caries; consult dentist for appropriate oral hygiene. Diabetic patients should note that the oral transmucosal lozenge contains 2 g of sugar/unit (about",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     teaspoon of sugar).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Sublingual spray (Subsys&reg;): Properly discard by cutting blister package with scissors where indicated on the container and attach upside down to the provided disposal bottle by pushing through the insert. Once attached, expel any remaining liquid by pressing the light purple vial holder; repeat procedure for any unused dosage units. After completion, flip down the top of the disposal bottle to close and shake; place disposal bottle in provided bag, seal it, and discard in trash container out of reach of children and pets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Sublingual tablet (Abstral&reg;):  Discard any unneeded portions by removing tablets from the blister packet and flushing down the toilet. If assistance required for disposal, contact the manufacturer or local Drug Enforcement Agency (DEA) office.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fentanyl is 50-100 times as potent as morphine; morphine 10 mg I.M. = fentanyl 0.1-0.2 mg I.M. Fentanyl has less hypotensive effects than morphine or meperidine due to minimal or no histamine release. I.V. product has a pH of 4.0-7.5.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ and International Evidence-Based Group for Neonatal Pain, &ldquo;Consensus Statement for the Prevention and Management of Pain in the Newborn,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2001, 155(2):173-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/11177093/pubmed\" id=\"11177093\" target=\"_blank\">",
"        11177093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Billmire DA, Neale HW, and Gregory RO, &ldquo;Use of I.V. Fentanyl in the Outpatient Treatment of Pediatric Facial Trauma,&rdquo;",
"      <i>",
"       J Trauma",
"      </i>",
"      , 1985, 25(11):1079-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/4057297/pubmed\" id=\"4057297\" target=\"_blank\">",
"        4057297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borland M, Jacobs I, King B, et al, \"A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine for Managing Acute Pain in Children in the Emergency Department,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(3):335-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/17067720/pubmed\" id=\"17067720\" target=\"_blank\">",
"        17067720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borland ML, Bergesio R, Pascoe EM, et al, \"Intranasal Fentanyl Is an Equivalent Analgesic to Oral Morphine in Paediatric Burns Patients for Dressing Changes: A Randomised Double Blind Crossover Study,\"",
"      <i>",
"       Burns",
"      </i>",
"      , 2005, 31(7):831-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/16005154 /pubmed\" id=\"16005154 \" target=\"_blank\">",
"        16005154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borland ML, Jacobs I, and Geelhoed G, \"Intranasal Fentanyl Reduces Acute Pain in Children in the Emergency Department: A Safety and Efficacy Study,\"",
"      <i>",
"       Emerg Med (Fremantle)",
"      </i>",
"      , 2002, 14(3):275-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/12487045/pubmed\" id=\"12487045\" target=\"_blank\">",
"        12487045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung S, Lim R, and Goldman RD, \"Intranasal Fentanyl Versus Placebo for Pain in Children During Catheterization for Voiding Cystourethrography,\"",
"      <i>",
"       Pediatr Radiol",
"      </i>",
"      , 2010, 40(7):1236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/20180109 /pubmed\" id=\"20180109 \" target=\"_blank\">",
"        20180109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole J, Shepherd M, and Young P, \"Intranasal Fentanyl in 1-3-Year-Olds: A Prospective Study of the Effectiveness of Intranasal Fentanyl as Acute Analgesia,\"",
"      <i>",
"       Emerg Med Australas",
"      </i>",
"      , 2009, 21(5):395-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/19840089/pubmed\" id=\"19840089\" target=\"_blank\">",
"        19840089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crellin D, Ling RX, and Babl F, \"Does the Standard Intravenous Solution of Fentanyl (50 microg/mL) Administered Intranasally Have Analgesic Efficacy?\"",
"      <i>",
"       Emerg Med Australas",
"      </i>",
"      , 2010, 22(1):62-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/20152004/pubmed\" id=\"20152004\" target=\"_blank\">",
"        20152004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finn M and Harris D, \"Intranasal Fentanyl for Analgesia in the Paediatric Emergency Department,\"",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2010, 27(4):300-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/20385685 /pubmed\" id=\"20385685 \" target=\"_blank\">",
"        20385685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herd D and Borland M, \"Intranasal Fentanyl Paediatric Clinical Practice Guidelines,\"",
"      <i>",
"       Emerg Med Australas",
"      </i>",
"      , 2009, 21(4):335.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/19682022/pubmed\" id=\"19682022\" target=\"_blank\">",
"        19682022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz R, Kelly HW, and Hsi A, &ldquo;Prospective Study on the Occurrence of Withdrawal in Critically Ill Children Who Receive Fentanyl by Continuous Infusion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(5):763-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/8181283/pubmed\" id=\"8181283\" target=\"_blank\">",
"        8181283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee HA and Anderson PO, &ldquo;Giving Partial Doses of Transdermal Patches,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(15):1759-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/9262751/pubmed\" id=\"9262751\" target=\"_blank\">",
"        9262751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leuschen MP, Willett LD, Hoie EB, et al, &ldquo;Plasma Fentanyl Levels in Infants Undergoing Extracorporeal Membrane Oxygenation,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1993, 105(5):885-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/8487566/pubmed\" id=\"8487566\" target=\"_blank\">",
"        8487566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lim S, Paech MJ, Sunderland VB, et al, &ldquo;Pharmacokinetics of Nasal Fentanyl,&rdquo;",
"      <i>",
"       J Pharm Pract Res",
"      </i>",
"      , 2003, 33:59-63.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manjushree R, Lahiri A, Ghosh BR, et al, \"Intranasal Fentanyl Provides Adequate Postoperative Analgesia in Pediatric Patients,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2002, 49(2):190-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/11823399/pubmed\" id=\"11823399\" target=\"_blank\">",
"        11823399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,\" 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roth B, Schlunder C, Houben F, et al, &ldquo;Analgesia and Sedation in Neonatal Intensive Care Using Fentanyl by Continuous Infusion,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1991, 17(3-4):121-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/1841826/pubmed\" id=\"1841826\" target=\"_blank\">",
"        1841826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saarenmaa E, Neuvonen PJ, and Fellman V, &ldquo;Gestational Age and Birth Weight Effects on Plasma Clearance of Fentanyl in Newborn Infants,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 136(6):767-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/10839874 /pubmed\" id=\"10839874 \" target=\"_blank\">",
"        10839874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saunders M, Adelgais K, and Nelson D, \"Use of Intranasal Fentanyl for the Relief of Pediatric Orthopedic Trauma Pain,\"",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 2010, 17(11):1155-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/21175512/pubmed\" id=\"21175512\" target=\"_blank\">",
"        21175512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schechter NL, Weisman SJ, Rosenblum M, et al, &ldquo;The Use of Oral Transmucosal Fentanyl Citrate for Painful Procedures in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(3):335-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/7862469/pubmed\" id=\"7862469\" target=\"_blank\">",
"        7862469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toussaint S, Maidl J, Schwagmeier R, et al, \"Patient-Controlled Intranasal Analgesia: Effective Alternative to Intravenous PCA for Postoperative Pain Relief,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2000, 47(4):299-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/10764171/pubmed\" id=\"10764171\" target=\"_blank\">",
"        10764171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/45/35546/abstract-text/2216645 /pubmed\" id=\"2216645 \" target=\"_blank\">",
"        2216645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13298 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35546=[""].join("\n");
var outline_f34_45_35546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708780\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052734\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442526\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052726\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170567\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170661\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233769\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874432\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052739\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472638\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472637\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170668\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052729\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052738\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170670\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170667\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052743\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052725\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052724\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170576\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432922\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170578\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170593\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052733\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052723\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052741\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052742\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052731\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052744\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13298|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=related_link\">",
"      Fentanyl: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/29/472?source=related_link\">",
"      Fentanyl: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_45_35547="Microbiology pacemaker endocarditis";
var content_f34_45_35547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology of pacemaker endocarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients (%)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulase-negative staphylococci",
"       </td>",
"       <td>",
"        99 (61)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        49 (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterobacteriaceae",
"       </td>",
"       <td>",
"        8 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptococci",
"       </td>",
"       <td>",
"        7 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomonas",
"       </td>",
"       <td>",
"        6 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candida",
"       </td>",
"       <td>",
"        3 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterococci",
"       </td>",
"       <td>",
"        3 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corynebacterium",
"       </td>",
"       <td>",
"        2 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propionibacterium acnes",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listeria",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micrococci",
"       </td>",
"       <td>",
"        1 (&lt;1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 18 patients had polymicrobial infection.",
"    </div>",
"    <div class=\"reference\">",
"     Data compiled from: Arber, N, Pras, E, Copperman, Y, et al. Medicine (Baltimore) 1994; 73:299; Duval, X, Selton-Suty, C, Alla, F, et al. Clin Infect Dis 2004; 39:68; Klug, D, Lacroix, D, Savoye, C, et al. Circulation 1997; 95:2098; and Cacoub, P, Leprince, P, Nataf, P, et al. Am J Cardiol 1998; 82:480.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35547=[""].join("\n");
var outline_f34_45_35547=null;
var title_f34_45_35548="Chronic abdominal pain history";
var content_f34_45_35548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    History to be obtained at the initial visit for children with chronic abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Onset and course of pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Timing, location, character, radiation of pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severity of pain reported by child and parent. Assessed by a pain rating scale of 1 to 10 or, with a young child, using rating scale with faces graded from smile to tears.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disruption of sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When in pain, how does the child or adolescent show it?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When child or adolescent is in pain, how does the family respond? What do they do about the pain?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous medical care and laboratory tests for the pain evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aggravating and relieving factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aggravating or relieving factors, including medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Associated symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Associated symptoms, including weight loss, reduced appetite, nausea, intestinal gas, diarrhea, and meals or specific foods (milk products)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any respiratory symptoms, such as chronic cough, wheezing, hoarse voice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Past history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of trauma or past surgeries",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Family history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Family history for gastrointestinal diagnoses, chronic pain disorders, or any other chronic illness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Habits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dietary history, any evidence of low-fiber diet",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Restrictive eating behavior/desire to lose weight",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Purging behavior/self-induced vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frequency of bowel movements, history of being \"too busy\" to evacuate completely, encopresis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recent excessive exercise",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Review of systems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dates of three last menstrual periods, relationship of pain with menses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of sexual activity and contraception",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Psychosocial history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disruption of normal activities, including school attendance/sports, by the pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any known stressors for the child and adolescent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Close relationship with any ill family members. Does the family member reside in the patient's home?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When stressed, how does the child or adolescent show it?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35548=[""].join("\n");
var outline_f34_45_35548=null;
var title_f34_45_35549="IV CMF for breast cancer";
var content_f34_45_35549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    IV cyclophosphamide, methotrexate, and fluorouracil chemotherapy for breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"        <br/>",
"        Total cycles: 6.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL normal saline (NS) or 5 percent dextrose in water (D5W) and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Methotrexate",
"        </strong>",
"       </td>",
"       <td>",
"        40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Drug is available in a 25 mg/mL solution that needs no further dilution. It can be administered as a slow IV push.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as IV push.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients should maintain adequate oral hydration (2 to 3 L/day) and void frequently to reduce risk of hemorrhagic cystitis",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        No specific premedication regimen is indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not indicated",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Lower starting dose of methotrexate may be needed in patients with renal impairment and in those with third space fluid collections (eg, ascites, pleural effusion). Methotrexate should not be administered in the setting of liver impairment. A lower starting dose of fluorouracil may be needed for patients with liver impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential on days 1 and 8 of each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess serum electrolytes and liver and renal function tests on or prior to day 1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        : If the ANC &le;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &le;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1 and day 8 of each cycle, therapy should be delayed until counts recover.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for diarrhea:",
"        </strong>",
"        Withhold fluorouracil for grade 2 or worse diarrhea and restart at a lower dose after complete resolution.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesia:",
"        </strong>",
"        Hold fluorouracil for grade 2 or greater palmar plantar erythrodysesthesia, and reduce subsequent dose by 20 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count; G-CSF: granulocyte-colony stimulating factor.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Jakesz R, et al. J Clin Oncol 2002; 20:4621.",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 30, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35549=[""].join("\n");
var outline_f34_45_35549=null;
var title_f34_45_35550="Pathways of complement activation";
var content_f34_45_35550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Pathways of complement activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three pathways of complement activation are shown. Each leads to generation of activated C3b. The classical pathway is triggered by antibody interacting with antigen, and the lectin pathway by a lectin binding to a sugar. The alternative pathway turns over continuously. Activation of the complement system leads to inflammation (release of anaphylatoxins C3a and C5a), membrane perturbation and lysis (via the membrane attack complex, C5b-9), and opsonization (deposition of C3b and C4b).",
"    <div class=\"footnotes\">",
"     MASP: mannose-binding lectin (MBL)-associated serine protease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35550=[""].join("\n");
var outline_f34_45_35550=null;
var title_f34_45_35551="Subcutaneous met melanoma";
var content_f34_45_35551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcutaneous melanoma metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT image demonstrating a subcutaneous metastasis from melanoma involving the left anterior upper chest wall. These lesions are particularly conspicuous on CT scans because of the density of the metastatic nodules relative to the low attenuation of the surrounding subcutaneous fat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Donohoe, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_45_35551=[""].join("\n");
var outline_f34_45_35551=null;
